0001516551-24-00011010-Q Skye Bioscience, Inc. 20241107202411071610161617161017 0 0001516551-24-000110 10-Q 68 20240930 20241107 20241107 Skye Bioscience, Inc. 0001516551 2834 450692882 NV 1231 10-Q 34 001-42009 241435725 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 Emerald Bioscience, Inc. 20190325 Nemus Bioscience, Inc. 20141030 LOAD GUARD LOGISTICS, INC. 20121107 10-Q 1 skye-20240930.htm 10-Q skye-20240930000151655 1Dec 31false2024Q3xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureskye:market_based_conditionutr:sqft00015165512024-01-012024-09-300001516551 2024-11-060001516551 2024-09-300001516551 2023-12-310001516551 2024-07-012024-09-300001516551 2023-07-012023-09-300001516551 2023-01-012023-09-300001516551us-gaap:RelatedPartyMember2024-01-012024-09-300001516551us-gaap:RelatedPartyMember2023-01-012023-09-300001516551us-gaap:NonrelatedPartyMember2024-01-012024-09-300001516551us-gaap:NonrelatedPartyMember2023-01-012023-09-300001516551 2022-12-310001516551 2023-09-300001516551us-gaap:CommonStockMember2023-12-310001516551us-gaap:AdditionalPaidInCapitalMember2023-12-310001516551us-gaap:RetainedEarningsMember2023-12-310001516551us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001516551 2024-01-012024-03-310001516551 2024-03-310001516551us-gaap:CommonStockMember2024-01-012024-03-310001516551us-gaap:RetainedEarningsMember2024-01-012024-03-310001516551us-gaap:CommonStockMember2024-03-310001516551us-gaap:AdditionalPaidInCapitalMember2024-03-310001516551us-gaap:RetainedEarningsMember2024-03-310001516551us-gaap:CommonStockMember2024-04-012024-06-300001516551us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001516551 2024-04-012024-06-300001516551us-gaap:RetainedEarningsMember2024-04-012024-06-300001516551us-gaap:CommonStockMember2024-06-300001516551us-gaap:AdditionalPaidInCapitalMember2024-06-300001516551us-gaap:RetainedEarningsMember2024-06-300001516551 2024-06-300001516551us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001516551us-gaap:CommonStockMember2024-07-012024-09-300001516551us-gaap:RetainedEarningsMember2024-07-012024-09-300001516551us-gaap:CommonStockMember2024-09-300001516551us-gaap:AdditionalPaidInCapitalMember2024-09-300001516551us-gaap:RetainedEarningsMember2024-09-300001516551us-gaap:CommonStockMember2022-12-310001516551us-gaap:AdditionalPaidInCapitalMember2022-12-310001516551us-gaap:RetainedEarningsMember2022-12-310001516551us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001516551 2023-01-012023-03-310001516551us-gaap:CommonStockMember2023-01-012023-03-310001516551us-gaap:RetainedEarningsMember2023-01-012023-03-310001516551us-gaap:CommonStockMember2023-03-310001516551us-gaap:AdditionalPaidInCapitalMember2023-03-310001516551us-gaap:RetainedEarningsMember2023-03-310001516551 2023-03-310001516551us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001516551 2023-04-012023-06-300001516551us-gaap:RetainedEarningsMember2023-04-012023-06-300001516551us-gaap:CommonStockMember2023-06-300001516551us-gaap:AdditionalPaidInCapitalMember2023-06-300001516551us-gaap:RetainedEarningsMember2023-06-300001516551 2023-06-300001516551us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001516551us-gaap:CommonStockMember2023-07-012023-09-300001516551us-gaap:RetainedEarningsMember2023-07-012023-09-300001516551us-gaap:CommonStockMember2023-09-300001516551us-gaap:AdditionalPaidInCapitalMember2023-09-300001516551us-gaap:RetainedEarningsMember2023-09-300001516551skye:AVIBuildingMember2024-01-012024-09-300001516551us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberskye:VDLMember2024-07-170001516551 2024-07-172024-07-170001516551us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberskye:VDLMember2024-07-172024-07-170001516551skye:BirdRockBioSubInc.BRBMember2023-08-180001516551skye:BirdRockBioSubInc.BRBMember2023-08-182023-08-180001516551us-gaap:MachineryAndEquipmentMember2024-09-300001516551us-gaap:MachineryAndEquipmentMember2023-12-310001516551us-gaap:ComputerEquipmentMember2024-09-300001516551us-gaap:ComputerEquipmentMember2023-12-310001516551us-gaap:LeaseholdImprovementsMember2024-09-300001516551us-gaap:LeaseholdImprovementsMember2023-12-310001516551skye:TwoThousandFifteenCommonStockWarrantsMember2024-09-300001516551skye:TwoThousandFifteenCommonStockWarrantsMember2024-01-012024-09-300001516551skye:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember2024-09-300001516551skye:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember2024-01-012024-09-300001516551skye:TwoThousandNineteenCommonStockWarrantsMember2024-09-300001516551skye:TwoThousandNineteenCommonStockWarrantsMember2024-01-012024-09-300001516551skye:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember2024-09-300001516551skye:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember2024-01-012024-09-300001516551skye:TwoThousandAndTwentyOneInducementWarrantsMember2024-09-300001516551skye:TwoThousandAndTwentyOneInducementWarrantsMember2024-01-012024-09-300001516551skye:TwoThousandAndTwentyOneInducementWarrantsToPlacementAgentMember2024-09-300001516551skye:TwoThousandAndTwentyOneInducementWarrantsToPlacementAgentMember2024-01-012024-09-300001516551skye:TwoThousandAndTwentyOneCommonStockWarrantsMember2024-09-300001516551skye:TwoThousandAndTwentyOneCommonStockWarrantsMember2024-01-012024-09-300001516551skye:TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember2024-09-300001516551skye:TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember2024-01-012024-09-300001516551skye:November2019EHTCommonStockWarrantsMember2024-09-300001516551skye:November2019EHTCommonStockWarrantsMember2024-01-012024-09-300001516551skye:December2019EHTCommonStockWarrantsMember2024-09-300001516551skye:December2019EHTCommonStockWarrantsMember2024-01-012024-09-300001516551skye:February2020EHTCommonStockWarrantsMember2024-09-300001516551skye:February2020EHTCommonStockWarrantsMember2024-01-012024-09-300001516551skye:August2023ConvertibleNoteCommonStockWarrantsMember2024-09-300001516551skye:August2023ConvertibleNoteCommonStockWarrantsMember2024-01-012024-09-300001516551skye:August2023PIPEFinancingCommonStockWarrantsMember2024-09-300001516551skye:August2023PIPEFinancingCommonStockWarrantsMember2024-01-012024-09-300001516551skye:March2024PIPEFinancingCommonStockWarrantsMember2024-09-300001516551skye:January2024PIPEFinancingPreFundedWarrantsMemberskye:January2024PIPEFinancingMember2024-01-310001516551skye:January2024PIPEFinancingMember2024-01-012024-01-310001516551skye:Convertible10NoteMemberus-gaap:ConvertibleDebtMember2023-12-310001516551skye:MultiDrawCreditAgreementMemberus-gaap:ConvertibleDebtMember2023-12-310001516551skye:Convertible10NoteMember2023-08-150001516551skye:Convertible10NoteMemberus-gaap:ConvertibleDebtMember2023-08-150001516551skye:Convertible10NoteMember2024-08-080001516551skye:Convertible10NoteMemberus-gaap:ConvertibleDebtMember2024-08-082024-08-080001516551skye:Convertible10NoteMember2024-09-300001516551skye:January2024PIPEFinancingMember2024-01-292024-01-290001516551skye:January2024PIPEFinancingPreFundedWarrantsMemberskye:January2024PIPEFinancingMember2024-01-290001516551skye:January2024PIPEFinancingPreFundedWarrantsMember2024-01-292024-01-290001516551skye:January2024PIPEFinancingMember2024-01-290001516551skye:January2024PIPEFinancingPreFundedWarrantsMemberskye:January2024PIPEFinancingMember2024-01-292024-01-290001516551skye:January2024PIPEFinancingMember2023-08-152023-08-150001516551skye:March2024PIPEFinancingMember2024-03-112024-03-110001516551skye:March2024PIPEFinancingMember2024-03-110001516551skye:PreFundedWarrantsMember2024-08-090001516551skye:A2014AmendedAndRestatedPlanMember2024-09-300001516551skye:A2024InducementEquityIncentivePlanMember2024-07-020001516551skye:A2024InducementEquityIncentivePlanMember2024-09-300001516551us-gaap:EmployeeStockOptionMemberskye:A2014AmendedAndRestatedPlanMember2023-12-310001516551us-gaap:EmployeeStockOptionMemberskye:A2014AmendedAndRestatedPlanMember2024-01-012024-03-310001516551us-gaap:EmployeeStockOptionMemberskye:A2014AmendedAndRestatedPlanMember2024-01-012024-09-300001516551us-gaap:EmployeeStockOptionMemberskye:A2014AmendedAndRestatedPlanMember2024-09-300001516551us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001516551skye:MeasuredAtGrantDateMemberus-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-09-300001516551skye:MeasuredAtGrantDateMemberus-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300001516551 2024-01-012024-09-300001516551srt:MinimumMember2024-01-012024-09-300001516551srt:MaximumMember2024-01-012024-09-300001516551us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-09-300001516551us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-300001516551skye:MeasuredAtGrantDateMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001516551skye:MeasuredAtGrantDateMemberus-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-09-300001516551skye:MeasuredAtGrantDateMemberus-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-09-300001516551skye:MeasuredAtModificationDateMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001516551us-gaap:RestrictedStockUnitsRSUMember2023-12-310001516551us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001516551us-gaap:RestrictedStockUnitsRSUMember2024-09-300001516551us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001516551us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001516551us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001516551us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001516551us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001516551us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001516551us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001516551us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001516551us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001516551us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001516551us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001516551us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001516551us-gaap:ConvertibleDebtSecuritiesMember2024-07-012024-09-300001516551us-gaap:ConvertibleDebtSecuritiesMember2023-07-012023-09-300001516551us-gaap:ConvertibleDebtSecuritiesMember2024-01-012024-09-300001516551us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-09-300001516551us-gaap:WarrantMember2024-07-012024-09-300001516551us-gaap:WarrantMember2023-07-012023-09-300001516551us-gaap:WarrantMember2024-01-012024-09-300001516551us-gaap:WarrantMember2023-01-012023-09-300001516551us-gaap:ConvertibleDebtMember2024-07-012024-09-300001516551us-gaap:ConvertibleDebtMember2023-07-012023-09-300001516551us-gaap:ConvertibleDebtMember2024-01-012024-09-300001516551us-gaap:ConvertibleDebtMember2023-01-012023-09-300001516551skye:WendyCunningVsSkyeBioscienceIncMemberskye:EconomicDamagesMember2023-01-182023-01-180001516551skye:WendyCunningVsSkyeBioscienceIncMemberskye:NonEconomicDamagesMember2023-01-182023-01-180001516551skye:WendyCunningVsSkyeBioscienceIncMemberskye:PunitiveDamagesMember2023-01-182023-01-180001516551skye:WendyCunningVsSkyeBioscienceIncMember2023-08-022023-08-020001516551skye:WendyCunningVsSkyeBioscienceIncMemberskye:PunitiveDamagesMember2023-08-022023-08-020001516551skye:WendyCunningVsSkyeBioscienceIncMember2023-08-170001516551skye:A2014AmendedAndRestatedPlanMemberus-gaap:SubsequentEventMember2024-10-222024-10-220001516551skye:A2014AmendedAndRestatedPlanMemberus-gaap:SubsequentEventMember2024-10-220001516551skye:A2014AmendedAndRestatedPlanMemberus-gaap:SubsequentEventMember2024-10-012024-11-070001516551 2024-09-252024-09-250001516551 2024-09-25UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-Q(Mark One)â˜’Â Â Â Â QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30, 2024orâ˜Â Â Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission File Number: 000-55136Skye Bioscience, Inc._____(Exact name of registrant as specified in its charter)Nevada45-0692882(State or other jurisdictionof incorporation or organization)(I.R.S. EmployerIdentification No.)11250 El Camino Real, Suite 100, San Diego, CA 92130(Address of principal executive offices) (Zip Code)(858) 410-0266(Registrantâ€™s telephone number, including area code)_____N/A_____(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchangeon which registeredCommon Stock, par value $0.001SKYENasdaq Global MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Â â˜’ YesÂ Â Â Â â˜ NoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜’ YesÂ Â Â Â Â â˜ NoIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜’Smaller reporting companyâ˜’Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â â˜ Yes â˜’ NoAs of NovemberÂ 6, 2024, there were 30,338,290Â shares of the issuerâ€™s $0.001 par value common stock issued and outstanding.TABLE OF CONTENTSPART I - FINANCIAL INFORMATIONItem 1.Financial Statements:2Condensed Consolidated Balance Sheets as of SeptemberÂ 30, 2024 (Unaudited) and December 31, 20232Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 (Unaudited)4Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 (Unaudited)5Condensed Consolidated Statements of Stockholdersâ€™ Equity (Deficit) for the Three and Nine Months Ended September 30, 2024 and 2023 (Unaudited)7Notes to the Unaudited Condensed Consolidated Financial Statements9Item 2.Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures about Market Risk30Item 4.Controls and Procedures30PART II - OTHER INFORMATIONItem 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities and Use of Proceeds31Item 3.Defaults Upon Senior Securities31Item 4.Mine Safety Disclosures31Item 5.Other Information31Item 6.Exhibits31PART I - FINANCIAL INFORMATIONItem 1. Financial Statements2SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETSSeptember 30,2024December 31,2023(Unaudited)ASSETSCurrent assetsCash and cash equivalents $67,412,614Â $1,256,453Â Restricted cash9,080,202Â 9,080,202Â Prepaid expenses664,604Â 194,259Â Other current assets2,650,809Â 1,119,929Â Total current assets79,808,229Â 11,650,843Â Property and equipment, net1,516,612Â 43,276Â Operating lease right-of-use asset184,509Â 237,983Â Other assets26,310Â 8,309Â Total assets$81,535,660Â $11,940,411Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY (DEFICIT)Current liabilitiesAccounts payable$780,025Â $1,155,785Â Accrued interest - related partyâ€”Â 126,027Â Accrued payroll liabilities903,271Â 888,381Â Accrued interest - legal contingencyâ€”Â 234,750Â Other current liabilities2,065,658Â 998,552Â Estimate for accrued legal contingencies and related expenses1,792,337Â 6,053,468Â Convertible note - related party, net of discountâ€”Â 4,371,998Â Operating lease liability, current portion82,932Â 72,038Â Total current liabilities5,624,223Â 13,900,999Â Non-current liabilitiesOperating lease liability, net of current portion108,062Â 171,230Â Total liabilities5,732,285Â 14,072,229Â Commitments and contingencies (Note 9)Stockholdersâ€™ equity (deficit)Preferred stock, $0.001 par value; 200,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; no shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023â€”Â â€”Â Common stock,

$0.001 par value; 100,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 30,338,290 and 12,349,243 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively30,338Â 12,349Â Additional paid-in-capital196,976,230Â 102,238,382Â Accumulated deficit(121,203,193)(104,382,549)Total stockholdersâ€™ equity (deficit)75,803,375Â (2,131,818)Total liabilities and stockholdersâ€™ equity (deficit)$81,535,660Â $11,940,411Â See accompanying notes to the unaudited condensed consolidated financial statements.3SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)For the Three Months EndedSeptember 30,For the For the Nine Months EndedSeptember 30,20242023202420232023Operating expensesResearch and development$4,883,337Â $1,254,653Â $10,908,538Â $4,227,967Â Cost to acquire IPR&D assetâ€”Â 21,215,214Â â€”Â 21,215,214Â General and administrative4,638,927Â 2,235,899Â 13,171,547Â 5,357,577Â Change in estimate for legal contingencies(4,553,468)â€”Â (4,553,468)(151,842)Total operating expenses4,968,796Â 24,705,766Â 19,526,617Â 30,648,916Â Operating loss(4,968,796)(24,705,766)(19,526,617)(30,648,916)Other (income) expenseInterest (income) expense(90,766)271,307Â 796,222Â 476,135Â Interest income(907,697)(16,562)(2,296,488)(49,669)(Gain) loss from asset sales(72,837)â€”Â (1,217,978)307,086Â Debt conversion inducement expenseâ€”Â â€”Â â€”Â 1,383,285Â Wind-down costsâ€”Â (14,677)â€”Â 455,504Â Other expense (income)801Â â€”Â 2,200Â (3)Total other (income) expense, net(1,070,499)240,068Â (2,716,044)2,572,338Â Loss before income taxes(3,898,297)(24,945,834)(16,810,573)(33,221,254)Â Provision for income taxes â€”Â â€”Â 10,071Â 3,600Â Net loss$(3,898,297)$(24,945,834)$(16,820,644)$(33,224,854)Loss per common share:Basic$(0.10)$(3.17)$(0.48)$(6.38)Diluted$(0.10)$(3.17)$(0.48)$(6.38)Weighted average shares of common stock outstanding used to compute earnings per share:Basic38,819,387Â 7,880,546Â 35,317,352Â 5,207,411Â Diluted38,819,387Â 7,880,546Â 35,317,352Â 5,207,411Â See accompanying notes to the unaudited condensed consolidated financial statements.4SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)For the Nine Months EndedSeptember 30,20242023Cash flows from operating activities:Net loss$(16,820,644)$(33,224,854)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization123,347Â 95,880Â Stock-based compensation expense6,228,270Â 394,657Â Change in fair value of derivative liabilitiesâ€”Â (3)Amortization of debt discount599,006Â 102,400Â Write-down of vendor deposits325,610Â â€”Â Change in estimate for legal contingencies(4,553,468)7,009Â (Gain) loss from divestiture of assets(1,217,978)307,086Â Loss from disposal of assets10,794Â â€”Â Debt conversion inducement expenseâ€”Â 1,383,285Â Accrued interest conversion expenseâ€”Â 15,952Â Cost to acquire IPR&D assetâ€”Â 21,215,214Â Foreign currency remeasurement gainâ€”Â (45,350)Changes in assets and liabilities:Prepaid expenses(470,345)782,265Â Other current assets(1,606,490)(236,779)Other assets(18,000)â€”Â Accounts payable(375,760)(112,021)Accounts payable - related partiesâ€”Â (113,601)Accrued interest - related party(126,027)60,274Â Accrued interest - legal contingency(234,750)â€”Â Accrued payroll liabilities14,889Â (11,904)Operating lease liability(52,274)(60,647)Other current liabilities1,109,443Â (570,473)Other current liabilities - related partiesâ€”Â (95,850)Net cash used in operating activities(17,064,377)(10,107,460)Cash flows from investing activities:Proceeds from the sale of assets, net of sales costs1,217,978Â 5,532,266Â Purchase of property and equipment(1,554,003)(5,533)Cash from asset acquisition, net of transaction costsâ€”Â 1,076,740Â Net cash (used in) provided by investing activities(336,025)6,603,473Â Cash flows from financing activities:Proceeds from convertible note - related partyâ€”Â 4,973,684Â Proceeds from the issuance of common stock and warrants, net of equity issuance costs of $6,434,447 and $265,053, respectively 83,556,563Â 11,734,947Â Financing costs allocated to warrants issued with convertible debtâ€”Â (6,026)Repayment of insurance premium loan payableâ€”Â (236,681)Net cash provided by financing activities83,556,563Â 16,465,924Â Net increase in cash and restricted cash66,156,161Â 12,961,937Â Cash, cash equivalents and restricted cash, beginning of period$10,336,655Â $1,249,107Â Cash, cash equivalents and restricted cash, end of period$76,492,816Â $14,211,044Â Supplemental disclosures of cash-flow information:Reconciliation of cash, cash equivalents and restricted cash:5Cash, and cash equivalents$67,412,614Â $5,126,245Â Restricted cash9,080,202Â 9,084,799Â Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows$76,492,816Â $14,211,044Â Supplemental disclosures of non-cash financing activities:Common stock warrant exercises$â€”Â $282,905Â Conversion of multi-draw credit agreementâ€”Â 1,565,470Â Conversion of accrued interest due to related partyâ€”Â 31,766Â Financing of insurance premiumâ€”Â 203,884Â Right of use asset obtained in exchange for operating lease liabilitiesâ€”Â 241,134Â Stock issued for assetsâ€”Â 20,532,846Â Conversion of convertible note - related party to common stock4,971,004Â â€”Â See accompanying notes to the unaudited condensed consolidated financial statements.6SKYE BIOSCIENCE, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (DEFICIT)(UNAUDITED)Common StockAdditionalPaid-InCapitalAccumulatedDeficitTotalStockholdersâ€™Equity/(Deficit)SharesAmountsBalance, January 1, 202412,349,243Â $12,349Â $102,238,382Â $(104,382,549)$(2,131,818)Stock-based compensation expenseâ€”Â â€”Â 2,478,179Â â€”Â 2,478,179Â Issuance of common stock and warrants, net of issuance costs of $6,434,44715,713,664Â 15,714Â 83,540,849Â â€”Â 83,556,563Â Net loss â€”Â â€”Â â€”Â (5,019,531)(5,019,531)Balance, March 31, 202428,062,907Â $28,063Â $188,257,410Â $(109,402,080)$78,883,393Â Stock-based compensation expense 5,000Â 5Â 1,828,469Â â€”Â 1,828,474Â Net loss â€”Â â€”Â â€”Â (7,902,816)(7,902,816)Balance, June 30, 202428,067,907Â $28,068Â $190,085,879Â $(117,304,896)$72,809,051Â Stock-based compensation expenseâ€”Â â€”Â 1,921,617Â â€”Â 1,921,617Â Conversion of convertible note - related party968,973Â 969Â 4,970,035Â â€”Â 4,971,004Â Exercise of pre-funded warrants1,301,410Â 1,301Â (1,301)â€”Â â€”Â Net lossâ€”Â â€”Â â€”Â (3,898,297)(3,898,297)Balance, September 30, 202430,338,290Â $30,338Â $196,976,230Â $(121,203,193)$75,803,375Â 7Common StockAdditionalPaid-InCapitalAccumulatedDeficitTotalStockholdersâ€™(Deficit)SharesAmountsBalance, January 1, 20233,654,119Â $3,654Â $63,726,057Â $(66,737,765)$(3,008,054)Stock-based compensation expenseâ€”Â â€”Â 131,579Â â€”Â 131,579Â Exercise of common stock warrants66,566Â 66Â 282,839Â â€”Â 282,905Â Conversion of multi-draw credit agreement - related party and accrued interest165,517Â 166Â 2,980,355Â â€”Â 2,980,521Â Net loss â€”Â â€”Â â€”Â (5,167,520)(5,167,520)Balance, March 31, 20233,886,202Â $3,886Â $67,120,830Â $(71,905,285)$(4,780,569)Stock-based compensation expenseâ€”Â â€”Â 102,871Â â€”Â 102,871Â Net loss â€”Â â€”Â â€”Â (3,111,500)(3,111,500)Balance, June 30, 20233,886,202Â $3,886Â $67,223,701Â $(75,016,785)$(7,789,198)Stock-based compensation expense â€”Â â€”Â 160,207Â â€”Â 160,207Â PIPE financing, net of equity issuance costs of 265,0532,989,981Â 2,990Â 11,731,957Â â€”Â 11,734,947Â Common stock issued in acquisition of IPR&D asset5,436,378Â 5,436Â 21,604,150Â â€”Â 21,609,586Â Warrants issued with convertible noteâ€”Â â€”Â 925,550Â â€”Â 925,550Â Common stock issued for fractional share adjustment in reverse stock split26,349Â 26Â (26)â€”Â â€”Â Net loss â€”Â â€”Â â€”Â (24,945,834)(24,945,834)Balance, September 30, 202312,338,910Â $12,338Â $101,645,539Â $(99,962,619)$1,695,258Â See accompanying notes to the unaudited condensed consolidated financial statements.8SKYE BIOSCIENCE, INC. AND SUBSIDIARIESNOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)1. Organization, Basis of Presentation and Significant Accounting PoliciesNature of OperationsSkye Bioscience, Inc. (the â€œCompanyâ€ or â€œSkyeâ€) was incorporated in Nevada on March 16, 2011. The Company is a clinical stage biopharmaceutical company developing next-generation molecules that modulate G protein-coupled receptors to treat obesity and metabolic diseases. As of SeptemberÂ 30, 2024, the Company has devoted substantially all its efforts to securing its product pipeline, carrying out its own research and development, preparing for and conducting clinical trials, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.Basis of PresentationThe accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods. The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, from which the prior year balance sheet information herein was derived. Certain reclassifications have been made to the amounts in prior periods to conform to the current periodâ€™s presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's condensed balance sheet, and condensed statement of cash flows and change in fair value of derivative liability and interest expense on the condensed statement of operations. Such reclassifications did not have a material impact on the Unaudited Condensed Consolidated Financial Statements.During the nine months ended September 30, 2024, there were no changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.Pronouncements ImplementedIn August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entityâ€™s Own Equity (Subtopic 815-40). The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entityâ€™s own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. This standard was effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted this standard as of January 1, 2024 and the adoption of this standard did not have an impact on the Company's Unaudited Condensed Consolidated Financial Statements or related disclosures. Recent Accounting Pronouncements Not Yet AdoptedIn December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entityâ€™s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company does not expect the impact of adopting ASU 2023-09 to be material on its consolidated financial statements.9In November 2023, the Financial Account Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2023-07 to be material on its consolidated financial statements.2. Asset Acquisitions and DispositionsSale of real estateThe wind down of Emerald Health Therapeutics, Inc. ("EHT's") operations included the disposition of real estate held by Avalite Sciences, Inc. ("AVI") (the "AVI building"). At the time of the Companyâ€™s acquisition of EHT on November 10, 2022 (the â€œEHT Acquisitionâ€), none of the purchase consideration was allocated to the fair value of the AVI building. As a result of the sale of the AVI building, for the nine months ended September 30, 2024, the Company recorded a gain of $1,145,141 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations.Divestiture of VDL, Release and Discharge AgreementOn February 9, 2023, the Company sold VerdÃ©lite Sciences, Inc. ("VDL"). For the nine months ended September 30, 2023, the Company has recorded a loss on sale of asset of $307,086 in other (income) expense based on the difference between the carrying amount of the assets sold and the net cash proceeds. On July 17, 2024, the Company reached a transaction, release and discharge agreement with the purchaser of VDL. Under the transaction, release and discharge agreement, the purchase price of VDL was adjusted in exchange for a full release of any future claims by VDL against the Company. As part of the agreement, the parties agreed to an installment payment schedule for the remaining aggregate balance of the purchase price of $2,047,080 through December 2027. The remainder of the purchase price receivable bears interest at 8%. Upon signing the transaction, release and discharge agreement, the Company received the first installment payment of $72,837 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations.BRB AcquisitionOn AugustÂ 18, 2023, the Company acquired 100% of the equity interests in Bird Rock Bio Sub, Inc. ("BRB") pursuant to an Agreement and Plan of Merger and Reorganization, dated August 15, 2023 (the "BRB Acquisition"). The purpose of the acquisition was to acquire BRB's clinical asset, nimacimab, an antibody targeting the CB1 receptor, for development to treat metabolic conditions. Pursuant to the BRB Acquisition, the Company issued 3,872,184 shares of Company common stock to the former preferred stockholders of BRB equal to $20,000,000 in base merger consideration priced at $5.16.In addition, the former preferred stockholders of BRB were entitled to additional merger consideration for each dollar invested in a concurrent private investment in public equity transaction (the "2023 PIPE Financing"). Because the 2023 PIPE Financing and BRB Acquisition occurred contemporaneously and in contemplation of each other, in accounting for the transaction, the Company allocated the shares issued as additional merger consideration between the BRB Acquisition and 2023 PIPE Financing using a residual allocation method, whereby the fair value of the consideration transferred was first allocated to the monetary assets and 2023 PIPE Financing proceeds with the remainder allocated to the in-process research and development (" IPR&D") asset, nimacimab. As a result, 1,564,194 additional shares of common stock were allocated to the BRB Acquisition. 10Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: August 18, 2023Purchase considerationCommon stock$21,609,586Â (a)Total consideration$21,609,586Â Assets acquired and liabilities assumed:IPR&D asset$21,215,214Â Cash and cash equivalents1,076,740Â Prepaid expenses4,800Â Accounts payable(73,473)Other current liabilities(613,695)Total net assets acquired$21,609,586Â (a) Equal to the aggregate of 5,436,378 shares of common stock issued, multiplied by the Company's closing stock price of $3.98 as of AugustÂ 18, 2023.The cost to acquire the IPR&D asset, nimacimab, was expensed on the date of the BRB Acquisition as it was determined to have no future alternative use. Accordingly, costs associated with the BRB Acquisition to acquire the asset were expensed as incurred. 113. Property and Equipment, Prepaid Expenses, Other Current Assets and LiabilitiesProperty and equipment, net consists of the following:As of September 30, 2024As of December 31, 2023Machinery and equipment$1,527,419Â $78,024Â Computer equipment74,868Â 46,732Â Leasehold improvements13,954Â 13,954Â Â Â Total property and equipment, gross1,616,241Â 138,710Â Less: accumulated depreciation(99,629)(95,434)Â Total property and equipment, net$1,516,612Â $43,276Â Depreciation expense for the three and nine months ended September 30, 2024 was $47,519 and $69,873, respectively. Depreciation expense for the three and nine months ended Sepember 30, 2023 was $12,788 and $38,107, respectively.Prepaid expenses consist of the following:As of September 30, 2024As of December 31, 2023Clinical expenses$64,878Â $61,352Â Financial advisory service agreement284,170Â â€”Â Other prepaid expenses315,556Â 132,907Â $664,604Â $194,259Â Other current assets consist of the following:Â As of September 30, 2024As of December 31, 2023AusIndustry incentive$9,033Â $540,604Â Vendor deposits2,216,427Â 403,439Â Other tax receivables3,678Â 158,242Â Other current assets421,671Â 17,644Â $2,650,809Â $1,119,929Â Other current liabilities consist of the following:Â As of September 30, 2024As of December 31, 2023Research and development costs $1,220,041Â $467,784Â Legal fees370,359Â 258,213Â EHT Acquisition related liabilitiesâ€”Â 180,897Â Professional and consulting fees410,512Â 69,468Â Other accrued liabilities64,746Â 22,190Â Â $2,065,658Â $998,552Â 124. Warrants There are significant judgements and estimates inherent in the determination of the fair value of the Companyâ€™s warrants. These judgements and estimates include assumptions regarding the Companyâ€™s future operating performance and the determination of the appropriate valuation methods. WarrantsWarrants vested and outstanding as of SeptemberÂ 30, 2024 are summarized as follows:SourceExercisePriceWeightedAverageRemainingContractualTerm(Years)Number ofWarrantsOutstanding2015 Common Stock Warrants$1,250.00Â 0.56400Â 2016 Common Stock Warrants to Service Providers287.50Â 2.08160Â 2019 Common Stock Warrants87.50Â 0.1432,000Â 2020 Common Stock Warrants to Placement Agent20.00Â 0.8332,668Â 2021 Inducement Warrants37.50Â 1.8184,667Â 2021 Inducement Warrants to Placement Agent47.00Â 1.815,927Â 2021 Common Stock Warrants22.50Â 1.99311,113Â 2021 Common Stock Warrants to

Placement Agent27.50Â 1.9921,778Â November 2019 EHT Common Stock Warrants72.25Â 0.1634,213Â December 2019 EHT Common Stock Warrants37.25Â 0.243,783Â February 2020 EHT Common Stock Warrants37.25Â 0.3580,694Â August 2023 Convertible Note Common Stock Warrants5.16Â 8.88340,000Â August 2023 PIPE Financing Common Stock Warrants5.16Â 8.882,325,537Â January 2024 Pre-Funded Warrants Common Stock 0.001Â Indefinite8,677,166Â Total warrants outstanding as of September 30, 202411,950,106Â As of SeptemberÂ 30, 2024, all of the Company's warrants are fully vested.January 2024 Pre-Funded Warrants In connection with the January 2024 PIPE Financing (as defined below), the Company issued the Pre-Funded Warrants (as defined below) (See Note 6). The Pre-Funded Warrants have an exercise price of $0.001 per share, and were exercisable immediately upon issuance until exercised in full. The gross proceeds from the issuance of these Pre-Funded Warrants was $22,991,015. The Company determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability or derivative. The Pre-Funded Warrants are indexed to the Companyâ€™s common stock and meets all other conditions for equity classification. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time issued. The Company also determined that the Pre-Funded Warrants should be included in the determination of basic and diluted earnings per share. `5. DebtThe Companyâ€™s convertible debt consists of the following:As of December 31, 2023Total principal value of convertible note - related party, net of discount$5,000,000Â Unamortized debt discount(610,749)Unamortized debt issuance costs(17,253)Carrying value of total convertible debt - related party$4,371,998Â 13Convertible Note - Related PartyOn AugustÂ 15, 2023, the Company entered into a secured note and warrant purchase agreement (the "Secured Note and Warrant Purchase Agreement") with MFDI, LLC (â€œMFDIâ€), pursuant to which the Company issued to MFDI a $5,000,000 secured convertible promissory note (the "Convertible Note") and a warrant to purchase 340,000 shares of common stock on AugustÂ 18, 2023 (the "Convertible Note Financing") (See Note 4). The Convertible Note had an interest rate of 10% per annum and had a fixed conversion rate of $5.16. On August 8, 2024, MFDI exercised the conversion option under the Convertible Note and converted the full principal balance of $5,000,000 under the Convertible Note. This conversion resulted in the issuance of 968,973 shares of the Company's common stock and the payment of accrued interest in cash, thereby fully satisfying the Company's debt obligations to MFDI. Accrued interest was payable quarterly within 30 days of the last day of each calendar quarter. The debt discounts related to the warrants, and debt issuance costs, were amortized over the term of the Convertible Note using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense in Other (income) expense within the Consolidated Statements of Operations. Through the date of conversion, the Convertible Note is classified as Level 2 of the fair value hierarchy model based on market prices that can be corroborated with observable market data for the Company's common stock. For the three and nine months ended September 30, 2024, the effective interest rate on the Convertible Note was 31.39%. Interest Expense (Income)The Companyâ€™s interest expense consists of the following:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Related party interest expense â€“ stated rate$53,425Â $60,274Â $302,741Â $76,227Â Insurance premium loan payable â€“ stated rateâ€”Â 2,162Â â€”Â 5,764Â Legal judgment interest (income) expense(384,897)(23,320)(234,751)158,851Â Bond premium59,929Â 59,930Â 59,929Â 59,930Â Premium on irrevocable letter of credit 69,297Â 69,861Â 69,297Â 69,861Â Other interest expenseâ€”Â â€”Â â€”Â 3,102Â Non-cash interest expense:Amortization of debt discount108,417Â 99,587Â 582,550Â 99,587Â Amortization of transaction costs3,063Â 2,813Â 16,456Â 2,813Â $(90,766)$271,307Â $796,222Â $476,135Â 6. Stockholdersâ€™ Equity and CapitalizationPIPE FinancingsJanuary 2024 PIPE FinancingOn JanuaryÂ 29, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on JanuaryÂ 31, 2024, the Company issued an aggregate of 11,713,664 shares of common stock and 9,978,739 pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 9,978,739 shares of common stock (the "January 2024 PIPE Financing") for an aggregate purchase price of $49,991,010. The January 2024 PIPE Financing was priced at $2.31 per common share and $2.30 per Pre-Funded Warrant based on the 5-day average share price preceding January 29, 2024. The Pre-Funded Warrants are exercisable at any time for an exercise price of $0.001. In connection with the January 2024 PIPE Financing, the Company incurred $3,823,752 in direct equity issuance costs for net proceeds of $46,167,258.March 2024 PIPE FinancingOn MarchÂ 11, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on MarchÂ 13, 2024, the Company issued an aggregate of 4,000,000 shares of common stock (the "March 2024 PIPE Financing") for an aggregate purchase price of $40,000,000. The March 2024 PIPE Financing was priced at $10.00 per common share.14In connection with the March 2024 PIPE Financing, the Company incurred $2,610,695 in direct equity issuance costs for net proceeds of approximately $37,389,305.Prefunded Warrant ExerciseOn July 1, 2024, 1,301,573 pre-funded warrants issued in the January 2024 PIPE Financing with an intrinsic value of $10,424,294 were exercised on a cashless basis, resulting in the issuance of 1,301,410 shares of Company's common stock. Conversion of DebtOn August 8, 2024, the Company issued 968,973 shares of common stock to MFDI upon conversion in full of the Convertible Note (see Note 5).7. Stock-Based CompensationStock Incentive PlanOn October 31, 2014, the Board of Directors of the Company ("Board") approved the Companyâ€™s 2014 Omnibus Incentive Plan. On June 14, 2022, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (as amended, the â€œ2014 Amended and Restated Planâ€) which replaced the 2014 Omnibus Incentive Plan in its entirety.On September 29, 2023, the Board and holders of the voting power of the outstanding capital stock of the Company adopted and approved Amendment No. 1 to the 2014 Amended and Restated Plan. Amendment No. 1 to the 2014 Amended and the Restated Plan became effective on November 6, 2023. As of SeptemberÂ 30, 2024, 2,464,345 shares were authorized for the issuance under the 2014 Amended and Restated Plan. As of SeptemberÂ 30, 2024, the Company had 27,578 shares available for future grant under the 2014 Amended and Restated Plan.2024 Inducement Equity Incentive Plan On July 2, 2024, the Board adopted the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). The Inducement Plan was adopted in order to grant share-based awards to newly hired employees as an inducement to join the Company. The terms of the Inducement Plan are substantially similar to the terms of the Companyâ€™s 2014 Amended and Restated Plan with the exception that awards may only be made to an employee who has not previously been an employee or member of the Board of Directors of the Company if the award is in connection with commencement of employment. The Company has reserved 600,000 shares of the Companyâ€™s common stock for issuance pursuant to awards granted under the Inducement Plan. As of SeptemberÂ 30, 2024, the Company had 246,500 shares available for future grant under the Inducement Plan. Stock OptionsThe following is a summary of option activity under the Companyâ€™s 2014 Amended and Restated Plan and the Inducement Plan, for the nine months ended SeptemberÂ 30, 2024:Number ofSharesWeightedAverageExercise PriceWeightedAverageRemainingContractualTerm (Years)Aggregate Intrinsic Value*Outstanding, December 31, 2023498,298Â $8.96Â 7.24$20,441Â Granted1,259,600Â 11.35Â Cancelled(10,048)126.76Â Forfeited(108,496)9.22Â Outstanding, September 30, 20241,639,354Â $10.05Â 8.33$158,794Â Exercisable, September 30, 2024519,839Â $11.36Â 5.76$71,783Â *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Companyâ€™s stock exceeded the exercise price of the stock options at SeptemberÂ 30, 2024 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options").The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2024, was $8.82. 15The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor81.73% - 99.96%Risk-free interest rate3.69% - 4.48%Expected term (years)5.27 - 6.08Restricted Stock UnitsOn February 29, 2024, the Company granted restricted stock units ("RSUs") to its executive management team and to certain members of the Board with market-based vesting conditions. The RSUs are eligible to vest subject to the achievement and attainment of certain market capitalization target goals and share price targets (market-based vesting conditions). The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market and performance conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions: Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor93.71%Risk-free interest rate4.16%Derived service periods (years)1.27 - 2.48On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor94.3%Risk-free interest rate3.76%Derived service periods (years)2.1116 The following is a summary of RSU activity during the period ended SeptemberÂ 30, 2024:Number ofSharesWeighted Average Grant Date Fair ValueUnvested, December 31, 2023847,777Â $3.66Â Granted290,000Â 13.87Â Unvested, September 30, 20241,137,777Â $6.26Â Common Stock Issued for ServicesAdditionally, during the nine months ended SeptemberÂ 30, 2024, the Company issued 5,000 shares of common stock to a service provider as compensation for services provided. Such shares were issued in a private placement outside of the Company's equity incentive plans.Stock-Based Compensation ExpenseThe Company recognizes stock-based compensation expense using the straight-line method over the requisite service period or derived service period. The Company recognized stock-based compensation expense for the stock options and the RSUs discussed above, in its Unaudited Condensed Consolidated Statements of Operations as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Research and development$360,845Â $33,724Â $1,056,564Â $90,725Â General and administrative1,560,772Â 126,483Â 5,171,706Â 303,932Â $1,921,617Â $160,207Â $6,228,270Â $394,657Â During the nine months ended SeptemberÂ 30, 2024, the first three market-based vesting conditions of the RSUs granted in August and September 2023 were met.Stock Compensation Adjustments Related to Board Member ResignationsOn July 2, 2024, the Board accepted the resignations of several Board members effective August 1, 2024. Concurrently, the Board approved a modification to the option awards granted such Board members, which modification accelerated the vesting of all unvested options as of the resignation date and extended the post-termination exercise period to December 31, 2025. As a result of the modification, the Company recognized $274,019 in incremental stock compensation expense during the three and nine months ended SeptemberÂ 30, 2024.The total amount of unrecognized compensation cost was $11,758,346 as of SeptemberÂ 30, 2024. This amount will be recognized over a weighted average period of 2.61 years. 178. Loss Per Share of Common StockThe following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)2024202320242023Basic EPS and diluted EPS:Loss (Numerator)Net loss$(3,898,297)$(24,945,834)$(16,820,644)$(33,224,854)Shares (Denominator)Weighted average common shares outstanding, including shares issuable upon the exercise of pre-funded warrants38,819,387Â 7,880,546Â 35,317,352Â 5,207,411Â Per-Share Amount$(0.10)$(3.17)$(0.48)$(6.38)The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)2024202320242023Stock options1,639,354Â 442,803Â 1,639,354Â 442,803Â Warrants3,272,940Â 3,280,940Â 3,272,940Â 3,280,940Â Unvested restricted stock units513,446Â 843,110Â 513,446Â 843,110Â Common shares underlying convertible debtâ€”Â 980,673Â â€”Â 980,673Â 9. Contingencies General Litigation and DisputesFrom time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Companyâ€™s operations or financial position, liquidity or results of operations.Wendy Cunning vs Skye Bioscience, Inc.The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The case, entitled Wendy Cunning vs Skye Bioscience, Inc., was filed in U.S. District Court (the "District Court") for the Central District of California (the â€œCunning Lawsuitâ€). On January 18, 2023, a jury rendered a verdict in favor of Ms. Cunning and awarded her $512,500 in economic damages (e.g., lost earnings, future earnings and interest), $840,960 in non-economic damages (e.g., emotional distress) and $3,500,000 in punitive damages. On August 2, 2023, the District Court ruled on the plaintiff's motion for attorney fees and awarded the plaintiff $1,200,008. Based on this order, the Company reduced the aggregate estimate for the legal contingency by $151,842, the difference between the attorney fees awarded by the District Court and the Company's previous estimate. On August 17, 2023, the Company obtained a stay on enforcement of the judgment in the Cunning Lawsuit by posting an appeal bond in the amount of $9,080,202. 18In March of 2023, the Company appealed the judgment in the Cunning Lawsuit to the United States Court of Appeals for the Ninth District (the "Ninth Circuit"). Subsequent to quarter end, on October 22, 2024, the Ninth Circuit issued its decision in the Company's favor which vacated the judgment and remanded the case back to the District Court for a new trial. As a result, the Company will be able to recover the $9,080,202 restriction on its cash related to the bond. Skye Bioscience, Inc. vs Partner Re Ireland InsuranceIn February 2023, the Company brought a suit against the Company's D&O insurance carrier, Partner Re Ireland Insurance DAC ("Partner Re"), bringing claims for (a) breach of contract, (2) tortious breach of the implied covenant of good faith and fair dealing and (3) declaratory relief that Partner Re is obligated to reimburse the Company for the defense fees and costs incurred in defense of the Cunning Lawsuit and must indemnify the Company for any settlement or judgment in the Cunning Lawsuit (the "Partner Re Lawsuit"). The Company's allegations arise out of Partner Re's refusal to reimburse the Company for costs incurred by the Company in defending the Cunning Lawsuit. The case, entitled Skye Bioscience, Inc., v. Partner Re Ireland Insurance DAC, was filed in the United Stated District Court for the Central District of California. On April 17, 2023, Partner Re filed a motion to dismiss the Company's complaint. On June 20, 2023, the court issued a ruling in favor of the Company and denied Partner Re's motion to dismiss the Company's lawsuit. In April 2024, the Company filed a motion for judgment on the pleadings. In June of 2024, the court granted in part and denied in part the Company's motion for judgment on the pleadings. The court granted the Company's motion for judgment on the pleadings with respect to Partner Re's affirmative defense related to whether the Cunning Lawsuit constituted a â€œSecurities Claimâ€ as defined in the Partner Re policy, rejecting what had been Partner Re's primary basis for denying coverage.The Company is pursuing up to $5,000,000 in coverage less the deductible to cover legal expenses incurred and any potential loss incurred from the Cunning Lawsuit. Estimate for accrued legal contingencies and related expensesFollowing the Ninth Circuit's favorable decision and the Company's mediation efforts with PartnerRe, a change in estimate for legal contingencies was recorded. As of SeptemberÂ 30, 2024, the Company has reversed the accrued interest on the original judgment and adjusted its potential loss for accrued legal contingencies and related expenses, which includes legal accruals and all other costs related to its ongoing litigation matters. Management uses significant judgment in developing its estimates related to legal contingencies and loss recoveries. These adjustments are based on the evaluation of case history, mediation efforts, the facts of the cases and take into consideration both future potential judgment amounts, damages and potential attorney fee awards if the cases were to be retried. The final amount of the loss and loss recoveries remain uncertain. The ultimate amount of the potential loss may be significantly less than the amount of the revised legal contingency and there is no guarantee that the Company will be successful in its efforts to recover additional losses. The Company believes that it is at least reasonably possible that the estimated amount of the potential loss may change in the near term.10. Subsequent EventsApproval of Amended and Restated Omnibus Incentive Plan On October 22, 2024, the Company's stockholders voted to approve the second amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares of the Company's common stock issuable thereunder by 1,535,655 to increase the number of incentive stock options that may be granted thereunder to 4,000,000, extend the expiration date of the plan to September 10, 2034, update the name of the plan to the â€œSkye Bioscience, Inc. Amended and Restated Omnibus Incentive Planâ€ and make certain administrative amendments (as so amended and restated, the "Amended and Restated Plan"). Stock Option GrantsSubsequent to SeptemberÂ 30, 2024, the Company granted an aggregate of 1,456,400 common stock options to members of management, employees and directors under the Amended and Restated Plan. San Francisco Office LeaseOn September 25, 2024, the Company entered into a new lease agreement for approximately 2,077 square feet of office space located at 632 Commercial Street, 5th Floor, San Francisco, California 94111. The

lease has a term of three years and two months, beginning on October 1, 2024, with a monthly rent of $9,000 and annual increases of 3%. This office space will support our continued growth and operational needs as we expand our development activities. No material changes to our financial position are anticipated as a result of this lease. 19Legal ContingenciesSee Note 9 for disclosure of the recognized subsequent event related to our estimate for legal contingencies.20Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements (unaudited) for the three and nine months ended September 30, 2024 and 2023, together with the notes thereto and the consolidated financial statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under â€œRisk Factorsâ€ and elsewhere in this Quarterly Report on Form 10-Q.SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSStatements in this Quarterly Report on Form 10-Q contain forward-looking statements that are based on managementâ€™s current expectations and assumptions and information currently available to management and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially and negatively affected. In some cases, you can identify forward-looking statements by terminology including â€œanticipates,â€ â€œbelieves,â€ â€œcan,â€ â€œcontinue,â€ â€œcould,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œplans,â€ â€œpotential,â€ â€œpredicts,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section below titled â€œRisk Factors,â€ including, without limitation, risks relating to:Â â€¢the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our current product candidate, nimacimabÍ¾â€¢the translation of our preclinical results and data and early clinical trial results in particular relating to safety, efficacy and durability into future clinical trials in humans;â€¢the timing, progress and results of our clinical trial for nimacimab and our estimates regarding the market opportunity for nimacimab if approved; â€¢the early stage of our product candidate presently under development;â€¢our ability to obtain and, if obtained, maintain regulatory approval of our current product candidate, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidateÍ¾â€¢our ability to retain or hire key scientific or management personnelÍ¾â€¢our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rightsÍ¾â€¢our dependence on third party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators, including global supply chain disruptionsÍ¾â€¢our ability to develop successful sales and marketing capabilities in the future as neededÍ¾â€¢the size and growth of the potential markets for our current product candidate, nimacimab, and any of our future product candidates, and the rate and degree of market acceptance of our current product candidate and any of our future product candidatesÍ¾â€¢our competitive position and the development of competing therapies that are or may become availableÍ¾â€¢regulatory developments in the United States and foreign countries; andâ€¢current pending litigation matters, including the Cunning Lawsuit.21We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, including the current global economic environment, the impacts of the high inflationary environment, and associated business disruptions such as delayed clinical trials, laboratory resources and supply chain limitations, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.Unless otherwise provided in this Quarterly Report on Form 10-Q, references to â€œwe,â€ â€œus,â€ â€œourâ€ and â€œSkyeâ€ in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation, together with its wholly owned subsidiaries, Nemus, a California corporation, SKYE Bioscience Pty Ltd ("SKYE Bioscience Australia"), an Australian proprietary limited company, Emerald Health Therapeutics, Inc. ("EHT") a corporation governed by the Business Corporations Act (British Columbia), Bird Rock Bio Sub, Inc. ("BRB"), a Delaware corporation and Ruiyi Acquisition Corp, a Delaware corporation. OverviewWe are a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein-coupled receptors ("GPCRs"). GPCRs regulate diverse physiological and pathological processes, particularly those that maintain metabolic homeostasis. Therapeutics that target these GPCR-associated pathways may represent novel approaches to address metabolic disorders.Our product candidate, nimacimab, is a peripherally-restricted negative allosteric modulating antibody specific for the human CB1 receptor (CB1), administered as a subcutaneous injectable initially for the treatment of obesity. During the three months ended September 30, 2024, we commenced our Phase 2 clinical trial, CBeyondTM, for nimacimab. The CBeyondTM clinical trial includes 120 patients, 18 clinical trial sites and an exploratory combination arm with a GLP-1 agonist to assess differences in weight loss, body composition, and other attributes. The CBeyondTM clinical trial continues to enroll patients and we expect to meet our goal of 50% enrollment by the end of 2024. We expect to provide interim and topline data in the second and fourth quarters of 2025, respectively. This CBeyondTM clinical trial's primary endpoint is to evaluate weight loss using nimacimab compared to placebo. Secondary endpoints include evaluations of safety and tolerability, neuropsychiatric and cognitive evaluation, change in body composition by Dual-Energy X-ray Absorptiometry (DEXA), and changes in key metabolic biomarkers such as triglycerides, and insulin and leptin sensitivity. We believe that nimacimab has competitive advantages that differentiate it within the CB1 inhibitor class. First, as a monoclonal antibody, it is a large molecule that has great difficulty crossing the blood-brain barrier and restricts its engagement to CB1 receptors present in tissue/organs within the periphery of the body (i.e., outside the brain). Second, it is a negative allosteric modulator, a unique binding mechanism compared to small-molecule CB1 inhibitors, which may confer advantages in terms of its therapeutic index. Our antibody-based CB1 inhibitor shares many of the characteristics of small molecule inverse agonists by targeting CB1 receptors in adipose tissue to directly increase fat metabolism and indirectly impact hunger hormones. However, we believe its virtually complete restriction to the periphery eliminates problematic central engagement in the brain. In the case of small-molecule CB1 inhibitors, CB1 inhibition in the brain has been associated with dose-dependent neuropsychiatric adverse events.We do not believe that central targeting of CB1 inhibition is required for meaningful efficacy. To demonstrate this, we have developed a diet-induced obesity (DIO) model using humanized mice with knock-in CB1 receptors to interrogate the in vivo efficacy of nimacimab, a humanized IgG4 anti-CB1 antibody. During November 2024, we shared initial data from our DIO study with nimacimab showing dose-dependent weight loss as well as positive changes in body composition and glycemic control upon treatment. Further analysis and repeat studies are underway but we believe that true peripheral CB1 inhibition can positively impact metabolic disorders including obesity. Given the distinct mechanism and beneficial attributes of nimacimab as a peripheral CB1 inhibitor, within the large and heterogeneous obesity landscape we believe there is significant opportunity for nimacimab to potentially complement GLP-1 agonists and other anti-obesity drug mechanisms of action as well as to have a potential role as a monotherapy.22In January 2024 and March 2024, we completed two private placement equity transactions (the "January and March PIPE Financings") with institutional accredited investors, in which we raised combined net aggregate proceeds of $83,556,563. The net capital raised from the January and March PIPE Financings along with the reallocation of funds from the elimination of our glaucoma program will allow us to fund our clinical trial for obesity through top-line Phase 2 data and provide us with the ability to expand upon our metabolic program.In April 2024, Skye uplisted to the NASDAQ Global MarketÂ® stock exchange from the OTCQB.On May 10, 2024, we entered into an Equity Distribution Agreement (the â€œATM Agreementâ€) with Piper Sandler & Co, as the sales agent (the â€œSales Agentâ€), under which we may, from time to time, sell up to $100,000,000 of shares of our common stock through the Sales Agent (the â€œATM Offeringâ€). We are not obligated to, and we cannot provide any assurances that we will make any sales of the shares under the ATM Agreement. We will pay the Sales Agent a commission for their services in acting as agent in the sale of common stock in an amount up to 3% of the gross sales price per share sold. During the three and nine months ended September 30, 2024, we did not issue any shares under the ATM Offering.In June 2024, we completed our Phase 2a double-masked randomized, placebo-controlled trial of SBI-100 Ophthalmic Emulsion (â€œSBI-100 OEâ€) in 56 patients with elevated intraocular pressure ("IOP") diagnosed with primary open-angle glaucoma or ocular hypertension. The primary endpoint evaluated the change in diurnal IOP in the treated arm vs. placebo over 2 weeks. The study did not achieve a statistically significant improvement in IOP over placebo. As a result, we eliminated our ocular program and strategically redirected our efforts and capital resources to our metabolic program. We have also terminated our license agreement with the University of Mississippi and other vendor contracts related to the manufacture, development, and sublicense of SBI-100. In August of 2024, the Convertible Note (as defined in Note 5 to the accompanying Unaudited Condensed ConsolidatedFinancial Statements). with a principal value of $5,000,000 was converted into 968,973 shares of our common stock. In March of 2023, we appealed the judgment in the Cunning Lawsuit (as defined in Note 9 to the accompanying Unaudited Condensed Consolidated Financial Statements) with the Ninth Circuit Court of Appeals (the "Ninth Circuit"). On October 22, 2024, the Ninth Circuit issued its decision on the appeal and vacated the judgment and remanded the case back to the District Court for a new trial. By the end of 2024, we expect to exonerate the bond and remove the restriction on our cash balance to extend our cash runway and reallocate the funds to further our clinical pipeline. We were incorporated under the laws of the State of Nevada on March 16, 2011, and our headquarters are based in San Diego, CA. We also maintain office space in San Francisco, CA. Since our incorporation, we have devoted substantially all of our efforts to building our product portfolio through the acquisition of clinical assets and licensing agreements, carrying out research and development, building infrastructure and raising capital. Financial OverviewRevenuesTo date, we have not generated any revenue. We do not expect to receive any revenue from our lead drug candidate, nimacimab, or any future drug candidates that we develop unless and until we obtain regulatory approval for, and commercialize, nimacimab or future drug candidates or generate revenue from collaborative agreements with third parties.Research and Development ExpensesDuring the three months ended September 30, 2024, we incurred $4,883,337 in research and development expenses primarily related to our Phase 2 clinical trial of nimacimab for obesity, manufacturing and residual costs from our legacy Phase 2a SBI-100 OE clinical trial. During the three months ended September 30, 2023, we incurred $1,254,653 in research and development expense primarily related to our efforts in conducting the Phase 1 SBI-100 OE clinical trial.During the nine months ended September 30, 2024, we incurred $10,908,538 in research and development expenses primarily related to our Phase 2 clinical trial of nimacimab for obesity, manufacturing and residual costs from our legacy Phase 2a SBI-100 OE clinical trial. During the nine months ended September 30, 2023, we incurred $4,227,967 in research and development expense primarily related to our efforts in conducting the Phase 1 SBI-100 OE clinical trial. We expect that our ongoing research and development expenses will consist of costs incurred for the development of our lead drug candidate, nimacimab, or our future drug candidates, including, but not limited to:Â â€¢employee-related expenses, which include salaries, benefits and stock-based compensation;Â â€¢payments to third party contract research organizations and investigative sites; andÂ â€¢payments to third party manufacturing organizations and consultants.23We expect to incur future research and development expenditures to support our preclinical, nonclinical, and clinical studies. Preclinical and nonclinical activities include early discovery efforts with novel molecules, laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess safety and efficacy. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming and the successful development of our lead drug candidate, nimacimab, and any future drug candidate is highly uncertain. Our future research and development expenses will depend on the clinical success of nimacimab and any future drug candidates as well as ongoing assessments of the commercial potential of such drug candidates. In addition, we cannot forecast with any degree of certainty which drug candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. We expect to incur increased research and development expenses in the future as we continue our efforts towards advancing our lead program for nimacimab.General and Administrative ExpensesOur general and administrative expenses have fluctuated year-over-year as we have entered into various strategic acquisitions to restructure and reposition our company. Additionally, as a business in the early stages of drug development we are in the process of scaling our operations by hiring additional employees and building the infrastructure necessary to increase efficiencies. These initiatives have resulted in additional costs related to the implementation of certain systems, insurance, facilities, legal, tax and accounting costs. As a public company, we expect to incur additional expenses related to insurance, investor relations activities, legal and other administration and professional services to comply with the rules and regulations of the SEC, FINRA and Nasdaq. Other significant costs are expected to include legal fees relating to patent and corporate matters, business development costs and fees for consulting services. To incentivize our employees and be competitive to retain strong talent we issued additional equity awards in 2023 and 2024, which have resulted in increased stock-based compensation expense. We also expect that certain general and administrative expenses which are commensurate with headcount, will continue to increase in the future in order to support our expected increase in research and development activities, including increased salaries, technology, facilities and other related costs.Other (Income) ExpenseOther (income) expense primarily includes a gain from the sale of the AVI building (see Note 2 to the accompanying Unaudited Condensed Consolidated Financial Statements), interest income and interest expense incurred from the Convertible Note which was converted during the three months ended September 30, 2024. Critical Accounting EstimatesThere have been no material changes in our Critical Accounting Estimates from the information provided in the "Critical Accounting Estimates" section of "Item 7- Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, except, for the addition of our critical accounting estimate related to the estimate for accrued legal contingencies and related expenses and loss recoveries. We follow ASC 450, subtopic 450-20 to report accounting for loss contingencies and recoveries. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to us, but which will only be resolved when one or more future events occur or fail to occur.We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies and recoveries related to legal proceedings that are pending or un-asserted claims that may result in such proceedings, we evaluate the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.If the assessment of a contingency or loss recovery indicates that it is probable that a material loss has been incurred or a loss recovery is realizable and the amount of the asset or liability can be estimated, then the estimated asset or liability would be recorded in our financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Recently Issued and Adopted Accounting PronouncementsSee Note 1 to the accompanying Unaudited Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our estimates in future periods, the impact upon adoption was not significant to our current estimates and operations.24Results of OperationsFor the three months ended September 30, 2024 and 2023 Research and Development ExpensesBelow is a summary of our research and development expenses during the three months ended September 30, 2024 and for the same period in 2023:Three Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Research and development expenses$4,883,337Â $1,254,653Â $3,628,684Â 289Â %Research and development expenses for the three months ended September 30, 2024, increased by $3,628,684 as compared to the same period in 2023. The net increase in research and development expenses was primarily due to an increase of $693,556 in research

and development salaries and equity based compensation, a net increase of $2,735,109 in contracted clinical and manufacturing costs from our Phase 2 clinical trial of nimacimab for obesity, an increase of $74,758 in consulting expense, and an increase of $122,174 in travel and other business expenses. Cost to acquire IPR&D assetBelow is a summary of our cost to acquire the IPR&D asset, nimacimab, pursuant to the BRB Acquisition (as defined in Note 2 of to the accompanying Unaudited Condensed Consolidated Financial Statements) during the three months ended September 30, 2024, and for the same period in 2023:Three Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Cost to acquire IPR&D asset$â€”Â $21,215,214Â $(21,215,214)(100)%Cost to acquire the IPR&D asset for the three months ended September 30, 2024, decreased by $21,215,214 as compared to the same period in 2023. The decrease is due to the cost of the acquired IPR&D in the BRB Acquisition during the three months ended September 30, 2023 and no acquisition of IPR&D in the same period during 2024.General and Administrative ExpensesBelow is a summary of our general and administrative expenses during the three months ended September 30, 2024, and for the same period in 2023: Three Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023General and administrative expenses$4,638,927Â $2,235,899Â $2,403,028Â 107Â %General and administrative expenses for the three months ended September 30, 2024, increased by $2,403,028 as compared to the same period in 2023. The increase in general and administrative expenses was primarily due to an increase in salaries and benefits of $1,826,208 driven by stock-based compensation expense from the achievement of certain performance based milestones related to RSUs granted to members of management and a member of the board of directors of the Company and increased headcount. During the three months ended September 30, 2024, professional fees increased by $214,192 due to services provided under a financial advisory agreement, increased corporate tax fees and corporate legal fees related to patent prosecution for nimacimab. The net increase included an offset of $164,000 from the reduction in general corporate legal expenses related to the Cunning Lawsuit and Partner Re case as compared to the prior period. 25Change in Estimate for Legal ContingenciesTotal change in estimate for legal contingencies for the three months ended September 30, 2024 and 2023, are as follows:Three Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Change in estimate for legal contingencies$(4,553,468)$â€”Â $(4,553,468)100Â %For the three months ended September 30, 2024, we recorded a change in estimate for legal contingencies (as defined in Note 9 to the accompanying Unaudited Condensed Consolidated Financial Statements) based on changes after September 30, 2024 to the facts and circumstances related to our legal proceedings that existed as of the balance sheet date.Other (Income) Expense Below is a summary of our other (income) expense for the three months ended September 30, 2024 and for the same period in 2023: Three Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Interest (income) expense$(90,766)$271,307Â $(362,073)(133)%Interest income(907,697)(16,562)(891,135)5381Â %(Gain) loss from asset sales(72,837)â€”Â (72,837)100Â %Wind-down costsâ€”Â (14,677)14,677Â (100)%Other expense$801Â $â€”Â 801Â 100Â %Total other (income) expense$(1,070,499)$240,068Â $(1,310,567)(546)%For the three months ended September 30, 2024, we had net other income of $1,070,499 related primarily to the increase in interest income of $891,135 resulting from interest earned on our cash and cash equivalents and the restricted cash on deposit with financial institutions, offset by a decrease in interest expense primarily from the reversal of accrued interest on our legal contingency, which was vacated. The interest income was offset by an increase in interest expense from the Convertible Note (as defined in Note 5 to the accompanying Unaudited Condensed Consolidated Financial Statements).For the three months ended September 30, 2023, we had net other expense of $240,068 related primarily to interest expense from the premiums on the irrevocable letter of credit and appeal bond for the Cunning Lawsuit (as defined in Note 9 to the accompanying Unaudited Condensed Consolidated Financial Statements), and interest expense from the Convertible Note. For the nine months ended September 30, 2024 and 2023 Research and Development ExpensesBelow is a summary of our research and development expenses during the nine months ended September 30, 2024 and for the same period in 2023:Nine Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Research and development expenses$10,908,538Â $4,227,967Â $6,680,571Â 158Â %Research and development expenses for the nine months ended September 30, 2024, increased by $6,680,571 as compared to the same period in 2023. The net increase in research and development expenses was primarily due to an increase of $1,494,336 in research and development salaries from increased headcount and equity based compensation, a net increase of $4,570,417 in contracted clinical costs and manufacturing associated with our clinical trial for nimacimab in obesity and the completion of our Phase 2a clinical trial for SBI-100 OE in glaucoma. In addition, we had increased travel expenses of $95,275 due to our increased presence at conferences and events during the nine months ended September 30, 2024. 26In connection with the discontinuation of our clinical trials for SBI-100 OE, we incurred contract cancellation fees and other general expenses of $335,022. In addition, there was an increase in consulting fees of $265,853 related to our Phase 2 clinical trial for nimacimab in obesity, which was offset by a decrease in license fees of $70,248 from the elimination of the SBI-200 license agreement with the University of Mississippi in the prior year. Cost to acquire IPR&D assetBelow is a summary of our cost to acquire the IPR&D in connection with the BRB Acquisition asset during the nine months ended September 30, 2024, and for the same period in 2023:Nine Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Cost to acquire IPR&D asset$â€”Â $21,215,214Â $(21,215,214)(100)%Cost to acquire the IPR&D asset for the nine months ended September 30, 2024, decreased by $21,215,214 as compared to the same period in 2023 .The decrease is due to the cost of the acquired IPR&D in the BRB Acquisition during the nine months ended September 30, 2024 and no acquisition of IPR&D in the same period during 2024.General and Administrative ExpensesBelow is a summary of our general and administrative expenses during the nine months ended September 30, 2024, and for the same period in 2023: Nine Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023General and administrative expenses$13,171,547Â $5,357,577Â $7,813,970Â 146Â %General and administrative expenses for the nine months ended September 30, 2024, increased by $7,813,970 as compared to the same period in 2023. The increase in general and administrative expenses was primarily due to an increase in salaries and benefits of $5,389,259 from increased headcount and the recognition of stock based compensation expense due to the achievement of certain performance based milestones related to RSUs granted to members of management and a members of the board of directors of the Company. During the nine months ended September 30, 2024, professional fees increased by $1,035,567 due to services provided under a financial advisory agreement, professional services related to the registration of the resale of shares issued in the January and March PIPE Financings and general corporate legal fees associated with our uplisting to Nasdaq, the filing of our shelf registration statement, legal fees related to nimacimab patent prosecution, increased tax fees due to increased tax complexity and the entry into the ATM Agreement. In addition, our general business expenses increased by $875,842 due to regulatory agency filing fees, the Nasdaq initial listing fee, recruiting fees, investor relations fees and corporate events. Other increases included consulting, insurance, marketing, software and travel of $127,188, $177,458, $130,907, $73,704 and $122,630, respectively. 27Change in Estimate for Legal ContingenciesTotal change in estimate for legal contingencies for the nine months ended September 30, 2024 and 2023, are as follows:Nine Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Change in estimate for legal contingencies$(4,553,468)$(151,842)$(4,401,626)2899Â %For the nine months ended September 30, 2024, we recorded a change in estimate for legal contingencies (as defined in Note 9 to the accompanying Unaudited Condensed Consolidated Financial Statements) based on changes after September 30, 2024 to the facts and circumstances related to our legal proceedings that existed as of the balance sheet date.Other (Income) Expense Below is a summary of our other (income) expense for the nine months ended September 30, 2024, and for the same period in 2023: Nine Months Ended September 30,20242023$ Change2024 vs. 2023% Change2024 vs. 2023Interest (income) expense$796,222Â $476,135Â $320,087Â 67Â %Interest income(2,296,488)(49,669)(2,246,819)4524Â %(Gain) loss from asset sales(1,217,978)307,086Â (1,525,064)(497)%Debt conversion inducement expenseâ€”Â 1,383,285Â (1,383,285)(100)%Wind-down costsâ€”Â 455,504Â (455,504)(100)%Other expense (income)2,200Â (3)2,203Â 100Â %Total other (income) expense$(2,716,044)$2,572,338Â $(5,288,382)(206)%For the nine months ended September 30, 2024, we had net other income of $2,716,044 related primarily to the gain on the sale of the AVI building and collections from the sale of VDL of $1,217,978, an increase in interest income of $2,246,819, offset by a net increase of $320,087 in interest expense from an increase in interest on our Convertible Note offset by the reversal of interest from the judgment related to the Cunning Lawsuit. In addition, during 2023, we incurred a one-time debt conversion inducement expense of $1,383,285 and recognized wind down costs of $455,504 from the EHT Acquisition. Liquidity and Capital Resources Liquidity We have incurred operating losses and negative cash flows from operations since our inception, and as of SeptemberÂ 30, 2024, we had working capital of $74,184,006, an accumulated deficit of $121,203,193, and stockholdersâ€™ equity of $75,803,375. We had unrestricted cash and cash equivalents in the amount of $67,412,614 as of SeptemberÂ 30, 2024, as compared to $1,256,453 as of DecemberÂ 31, 2023. For the nine months ended September 30, 2024 and 2023, the Company incurred losses from operations of $19,526,617 and $30,648,916, respectively. For the nine months ended September 30, 2024 and 2023, the Company incurred net losses of $16,820,644 and $33,224,854, respectively. In January 2024 and March 2024, we completed the January and March PIPE Financings (as such terms are defined in Note 6 to the accompanying Unaudited Condensed Consolidated Financial Statements), in which we raised combined net aggregate proceeds of $83,556,563. We expect the capital from the January and March PIPE Financings to fund our Phase 2 clinical trial for obesity through top line Phase 2 data in late 2025 and the potential expansion of our metabolic program. In May 2024, we entered into the ATM Agreement under which the Company may, sell up to $100,000,000 of shares of common stock through the Sales Agent. The Company has not sold any shares under the ATM Agreement as of the date hereof and is not obligated to, and cannot provide any assurances that the Company will continue to, make any sales of the shares under the ATM Agreement. 28In July 2024, 1,301,573 pre-funded warrants, with an intrinsic value of $10,424,294, were exercised on a cashless basis, resulting in the issuance 1,301,410 shares of our common stock (see Note 6 to the accompanying Unaudited Condensed Consolidated Financial Statements).In August 2024, the holder of the Convertible Note exercised their conversion option and converted the principal balance of $5,000,000 into 968,973 shares of our common stock. In March of 2023, we appealed the judgment in the Cunning Lawsuit to the Ninth District Court of Appeals (the "Ninth Circuit"). In October of 2024, the Ninth Circuit issued its decision and vacated the $6,053,468 judgment and remanded the case back to the District Court for the Central District of California for a new trial. By the end of 2024, we expect to exonerate the bond and recover the $9,080,202 restriction on our cash balance to extend our cash runway and reallocate the funds to further our clinical pipeline. The Companyâ€™s Unaudited Condensed Consolidated Financial Statements have been prepared on the basis of the Company continuing as a going concern for the next 12 months. Based on its current operational requirements, the Company believes that its current cash will be sufficient to fund its projected operations for at least 12 months from the date of the issuance of these consolidated financial statements. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain.Our future capital requirements will depend on many factors, including:â€¢the scope, rate of progress, results and costs of our clinical trials, preclinical studies and other related activities;â€¢our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;â€¢the timing of, and the costs involved in, obtaining regulatory approvals for any of nimacimab or any future drug candidates;â€¢the number and characteristics of the drug candidates we seek to develop or commercialize;â€¢the cost of manufacturing clinical supplies, and establishing commercial supplies, of our drug candidates;â€¢the cost of commercialization activities if our current or future drug candidates are approved for sale, including marketing, sales and distribution costs;â€¢the expenses needed to attract and retain skilled personnel;â€¢the costs associated with being a public company;â€¢the amount of revenue, if any, received from commercial sales of our drug candidates, should any of our drug candidates receive marketing approval; andâ€¢the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing possible patent claims, including litigation costs and the outcome of any such litigation.Cash FlowsThe following is a summary of our cash flows for the periods indicated and has been derived from our Unaudited Condensed Consolidated Financial Statements which are included elsewhere in this Quarterly Report on Form 10-Q:Nine Months Ended September 30,20242023Net cash used in operating activities$(17,064,377)$(10,107,460)Net cash (used in) provided by investing activities(336,025)6,603,473Â Net cash provided by financing activities83,556,563Â 16,465,924Â Cash Flows from Operating Activities The primary use of cash for our operating activities during the period was to fund research development activities for our clinical product candidates and general and administrative activities. Our cash used in operating activities also reflected changes in our working capital, net of adjustments for non-cash charges, such as stock-based compensation, depreciation and amortization, amortization of debt discount and the (gain) loss from divestiture of assets.Cash used in operating activities of $17,064,377 during the nine months ended September 30, 2024, reflected a net loss of $16,820,644, partially offset by aggregate non-cash charges of $1,515,581 and included a $1,759,314 net change in our operating assets and liabilities. Non-cash charges included $6,228,270 for stock-based compensation expense primarily attributable to the vesting of RSUs related to the achievement of certain market based performance milestones, $599,006 in non-cash interest expense debt 29amortization expense, $1,217,978 gain from the sale of a real estate asset, $123,347 in depreciation and amortization and $325,610 from the write-off of vendor deposits. The net change in our operating assets and liabilities included a $2,076,835 cash outflow from changes in our prepaid expenses and other current assets, a $711,281 net cash outflow from changes in our accrued expenses and other current liabilities and a $375,760 cash outflow from the repayment of our accounts payable.Cash used in operating activities of $10,107,460 during the nine months ended September 30, 2023, reflected a net loss of $33,224,854, partially offset by aggregate non-cash charges of $23,476,130 and included a $358,736 net change in our operating assets and liabilities. Cash Flows from Investing Activities During the nine months ended September 30, 2024, the Company purchased $1,554,003 in machinery and office equipment and recognized $1,217,978 in net proceeds from the sale of the AVI building and the collection of receivables from the sale of VDL (see Note 2 to the accompanying Unaudited Condensed Consolidated Financial Statements).During the nine months ended September 30, 2023, the Company purchased $5,533 in machinery office equipment, received $5,532,266 in proceeds related to the divestiture of VDL and received $1,076,740 in cash from the acquisition of BRB.Cash Flows from Financing Activities Cash flows from financing activities primarily reflect proceeds from the sale of our securities and loan repayments.During the nine months ended September 30, 2024, cash provided by financing activities included $83,556,563 in proceeds received in connection with the January and March PIPE Financings, net of issuance costs. During the nine months ended September 30, 2023, cash provided by financing activities included $4,973,684 in proceeds received in connection with the Convertible Note net of issuance costs, and $11,734,947 in proceeds received in connection with the 2023 PIPE Financing, net of issuance costs, offset by a $236,681 repayment on our insurance premium loan payable.Off-Balance Sheet ArrangementsThere are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.Item 3. Quantitative and Qualitative Disclosures about Market Risk.Not applicable.Item 4. Controls and Procedures.Evaluation of disclosure controls and procedures. We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily is required to apply its judgement in evaluating the cost-benefit relationship of possible controls and procedures.We conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of SeptemberÂ 30, 2024. Based upon their evaluation and subject to the foregoing, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.Changes in internal controls. Management determined there were no changes in internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.30PART II - OTHER INFORMATIONItem 1. Legal ProceedingsFor a description of material legal proceedings, see Note 9, "General Litigation and Disputes" to the accompanying Unaudited Condensed

Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. Item 1A. Risk Factors.There have been no material changes in or additions to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2023 and our quarterly report on Form 10-Q for the three months ended March 31, 2024. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.None.Item 3. Defaults Upon Senior Securities.None.Item 4. Mine Safety Disclosures.Not applicable.Item 5. Other Information.Rule 10b5-1 and Non-Rule 10b5-1 Trading ArrangementsDuring the three months ended SeptemberÂ 30, 2024, neither the Company or any of its officers (as that term is defined by the SEC in Rule 16a-1(f) under the Exchange Act) or directors adopted or terminated a Rule 10b5-1 trading arrangement or a non Rule 10b5-1 trading arrangement for the sale of the Companyâ€™s common stock. Item 6. Exhibits.3.1Amended and Restated Articles of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 22, 2024)3.2Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 2, 2021) 10.1*Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan 10.2Employment Agreement between the Registrant and Dr. Puneet Arora (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on September 4, 2024)31.1*Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 193431.2*Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 193432.1*Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2*Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002101The following materials from the Skye Biosciences, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets (Unaudited), (ii) Condensed Consolidated Statements of Operations (Unaudited), (iii) Condensed Consolidated Statements of Cash Flows (Unaudited), (iv) Condensed Consolidated Statements of Stockholdersâ€™ Deficit (Unaudited), and (v) related Notes to the Unaudited Condensed Consolidated Financial Statements.104Cover Page Interactive Data File (embedded within the Inline XBRL document)_____31(*)Filed herewith. + Â Â Â Â Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted exhibits or schedules upon request. 32SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Skye Bioscience, Inc.,a Nevada corporationNovember 7, 2024By:/s/ Punit DhillonPunit DhillonIts:Chief Executive Officer, Secretary and Director(Principal Executive Officer)November 7, 2024By:/s/ Kaitlyn ArsenaultKaitlyn ArsenaultIts:Chief Financial Officer(Principal Financial and Accounting Officer)33 EX-10.1 2 skyeex101bio-amendedandres.htm EX-10.1 DocumentSKYE BIOSCIENCE, INC.AMENDED AND RESTATED OMNIBUS INCENTIVE PLANARTICLE IPURPOSE AND ADOPTION OF THE PLAN1.01Â Â Â Â Purpose.Â  The purpose of the Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan (as may be further amended from time to time, the â€œPlanâ€) is to assist in attracting and retaining highly competent employees, executive officers, directors and Consultants to act as an incentive in motivating selected employees, executive officers, directors and Consultants of the CompanyÂ and its Subsidiaries to achieve long-term corporate objectives.1.02Â Â Â Â Adoption and Term.Â  The Plan was initially approved and adopted by the Board to be effective as of October 31, 2014. The Plan, as most recently amended and restated, was approved by the Board on September 10, 2024 (the â€œAmendment and Restatement Dateâ€), subject to the approval of the stockholders of the Company.Â  The Plan shall remain in effect until the tenth (10th) anniversary of the Amendment and Restatement Date, or until terminated by action of the Board, whichever occurs sooner.ARTICLE IIDEFINITIONSFor the purpose of this Plan, capitalized terms shall have the following meanings:2.01Â Â Â Â â€œAdministratorâ€Â has the meaning specified in Section 3.2.02Â Â Â Â â€œAffiliateâ€Â means an entity in which, directly or indirectly through one or more intermediaries, the Company has at least a fifty percent (50%) ownership interest or, where permissible under Section 409A of the Code, at least a twenty percent (20%) ownership interest;Â provided,Â however, for purposes of any grant of an Incentive Stock Option, â€œAffiliateâ€ means a corporation which, for purposes of Section 424 of the Code, is a parent or subsidiary of the Company, directly or indirectly. 2.03Â Â Â Â â€œAwardâ€Â means any one or a combination of Non-Qualified Stock Options or Incentive Stock Options described in Article VI, Stock Appreciation Rights described in Article VI, Restricted Shares and Restricted Stock Units described in Article VII, Performance Awards described in Article VIII, other stock-based Awards described in Article IX, or any other Award made under the terms of the Plan.2.04Â Â Â Â â€œAward Agreementâ€Â means a written agreement between the Company and a Participant or a written acknowledgment from the Company to a Participant specifically setting forth the terms and conditions of an Award granted under the Plan.2.05Â Â Â Â â€œAward Periodâ€Â means, with respect to an Award, the period of time, if any, set forth in the Award Agreement during which specified target performance goals must be achieved or other conditions set forth in the Award Agreement must be satisfied.2.06Â Â Â Â â€œBeneficiaryâ€Â means an individual, trust or estate who or which, by a written designation of the Participant filed with the Company, or if no such written designation is filed, by operation of law, succeeds to the rights and obligations of the Participant under the Plan and the Award Agreement upon the Participant's death.2.07Â Â Â Â â€œBoardâ€Â means the Board of Directors of the Company.2.08Â Â Â Â â€œCauseâ€ means (a) if a Participant is a party to a written employment, severance or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term â€œcauseâ€ is defined, â€œCauseâ€ as defined in such agreement, and (b) if no such agreement exists, (i) the Administratorâ€™s determination that the Participant failed to substantially perform the Participantâ€™s duties (other than a failure resulting from the Participantâ€™s Disability); (ii) the Administratorâ€™s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participantâ€™s immediate supervisor; (iii) the Participantâ€™s unauthorized use or disclosure of confidential information or trade secrets of the Company or any of its Subsidiaries or any material breach of a written agreement between the Participant and the Company; (iv) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participantâ€™s conviction, plea of no contest, plea of nolo contendere, or imposition of un-adjudicated probation for any felony or indictable offense or crime involving moral turpitude; (v) the Participantâ€™s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participantâ€™s duties and responsibilities for the Company or any of its Subsidiaries; or (vi) the Participantâ€™s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries.2.09Â Â Â Â â€œCanadian Personâ€ means any person subject to tax under the laws of Canada or any province or territory situated therein in respect of an Award.2.10Â Â Â Â â€œChange in Controlâ€Â means, and shall be deemed to have occurred upon the occurrence of, any one of the following events:(a)Â Â Â Â The acquisition in one or more transactions, other than from the Company, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act), other than the Company, an Affiliate or any employee benefit plan (or related trust) sponsored or maintained by the Company or an Affiliate, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of a number of Company Voting Securities in excess of 50% of the Company Voting Securities unless such acquisition has been approved by the Board;(b)Â Â Â Â Any election has occurred of persons to the Board that causes two-thirds of the Board to consist of persons other than (i) persons who were members of the Board on the 2Amendment and Restatement Date and (ii) persons who were nominated for elections as members of the Board at a time when two-thirds of the Board consisted of persons who were members of the Board on the Amendment and Restatement Date, provided, however, that any person nominated for election by a Board at least two-thirds of whom constituted persons described in clauses (i) and/or (ii) or by persons who were themselves nominated by such Board shall, for this purpose, be deemed to have been nominated by a Board composed of persons described in clause (i);(c)Â Â Â Â The consummation (i.e. closing) of a reorganization, merger or consolidation involving the Company, unless, following such reorganization, merger or consolidation, all or substantially all of the individuals and entities who were the respective beneficial owners of the Outstanding Common Stock and Company Voting Securities immediately prior to such reorganization, merger or consolidation, following such reorganization, merger or consolidation beneficially own, directly or indirectly, more than 75% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or trustees, as the case may be, of the entity resulting from such reorganization, merger or consolidation in substantially the same proportion as their ownership of the Outstanding Common Stock and Company Voting Securities immediately prior to such reorganization, merger or consolidation, as the case may be;(d)Â Â Â Â The consummation (i.e. closing) of a sale or other disposition of all or substantially all the assets of the Company, unless, following such sale or disposition, all or substantially all of the individuals and entities who were the respective beneficial owners of the Outstanding Common Stock and Company Voting Securities immediately prior to such sale or disposition, following such sale or disposition beneficially own, directly or indirectly, more than 75% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or trustees, as the case may be, of the entity purchasing such assets in substantially the same proportion as their ownership of the Outstanding Common Stock and Company Voting Securities immediately prior to such sale or disposition, as the case may be; or(e)Â Â Â Â a complete liquidation or dissolution of the Company.2.11Â Â Â Â â€œCodeâ€Â means the Internal Revenue Code of 1986, as amended. References to a section of the Code shall include that section and any comparable section or sections of any future legislation that amends, supplements or supersedes said section.2.12Â Â Â Â â€œCommon Stockâ€Â means the common stock of the Company, par value $0.001 per share.2.13Â Â Â Â â€œCompanyâ€Â or â€œSkyeâ€ means Skye Bioscience, Inc., a Nevada corporation, and its successors.32.14Â Â Â Â â€œCompany Voting Securitiesâ€Â means the combined voting power of all outstanding voting securities of the Company entitled to vote generally in the election of directors to the Board.2.15Â Â Â Â â€œConsultantâ€ means an individual consultant or an employee, executive officer or director of a consultant entity who spends a significant amount of time and attention on the affairs and business of the Company or a Subsidiary, other than a Participant that is an employee, who:(a)Â Â Â Â is engaged to provide services on a bona fide basis to the Company or a Subsidiary, other than services provided in relation to a distribution of securities of the Company or a Subsidiary;(b)Â Â Â Â provides the services under a written contract with the Company or a Subsidiary; and(c)Â Â Â Â spends or will spend a significant amount of time and attention on the affairs and business of the Company or a Subsidiary.2.16Â Â Â Â â€œDate of Grantâ€Â means the date designated by the Administrator as the date as of which it grants an Award, which shall not be earlier than the date on which the Administrator approves the granting of such Award.2.17Â Â Â Â â€œDisabilityâ€ means (a) if a Participant is a party to a written employment, severance or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term â€œdisabilityâ€ is defined, â€œDisabilityâ€ as defined in such agreement, and (b) if no such agreement exists, a permanent and total disability under Section 22(e)(3) of the Code, as amended.2.18Â Â Â Â â€œDividend Equivalent Accountâ€Â means a bookkeeping account in accordance with SectionÂ 11.17 and related to an Award that is credited with the amount of any cash dividends or stock distributions that would be payable with respect to the shares of Common Stock subject to such Awards had such shares been outstanding shares of Common Stock.2.19Â Â Â Â â€œExchange Actâ€Â means the Securities Exchange Act of 1934, as amended.2.20Â Â Â Â â€œExercise Priceâ€Â means, with respect to a Stock Appreciation Right, the amount established by the Administrator in the Award Agreement which is to be subtracted from the Fair Market Value on the date of exercise in order to determine the amount of the payment to be made to the Participant, as further described in Section 6.02(b).2.21Â Â Â Â â€œFair Market Valueâ€ means, as of any applicable date:Â  (a)Â Â Â Â for Canadian persons, if the Common Stock is listed on the Canadian Securities Exchange, the closing sales price of the Common Stock on the exchange on that date, or, if no sale of the Common Stock occurred on that date, on the next preceding date on which there was a reported sale; 4(b)Â Â Â Â for US persons, if the Common Stock is listed on a national securities exchange or is authorized for quotation on the Nasdaq National Market System (â€œNMSâ€), the closing sales price of the Common Stock on the exchange or NMS, as the case may be, on that date, or, if no sale of the Common Stock occurred on that date, on the next preceding date on which there was a reported sale; (c)Â Â Â Â if none of the above apply for the particular person, the closing bid price as reported by the Nasdaq Capital Market on that date, or if no price was reported for that date, on the next preceding date for which a price was reported; (d)Â Â Â Â if none of the above apply for the particular person, the last reported bid price published in the â€œpink sheetsâ€ or displayed on the Financial Industry Regulatory Authority (â€œFINRAâ€), Electronic Bulletin Board, or OTC Markets, Inc. as the case may be; or(e)Â Â Â Â if none of the above apply, the fair market value of the Common Stock as determined under procedures established by the Administrator.2.22Â Â Â Â â€œIncentive Stock Optionâ€Â means a stock option within the meaning of Section 422 of the Code.2.23Â Â Â Â â€œNon-Qualified Stock Optionâ€Â means a stock option which is not an Incentive Stock Option.2.24Â Â Â Â â€œOptionsâ€Â means all Non-Qualified Stock Options and Incentive Stock Options granted at any time under the Plan.2.25Â Â Â Â â€œOutstanding Common Stockâ€Â means, at any time, the issued and outstanding shares of Common Stock.2.26Â Â Â Â â€œParticipantâ€Â means an employee, director or Consultant of the Company or any Subsidiary, or a Permitted Assign thereof, who receives an Award under the Plan in accordance with Section 5.01, who enters into an Award Agreement with respect to such Award that is fully executed and delivered by all parties thereto, and, with respect to Canadian Persons, whose participation in the distribution is voluntary. Participation in a distribution is considered â€œvoluntaryâ€ if:(a)Â Â Â Â in the case of an employee or the employeeâ€™s Permitted Assign, the employee or the employeeâ€™s Permitted Assign is not induced to participate in the distribution by expectation of employment or continued employment of the employee with the Company;(b)Â Â Â Â in the case of a Consultant or the Consultantâ€™s Permitted Assign, the Consultant or the Consultantâ€™s Permitted Assign is not induced to participate in the distribution by expectation of engagement of the Consultant to provide services or continued engagement of the Consultant to provide services to the Company; and5(c)Â Â Â Â in the case of an employee of a Consultant, the individual is not induced by the Company or the Consultant to participate in the distribution by expectation of employment or continued employment with the Consultant.2.27Â Â Â Â â€œPerformance Awardsâ€Â means Awards granted in accordance with Article VIII.2.28Â Â Â Â â€œPerformance Goalsâ€Â mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include, without limitation, the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholdersâ€™ equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; market capitalization; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human capital management (including diversity and inclusion); supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Companyâ€™s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies.2.29Â Â Â Â â€œPermitted Assignâ€ means, for a person that is an employee, executive officer, director or Consultant of the Company or of a Subsidiary: (a) a trustee, custodian, or administrator acting on behalf of, or for the benefit of the person; (b) a holding entity of the person; (c) a â€œregistered retirement savings planâ€, â€œregistered retirement income fundâ€, or â€œtax-free savings accountâ€ (all within the meaning of the Income Tax Act (Canada)) of the person; (d) a spouse of the person; (e) a trustee, custodian, or administrator acting on behalf of, or for the benefit of the spouse of the person; (f) a holding entity of the spouse of the person; or (g) a â€œregistered retirement savings planâ€, â€œregistered retirement income fundâ€, or â€œtax-free savings accountâ€ (all within the meaning of the Income Tax Act

(Canada)) of the spouse of the person.62.30Â Â Â Â â€œPlanâ€Â has the meaning given to such term in Section 1.01.2.31Â Â Â Â â€œPurchase Priceâ€ with respect to Options, shall have the meaning set forth in Section 6.01(b). 2.32Â Â Â Â â€œRelated Personâ€ means, for the Company: (a) a director or executive officer of the Company or an Affiliate of the Company; (b) an associate of a director or executive officer of the Company or an Affiliate of the Company; or (c) a Permitted Assign of a director or executive officer of the Company or an Affiliate of the Company.2.33Â Â Â Â â€œRestricted Sharesâ€Â means Common Stock subject to restrictions imposed in connection with Awards granted under Article VII.2.34Â Â Â Â â€œRestricted Stock Unitâ€Â means a unit representing the right to receive Common Stock or the value thereof in the future subject to restrictions imposed in connection with Awards granted under Article VII.2.35Â Â Â Â â€œRule 16b-3â€Â means Rule 16b-3 promulgated by the Securities and Exchange Commission under Section 16 of the Exchange Act, as the same may be amended from time to time, and any successor rule.2.36Â Â Â Â â€œStock Appreciation Rightsâ€Â means awards granted in accordance with Article VI.2.37Â Â Â Â â€œSubsidiaryâ€ means any corporation in which the Company owns, directly or indirectly, at least 50% of the total combined voting power of all classes of stock, or any other entity (including partnerships and joint ventures) in which the Company owns, directly or indirectly, at least 50% of the combined equity thereof; provided, however, that for purposes of determining whether any individual may be a Participant for purposes of any grant of an Incentive Stock Option, â€œSubsidiaryâ€ shall have the meaning ascribed to such term in Section 424(f) of the Code.2.38Â Â Â Â â€œTermination of Serviceâ€Â means the voluntary or involuntary termination of a Participantâ€™s service as an employee, director or consultant with the Company or an Affiliate for any reason, including death, Disability, retirement or as the result of the divestiture of the Participantâ€™s employer or any similar transaction in which the Participantâ€™s employer ceases to be the Company or one of its Subsidiaries.Â  Whether entering military or other government service shall constitute Termination of Service, or whether and when a Termination of Service shall occur as a result of Disability, shall be determined in each case by the Administrator in its sole discretion.ARTICLE IIIADMINISTRATION3.01Â Â Â Â Administrator.7(a)Â Â Â Â Duties and Authority.Â  The Plan shall be administered by the Board, or at the discretion of the Board, by a committee of the Board consisting of not less than two (2) directors (the Board or such committee of the Board, the â€œAdministratorâ€); provided, however, that if any member of the Administrator is not a â€œNon-Employee Directorâ€ within the meaning of Rule 16b-3, then any Awards granted to individuals subject to the reporting requirements of Section 16 of the Exchange Act shall be approved by the Board.Â  The Administrator shall have exclusive and final authority in each determination, interpretation or other action affecting the Plan and its Participants.The Administrator shall have the sole discretionary authority to interpret the Plan, to establish and modify administrative rules for the Plan, to impose such conditions and restrictions on Awards as it determines appropriate, and to make all factual determinations with respect to and take such steps in connection with the Plan and Awards granted hereunder as it may deem necessary or advisable.Â  The Administrator may delegate such of its powers and authority under the Plan as it deems appropriate to a subcommittee of the Administrator or designated officers or employees of the Company.Â  In the event of such delegation of authority or exercise of authority by the Board, references in the Plan to the Administrator shall be deemed to refer, as appropriate, to the delegate of the Administrator or the Board.Â  Actions taken by the Administrator or any subcommittee thereof, and any delegation by the Administrator to designated officers or employees, under this Section 3.01 shall comply with Section 16(b) of the Exchange Act, and the regulations promulgated under such statutory provisions, or the respective successors to such statutory provisions or regulations, as in effect from time to time, to the extent applicable.(b)Â Â Â Â Indemnification.Â  Each person who is or shall have been a member of the Board or the Administrator, or an officer or employee of the Company to whom authority was delegated in accordance with the Plan shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such individual in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company's approval, or paid by him or her in satisfaction of any judgment in any such action, suit, or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf; provided, however, that the foregoing indemnification shall not apply to any loss, cost, liability, or expense that is a result of his or her own willful misconduct.Â  The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Companyâ€™s Articles of Incorporation or Bylaws, conferred in a separate agreement with the Company, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.8ARTICLE IVSHARES4.01Â Â Â Â Share Reserve.(a)Â Â Â Â General. The total number of shares authorized to be issued under the Plan, since its inception, shall equal 4,000,000. The foregoing share limit shall be subject to adjustment in accordance with Section 11.07. The shares to be offered under the Plan shall be authorized and unissued Common Stock, or issued Common Stock that shall have been reacquired by the Company.(b)Â Â Â Â Automatic Increases. The aggregate number of shares of Common Stock reserved for awards under Section 4.01(a) will automatically increase on January 1 of each year, for a period of no more than ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032 in an amount equal to 5% of the total number of shares of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for the year will be a lesser number of shares of Common Stock than provided herein.(c)Â Â Â Â Incentive Stock Option Limitation. Subject to the adjustment in Section 11.07, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 4,000,000 provided that such number will automatically increase on January 1 of each year, for a period of no more than ten years, commencing on January 1, 2023 and ending on (and including) January 1, 2032 in an amount equal to 5% of the total number of shares of Common Stock outstanding on the Amendment and Restatement Date. Notwithstanding the foregoing, the Board may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for the year will be a lesser number of shares of Common Stock than provided herein.4.02Â Â Â Â Limits on Awards. Unless securityholder approval is obtained in accordance with applicable securities laws, the following limitations shall apply to the Plan and all Awards: (a)Â Â Â Â the number of securities, calculated on a fully diluted basis, reserved for issuance under the Awards granted to: (i) Related Persons, shall not exceed 10% of the outstanding securities of the Company, or (ii) a Related Person, shall not exceed 5% of the outstanding securities of the Company; and(b)Â Â Â Â the number of securities, calculated on a fully diluted basis, issued within 12 months, to: (i) Related Persons, shall not exceed 10% of the outstanding securities of the Company, or (ii) a Related Person, shall not exceed 5% of the outstanding securities of the Company.4.03Â Â Â Â Shares Subject to Terminated Awards.Â  Common Stock covered by any unexercised portions of Options or Stock Appreciation Rights or terminated or forfeited Awards, 9and Common Stock subject to any Awards that are otherwise surrendered by the Participant may again be subject to new Awards under the Plan.Â  Shares of Common Stock surrendered to or withheld by the Company in payment or satisfaction of the Purchase Price of an Option or tax withholding obligation with respect to an Award shall be available for the grant of new Awards under the Plan.Â  In the event of the exercise of Stock Appreciation Rights, whether or not granted in tandem with Options, only the number of shares of Common Stock actually issued in payment of such Stock Appreciation Rights shall be charged against the number of shares of Common Stock available for the grant of Awards hereunder.4.04Â Â Â Â Non-Employee Director Compensation. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as compensation for services as a non-employee Director during any calendar year of the Company may not exceed $1,000,000 (increased to $1,500,000 in the calendar year of a non-employee Directorâ€™s initial service as a non-employee director or any calendar year during which a non-employee Director serves as chairman of the Board or lead independent Director, which limits shall not apply to the compensation for any non-employee Director of the Company who serves in any capacity in addition to that of a non-employee Director for which he or she receives additional compensation or any compensation paid to any non-employee Director prior to the calendar year following the calendar year in which the Amendment and Restatement Date occurs). The Administrator may make exceptions to this limit for individual non-employee Directors, as the Administrator may determine in its discretion.ARTICLE VPARTICIPATION5.01Â Â Â Â Eligible Participants.Â  Participants in the Plan shall be such employees, directors and Consultants of the Company and its Subsidiaries as the Administrator, in its sole discretion, may designate from time to time. The Administratorâ€™s designation of a Participant in any year shall not require the Administrator to designate such person to receive Awards or grants in any other year. The designation of a Participant to receive Awards or grants under one portion of the Plan does not require the Administrator to include such Participant under other portions of the Plan. The Administrator shall consider such factors as it deems pertinent in selecting Participants and in determining the type and amount of their respective Awards.10ARTICLE VISTOCK OPTIONS AND STOCK APPRECIATION RIGHTS6.01Â Â Â Â Option Awards.(a)Â Â Â Â Grant of Options.Â  The Administrator may grant, to such Participants as the Administrator may select, Options entitling the Participant to purchase shares of Common Stock from the Company in such number, at such price, and on such terms and subject to such conditions, not inconsistent with the terms of this Plan, as may be established by the Administrator.Â  The terms of any Option granted under this Plan shall be set forth in an Award Agreement.(b)Â Â Â Â Purchase Price of Options.Â  The Purchase Price of each share of Common Stock which may be purchased upon exercise of any Option granted under the Plan shall be determined by the Administrator; provided, however, that in no event shall the Purchase Price be less than the Fair Market Value on the Date of Grant; provided further that, with respect to Canadian persons, in no event shall the Purchase Price be less than the greater of the Fair Market Value on (a) the trading day prior to the Date of Grant and (b) the Date of Grant. (c)Â Â Â Â Designation of Options.Â  The Administrator shall designate, at the time of the grant of each Option, the Option as an Incentive Stock Option or a Non-Qualified Stock Option;Â provided, however,Â that an Option may be designated as an Incentive Stock Option only if the applicable Participant is an employee of the Company or a Subsidiary on the Date of Grant.(d)Â Â Â Â Option Term.Â  The term of each Option shall be fixed by the Administrator, but, subject to the special restrictions applicable to Incentive Stock Options specified in Section 6.01(e), no Option shall be exercisable more than ten (10) years after the Date of Grant.(e)Â Â Â Â Special Incentive Stock Option Rules.Â  No Participant may be granted Incentive Stock Options under the Plan (or any other plans of the Company) that would result in Incentive Stock Options to purchase shares of Common Stock with an aggregate Fair Market Value (measured on the Date of Grant) of more than $100,000 first becoming exercisable by the Participant in any one calendar year.Â  Notwithstanding any other provision of the Plan to the contrary, the Purchase Price of each Incentive Stock Option shall be equal to or greater than the Fair Market Value of the Common Stock subject to the Incentive Stock Option as of the Date of Grant of the Incentive Stock Option;Â provided,Â however, that no Incentive Stock Option shall be granted to any person who, at the time the Option is granted, owns stock (including stock owned by application of the constructive ownership rules in Section 424(d) of the Code) possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company, unless at the time the Incentive Stock Option is granted the price of the Option is at least one hundred ten percent (110%) of the Fair Market Value of the Common Stock subject to the Incentive Stock Option and the Incentive Stock Option by its terms is not exercisable for more than five years from the Date of Grant.11(f)Â Â Â Â Rights as a Stockholder.Â  A Participant or a transferee of an Option pursuant to Section 11.04 shall have no rights as a stockholder with respect to Common Stock covered by an Option until the Participant or transferee shall have become the holder of record of any such shares, and no adjustment shall be made for dividends in cash or other property or distributions or other rights with respect to any such Common Stock for which the record date is prior to the date on which the Participant or a transferee of the Option shall have become the holder of record of any such shares covered by the Option; provided, however, that Participants are entitled to share adjustments to reflect capital changes under Section 11.07.(g)Â Â Â Â Exercise Due to Death or Disability.Â  If an optionee's employment with the Company terminates by reason of death or Disability, the Option may thereafter be immediately exercised, to the extent then exercisable (or on such accelerated basis as the Administrator shall determine at or after the grant), by the legal representative of the optionee, by the legal representative of the estate of the optionee, or by the legatee of the optionee under the will of the optionee, within such period of time as is specified in the Award Agreement from the date of such death or Disability. (h)Â Â Â Â Period of Exercise After Termination of Employment.Â  Except as otherwise provided in this paragraph or otherwise determined by the Administrator, if an optionee's employment with the Company terminates for any reason other than death or Disability (except for termination for Cause), the optionee must exercise his or her Options, to the extent then exercisable (or on such accelerated basis as the Administrator shall determine at or after grant), within such period of time as is specified in the Award Agreement from the date of such termination.Â  If the optionee does not exercise his or her Options within such specified period, the Options automatically terminate, and such Options become null and void.(i)Â Â Â Â Acceleration or Extension of Exercise Time.Â  The Administrator, in its sole discretion, shall have the right (but shall not be obligated), exercisable on or at any time after the Date of Grant, to permit the exercise of an Option or Stock Appreciation Right (i) prior to the time such Option or Stock Appreciation Right would become exercisable under the terms of the Award Agreement, (ii) after the termination of the Option or Stock Appreciation Right under the terms of the Award Agreement, or (iii) after the expiration of the Option or Stock Appreciation Right.6.02Â Â Â Â Stock Appreciation Rights.(a)Â Â Â Â Stock Appreciation Right Awards.Â  The Administrator is authorized to grant to any Participant one or more Stock Appreciation Rights.Â  Such Stock Appreciation Rights may be granted either independent of or in tandem with Options granted to the same Participant. Stock Appreciation Rights granted in tandem with Options may be granted simultaneously with, or, in the case of Non-Qualified Stock Options, subsequent to, the grant to such Participant of the related Option; provided however, that: (i) any Option covering any share of Common Stock shall expire and not be exercisable upon the exercise of any Stock Appreciation Right with respect to the same share, (ii) any Stock Appreciation Right covering any share of Common Stock shall expire and not be exercisable upon the exercise of any related Option with respect to the same share, and (iii) an Option and Stock Appreciation Right covering the same share of 12Common Stock may not be exercised simultaneously.Â  Upon exercise of a Stock Appreciation Right with respect to a share of Common Stock, the Participant shall be entitled to receive an amount equal to the excess, if any, of (A) the Fair Market Value of a share of Common Stock on the date of exercise over (B) the Exercise Price of such Stock Appreciation Right established in the Award Agreement, which amount shall be payable as provided in Section 6.02(c).(b)Â Â Â Â Exercise Price. The Exercise Price established under any Stock Appreciation Right granted under this Plan shall be determined by the Administrator, but in the case of Stock Appreciation Rights granted in tandem with Options shall not be less than the Purchase Price of the related Option; provided, however, that in no event shall the Exercise Price be less than the Fair Market Value on the Date of Grant.Â  Upon exercise of Stock Appreciation Rights granted in tandem with options, the number of shares subject to exercise under any related Option shall automatically be reduced by the number of shares of Common Stock represented by the Option or portion thereof which are surrendered as a result of the exercise of such Stock Appreciation Rights.(c)Â Â Â Â Payment of Incremental Value.Â  Any payment which may become due from the Company by reason of a Participant's exercise of a Stock Appreciation Right may be paid to the Participant as determined by the Administrator (i) all in cash, (ii) all in Common Stock, or (iii) in any combination of cash and Common Stock.Â  In the event that all or a portion of the payment is made in Common Stock, the number of shares of Common Stock delivered in satisfaction of such payment shall be determined by dividing the amount of such payment or portion thereof by the Fair Market Value on the Exercise Date.Â  No fractional share of Common Stock shall be issued to make any payment in respect of Stock Appreciation Rights; if any fractional share would be issuable, the combination of cash and Common Stock payable to the Participant shall be adjusted as directed by the Administrator to avoid the issuance of any fractional share.6.03Â Â Â Â Terms of Stock Options and Stock Appreciation Rights. (a)Â Â Â Â Conditions on Exercise.Â  An Award Agreement with respect to Options or Stock Appreciation Rights may contain such waiting periods, exercise dates and restrictions on exercise (including, but not limited to, periodic installments) as may be determined by the Administrator.Â  In the event the Administrator grants an Option or Stock Appreciation Right that would be subject to Section 409A of the Code, the Administrator may include such additional terms, conditions and restrictions on the exercise of such Option or Stock Appreciation Right as the Administrator deems necessary or advisable in order to comply with the requirements of Section 409A of the Code.(b)Â Â Â Â Duration of Options and Stock Appreciation Rights.Â  Options

and Stock Appreciation Rights shall terminate upon the first to occur of the following events:(i)Â Â Â Â Expiration of the Option or Stock Appreciation Right as provided in the Award Agreement; or13(ii)Â Â Â Â Termination of the Award in the event of a Participant's Disability, retirement, death or other Termination of Service as provided in the Award Agreement; or(iii)Â Â Â Â In the case of an Option, ten years from the Date of Grant (five years in certain cases, as described in Section 6.01(e)); or(iv)Â Â Â Â Solely in the case of a Stock Appreciation Right granted in tandem with an Option, upon the expiration of the related Option.6.04Â Â Â Â Exercise Procedures.Â  Each Option and Stock Appreciation Right granted under the Plan shall be exercised under such procedures and by such methods as the Board may establish or approve from time to time.Â  The Purchase Price of shares purchased upon exercise of an Option granted under the Plan shall be paid in full in cash by the Participant pursuant to the Award Agreement; provided, however, that the Administrator may (but shall not be required to) permit payment to be made (a) except in the case of a Participant that is a Canadian Person, by delivery to the Company of shares of Common Stock held by the Participant, (b) by a â€œnet exerciseâ€ method under which Options are exchanged for a number of shares of Common Stock equal to the number of shares that would otherwise be issued upon the Optionsâ€™ exercise minus a number of shares having a Fair Market Value equal to the Optionsâ€™ aggregate Purchase Price (rounded up to the nearest whole number of shares), or (c) such other consideration as the Administrator deems appropriate and in compliance with applicable law (including payment under an arrangement constituting a brokerage transaction as permitted under the provisions of Regulation T applicable to cashless exercises promulgated by the Federal Reserve Board, unless prohibited by Section 402 of the Sarbanes-Oxley Act of 2002).Â  In the event that any Common Stock shall be transferred to the Company to satisfy all or any part of the Purchase Price, the part of the Purchase Price deemed to have been satisfied by such transfer of Common Stock shall be equal to the product derived by multiplying the Fair Market Value as of the date of exercise times the number of shares of Common Stock transferred to the Company.Â  The Participant may not transfer to the Company in satisfaction of the Purchase Price any fractional share of Common Stock.ARTICLE VIIRESTRICTED SHARES AND RESTRICTED STOCK UNITS7.01Â Â Â Â Award of Restricted Stock and Restricted Stock Units.Â Â The Administrator may grant to any Participant an Award of Restricted Shares consisting of a specified number of shares of Common Stock issued to the Participant subject to such terms, conditions and forfeiture and transfer restrictions, whether based on performance standards, periods of service, retention by the Participant of ownership of specified shares of Common Stock or other criteria, as the Administrator shall establish.Â  The Administrator may also grant Restricted Stock Units representing the right to receive shares of Common Stock in the future subject to such terms, conditions and restrictions, whether based on performance standards, periods of service, retention by the Participant of ownership of specified shares of Common Stock or other criteria, as the Administrator shall establish.Â  The terms of any Restricted Share and Restricted Stock Unit 14Awards granted under this Plan shall be set forth in an Award Agreement which shall contain provisions determined by the Administrator and not inconsistent with this Plan.7.02Â Â Â Â Restricted Shares.(a)Â Â Â Â Issuance of Restricted Shares.Â  As soon as practicable after the Date of Grant of a Restricted Share Award by the Administrator, the Company shall cause to be transferred on the books of the Company, or its agent, Common Stock, registered on behalf of the Participant, evidencing the Restricted Shares covered by the Award, but subject to forfeiture to the Company as of the Date of Grant if an Award Agreement with respect to the Restricted Shares covered by the Award is not duly executed by the Participant and timely returned to the Company.Â  All Common Stock covered by Awards under this Article VII shall be subject to the restrictions, terms and conditions contained in the Plan and the Award Agreement entered into by the Participant.Â  Until the lapse or release of all restrictions applicable to an Award of Restricted Shares, the share certificates representing such Restricted Shares may be held in custody by the Company, its designee, or, if the certificates bear a restrictive legend, by the Participant.Â  Upon the lapse or release of all restrictions with respect to an Award as described in Section 7.02(d), one or more share certificates, registered in the name of the Participant, for an appropriate number of shares as provided in Section 7.02(d), free of any restrictions set forth in the Plan and the Award Agreement shall be delivered to the Participant.(b)Â Â Â Â Stockholder Rights.Â  Beginning on the Date of Grant of the Restricted Share Award and subject to execution of the Award Agreement as provided in Section 7.02(a), the Participant shall become a stockholder of the Company with respect to all shares subject to the Award Agreement and shall have all of the rights of a stockholder, including, but not limited to, the right to vote such shares and the right to receive dividends; provided, however, that any Common Stock distributed as a dividend or otherwise with respect to any Restricted Shares as to which the restrictions have not yet lapsed, shall be subject to the same restrictions as such Restricted Shares and held or restricted as provided in Section 7.02(a).(c)Â Â Â Â Restriction on Transferability.Â  None of the Restricted Shares may be assigned or transferred (other than by will or the laws of descent and distribution, or to a revocable inter vivos trust with respect to which the Participant is treated as the owner under Sections 671 through 677 of the Code, except to the extent that Section 16 of the Exchange Act limits a Participant's right to make such transfers), pledged or sold prior to lapse of the restrictions applicable thereto.(d)Â Â Â Â Delivery of Shares Upon Vesting.Â  Upon expiration or earlier termination of the forfeiture period without a forfeiture and the satisfaction of or release from any other conditions prescribed by the Administrator, or at such earlier time as provided under the provisions of Section 7.04, the restrictions applicable to the Restricted Shares shall lapse.Â  (e)Â Â Â Â Forfeiture of Restricted Shares.Â  Subject to Sections 7.02(f) and 7.04, all Restricted Shares shall be forfeited and returned to the Company and all rights of the Participant with respect to such Restricted Shares shall terminate unless the Participant continues in the service of the Company or an Affiliate as an employee until the expiration of the forfeiture 15period for such Restricted Shares and satisfies any and all other conditions set forth in the Award Agreement.Â  The Administrator shall determine the forfeiture period (which may, but need not, lapse in installments) and any other terms and conditions applicable with respect to any Restricted Share Award.(f)Â Â Â Â Waiver of Forfeiture Period.Â  Notwithstanding anything contained in this Article VII to the contrary, the Administrator may, in its sole discretion, waive the forfeiture period and any other conditions set forth in any Award Agreement under appropriate circumstances (including the death, Disability or Retirement of the Participant or a material change in circumstances arising after the date of an Award) and subject to such terms and conditions (including forfeiture of a proportionate number of the Restricted Shares) as the Administrator shall deem appropriate.7.03Â Â Â Â Restricted Stock Units.(a)Â Â Â Â Settlement of Restricted Stock Units.Â  Payments shall be made to Participants with respect to their Restricted Stock Units as soon as practicable after the Administrator has determined that the terms and conditions applicable to such Award have been satisfied or at a later date if distribution has been deferred.Â  Payments to Participants with respect to Restricted Stock Units shall be made in the form of Common Stock, or cash or a combination of both, as the Administrator may determine.Â  The amount of any cash to be paid in lieu of Common Stock shall be determined on the basis of the Fair Market Value of the Common Stock on the date any such payment is processed.Â  As to shares of Common Stock which constitute all or any part of such payment, the Administrator may impose such restrictions concerning their transferability and/or their forfeiture as may be provided in the applicable Award Agreement or as the Administrator may otherwise determine, provided such determination is made on or before the date certificates for such shares are first delivered to the applicable Participant. Notwithstanding any provision herein to the contrary, no payment shall be made to any Participant that is a Canadian Person in respect of a Restricted Stock Unit later than the end of the third year following the year in respect of which such Restricted Stock Unit was issued.(b)Â Â Â Â Stockholder Rights.Â  Until the lapse or release of all restrictions applicable to an Award of Restricted Stock Units, no shares of Common Stock shall be issued in respect of such Awards and no Participant shall have any rights as a stockholder of the Company with respect to the shares of Common Stock covered by such Award of Restricted Stock Units.(c)Â Â Â Â Waiver of Forfeiture Period.Â  Notwithstanding anything contained in this Section 7.03 to the contrary, the Administrator may, in its sole discretion, waive the forfeiture period and any other conditions set forth in any Award Agreement under appropriate circumstances (including the death, Disability or retirement of the Participant or a material change in circumstances arising after the date of an Award) and subject to such terms and conditions (including forfeiture of a proportionate number of shares issuable upon settlement of the Restricted Stock Units constituting an Award) as the Administrator shall deem appropriate.(d)Â Â Â Â Deferral of Payment.Â  If approved by the Administrator and set forth in the applicable Award Agreement, a Participant may elect to defer the amount payable with respect to 16the Participant's Restricted Stock Units in accordance with such terms as may be established by the Administrator, subject to the requirements of Section 409A of the Code.ARTICLE VIIIPERFORMANCE AWARDS8.01Â Â Â Â Performance Awards.(a)Â Â Â Â Award Periods and Calculations of Potential Incentive Amounts.Â  The Administrator may grant Performance Awards to Participants.Â  A Performance Award shall consist of the right to receive a payment (measured by the Fair Market Value of a specified number of shares of Common Stock, increases in such Fair Market Value during the Award Period and/or a fixed cash amount) contingent upon the extent to which certain performance targets have been met during an Award Period.Â  The Award Period shall be determined by the Administrator.Â  (b)Â Â Â Â Performance Targets.Â  Subject to Section 11.18, the performance targets applicable to a Performance Award may include such goals related to the performance of the Company or, where relevant, any one or more of its Subsidiaries or divisions and/or the performance of a Participant as may be established by the Administrator in its discretion.Â  The performance targets established by the Administrator may vary for different Award Periods and need not be the same for each Participant receiving a Performance Award in an Award Period.(c)Â Â Â Â Earning Performance Awards.Â  The Administrator, at or as soon as practicable after the Date of Grant, shall prescribe a formula to determine the percentage of the Performance Award to be earned based upon the degree of attainment of the applicable performance targets.(d)Â Â Â Â Payment of Earned Performance Awards.Â  Subject to the requirements of Section 11.05, payments of earned Performance Awards shall be made in cash or Common Stock, or a combination of cash and Common Stock, in the discretion of the Administrator.Â  The Administrator, in its sole discretion, may define, and set forth in the applicable Award Agreement, such terms and conditions with respect to the payment of earned Performance Awards as it may deem desirable.8.02Â Â Â Â Termination of Service.Â  In the event of a Participant's Termination of Service during an Award Period, the Participant's Performance Awards shall be forfeited except as may otherwise be provided in the applicable Award Agreement.ARTICLE IXOTHER STOCK-BASED AWARDS9.01Â Â Â Â Grant of Other Stock-Based Awards.Â  Other stock-based awards, consisting of stock purchase rights (with or without loans to Participants by the Company containing such 17terms as the Administrator shall determine), Awards of Common Stock, or Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, may be granted either alone or in addition to or in conjunction with other Awards under the Plan. Subject to the provisions of the Plan, the Administrator shall have sole and complete authority to determine the persons to whom and the time or times at which such Awards shall be made, the number of shares of Common Stock to be granted pursuant to such Awards, and all other conditions of the Awards.Â  Any such Award shall be confirmed by an Award Agreement executed by the Administrator and the Participant, which Award Agreement shall contain such provisions as the Administrator determines to be necessary or appropriate to carry out the intent of this Plan with respect to such Award.9.02Â Â Â Â Terms of Other Stock-Based Awards.Â  In addition to the terms and conditions specified in the Award Agreement, Awards made pursuant to this Article IX shall be subject to the following:(a)Â Â Â Â Any Common Stock subject to Awards made under this Article IX may not be sold, assigned, transferred, pledged or otherwise encumbered prior to the date on which the shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses; and(b)Â Â Â Â If specified by the Administrator in the Award Agreement, the recipient of an Award under this Article IX shall be entitled to receive, currently or on a deferred basis, interest or dividends or dividend equivalents with respect to the Common Stock or other securities covered by the Award; and(c)Â Â Â Â The Award Agreement with respect to any Award shall contain provisions dealing with the disposition of such Award in the event of a Termination of Service prior to the exercise, payment or other settlement of such Award, whether such termination occurs because of Retirement, Disability, death or other reason, with such provisions to take account of the specific nature and purpose of the Award.ARTICLE X[RESERVED]ARTICLE XITERMS APPLICABLE GENERALLY TO AWARDSGRANTED UNDER THE PLAN11.01Â Â Â Â Plan Provisions Control Award Terms.Â  Except as provided in Section 11.16, the terms of the Plan shall govern all Awards granted under the Plan, and in no event shall the Administrator have the power to grant any Award under the Plan which is contrary to any of the provisions of the Plan.Â  In the event any provision of any Award granted under the Plan shall conflict with any term in the Plan as constituted on the Date of Grant of such Award, the term in the Plan shall control.Â  Except as provided in Section 11.03 and Section 11.07, the terms of any 18Award granted under the Plan may not be changed after the Date of Grant of such Award so as to materially decrease the value of the Award without the express written approval of the holder.11.02Â Â Â Â Award Agreement.Â  No person shall have any rights under any Award granted under the Plan unless and until the Company and the Participant to whom such Award shall have been granted shall have executed and delivered an Award Agreement or received any other Award acknowledgment authorized by the Administrator expressly granting the Award to such person and containing provisions setting forth the terms of the Award.11.03Â Â Â Â Modification of Award After Grant.Â  No Award granted under the Plan to a Participant may be modified (unless such modification does not materially decrease the value of the Award) after the Date of Grant except by express written agreement between the Company and the Participant, provided that any such change (a) shall not be inconsistent with the terms of the Plan, and (b) shall be approved by the Administrator.11.04Â Â Â Â Limitation on Transfer.Â  Except as provided in Section 7.02(c) in the case of Restricted Shares, a Participant's rights and interest under the Plan may not be assigned or transferred other than by will or the laws of descent and distribution, and during the lifetime of a Participant, only the Participant personally (or the Participant's personal representative) may exercise rights under the Plan.Â  The Participant's Beneficiary may exercise the Participant's rights to the extent they are exercisable under the Plan following the death of the Participant.11.05Â Â Â Â Taxes.Â  The Company shall be entitled, if the Administrator deems it necessary or desirable, to withhold (or secure payment from the Participant in lieu of withholding) the amount of any withholding or other tax required by law to be withheld or paid by the Company with respect to an Award, and the Company may defer payment or issuance of the cash or shares upon exercise or vesting of an Award unless indemnified to its satisfaction against any liability for any such tax. The amount and method of such withholding or tax payment shall be determined by the Administrator and shall be payable by the Participant at such time as the Administrator determines in accordance with the following rules:(a)Â Â Â Â The Administrator may require or, if approved by the Administrator, the Participant (provided that he or she is not a Canadian Person) may elect, to have the withholding requirement satisfied (i) if approved in advance by the Administrator, by having withheld from such Award at the appropriate time that number of shares of Common Stock, rounded down to the nearest whole share, whose Fair Market Value is equal to the minimum statutory withholding with respect to the Award or such greater amount that is permitted by applicable law and by the Administrator, provided such greater amount does not exceed the maximum statutory rates in the applicable jurisdictions or cause adverse accounting consequences for the Company, (ii) by direct payment to the Company in cash of the amount of any taxes required to be withheld with respect to such Award (iii) by withholding from the wages or other cash compensation paid to the Participant, (iv) by such other method that is approved by the Administrator or (v) by a combination of the foregoing methods. Participants that are Canadian Persons shall be required to meet their withholding requirements in the manner described in paragraph 11.05(a)(ii).19(b)Â Â Â Â In the case of Participants who are subject to Section 16 of the Exchange Act, the Administrator may impose such limitations and restrictions as it deems necessary or appropriate with respect to the sale, delivery or withholding of shares of Common Stock to meet tax withholding obligations.11.06Â Â Â Â Surrender of Awards; Authorization of Repricing.Â  Any Award granted under the Plan may be surrendered to the Company for cancellation on such terms as the Administrator and the holder approve.Â  Without requiring stockholder approval, the Administrator may substitute a new Award under this Plan in connection with the surrender by the Participant of an equity compensation award previously granted under this Plan or any other plan sponsored by the Company, including the substitution or grant of (i) an Option or Stock Appreciation Right with a lower exercise price than the Option or Stock Appreciation Right being surrendered, (ii) a different type of Award upon the surrender or cancellation of an Option or Stock Appreciation Right with an exercise price above the Fair Market Value of the underlying Common Stock on the date of such substitution or grant, or (iii) any other Award constituting a repricing of an Option or Stock Appreciation Right.11.07Â Â Â Â Adjustments to Reflect Capital Changes.(a)Â Â Â Â Recapitalization.Â  In the event of any corporate event or transaction (including, but not limited to, a change in the Common Stock or the capitalization of the Company) such as a merger, consolidation, reorganization, recapitalization, separation, partial or complete liquidation, stock dividend, stock split, reverse stock split, split up, spin-off, or other distribution of stock or property of the Company, a combination or exchange of Common Stock, dividend in kind, or other like change in capital structure, number of outstanding shares of Common Stock, distribution (other than normal cash dividends) to stockholders of the Company, or any similar corporate event or transaction, the Administrator, in order to prevent dilution or enlargement of Participants' rights under this Plan, shall make equitable and appropriate adjustments and substitutions, as applicable, to or of the number and kind of shares subject to outstanding Awards, the Purchase Price or Exercise Price for such shares, the number and kind of shares available for future issuance under the Plan and the maximum number of shares in respect of

which Awards can be made to any Participant in any calendar year, and other determinations applicable to outstanding Awards.Â  The Administrator shall have the power and sole discretion to determine the amount of the adjustment to be made in each case.(b)Â Â Â Â Change in Control. Upon a Change in Control or a merger, reorganization or other transaction following which the Company is not the surviving entity, except as otherwise provided in an Award Agreement or in an employment, change in control, severance or similar agreement to which the Company and the Participant are parties, all outstanding Awards shall be treated in the manner described in the definitive transaction agreement to which the Company is party (or, if there is no such agreement, in the manner determined by the Administrator), which agreement or determination need not treat all Awards in an identical manner. The treatment specified in the definitive transaction agreement or as determined by the Administrator may include, without limitation, one or more of the following with respect to outstanding Awards:(i)Â Â Â Â the cancellation of Awards (whether vested or unvested);20(ii)Â Â Â Â the assumption or substitution of Awards with appropriate adjustments as to the number and kind of Shares or other securities or property and applicable exercise price, base amount or purchase price;(iii)Â Â Â Â the acceleration of vesting of Awards;(iv)Â Â Â Â the cancellation of vested Awards, together with a payment to the Participants holding such vested Awards so canceled of an amount based upon the consideration being paid per Share in connection with such Change in Control or other transaction in cash or, in the sole discretion of the Administrator, in the form of such other consideration necessary for a Participant to receive property, cash or securities (or a combination thereof) as the Participant would have been entitled to receive upon such Change in Control or other transaction, if the Participant had been, immediately prior to such Change in Control, the holder of the number of Shares covered by the Award at such time, less any applicable exercise price or base amount; provided, however, that holders of vested Options and vested SARs shall be entitled to such consideration only if the per-Share consideration exceeds the applicable exercise price or base amount, and to the extent that the per-Share consideration is less than or equal to the applicable exercise price or base amount, such vested Options and vested SARs shall be cancelled for no consideration; or(v)Â Â Â Â the replacement of Awards with a cash incentive program that preserves the value of the Awards so replaced (determined as of such Change in Control or other transaction).(c)Â Â Â Â Acquisition or other Transactions.Â  After any merger, stock purchase, asset purchase or other form of transaction in which the Company or an Affiliate shall be a surviving corporation, the Administrator may grant substituted or assumed Awards under the provisions of the Plan, pursuant to and in compliance with the requirements of Section 424 of the Code or (in the case of Options issued to Canadian Persons) subsection 7(1.4) of the Income Tax Act (Canada), replacing old equity awards granted under a plan of another party to the transaction whose shares or stock subject to the old equity awards may no longer be issued following the transaction.Â  The foregoing adjustments and manner of application of the foregoing provisions shall be determined by the Administrator in its sole discretion.Â  Any such adjustments may provide for the elimination of any fractional shares which might otherwise become subject to any Options. Additionally, available shares under a stockholder approved plan of an acquired company (as appropriately adjusted to reflect such acquisition) may be used for Awards under the Plan and shall not be counted against the Share limit set forth in 4.01, except as required by the rules of any applicable stock exchange.11.08Â Â Â Â No Right to Continued Service.Â  No person shall have any claim of right to be granted an Award under this Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any Participant any right to be retained in the service of the Company or any of its Subsidiaries.11.09Â Â Â Â Awards Not Includable for Benefit Purposes.Â  Payments received by a Participant pursuant to the provisions of the Plan shall not be included in the determination of benefits under 21any pension, group insurance or other benefit plan applicable to the Participant which is maintained by the Company or any of its Subsidiaries, except as may be provided under the terms of such plans or determined by the Board.11.10Â Â Â Â Governing Law.Â  All determinations made and actions taken pursuant to the Plan shall be governed by the laws of NevadaÂ and construed in accordance therewith. 11.11Â Â Â Â No Strict Construction.Â  No rule of strict construction shall be implied against the Company, the Administrator, or any other person in the interpretation of any of the terms of the Plan, any Award granted under the Plan or any rule or procedure established by the Administrator.11.12Â Â Â Â Compliance with Rule 16b-3.Â  It is intended that, unless the Administrator determines otherwise, Awards under the Plan be eligible for exemption under Rule 16b-3.Â  The Board is authorized to amend the Plan and to make any such modifications to Award Agreements to comply with Rule 16b-3, as it may be amended from time to time, and to make any other such amendments or modifications as it deems necessary or appropriate to better accomplish the purposes of the Plan in light of any amendments made to Rule 16b-3.11.13Â Â Â Â Captions.Â  The captions (i.e., all Section headings) used in the Plan are for convenience only, do not constitute a part of the Plan, and shall not be deemed to limit, characterize or affect in any way any provisions of the Plan, and all provisions of the Plan shall be construed as if no captions have been used in the Plan.11.14Â Â Â Â Severability.Â  Whenever possible, each provision in the Plan and every Award at any time granted under the Plan shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of the Plan or any Award at any time granted under the Plan shall be held to be prohibited by or invalid under applicable law, then (a) such provision shall be deemed amended to accomplish the objectives of the provision as originally written to the fullest extent permitted by law and (b) all other provisions of the Plan and every other Award at any time granted under the Plan shall remain in full force and effect.11.15Â Â Â Â Amendment and Termination.(a)Â Â Â Â Amendment.Â  The Board shall have complete power and authority to amend the Plan at any time; provided, however, that the Board shall not, without the requisite affirmative approval of stockholders of the Company, make any amendment which requires stockholder approval under the Code or under any other applicable law or rule of any stock exchange which lists Common Stock or Company Voting Securities.Â  No termination or amendment of the Plan may, without the consent of the Participant to whom any Award shall theretofore have been granted under the Plan, adversely affect the right of such individual under such Award.(b)Â Â Â Â Termination.Â  The Board shall have the right and the power to terminate the Plan at any time. No Award shall be granted under the Plan after the termination of the Plan, but the termination of the Plan shall not have any other effect and any Award outstanding at the 22time of the termination of the Plan may be exercised after termination of the Plan at any time prior to the expiration date of such Award to the same extent such Award would have been exercisable had the Plan not terminated.11.16Â Â Â Â Foreign Qualified Awards.Â  Awards under the Plan may be granted to such employees of the Company and its Subsidiaries who are residing in foreign jurisdictions as the Administrator in its sole discretion may determine from time to time. The Administrator may adopt such supplements to the Plan as may be necessary or appropriate to comply with the applicable laws of such foreign jurisdictions and to afford Participants favorable treatment under such laws; provided, however, that no Award shall be granted under any such supplement with terms or conditions inconsistent with the provision set forth in the Plan.11.17Â Â Â Â Dividend Equivalents.Â  For any Award granted under the Plan, the Administrator shall have the discretion, upon the Date of Grant or thereafter, to establish a Dividend Equivalent Account with respect to the Award, and the applicable Award Agreement or an amendment thereto shall confirm such establishment.Â  If a Dividend Equivalent Account is established, the following terms shall apply:(a)Â Â Â Â Terms and Conditions.Â  Dividend Equivalent Accounts shall be subject to such terms and conditions as the Administrator shall determine and as shall be set forth in the applicable Award Agreement.Â  Such terms and conditions may include, without limitation, for the Participant's Account to be credited as of the record date of each cash dividend on the Common Stock with an amount equal to the cash dividends which would be paid with respect to the number of shares of Common Stock then covered by the related Award if such shares of Common Stock had been owned of record by the Participant on such record date.(b)Â Â Â Â Unfunded Obligation.Â  Dividend Equivalent Accounts shall be established and maintained only on the books and records of the Company and no assets or funds of the Company shall be set aside, placed in trust, removed from the claims of the Company's general creditors, or otherwise made available until such amounts are actually payable as provided hereunder.11.18Â Â Â Â Adjustment of Performance Goals and Targets.Â  Notwithstanding any provision of the Plan to the contrary, the Administrator shall have the authority to adjust any Performance Goal, performance target or other performance-based criteria established with respect to any Award under the Plan if circumstances occur (including, but not limited to, unusual or nonrecurring events, changes in tax laws or accounting principles or practices or changed business or economic conditions) that cause any such Performance Goal, performance target or performance-based criteria to be inappropriate in the judgment of the Administrator.11.19Â Â Â Â Legality of Issuance.Â  Notwithstanding any provision of this Plan or any applicable Award Agreement to the contrary, the Administrator shall have the sole discretion to impose such conditions, restrictions and limitations (including suspending exercises of Options or Stock Appreciation Rights and the tolling of any applicable exercise period during such suspension) on the issuance of Common Stock with respect to any Award unless and until the Administrator determines that such issuance complies with (i) any applicable registration 23requirements under the Securities Act of 1933, as amended, or the Administrator has determined that an exemption therefrom is available, (ii) any applicable listing requirement of any stock exchange on which the Common Stock is listed, (iii) any applicable Company policy or administrative rules, and (iv) any other applicable provision of state, federal or foreign law, including foreign securities laws where applicable.11.20Â Â Â Â Restrictions on Transfer.Â  Regardless of whether the offering and sale of Common Stock under the Plan have been registered under the Securities Act of 1933, as amended, or have been registered or qualified under the securities laws of any state, the Company may impose restrictions upon the sale, pledge, or other transfer of such Common Stock (including the placement of appropriate legends on stock certificates) if, in the judgment of the Company and its counsel, such restrictions are necessary or desirable to achieve compliance with the provisions of the Securities Act of 1933, as amended, the securities laws of any state, the United States or any other applicable foreign law.11.21Â Â Â Â Further Assurances.Â  As a condition to receipt of any Award under the Plan, a Participant shall agree, upon demand of the Company, to do all acts and execute, deliver and perform all additional documents, instruments and agreements which may be reasonably required by the Company, to implement the provisions and purposes of the Plan.11.22Â Â Â Â Provisions for Foreign Participants. The Administrator will have the power, subject to, and within the limitations of, the express provisions of the Plan, to adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to Participants who are foreign nationals or employed outside the United States (provided that Administrator approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).11.23Â Â Â Â Clawback/Recovery.Â Â All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Companyâ€™s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. Â In addition, the Administrator may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired Shares or other cash or property upon the occurrence of Cause. Â No recovery of compensation under such a clawback policy will be an event giving rise to a Participantâ€™s right to voluntary terminate employment upon a â€œresignation for good reasonâ€ or for a â€œconstructive terminationâ€ or any similar term under any plan of or agreement with the Company.24 EX-31.1 3 skye-20240930xex311xsectio.htm EX-31.1 DocumentEXHIBIT 31.1Certification of Principal Executive Officer,Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Punit Dhillon, certify that:1.I have reviewed this quarterly report on Form 10-Q of Skye Bioscience, Inc. for the quarter ended SeptemberÂ 30, 2024;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ Punit DhillonPunit DhillonChief Executive Officer, Chairman of the Board, and DirectorDate: November 7, 2024 EX-31.2 4 skye-20240930xex312xsectio.htm EX-31.2 DocumentEXHIBIT 31.2Certification of Principal Financial Officer,Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Kaitlyn Arsenault, certify that:1.I have reviewed this quarterly report on Form 10-Q of Skye Bioscience, Inc. for the quarter ended SeptemberÂ 30, 2024;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting./s/ Kaitlyn ArsenaultKaitlyn ArsenaultChief Financial Officer(Principal Accounting Officer)Date: November 7, 2024 EX-32.1 5 skye-20240930xex321xsectio.htm EX-32.1 DocumentEXHIBIT 32.1Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002In connection with the Quarterly Report of Skye Bioscience, Inc. a Nevada corporation (the â€œCompanyâ€) on Form 10-Q for the quarter ended SeptemberÂ 30,

2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), Punit Dhillon, Chief Executive Officer, Chairman of the Board, and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request./s/ Punit DhillonPunit DhillonChief Executive Officer, Chairman of the Board, and DirectorDate: November 7, 2024 EX-32.2 6 skye-20240930xex322xsectio.htm EX-32.2 DocumentEXHIBIT 32.2Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350,as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002In connection with the Quarterly Report of Skye Bioscience, Inc. a Nevada corporation (the â€œCompanyâ€) on Form 10-Q for the quarter ended SeptemberÂ 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), Kaitlyn Arsenault, Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request./s/ Kaitlyn ArsenaultKaitlyn ArsenaultChief Financial Officer(Principal Accounting Officer)Date: November 7, 2024 EX-101.SCH 7 skye-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ (DEFICIT) EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ (DEFICIT) EQUITY (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Asset Acquisitions and Dispositions link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Stockholders' Equity and Capitalization link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Loss Per Share of Common Stock link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Asset Acquisitions and Dispositions (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Loss Per Share of Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Asset Acquisitions and Dispositions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Warrants - Schedule of Warrants Vested and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Warrants - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Debt - Schedule of Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Debt - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Stockholders' Equity and Capitalization (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Loss Per Share of Common Stock - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 skye-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 skye-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 skye-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Non-Economic Damages Non-Economic Damages [Member] Non-Economic Damages Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Coverage received to cover legal expenses Loss Contingency, Net Cash Received To Cover Legal Expenses Loss Contingency, Net Cash Received To Cover Legal Expenses Statistical Measurement [Domain] Statistical Measurement [Domain] Prepaid expenses Increase (Decrease) in Prepaid Expense Total net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Schedule of prepaid expenses Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Cover [Abstract] Net increase in cash and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other current liabilities Total other current liabilities Other Liabilities, Current Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Conversion of multi-draw credit agreement - related party and accrued interest (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease liability Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Financing costs allocated to warrants issued with convertible debt Proceeds From Issuance Of Common Stock And Warrants Proceeds From Issuance Of Common Stock And Warrants Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Other current liabilities - related parties Increase (Decrease) in Due to Other Related Parties, Current Disposal group, including discontinued operation, consideration receivable, interest rate Disposal Group, Including Discontinued Operation, Consideration Receivable, Interest Rate Disposal Group, Including Discontinued Operation, Consideration Receivable, Interest Rate Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Plan Name [Domain] Plan Name [Domain] Sale of stock (in dollars per share) Sale of Stock, Price Per Share Proceeds from issuance or sale of equity Proceeds from Issuance or Sale of Equity August 2023 PIPE Financing Common Stock Warrants August 2023 PIPE Financing Common Stock Warrants [Member] August 2023 PIPE Financing Common Stock Warrants Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Prefunded Warrants Pre-Funded Warrants [Member] Pre-Funded Warrants 2021 Common Stock Warrants Two Thousand And Twenty One Common Stock Warrants [Member] Two Thousand And Twenty One Common Stock Warrants Proceeds from convertible note - related party Proceeds from Convertible Debt Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net proceeds from transaction Sale of Stock, Consideration Received on Transaction Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Plan Name [Axis] Plan Name [Axis] Total compensatory damages Loss Contingency, Damages Awarded, Value Prepaid expenses Total prepaid expense Prepaid Expense, Current Warrants Warrants And Derivative Liabilities [Text Block] The entire disclosure for Warrants and Derivative Liabilities. Equity Components [Axis] Equity Components [Axis] Loss contingency accrual, period increase (decrease) Loss Contingency Accrual, Period Increase (Decrease) Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Exercise of pre-funded warrants Stock Issued During Period, Value, Stock Dividend Other current assets Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Right of use asset obtained in exchange for operating lease liabilities Release Of Share Liability To Additional Paid-In-Capital Release Of Share Liability To Additional Paid-In-Capital Insider Trading Policies and Procedures [Line Items] Amount paid Proceeds from Divestiture of Businesses Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid-in-capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Earnings Per Share, Diluted [Abstract] Earnings Per Share, Diluted [Abstract] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Supplemental disclosures of non-cash financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Debt issuance costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] 2016 Common Stock Warrants to Service Providers Two Thousand Sixteen Common Stock Warrants To Service Providers [Member] Represents two thousand sixteen Common Stock Warrants to Service Providers. Estimate for accrued legal contingencies and related expenses Loss Contingency, Accrual, Current Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Debt conversion inducement expense Induced Conversion of Convertible Debt Expense Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Total number of warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Anti-dilutive excluded from the calculation of diluted loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Bird Rock Bio Sub, Inc. (BRB) Bird Rock Bio Sub, Inc. (BRB) [Member] Bird Rock Bio Sub, Inc. (BRB) 2021 Inducement Warrants Two Thousand And Twenty One Inducement Warrants [Member] Two Thousand And Twenty One Inducement Warrants Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Asset Acquisition [Axis] Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accrued interest conversion expense Accrued Interest Conversion Expense Accrued Interest Conversion Expense Share-Based Payment Arrangement, Option Stock options Share-Based Payment Arrangement, Option [Member] Depreciation and amortization Depreciation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total principal value of convertible note - related party, net of discount Convertible 10% Note [Member] Convertible 10% Note Preferred stock, shares outstanding in shares) Preferred Stock, Shares Outstanding Unvested restricted stock units Warrant [Member] Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] January 2024 Pre-Funded Warrants Common Stock March 2024 PIPE Financing Common Stock Warrants [Member] March 2024 PIPE Financing Common Stock Warrants Earnings Per Share, Basic: Earnings Per Share, Basic [Abstract] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Convertible Debt Convertible Debt [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liability, current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Computer equipment Computer Equipment [Member] Accrued interest - related party Increase (Decrease) in Other Accrued Liabilities Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Event [Line Items] Subsequent Event [Line Items] Economic Damages Economic Damages [Member] Economic Damages Total property and equipment, gross Property, Plant and Equipment, Gross Cash from asset acquisition, net of transaction costs Payments for (Proceeds from) Previous Acquisition Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award,

Options, Outstanding, Weighted Average Exercise Price [Abstract] 2019 Common Stock Warrants Two Thousand Nineteen Common Stock Warrants [Member] Information about 2019 common stock warrants. Change in fair value of derivative liabilities Increase (Decrease) in Derivative Liabilities Measured At Grant Date Measured At Grant Date [Member] Measured At Grant Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted average common shares outstanding â€“ diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total stockholdersâ€™ equity (deficit) Beginning balance Ending balance Equity, Attributable to Parent Related Party Related Party [Member] March 2024 PIPE Financing March 2024 PIPE Financing [Member] March 2024 PIPE Financing Litigation Case [Axis] Litigation Case [Axis] Interest (income) expense Interest expense Interest Expense, Nonoperating 2020 Common Stock Warrants to Placement Agent Two Thousand And Twenty Common Stock Warrants To Placement Agent [Member] Two Thousand And Twenty Common Stock Warrants To Placement Agent Accounts payable - related parties Increase (Decrease) in Accounts Payable, Related Parties Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of authorized shares reserved for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Carrying value of total convertible debt - related party Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Warrants Convertible Debt Securities [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Legal fees Legal Professional Fee Accrual Legal Professional Fee Accrual ASSETS Assets [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Equity [Line Items] Equity [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Nonrelated Party Nonrelated Party [Member] Weighted Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term August 2023 Convertible Note Common Stock Warrants August 2023 Convertible Note Common Stock Warrants [Member] August 2023 Convertible Note Common Stock Warrants Non-cash interest expense: Non Cash Interest Expense [Abstract] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Event [Table] Subsequent Event [Table] Maximum Maximum [Member] EHT Acquisition related liabilities Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Cost to acquire IPR&D asset In Process Research and Development Expense In Process Research and Development Expense Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Exercise of common stock warrants Stock Issued During Period, Value, Warrant Exercises Stock Issued During Period, Value, Warrant Exercises Unamortized debt discount Debt Instrument, Unamortized Discount Leasehold improvements Leasehold Improvements [Member] Underlying common stock price (in dollars per share) Shares Issued, Price Per Share Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Schedule of fair value assumptions of stock option granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Asset Acquisitions and Dispositions Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Exercise of pre-funded warrants (in shares) Stock Issued During Period, Shares, Warrant Exercises Stock Issued During Period, Shares, Warrant Exercises Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Stock-based compensation expense (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Schedule of anti-dilutive securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Insurance premium loan payable â€“ stated rate Insurance Premium Expense Insurance Premium Expense Subsequent Event Type [Domain] Subsequent Event Type [Domain] Warrants and Rights Note Disclosure [Abstract] Warrants and Rights Note Disclosure [Abstract] Pronouncements Implemented and Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Schedule of warrants vested and outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Foreign currency remeasurement gain Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Loss from disposal of assets Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Provision for income taxes Income Tax Expense (Benefit) Other (income) expense Nonoperating Income (Expense) [Abstract] Loss contingency, appeal bond Loss Contingency, Appeal Bond Loss Contingency, Appeal Bond Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Vendor deposits Deposits Assets, Current Wendy Cunning Vs Skye Bioscience, Inc Wendy Cunning Vs Skye Bioscience, Inc [Member] Wendy Cunning Vs Skye Bioscience, Inc Warrants issued with convertible note Adjustments to Additional Paid in Capital, Warrant Issued Stock issued during period, shares, acquisitions, period increase (decrease) (in shares) Stock Issued During Period, Shares, Acquisitions, Period Increase (Decrease) Stock Issued During Period, Shares, Acquisitions, Period Increase (Decrease) Net loss Net Income (Loss) Available to Common Stockholders, Diluted Recognized weighted average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total other (income) expense, net Nonoperating Income (Expense) Asset acquisition, equity interest issued or issuable, number of shares (in shares) Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total liabilities and stockholdersâ€™ equity (deficit) Liabilities and Equity Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued payroll liabilities Employee-related Liabilities, Current Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Conversion of accrued interest due to related party Conversion of Accrued Interest Due to Related Party Conversion of Accrued Interest Due to Related Party Equity [Table] Equity [Table] Represents tabular disclosure of Equity. Organization, Basis of Presentation and Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent February 2020 EHT Common Stock Warrants February 2020 EHT Common Stock Warrants [Member] February 2020 EHT Common Stock Warrants Individual: Individual [Axis] 2015 Common Stock Warrants Two Thousand Fifteen Common Stock Warrants [Member] Represents 2015 Common Stock Warrants. Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Total principal value of convertible multi-draw credit agreement - related party Multi Draw Credit Agreement [Member] Represents the information about Multi-Draw Credit Agreement (the "Credit Agreement"). Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Cash and cash equivalents Asset Acquisition, Cash And Cash Equivalents Asset Acquisition, Cash And Cash Equivalents Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Aggregate purchase price Disposal Group, Including Discontinued Operation, Consideration Operating expenses Operating Expenses [Abstract] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Unvested, beginning balance (in dollars per share) Unvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERSâ€™ EQUITY (DEFICIT) Liabilities and Equity [Abstract] Employee benefits and share-based compensation Employee Benefits and Share-Based Compensation Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Common stock Payments for Asset Acquisitions Payments for Asset Acquisitions Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Balance at the beginning (in dollars per share) Balance at the ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Balance at the beginning (in shares) Balance at the ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Common stock warrant exercises Common Stock Warrant Exercises Common Stock Warrant Exercises Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Prepaid Financial Advisory Service Agreement Prepaid Financial Advisory Service Agreement Prepaid Financial Advisory Service Agreement Schedule of other current assets Schedule of Other Current Assets [Table Text Block] Total principal value of convertible note - related party, net of discount Long-Term Debt, Gross Exercise Price Award Exercise Price Related party interest expense â€“ stated rate Interest Expense, Related Party, Stated Rate Interest Expense, Related Party, Stated Rate Other interest expense Interest Expense, Other Asset Acquisition [Table] Asset Acquisition [Table] Loss Per Share of Common Stock Earnings Per Share [Text Block] Accrued payroll liabilities Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Accrued interest - related party Interest Payable, Related Parties, Current Interest Payable, Related Parties, Current Schedule of debt Convertible Debt [Table Text Block] Restricted cash Restricted cash Restricted Cash and Cash Equivalents, Current Stockholdersâ€™ equity (deficit) Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade All Individuals All Individuals [Member] PEO PEO [Member] Name Trading Arrangement, Individual Name Other expense (income) Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Other assets Increase (Decrease) in Other Noncurrent Assets 2021 Common Stock Warrants to Placement Agent Two Thousand And Twenty One Common Stock Warrants To Placement Agent [Member] Two Thousand And Twenty One Common Stock Warrants To Placement Agent Payments for Repurchase of Warrants Payments for Repurchase of Warrants Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Class of warrant or right, average share price, threshold trading days Class Of Warrant Or Right, Average Share Price, Threshold Trading Days Class Of Warrant Or Right, Average Share Price, Threshold Trading Days Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Common stock, capital shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] 2014 Amended and Restated Plan 2014 Amended and Restated Plan [Member] 2014 Amended and Restated Plan Related Party [Domain] Related and Nonrelated Parties [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Other current assets Other Assets, Miscellaneous, Current Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Operating lease, area of leased space Operating Lease, Area of Leased Space Operating Lease, Area of Leased Space Asset Acquisition [Line Items] Asset Acquisition [Line Items] Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Other Current Assets [Text Block] Volatility factor Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Stock issued during period, shares, conversion of units (in shares) Stock Issued During Period, Shares, Conversion of Units Weighted Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] 2021 Inducement Warrants to Placement Agent Two Thousand And Twenty One Inducement Warrants To Placement Agent [Member] Two Thousand And Twenty One Inducement Warrants To Placement Agent Non-current liabilities Liabilities, Noncurrent [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions PEO Total Compensation Amount PEO Total Compensation Amount Operating leases, monthly rental expense Operating Leases, Monthly Rental Expense Operating Leases, Monthly Rental Expense Punitive Damages Punitive Damages [Member] Punitive Damages Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Accrued interest - legal contingency Interest Payable, Current Common stock issuance costs Payments of Stock Issuance Costs Contingencies Commitments and Contingencies Disclosure [Text Block] 2024 Inducement Equity Incentive Plan 2024 Inducement Equity Incentive Plan [Member] 2024 Inducement Equity Incentive Plan Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Number of Warrants Vested and Outstanding (in shares) Class Of Warrant Or Right, Warrants Vested And Outstanding Class Of Warrant Or Right, Warrants Vested And Outstanding Measured At Modification Date Measured At Modification Date [Member] Measured At Modification Date Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of common stock and warrants, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Other accrued liabilities Other Sundry Liabilities, Current Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] AVI Building AVI Building [Member] AVI Building Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity and Capitalization Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] November 2019 EHT Common Stock

Warrants November 2019 EHT Common Stock Warrants [Member] November 2019 EHT Common Stock Warrants Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Wind-down costs Wind-Down Costs Wind-Down Costs City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Changes in assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] (Gain) loss from asset sales (Gain) loss from asset sales Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Stock issued for assets Stock Issued For Assets, Net Of Equity Issuance Costs Stock Issued For Assets, Net Of Equity Issuance Costs Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average fair value of stock options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Loss per common share: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of Nonvested Share Activity Schedule of Nonvested Share Activity [Table Text Block] Supplemental disclosures of cash-flow information: Supplemental Cash Flow Elements [Abstract] Debt issuance costs, gross Debt Issuance Costs, Gross General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Write-down of vendor deposits Vendor Deposit Write-Down Vendor Deposit Write-Down Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Credit Facility [Axis] Credit Facility [Axis] VDL VDL [Member] VDL Prepaid expenses Asset Acquisition, Prepaid Expenses Asset Acquisition, Prepaid Expenses January 2024 PIPE Financing January 2024 PIPE Financing [Member] January 2024 PIPE Financing Amendment Flag Amendment Flag Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Clinical expenses Prepaid Clinical Expenses Prepaid Clinical Expenses Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation, depletion and amortization Depreciation, Depletion and Amortization Machinery and equipment Machinery and Equipment [Member] Convertible note - related party, net of discount Convertible Debt, Current Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain] Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Unamortized debt issuance costs Debt Issuance Costs, Net Debt Debt Disclosure [Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt, face amount Debt Instrument, Face Amount Issuance of common stock and warrants, net of issuance costs of $6,434,447 Stock Issued During Period, Value, New Issues Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Conversion of multi-draw credit agreement Conversion of Multi-Draw Credit Agreement Conversion of Multi-Draw Credit Agreement Common stock, $0.001 par value; 100,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 30,338,290 and 12,349,243 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Common stock issued in acquisition of IPR&D asset Stock Issued During Period, Value, Acquisitions Cash and cash equivalents Cash, and cash equivalents Cash and Cash Equivalents, at Carrying Value IPR&D asset Indefinite-Lived Intangible Assets Acquired Common stock issued in acquisition of IPR&D asset (in shares) Stock Issued During Period, Shares, Acquisitions Other current liabilities Increase (Decrease) in Other Current Liabilities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Asset acquisition, share price (in dollars per share) Asset Acquisition, Share Price Asset Acquisition, Share Price Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.001 par value; 200,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; no shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued AusIndustry incentive Tax Rebate, Current Tax Rebate, Current Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Basic (in dollars per share) Earnings Per Share, Basic Premium on irrevocable letter of credit Premium on Irrevocable Letter of Credit Premium on Irrevocable Letter of Credit Proceeds from the issuance of common stock and warrants, net of equity issuance costs of $6,434,447 and $265,053, respectively Proceeds from Issuance of Common Stock December 2019 EHT Common Stock Warrants December 2019 EHT Common Stock Warrants [Member] December 2019 EHT Common Stock Warrants Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Weighted Average Remaining Contractual Term (Years) Class Of Warrant Or Right, Term Of Warrant Class Of Warrant Or Right, Term Of Warrant Other prepaid expenses Other Prepaid Expense, Current Change in estimate for legal contingencies Gain (Loss) from Estimated Legal Contingency Gain (Loss) from Estimated Legal Contingency Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net loss Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Other tax receivables Income Taxes Receivable, Current Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Financing of insurance premium Financing Of Insurance Premium Financing Of Insurance Premium Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 9) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Title of 12(g) Security Title of 12(g) Security Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Conversion of convertible note - related party to common stock Noncash Conversion of Convertible Note Noncash Conversion of Convertible Note Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Repayment of insurance premium loan payable Repayments of Short-Term Debt Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Total consideration Asset Acquisition, Consideration Transferred Entity Address, City or Town Entity Address, City or Town Common stock issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of stock option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Common stock issued for fractional share adjustment in reverse stock split (in shares) Stock Issued During Period, Shares, Reverse Stock Splits Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net loss for three months ended Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Conversion of multi-draw credit agreement - related party and accrued interest Stock Issued During Period, Value, Conversion of Convertible Securities Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortization of debt discount Amortization of Debt Discount (Premium) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] January 2024 PIPE Financing Pre-Funded Warrants January 2024 PIPE Financing Pre-Funded Warrants [Member] January 2024 PIPE Financing Pre-Funded Warrants Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Weighted average shares of common stock outstanding used to compute earnings per share: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Lessee, operating lease, term (in years) Lessee, Operating Lease, Term of Contract Name Forgone Recovery, Individual Name Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Other current liabilities Asset Acquisition, Other Current Liabilities Asset Acquisition, Other Current Liabilities Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Research and development costs Accrued Research And Development Costs, Current Accrued Research And Development Costs, Current Change in estimate for legal contingencies Loss Contingency Accrual, Provision Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Unvested, beginning balance (in shares) Unvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Asset acquisition, percentage of voting interests acquired Asset Acquisition, Percentage of Voting Interests Acquired Asset Acquisition, Percentage of Voting Interests Acquired Other current assets Increase (Decrease) in Other Current Assets PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Bond premium Bond Premium Bond Premium Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Other Assets And Liabilities, Current [Abstract] Other Assets And Liabilities, Current Fair value of warrants Warrants and Rights Outstanding Adjustment to Compensation: Adjustment to Compensation [Axis] Legal judgment interest (income) expense Legal Fees, Interest Expense Legal Fees, Interest Expense Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Number of market based conditions met Number Of Market Based Conditions Met Number Of Market Based Conditions Met Litigation Case [Domain] Litigation Case [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Amortization of transaction costs Amortization of Debt Issuance Costs Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Accounts payable Asset Acquisition, Accounts Payable Asset Acquisition, Accounts Payable Related Party [Axis] Related and Nonrelated Parties [Axis] Basic (in shares) Weighted average common shares outstanding â€“ basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Proceeds from the sale of assets, net of sales costs Proceeds from Sale of Productive Assets Schedule of interest expense Schedule Of Interest Expense [Table Text Block] Tabular disclosure of interest expense. Restricted Stock Units Restricted Stock Units (RSUs) [Member] Amortization of debt discount Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Professional and consulting fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Schedule of other current liabilities Other Current Liabilities [Table Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Lessee, operating lease, annual rent increase, percent Lessee, Operating Lease, Annual Rent Increase, Percent Lessee, Operating Lease, Annual Rent Increase, Percent Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 11 skye-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 06, 2024 Cover [Abstract] Â Â  Document Type 10-Q Â  Document Quarterly Report true Â  Document Period End Date Sep. 30, 2024 Â  Document Transition Report false Â  Entity File Number 000-55136 Â  Entity Registrant Name Skye Bioscience, Inc. Â  Entity Incorporation, State or Country Code NV Â  Entity Tax Identification Number 45-0692882 Â  Entity Address, Address Line One 11250 El Camino Real, Â  Entity Address, Address Line Two Suite 100 Â  Entity Address, City or Town San Diego Â  Entity Address, State or Province CA Â  Entity Address, Postal Zip Code 92130 Â  City Area Code 858 Â  Local Phone Number 410-0266 Â  Title of 12(g) Security Common Stock, par value $0.001 Â  Trading Symbol SKYE Â  Security Exchange Name NASDAQ Â  Entity Current Reporting Status Yes Â  Entity Interactive Data Current Yes Â  Entity Filer Category Non-accelerated Filer Â  Entity Small Business true Â  Entity Emerging Growth Company false Â  Entity Shell Company false Â  Entity Common Stock, Shares Outstanding Â  30,338,290 Entity Central Index Key 0001516551 Â  Current Fiscal Year End Date --12-31 Â  Amendment Flag false Â  Document Fiscal Year Focus 2024 Â  Document Fiscal Period Focus Q3 Â  X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2

Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(g) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection g + Details Name: dei_Security12gTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â  Cash and cash equivalents $ 67,412,614 $ 1,256,453 Restricted cash 9,080,202 9,080,202 Prepaid expenses 664,604 194,259 Other current assets 2,650,809 1,119,929 Total current assets 79,808,229 11,650,843 Property and equipment, net 1,516,612 43,276 Operating lease right-of-use asset 184,509 237,983 Other assets 26,310 8,309 Total assets 81,535,660 11,940,411 Current liabilities Â Â  Accounts payable 780,025 1,155,785 Accrued interest - related party 0 126,027 Accrued payroll liabilities 903,271 888,381 Accrued interest - legal contingency 0 234,750 Other current liabilities 2,065,658 998,552 Estimate for accrued legal contingencies and related expenses 1,792,337 6,053,468 Convertible note - related party, net of discount 0 4,371,998 Operating lease liability, current portion 82,932 72,038 Total current liabilities 5,624,223 13,900,999 Non-current liabilities Â Â  Operating lease liability, net of current portion 108,062 171,230 Total liabilities 5,732,285 14,072,229 Commitments and contingencies (Note 9) Stockholdersâ€™ equity (deficit) Â Â  Preferred stock, $0.001 par value; 200,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; no shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 0 0 Common stock, $0.001 par value; 100,000,000 shares authorized at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023; 30,338,290 and 12,349,243 shares issued and outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively 30,338 12,349 Additional paid-in-capital 196,976,230 102,238,382 Accumulated deficit (121,203,193) (104,382,549) Total stockholdersâ€™ equity (deficit) 75,803,375 (2,131,818) Total liabilities and stockholdersâ€™ equity (deficit) $ 81,535,660 $ 11,940,411 X - DefinitionInterest Payable, Related Parties, Current + ReferencesNo definition available. + Details Name: skye_InterestPayableRelatedPartiesCurrent Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section

S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Â  Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 200,000 200,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding in shares) 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 100,000,000 100,000,000 Common stock, shares issued (in shares) 30,338,290 12,349,243 Common stock, shares outstanding (in shares) 30,338,290 12,349,243 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses Â Â Â Â  Research and development $ 4,883,337 $ 1,254,653 $ 10,908,538 $ 4,227,967 Cost to acquire IPR&D asset 0 21,215,214 0 21,215,214 General and administrative 4,638,927 2,235,899 13,171,547 5,357,577 Change in estimate for legal contingencies (4,553,468) 0 (4,553,468) (151,842) Total operating expenses 4,968,796 24,705,766 19,526,617 30,648,916 Operating loss (4,968,796) (24,705,766) (19,526,617) (30,648,916) Other (income) expense Â Â Â Â  Interest (income) expense (90,766) 271,307 796,222 476,135 Interest income (907,697) (16,562) (2,296,488) (49,669) (Gain) loss from asset sales (72,837) 0 (1,217,978) 307,086 Debt conversion inducement expense 0 0 0 1,383,285 Wind-down costs 0 (14,677) 0 455,504 Other expense (income) 801 0 2,200 (3) Total other (income) expense, net (1,070,499) 240,068 (2,716,044) 2,572,338 Loss before income taxes (3,898,297) (24,945,834) (16,810,573) (33,221,254) Provision for income taxes 0 0 10,071 3,600 Net loss $ (3,898,297) $ (24,945,834) $ (16,820,644) $ (33,224,854) Loss per common share: Â Â Â Â  Basic (in dollars per share) $ (0.10) $ (3.17) $ (0.48) $ (6.38) Diluted (in dollars per share) $ (0.10) $ (3.17) $ (0.48) $ (6.38) Weighted average shares of common stock outstanding used to compute earnings per share: Â Â Â Â  Basic (in shares) 38,819,387 7,880,546 35,317,352 5,207,411 Diluted (in shares) 38,819,387 7,880,546 35,317,352 5,207,411 X - DefinitionGain (Loss) from Estimated Legal Contingency + ReferencesNo definition available. + Details Name: skye_GainLossFromEstimatedLegalContingency Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIn Process Research and Development Expense + ReferencesNo definition available. + Details Name: skye_InProcessResearchAndDevelopmentExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWind-Down Costs + ReferencesNo definition available. + Details Name: skye_WindDownCosts Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionConsideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 40 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481194/470-20-40-16 + Details Name: us-gaap_InducedConversionOfConvertibleDebtExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name

Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â  Net loss $ (16,820,644) $ (33,224,854) Adjustments to reconcile net loss to net cash used in operating activities: Â Â  Depreciation and amortization 123,347 95,880 Stock-based compensation expense 6,228,270 394,657 Change in fair value of derivative liabilities 0 (3) Amortization of debt discount 599,006 102,400 Write-down of vendor deposits 325,610 0 Change in estimate for legal contingencies (4,553,468) 7,009 (Gain) loss from asset sales (1,217,978) 307,086 Loss from disposal of assets 10,794 0 Debt conversion inducement expense 0 1,383,285 Accrued interest conversion expense 0 (15,952) Cost to acquire IPR&D asset 0 21,215,214 Foreign currency remeasurement gain 0 (45,350) Changes in assets and liabilities: Â Â  Prepaid expenses (470,345) 782,265 Other current assets (1,606,490) (236,779) Other assets (18,000) 0 Accounts payable (375,760) (112,021) Accounts payable - related parties 0 (113,601) Accrued payroll liabilities 14,889 (11,904) Operating lease liability (52,274) (60,647) Other current liabilities 1,109,443 (570,473) Other current liabilities - related parties 0 (95,850) Net cash used in operating activities (17,064,377) (10,107,460) Cash flows from investing activities: Â Â  Proceeds from the sale of assets, net of sales costs 1,217,978 5,532,266 Purchase of property and equipment (1,554,003) (5,533) Cash from asset acquisition, net of transaction costs 0 1,076,740 Net cash (used in) provided by investing activities (336,025) 6,603,473 Cash flows from financing activities: Â Â  Proceeds from convertible note - related party 0 4,973,684 Proceeds from the issuance of common stock and warrants, net of equity issuance costs of $6,434,447 and $265,053, respectively 83,556,563 11,734,947 Financing costs allocated to warrants issued with convertible debt 0 (6,026) Repayment of insurance premium loan payable 0 (236,681) Net cash provided by financing activities 83,556,563 16,465,924 Net increase in cash and restricted cash 66,156,161 12,961,937 Cash, cash equivalents and restricted cash, beginning of period 10,336,655 1,249,107 Cash, cash equivalents and restricted cash, end of period 76,492,816 14,211,044 Reconciliation of cash, cash equivalents and restricted cash: Â Â  Cash, and cash equivalents 67,412,614 5,126,245 Restricted cash 9,080,202 9,084,799 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows 76,492,816 14,211,044 Supplemental disclosures of non-cash financing activities: Â Â  Common stock warrant exercises 0 282,905 Conversion of multi-draw credit agreement 0 1,565,470 Conversion of accrued interest due to related party 0 31,766 Financing of insurance premium 0 203,884 Right of use asset obtained in exchange for operating lease liabilities 0 241,134 Stock issued for assets 0 20,532,846 Conversion of convertible note - related party to common stock 4,971,004 0 Related Party Â Â  Changes in assets and liabilities: Â Â  Accrued interest - related party (126,027) 60,274 Nonrelated Party Â Â  Changes in assets and liabilities: Â Â  Accrued interest - related party $ (234,750) $ 0 X - DefinitionAccrued Interest Conversion Expense + ReferencesNo definition available. + Details Name: skye_AccruedInterestConversionExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon Stock Warrant Exercises + ReferencesNo definition available. + Details Name: skye_CommonStockWarrantExercises Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConversion of Accrued Interest Due to Related Party + ReferencesNo definition available. + Details Name: skye_ConversionOfAccruedInterestDueToRelatedParty Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConversion of Multi-Draw Credit Agreement + ReferencesNo definition available. + Details Name: skye_ConversionOfMultiDrawCreditAgreement Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFinancing Of Insurance Premium + ReferencesNo definition available. + Details Name: skye_FinancingOfInsurancePremium Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIn Process Research and Development Expense + ReferencesNo definition available. + Details Name: skye_InProcessResearchAndDevelopmentExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash Conversion of Convertible Note + ReferencesNo definition available. + Details Name: skye_NoncashConversionOfConvertibleNote Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds From Issuance Of Common Stock And Warrants + ReferencesNo definition available. + Details Name: skye_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRelease Of Share Liability To Additional Paid-In-Capital + ReferencesNo definition available. + Details Name: skye_ReleaseOfShareLiabilityToAdditionalPaidInCapital Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock Issued For Assets, Net Of Equity Issuance Costs + ReferencesNo definition available. + Details Name: skye_StockIssuedForAssetsNetOfEquityIssuanceCosts Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionVendor Deposit Write-Down + ReferencesNo definition available. + Details Name: skye_VendorDepositWriteDown Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b)

-SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in current liabilities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConsideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 40 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481194/470-20-40-16 + Details Name: us-gaap_InducedConversionOfConvertibleDebtExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualProvision Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForProceedsFromPreviousAcquisition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals) - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Statement of Cash Flows [Abstract] Â Â Debt issuance costs $ 6,434,447 $ 265,053 X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ (DEFICIT) EQUITY (UNAUDITED) - USD ($) Total Common Stock Additional Paid-In Capital Accumulated Deficit Beginning balance (in shares) at Dec. 31, 2022 Â 3,654,119 Â Â Beginning balance at Dec. 31, 2022 $ (3,008,054) $ 3,654 $ 63,726,057 $ (66,737,765) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense 131,579 Â 131,579 Â Exercise of pre-funded warrants (in shares) Â 66,566 Â Â Exercise of common stock warrants 282,905 $ 66 282,839 Â Conversion of multi-draw credit agreement - related party and accrued interest (in shares) Â 165,517 Â Â Conversion of multi-draw credit agreement - related party and accrued interest 2,980,521 $ 166 2,980,355 Â Net loss (5,167,520) Â Â (5,167,520) Ending balance (in shares) at Mar. 31, 2023 Â 3,886,202 Â Â Ending balance at Mar. 31, 2023 (4,780,569) $ 3,886 67,120,830 (71,905,285) Beginning balance (in shares) at Dec. 31, 2022 Â 3,654,119 Â Â Beginning balance at Dec. 31, 2022 (3,008,054) $ 3,654 63,726,057 (66,737,765) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Net loss (33,224,854) Â Â Â Ending balance (in shares) at Sep. 30, 2023 Â 12,338,910 Â Â Ending balance at Sep. 30, 2023 1,695,258 $ 12,338 101,645,539 (99,962,619) Beginning balance (in shares) at Mar. 31, 2023 Â 3,886,202 Â Â Beginning balance at Mar. 31, 2023 (4,780,569) $ 3,886 67,120,830 (71,905,285) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense 102,871 Â 102,871 Â Net loss (3,111,500) Â Â (3,111,500) Ending balance (in shares) at Jun. 30, 2023 Â 3,886,202 Â Â Ending balance at Jun. 30, 2023 (7,789,198) $ 3,886 67,223,701 (75,016,785) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense 160,207 Â 160,207 Â Warrants issued with convertible note 925,550 Â 925,550 Â Common stock issued for fractional share adjustment in reverse stock split (in shares) Â 26,349 Â Â Exercise of pre-funded warrants 0 $ 26 (26) Â Issuance of common stock and warrants, net of issuance costs (in shares) Â 2,989,981 Â Â Issuance of common stock and warrants, net of issuance costs of $6,434,447 11,734,947 $ 2,990 11,731,957 Â Common stock issued in acquisition of IPR&D asset (in shares) Â 5,436,378 Â Â Common stock issued in acquisition of IPR&D asset 21,609,586 $ 5,436 21,604,150 Â Net loss (24,945,834) Â Â (24,945,834) Ending balance (in shares) at Sep. 30, 2023 Â 12,338,910 Â Â Ending balance at Sep. 30, 2023 1,695,258 $ 12,338 101,645,539 (99,962,619) Beginning balance (in shares) at Dec. 31, 2023 Â 12,349,243 Â Â Beginning balance at Dec. 31, 2023 (2,131,818) $ 12,349 102,238,382 (104,382,549) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense 2,478,179 Â 2,478,179 Â Issuance of common stock and warrants, net of issuance costs (in shares) Â 15,713,664 Â Â Issuance of common stock and warrants, net of issuance costs of $6,434,447 83,556,563 $ 15,714 83,540,849 Â Net loss (5,019,531) Â Â (5,019,531) Ending balance (in shares) at Mar. 31, 2024 Â 28,062,907 Â Â Ending balance at Mar. 31, 2024 78,883,393 $ 28,063 188,257,410 (109,402,080) Beginning balance (in shares) at Dec. 31, 2023 Â 12,349,243 Â Â Beginning balance at Dec. 31, 2023 (2,131,818) $ 12,349 102,238,382 (104,382,549) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Net loss (16,820,644) Â Â Â Ending balance (in shares) at Sep. 30, 2024 Â 30,338,290 Â Â Ending balance at Sep. 30, 2024 75,803,375 $ 30,338 196,976,230 (121,203,193) Beginning balance (in shares) at Mar. 31, 2024 Â 28,062,907 Â Â Beginning balance at Mar. 31, 2024 78,883,393 $ 28,063 188,257,410 (109,402,080) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense (in shares) Â 5,000 Â Â Stock-based compensation expense 1,828,474 $ 5 1,828,469 Â Net loss (7,902,816) Â Â (7,902,816) Ending balance (in shares) at Jun. 30, 2024 Â 28,067,907 Â Â Ending balance at Jun. 30, 2024 72,809,051 $ 28,068 190,085,879 (117,304,896) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Stock-based compensation expense 1,921,617 Â 1,921,617 Â Common stock issued for fractional share adjustment in reverse stock split (in shares) Â 1,301,410 Â Â Exercise of pre-funded warrants 0 $ 1,301 (1,301) Â Conversion of multi-draw credit agreement - related party and accrued interest (in shares) Â 968,973 Â Â Conversion of multi-draw credit agreement - related party and accrued interest 4,971,004 $ 969 4,970,035 Â Net loss (3,898,297) Â Â (3,898,297) Ending balance (in shares) at Sep. 30, 2024 Â 30,338,290 Â Â Ending balance at Sep. 30, 2024 $ 75,803,375 $ 30,338 $ 196,976,230 $ (121,203,193) X - DefinitionStock Issued During Period, Shares, Warrant Exercises + ReferencesNo definition available. + Details Name: skye_StockIssuedDuringPeriodSharesWarrantExercises Namespace Prefix: skye_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock Issued During Period, Value, Warrant Exercises + ReferencesNo definition available. + Details Name: skye_StockIssuedDuringPeriodValueWarrantExercises Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12:

http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionReduction in the number of shares during the period as a result of a reverse stock split. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued to shareholders as a dividend during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockDividend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -

Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ (DEFICIT) EQUITY (UNAUDITED) (Parenthetical) - USD ($) Mar. 31, 2024 Sep. 30, 2023 Statement of Stockholders' Equity [Abstract] Â  Â  Debt issuance costs, gross $ 6,434,447 $ 265,053 X - DefinitionAmount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DeferredFinanceCostsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Organization, Basis of Presentation and Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â  Organization, Basis of Presentation and Significant Accounting Policies Organization, Basis of Presentation and Significant Accounting PoliciesNature of OperationsSkye Bioscience, Inc. (the â€œCompanyâ€ or â€œSkyeâ€) was incorporated in Nevada on March 16, 2011. The Company is a clinical stage biopharmaceutical company developing next-generation molecules that modulate G protein-coupled receptors to treat obesity and metabolic diseases. As of SeptemberÂ 30, 2024, the Company has devoted substantially all its efforts to securing its product pipeline, carrying out its own research and development, preparing for and conducting clinical trials, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.Basis of PresentationThe accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods. The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, from which the prior year balance sheet information herein was derived. Certain reclassifications have been made to the amounts in prior periods to conform to the current periodâ€™s presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's condensed balance sheet, and condensed statement of cash flows and change in fair value of derivative liability and interest expense on the condensed statement of operations. Such reclassifications did not have a material impact on the Unaudited Condensed Consolidated Financial Statements.During the nine months ended September 30, 2024, there were no changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.Pronouncements ImplementedIn August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entityâ€™s Own Equity (Subtopic 815-40). The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entityâ€™s own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. This standard was effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted this standard as of January 1, 2024 and the adoption of this standard did not have an impact on the Company's Unaudited Condensed Consolidated Financial Statements or related disclosures. Recent Accounting Pronouncements Not Yet AdoptedIn December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entityâ€™s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company does not expect the impact of adopting ASU 2023-09 to be material on its consolidated financial statements.In November 2023, the Financial Account Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2023-07 to be material on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Asset Acquisitions and Dispositions 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â  Asset Acquisitions and Dispositions Asset Acquisitions and DispositionsSale of real estateThe wind down of Emerald Health Therapeutics, Inc. ("EHT's") operations included the disposition of real estate held by Avalite Sciences, Inc. ("AVI") (the "AVI building"). At the time of the Companyâ€™s acquisition of EHT on November 10, 2022 (the â€œEHT Acquisitionâ€), none of the purchase consideration was allocated to the fair value of the AVI building. As a result of the sale of the AVI building, for the nine months ended September 30, 2024, the Company recorded a gain of $1,145,141 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations.Divestiture of VDL, Release and Discharge AgreementOn February 9, 2023, the Company sold VerdÃ©lite Sciences, Inc. ("VDL"). For the nine months ended September 30, 2023, the Company has recorded a loss on sale of asset of $307,086 in other (income) expense based on the difference between the carrying amount of the assets sold and the net cash proceeds. On July 17, 2024, the Company reached a transaction, release and discharge agreement with the purchaser of VDL. Under the transaction, release and discharge agreement, the purchase price of VDL was adjusted in exchange for a full release of any future claims by VDL against the Company. As part of the agreement, the parties agreed to an installment payment schedule for the remaining aggregate balance of the purchase price of $2,047,080 through December 2027. The remainder of the purchase price receivable bears interest at 8%. Upon signing the transaction, release and discharge agreement, the Company received the first installment payment of $72,837 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations.BRB AcquisitionOn AugustÂ 18, 2023, the Company acquired 100% of the equity interests in Bird Rock Bio Sub, Inc. ("BRB") pursuant to an Agreement and Plan of Merger and Reorganization, dated August 15, 2023 (the "BRB Acquisition"). The purpose of the acquisition was to acquire BRB's clinical asset, nimacimab, an antibody targeting the CB1 receptor, for development to treat metabolic conditions. Pursuant to the BRB Acquisition, the Company issued 3,872,184 shares of Company common stock to the former preferred stockholders of BRB equal to $20,000,000 in base merger consideration priced at $5.16.In addition, the former preferred stockholders of BRB were entitled to additional merger consideration for each dollar invested in a concurrent private investment in public equity transaction (the "2023 PIPE Financing"). Because the 2023 PIPE Financing and BRB Acquisition occurred contemporaneously and in contemplation of each other, in accounting for the transaction, the Company allocated the shares issued as additional merger consideration between the BRB Acquisition and 2023 PIPE Financing using a residual allocation method, whereby the fair value of the consideration transferred was first allocated to the monetary assets and 2023 PIPE Financing proceeds with the remainder allocated to the in-process research and development (" IPR&D") asset, nimacimab. As a result, 1,564,194 additional shares of common stock were allocated to the BRB Acquisition. Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: August 18, 2023Purchase considerationCommon stock$21,609,586Â (a)Total consideration$21,609,586Â Assets acquired and liabilities assumed:IPR&D asset$21,215,214Â Cash and cash equivalents1,076,740Â Prepaid expenses4,800Â Accounts payable(73,473)Other current liabilities(613,695)Total net assets acquired$21,609,586Â (a) Equal to the aggregate of 5,436,378 shares of common stock issued, multiplied by the Company's closing stock price of $3.98 as of AugustÂ 18, 2023.The cost to acquire the IPR&D asset, nimacimab, was expensed on the date of the BRB Acquisition as it was determined to have no future alternative use. Accordingly, costs associated with the BRB Acquisition to acquire the asset were expensed as incurred. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities 9 Months Ended Sep. 30, 2024 Other Assets And Liabilities, Current [Abstract] Â  Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Property and Equipment, Prepaid Expenses, Other Current Assets and LiabilitiesProperty and equipment, net consists of the following:As of September 30, 2024As of December 31, 2023Machinery and equipment$1,527,419Â $78,024Â Computer equipment74,868Â 46,732Â Leasehold improvements13,954Â 13,954Â Â Â Total property and equipment, gross1,616,241Â 138,710Â Less: accumulated depreciation(99,629)(95,434)Â Total property and equipment, net$1,516,612Â $43,276Â Depreciation expense for the three and nine months ended September 30, 2024 was $47,519 and $69,873, respectively. Depreciation expense for the three and nine months ended Sepember 30, 2023 was $12,788 and $38,107, respectively.Prepaid expenses consist of the following:As of September 30, 2024As of December 31, 2023Clinical expenses$64,878Â $61,352Â Financial advisory service agreement284,170Â â€”Â Other prepaid expenses315,556Â 132,907Â $664,604Â $194,259Â Other current assets consist of the following:Â As of September 30, 2024As of December 31, 2023AusIndustry incentive$9,033Â $540,604Â Vendor deposits2,216,427Â 403,439Â Other tax receivables3,678Â 158,242Â Other current assets421,671Â 17,644Â $2,650,809Â $1,119,929Â Other current liabilities consist of the following:Â As of September 30, 2024As of December 31, 2023Research and development costs $1,220,041Â $467,784Â Legal fees370,359Â 258,213Â EHT Acquisition related liabilitiesâ€”Â 180,897Â Professional and consulting fees410,512Â 69,468Â Other accrued liabilities64,746Â 22,190Â Â $2,065,658Â $998,552Â  X - DefinitionOther Assets And Liabilities, Current + ReferencesNo definition available. + Details Name: skye_OtherAssetsAndLiabilitiesCurrentAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â  Warrants Warrants There are significant judgements and estimates inherent in the determination of the fair value of the Companyâ€™s warrants. These judgements and estimates include assumptions regarding the Companyâ€™s future operating performance and the determination of the appropriate valuation methods. WarrantsWarrants vested and outstanding as of SeptemberÂ 30, 2024 are summarized as follows:SourceExercisePriceWeightedAverageRemainingContractualTerm(Years)Number ofWarrantsOutstanding2015 Common Stock Warrants$1,250.00Â 0.56400Â 2016 Common Stock Warrants to Service Providers287.50Â 2.08160Â 2019 Common Stock Warrants87.50Â 0.1432,000Â 2020 Common Stock Warrants to Placement Agent20.00Â 0.8332,668Â 2021 Inducement

Warrants37.50Â 1.8184,667Â 2021 Inducement Warrants to Placement Agent47.00Â 1.815,927Â 2021 Common Stock Warrants22.50Â 1.99311,113Â 2021 Common Stock Warrants to Placement Agent27.50Â 1.9921,778Â November 2019 EHT Common Stock Warrants72.25Â 0.1634,213Â December 2019 EHT Common Stock Warrants37.25Â 0.243,783Â February 2020 EHT Common Stock Warrants37.25Â 0.3580,694Â August 2023 Convertible Note Common Stock Warrants5.16Â 8.88340,000Â August 2023 PIPE Financing Common Stock Warrants5.16Â 8.882,325,537Â January 2024 Pre-Funded Warrants Common Stock 0.001Â Indefinite8,677,166Â Total warrants outstanding as of September 30, 202411,950,106Â As of SeptemberÂ 30, 2024, all of the Company's warrants are fully vested.January 2024 Pre-Funded Warrants In connection with the January 2024 PIPE Financing (as defined below), the Company issued the Pre-Funded Warrants (as defined below) (See Note 6). The Pre-Funded Warrants have an exercise price of $0.001 per share, and were exercisable immediately upon issuance until exercised in full. The gross proceeds from the issuance of these Pre-Funded Warrants was $22,991,015. The Company determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability or derivative. The Pre-Funded Warrants are indexed to the Companyâ€™s common stock and meets all other conditions for equity classification. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time issued. The Company also determined that the Pre-Funded Warrants should be included in the determination of basic and diluted earnings per share. ` X - DefinitionThe entire disclosure for Warrants and Derivative Liabilities. + ReferencesNo definition available. + Details Name: skye_WarrantsAndDerivativeLiabilitiesTextBlock Namespace Prefix: skye_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Debt 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â  Debt DebtThe Companyâ€™s convertible debt consists of the following:As of December 31, 2023Total principal value of convertible note - related party, net of discount$5,000,000Â Unamortized debt discount(610,749)Unamortized debt issuance costs(17,253)Carrying value of total convertible debt - related party$4,371,998Â Convertible Note - Related PartyOn AugustÂ 15, 2023, the Company entered into a secured note and warrant purchase agreement (the "Secured Note and Warrant Purchase Agreement") with MFDI, LLC (â€œMFDIâ€), pursuant to which the Company issued to MFDI a $5,000,000 secured convertible promissory note (the "Convertible Note") and a warrant to purchase 340,000 shares of common stock on AugustÂ 18, 2023 (the "Convertible Note Financing") (See Note 4). The Convertible Note had an interest rate of 10% per annum and had a fixed conversion rate of $5.16. On August 8, 2024, MFDI exercised the conversion option under the Convertible Note and converted the full principal balance of $5,000,000 under the Convertible Note. This conversion resulted in the issuance of 968,973 shares of the Company's common stock and the payment of accrued interest in cash, thereby fully satisfying the Company's debt obligations to MFDI. Accrued interest was payable quarterly within 30 days of the last day of each calendar quarter. The debt discounts related to the warrants, and debt issuance costs, were amortized over the term of the Convertible Note using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense in Other (income) expense within the Consolidated Statements of Operations. Through the date of conversion, the Convertible Note is classified as Level 2 of the fair value hierarchy model based on market prices that can be corroborated with observable market data for the Company's common stock. For the three and nine months ended September 30, 2024, the effective interest rate on the Convertible Note was 31.39%. Interest Expense (Income)The Companyâ€™s interest expense consists of the following:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2024202320242023Related party interest expense â€“ stated rate$53,425Â $60,274Â $302,741Â $76,227Â Insurance premium loan payable â€“ stated rateâ€”Â 2,162Â â€“Â 5,764Â Legal judgment interest (income) expense(384,897)(23,320)(234,751)158,851Â Bond premium59,929Â 59,930Â 59,929Â 59,930Â Premium on irrevocable letter of credit 69,297Â 69,861Â 69,297Â 69,861Â Other interest expenseâ€”Â â€“Â â€“Â 3,102Â Non-cash interest expense:Amortization of debt discount108,417Â 99,587Â 582,550Â 99,587Â Amortization of transaction costs3,063Â 2,813Â 16,456Â 2,813Â $(90,766)$271,307Â $796,222Â $476,135Â  X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity and Capitalization 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â  Stockholders' Equity and Capitalization Stockholdersâ€™ Equity and CapitalizationPIPE FinancingsJanuary 2024 PIPE FinancingOn JanuaryÂ 29, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on JanuaryÂ 31, 2024, the Company issued an aggregate of 11,713,664 shares of common stock and 9,978,739 pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 9,978,739 shares of common stock (the "January 2024 PIPE Financing") for an aggregate purchase price of $49,991,010. The January 2024 PIPE Financing was priced at $2.31 per common share and $2.30 per Pre-Funded Warrant based on the 5-day average share price preceding January 29, 2024. The Pre-Funded Warrants are exercisable at any time for an exercise price of $0.001. In connection with the January 2024 PIPE Financing, the Company incurred $3,823,752 in direct equity issuance costs for net proceeds of $46,167,258.March 2024 PIPE FinancingOn MarchÂ 11, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on MarchÂ 13, 2024, the Company issued an aggregate of 4,000,000 shares of common stock (the "March 2024 PIPE Financing") for an aggregate purchase price of $40,000,000. The March 2024 PIPE Financing was priced at $10.00 per common share.In connection with the March 2024 PIPE Financing, the Company incurred $2,610,695 in direct equity issuance costs for net proceeds of approximately $37,389,305.Prefunded Warrant ExerciseOn July 1, 2024, 1,301,573 pre-funded warrants issued in the January 2024 PIPE Financing with an intrinsic value of $10,424,294 were exercised on a cashless basis, resulting in the issuance of 1,301,410 shares of Company's common stock. Conversion of DebtOn August 8, 2024, the Company issued 968,973 shares of common stock to MFDI upon conversion in full of the Convertible Note (see Note 5). X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â  Stock-Based Compensation Stock-Based CompensationStock Incentive PlanOn October 31, 2014, the Board of Directors of the Company ("Board") approved the Companyâ€™s 2014 Omnibus Incentive Plan. On June 14, 2022, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (as amended, the â€œ2014 Amended and Restated Planâ€) which replaced the 2014 Omnibus Incentive Plan in its entirety.On September 29, 2023, the Board and holders of the voting power of the outstanding capital stock of the Company adopted and approved Amendment No. 1 to the 2014 Amended and Restated Plan. Amendment No. 1 to the 2014 Amended and the Restated Plan became effective on November 6, 2023. As of SeptemberÂ 30, 2024, 2,464,345 shares were authorized for the issuance under the 2014 Amended and Restated Plan. As of SeptemberÂ 30, 2024, the Company had 27,578 shares available for future grant under the 2014 Amended and Restated Plan.2024 Inducement Equity Incentive Plan On July 2, 2024, the Board adopted the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). The Inducement Plan was adopted in order to grant share-based awards to newly hired employees as an inducement to join the Company. The terms of the Inducement Plan are substantially similar to the terms of the Companyâ€™s 2014 Amended and Restated Plan with the exception that awards may only be made to an employee who has not previously been an employee or member of the Board of Directors of the Company if the award is in connection with commencement of employment. The Company has reserved 600,000 shares of the Companyâ€™s common stock for issuance pursuant to awards granted under the Inducement Plan. As of SeptemberÂ 30, 2024, the Company had 246,500 shares available for future grant under the Inducement Plan. Stock OptionsThe following is a summary of option activity under the Companyâ€™s 2014 Amended and Restated Plan and the Inducement Plan, for the nine months ended SeptemberÂ 30, 2024:Number ofSharesWeightedAverageExercise PriceWeightedAverageRemainingContractualTerm (Years)Aggregate Intrinsic Value*Outstanding, December 31, 2023498,298Â $8.96Â 7.24$20,441Â Granted1,259,600Â 11.35Â Cancelled(10,048)126.76Â Forfeited(108,496)9.22Â Outstanding, September 30, 20241,639,354Â $10.05Â 8.33$158,794Â Exercisable, September 30, 2024519,839Â $11.36Â 5.76$71,783Â *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Companyâ€™s stock exceeded the exercise price of the stock options at SeptemberÂ 30, 2024 for those stock options for which the quoted market price was in excess of

the exercise price ("in-the-money options").The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2024, was $8.82. The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor81.73% - 99.96%Risk-free interest rate3.69% - 4.48%Expected term (years)5.27 - 6.08Restricted Stock UnitsOn February 29, 2024, the Company granted restricted stock units ("RSUs") to its executive management team and to certain members of the Board with market-based vesting conditions. The RSUs are eligible to vest subject to the achievement and attainment of certain market capitalization target goals and share price targets (market-based vesting conditions). The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market and performance conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions: Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor93.71%Risk-free interest rate4.16%Derived service periods (years)1.27 - 2.48On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor94.3%Risk-free interest rate3.76%Derived service periods (years)2.11 The following is a summary of RSU activity during the period ended SeptemberÂ 30, 2024:Number ofSharesWeighted Average Grant Date Fair ValueUnvested, December 31, 2023847,777Â $3.66Â Granted290,000Â 13.87Â Unvested, September 30, 20241,137,777Â $6.26Â Common Stock Issued for ServicesAdditionally, during the nine months ended SeptemberÂ 30, 2024, the Company issued 5,000 shares of common stock to a service provider as compensation for services provided. Such shares were issued in a private placement outside of the Company's equity incentive plans.Stock-Based Compensation ExpenseThe Company recognizes stock-based compensation expense using the straight-line method over the requisite service period or derived service period. The Company recognized stock-based compensation expense for the stock options and the RSUs discussed above, in its Unaudited Condensed Consolidated Statements of Operations as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Research and development$360,845Â $33,724Â $1,056,564Â $90,725Â General and administrative1,560,772Â 126,483Â 5,171,706Â 303,932Â $1,921,617Â $160,207Â $6,228,270Â $394,657Â During the nine months ended SeptemberÂ 30, 2024, the first three market-based vesting conditions of the RSUs granted in August and September 2023 were met.Stock Compensation Adjustments Related to Board Member ResignationsOn July 2, 2024, the Board accepted the resignations of several Board members effective August 1, 2024. Concurrently, the Board approved a modification to the option awards granted such Board members, which modification accelerated the vesting of all unvested options as of the resignation date and extended the post-termination exercise period to December 31, 2025. As a result of the modification, the Company recognized $274,019 in incremental stock compensation expense during the three and nine months ended SeptemberÂ 30, 2024.The total amount of unrecognized compensation cost was $11,758,346 as of SeptemberÂ 30, 2024. This amount will be recognized over a weighted average period of 2.61 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Loss Per Share of Common Stock 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â  Loss Per Share of Common Stock Loss Per Share of Common StockThe following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)2024202320242023Basic EPS and diluted EPS:Loss (Numerator)Net loss$(3,898,297)$(24,945,834)$(16,820,644)$(33,224,854)Shares (Denominator)Weighted average common shares outstanding, including shares issuable upon the exercise of pre-funded warrants38,819,387Â 7,880,546Â 35,317,352Â 5,207,411Â Per-Share Amount$(0.10)$(3.17)$(0.48)$(6.38)The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)20242023202420232Stock options1,639,354Â 442,803Â 1,639,354Â 442,803Â Warrants3,272,940Â 3,280,940Â 3,272,940Â 3,280,940Â Unvested restricted stock units513,446Â 843,110Â 513,446Â 843,110Â Common shares underlying convertible debtâ€”Â 980,673Â â€”Â 980,673Â  X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â  Contingencies Contingencies General Litigation and DisputesFrom time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Companyâ€™s operations or financial position, liquidity or results of operations.Wendy Cunning vs Skye Bioscience, Inc.The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The case, entitled Wendy Cunning vs Skye Bioscience, Inc., was filed in U.S. District Court (the "District Court") for the Central District of California (the â€œCunning Lawsuitâ€). On January 18, 2023, a jury rendered a verdict in favor of Ms. Cunning and awarded her $512,500 in economic damages (e.g., lost earnings, future earnings and interest), $840,960 in non-economic damages (e.g., emotional distress) and $3,500,000 in punitive damages. On August 2, 2023, the District Court ruled on the plaintiff's motion for attorney fees and awarded the plaintiff $1,200,008. Based on this order, the Company reduced the aggregate estimate for the legal contingency by $151,842, the difference between the attorney fees awarded by the District Court and the Company's previous estimate. On August 17, 2023, the Company obtained a stay on enforcement of the judgment in the Cunning Lawsuit by posting an appeal bond in the amount of $9,080,202. In March of 2023, the Company appealed the judgment in the Cunning Lawsuit to the United States Court of Appeals for the Ninth District (the "Ninth Circuit"). Subsequent to quarter end, on October 22, 2024, the Ninth Circuit issued its decision in the Company's favor which vacated the judgment and remanded the case back to the District Court for a new trial. As a result, the Company will be able to recover the $9,080,202 restriction on its cash related to the bond. Skye Bioscience, Inc. vs Partner Re Ireland InsuranceIn February 2023, the Company brought a suit against the Company's D&O insurance carrier, Partner Re Ireland Insurance DAC ("Partner Re"), bringing claims for (a) breach of contract, (2) tortious breach of the implied covenant of good faith and fair dealing and (3) declaratory relief that Partner Re is obligated to reimburse the Company for the defense fees and costs incurred in defense of the Cunning Lawsuit and must indemnify the Company for any settlement or judgment in the Cunning Lawsuit (the "Partner Re Lawsuit"). The Company's allegations arise out of Partner Re's refusal to reimburse the Company for costs incurred by the Company in defending the Cunning Lawsuit. The case, entitled Skye Bioscience, Inc., v. Partner Re Ireland Insurance DAC, was filed in the United Stated District Court for the Central District of California. On April 17, 2023, Partner Re filed a motion to dismiss the Company's complaint. On June 20, 2023, the court issued a ruling in favor of the Company and denied Partner Re's motion to dismiss the Company's lawsuit. In April 2024, the Company filed a motion for judgment on the pleadings. In June of 2024, the court granted in part and denied in part the Company's motion for judgment on the pleadings. The court granted the Company's motion for judgment on the pleadings with respect to Partner Re's affirmative defense related to whether the Cunning Lawsuit constituted a â€œSecurities Claimâ€ as defined in the Partner Re policy, rejecting what had been Partner Re's primary basis for denying coverage.The Company is pursuing up to $5,000,000 in coverage less the deductible to cover legal expenses incurred and any potential loss incurred from the Cunning Lawsuit. Estimate for accrued legal contingencies and related expenses X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â  Subsequent Events Subsequent EventsApproval of Amended and Restated Omnibus Incentive Plan On October 22, 2024, the Company's stockholders voted to approve the second amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares of the Company's common stock issuable thereunder by 1,535,655 to increase the number of incentive stock options that may be granted thereunder to 4,000,000, extend the expiration date of the plan to September 10, 2034, update the name of the plan to the â€œSkye Bioscience, Inc. Amended and Restated Omnibus Incentive Planâ€ and make certain administrative amendments (as so amended and restated, the "Amended and Restated Plan"). Stock Option GrantsSubsequent to SeptemberÂ 30, 2024, the Company granted an aggregate of 1,456,400 common stock options to members of management, employees and directors under the Amended and Restated Plan. San Francisco Office LeaseOn September 25, 2024, the Company entered into a new lease agreement for approximately 2,077 square feet of office space located at 632 Commercial Street, 5th Floor, San Francisco, California 94111. The lease has a term of three years and two months, beginning on October 1, 2024, with a monthly rent of $9,000 and annual increases of 3%. This office space will support our continued growth and operational needs as we expand our development activities. No material changes to our financial position are anticipated as a result of this lease. Legal ContingenciesSee Note 9 for disclosure of the recognized subsequent event related to our estimate for legal contingencies. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â  Net loss for three months ended $ (3,898,297) $ (7,902,816) $ (5,019,531) $ (24,945,834) $ (3,111,500) $ (5,167,520) $ (16,820,644) $ (33,224,854) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â  Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Organization, Basis of Presentation and Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â  Basis of Presentation Basis of PresentationThe accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods. The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, from which the prior year balance sheet information herein was derived. Certain reclassifications have been made to the amounts in prior periods to conform to the current periodâ€™s presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's condensed balance sheet, and condensed statement of cash flows and change in fair value of derivative liability and interest expense on the condensed statement of operations. Such reclassifications did not have a material impact on the Unaudited Condensed Consolidated Financial Statements. Pronouncements Implemented and Recent Accounting Pronouncements Not Yet Adopted Pronouncements ImplementedIn August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entityâ€™s Own Equity (Subtopic 815-40). The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entityâ€™s own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. This standard was effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted this standard as of January 1, 2024 and the adoption of this standard did not have an impact on the Company's Unaudited Condensed Consolidated Financial Statements or related disclosures. Recent Accounting Pronouncements Not Yet AdoptedIn December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entityâ€™s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company does not expect the impact of adopting ASU 2023-09 to be material on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Asset Acquisitions and Dispositions (Tables) 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â  Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: August 18, 2023Purchase considerationCommon stock$21,609,586Â (a)Total consideration$21,609,586Â Assets acquired and liabilities assumed:IPR&D asset$21,215,214Â Cash and cash equivalents1,076,740Â Prepaid expenses4,800Â Accounts payable(73,473)Other current liabilities(613,695)Total net assets acquired$21,609,586Â (a) Equal to the aggregate of 5,436,378 shares of common stock issued, multiplied by the Company's closing stock price of $3.98 as of AugustÂ 18, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Other Assets And Liabilities, Current [Abstract] Â  Property, Plant and Equipment Property and equipment, net consists of the following:As of September 30, 2024As of December 31, 2023Machinery and equipment$1,527,419Â $78,024Â Computer equipment74,868Â 46,732Â Leasehold improvements13,954Â 13,954Â Â Â Total property and equipment, gross1,616,241Â 138,710Â Less: accumulated depreciation(99,629)(95,434)Â Total property and equipment, net$1,516,612Â $43,276Â  Schedule of prepaid expenses Prepaid expenses consist of the following:As of September 30, 2024As of December 31, 2023Clinical expenses$64,878Â $61,352Â Financial advisory service agreement284,170Â â€”Â Other prepaid expenses315,556Â 132,907Â $664,604Â $194,259Â  Schedule of other current assets Other current assets consist of the following:Â As of September 30, 2024As of December 31, 2023AusIndustry incentive$9,033Â $540,604Â Vendor deposits2,216,427Â 403,439Â Other tax receivables3,678Â 158,242Â Other current assets421,671Â 17,644Â $2,650,809Â $1,119,929Â  Schedule of other current liabilities Other current liabilities consist of the following:Â As of September 30, 2024As of December 31, 2023Research and development costs $1,220,041Â $467,784Â Legal fees370,359Â 258,213Â EHT Acquisition related liabilitiesâ€”Â 180,897Â Professional and consulting fees410,512Â 69,468Â Other accrued liabilities64,746Â 22,190Â Â $2,065,658Â $998,552Â  X - DefinitionOther Assets And Liabilities, Current + ReferencesNo definition available. + Details Name: skye_OtherAssetsAndLiabilitiesCurrentAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other current liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants (Tables) 9 Months Ended Sep. 30, 2024 Warrants and Rights Note Disclosure [Abstract] Â  Schedule of warrants vested and outstanding Warrants vested and outstanding as of SeptemberÂ 30, 2024 are summarized as follows:SourceExercisePriceWeightedAverageRemainingContractualTerm(Years)Number ofWarrantsOutstanding2015 Common Stock Warrants$1,250.00Â 0.56400Â 2016 Common Stock Warrants to Service Providers287.50Â 2.08160Â 2019 Common Stock Warrants87.50Â 0.1432,000Â 2020 Common Stock Warrants to Placement Agent20.00Â 0.8332,668Â 2021 Inducement Warrants37.50Â 1.8184,667Â 2021 Inducement Warrants to Placement Agent47.00Â 1.815,927Â 2021 Common Stock Warrants22.50Â 1.99311,113Â 2021 Common Stock Warrants to Placement Agent27.50Â 1.9921,778Â November 2019 EHT Common Stock Warrants72.25Â 0.1634,213Â December 2019 EHT Common Stock Warrants37.25Â 0.243,783Â February 2020 EHT Common Stock Warrants37.25Â 0.3580,694Â August 2023 Convertible Note Common Stock Warrants5.16Â 8.88340,000Â August 2023 PIPE Financing Common Stock Warrants5.16Â 8.882,325,537Â January 2024 Pre-Funded Warrants Common Stock 0.001Â Indefinite8,677,166Â Total warrants outstanding as of September 30, 202411,950,106Â  X -

DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsNoteDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of debt The Companyâ€™s convertible debt consists of the following:As of December 31, 2023Total principal value of convertible note - related party, net of discount$5,000,000Â Unamortized debt discount(610,749)Unamortized debt issuance costs(17,253)Carrying value of total convertible debt - related party$4,371,998Â Schedule of interest expense The Companyâ€™s interest expense consists of the following:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Related party interest expense â€“ stated rate$53,425Â $60,274Â $302,741Â $76,227Â Insurance premium loan payable â€“ stated rateâ€”Â 2,162Â â€”Â 5,764Â Legal judgment interest (income) expense(384,897)(23,320)(234,751)158,851Â Bond premium59,929Â 59,930Â 59,929Â 59,930Â Premium on irrevocable letter of credit 69,297Â 69,861Â 69,297Â 69,861Â Other interest expenseâ€”Â â€”Â â€”Â 3,102Â Non-cash interest expense:Amortization of debt discount108,417Â 99,587Â 582,550Â 99,587Â Amortization of transaction costs3,063Â 2,813Â 16,456Â 2,813Â $(90,766)$271,307Â $796,222Â $476,135Â X - DefinitionTabular disclosure of interest expense. + ReferencesNo definition available. + Details Name: skye_ScheduleOfInterestExpenseTableTextBlock Namespace Prefix: skye_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of stock option activity The following is a summary of option activity under the Companyâ€™s 2014 Amended and Restated Plan and the Inducement Plan, for the nine months ended SeptemberÂ 30, 2024:Number ofSharesWeightedAverageExercise PriceWeightedAverageRemainingContractualTerm (Years)Aggregate Intrinsic Value*Outstanding, December 31, 2023498,298Â $8.96Â 7.24$20,441Â Granted1,259,600Â 11.35Â Cancelled(10,048)126.76Â Forfeited(108,496)9.22Â Outstanding, September 30, 20241,639,354Â $10.05Â 8.33$158,794Â Exercisable, September 30, 2024519,839Â $11.36Â 5.76$71,783Â *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Companyâ€™s stock exceeded the exercise price of the stock options at SeptemberÂ 30, 2024 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). Schedule of fair value assumptions of stock option granted The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor81.73% - 99.96%Risk-free interest rate3.69% - 4.48%Expected term (years)5.27 - 6.08The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions: Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor93.71%Risk-free interest rate4.16%Derived service periods (years)1.27 - 2.48On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions:Nine Months EndedSeptember 30, 2024Dividend yield0.00%Volatility factor94.3%Risk-free interest rate3.76%Derived service periods (years)2.11 Schedule of Nonvested Share Activity The following is a summary of RSU activity during the period ended SeptemberÂ 30, 2024:Number ofSharesWeighted Average Grant Date Fair ValueUnvested, December 31, 2023847,777Â $3.66Â Granted290,000Â 13.87Â Unvested, September 30, 20241,137,777Â $6.26Â Schedule of stock-based compensation expense The Company recognized stock-based compensation expense for the stock options and the RSUs discussed above, in its Unaudited Condensed Consolidated Statements of Operations as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,20242023202420232Research and development$360,845Â $33,724Â $1,056,564Â $90,725Â General and administrative1,560,772Â 126,483Â 5,171,706Â 303,932Â $1,921,617Â $160,207Â $6,228,270Â $394,657Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Loss Per Share of Common Stock (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of earnings per share, basic and diluted The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)20242023202420232Basic EPS and diluted EPS:Loss (Numerator)Net loss$(3,898,297)$(24,945,834)$(16,820,644)$(33,224,854)Shares (Denominator)Weighted average common shares outstanding, including shares issuable upon the exercise of pre-funded warrants38,819,387Â 7,880,546Â 35,317,352Â 5,207,411Â Per-Share Amount$(0.10)$(3.17)$(0.48)$(6.38) Schedule of anti-dilutive securities The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:Three Months EndedSeptember 30, (Unaudited)Nine Months EndedSeptember 30, (Unaudited)2024202320242023Stock options1,639,354Â 442,803Â 1,639,354Â 442,803Â Warrants3,272,940Â 3,280,940Â 3,272,940Â 3,280,940Â Unvested restricted stock units513,446Â 843,110Â 513,446Â 843,110Â Common shares underlying convertible debtâ€”Â 980,673Â â€”Â 980,673Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Asset Acquisitions and Dispositions - Narrative (Details) - USD ($) 3 Months Ended 9 Months Ended Jul. 17, 2024 Aug. 18, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Asset Acquisition [Line Items] Â Â Â Â Â Â (Gain) loss from asset sales Â Â $ 72,837 $ 0 $ 1,217,978 $ (307,086) Disposal group, including discontinued operation, consideration receivable, interest rate 8.00% Â Â Â Â Â Common stock issued in acquisition of IPR&D asset Â Â Â $ 21,609,586 Â Â Bird Rock Bio Sub, Inc. (BRB) Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â Asset acquisition, percentage of voting interests acquired Â 100.00% Â Â Â Â Common stock issued in acquisition of IPR&D asset (in shares) Â 3,872,184 Â Â Â Â Common stock issued in acquisition of IPR&D asset Â $ 20,000,000 Â Â Â Â Underlying common stock price (in dollars per share) Â $ 5.16 Â Â Â Â Stock issued during period, shares, acquisitions, period increase (decrease) (in shares) Â 1,564,194 Â Â Â Â AVI Building Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â (Gain) loss from asset sales Â Â Â Â $ 1,145,141 Â Discontinued Operations, Disposed of by Sale | VDL Â Â Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Â Â Aggregate purchase price $ 2,047,080 Â Â Â Â Â Amount paid $ 72,837 Â Â Â Â Â X - DefinitionAsset Acquisition, Percentage of Voting Interests Acquired + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionPercentageOfVotingInterestsAcquired Namespace Prefix: skye_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Consideration Receivable, Interest Rate + ReferencesNo definition available. + Details Name: skye_DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableInterestRate Namespace Prefix: skye_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionStock Issued During Period, Shares, Acquisitions, Period Increase (Decrease) + ReferencesNo definition available. + Details Name: skye_StockIssuedDuringPeriodSharesAcquisitionsPeriodIncreaseDecrease Namespace Prefix: skye_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=skye_BirdRockBioSubInc.BRBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=skye_AVIBuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=skye_VDLMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details) - Bird Rock Bio Sub, Inc. (BRB) Aug. 18, 2023 USD ($) $ / shares shares Asset Acquisition [Line Items] Â  Common stock $ 21,609,586 Total consideration 21,609,586 IPR&D asset 21,215,214 Cash and cash equivalents 1,076,740 Prepaid expenses 4,800 Accounts payable (73,473) Other current liabilities (613,695) Total net assets acquired $ 21,609,586 Asset acquisition, equity interest issued or issuable, number of shares (in shares) | shares 5,436,378 Asset acquisition, share price (in dollars per share) | $ / shares $ 3.98 X - DefinitionAsset Acquisition, Accounts Payable + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionAccountsPayable Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAsset Acquisition, Assets Acquired And Liabilities Assumed, Net + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAsset Acquisition, Cash And Cash Equivalents + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionCashAndCashEquivalents Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAsset Acquisition, Equity Interest Issued or Issuable, Number of Shares + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares Namespace Prefix: skye_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAsset Acquisition, Other Current Liabilities + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionOtherCurrentLiabilities Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAsset Acquisition, Prepaid Expenses + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionPrepaidExpenses Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAsset Acquisition, Share Price + ReferencesNo definition available. + Details Name: skye_AssetAcquisitionSharePrice Namespace Prefix: skye_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPayments for Asset Acquisitions + ReferencesNo definition available. + Details Name: skye_PaymentsForAssetAcquisitions Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefinitelivedIntangibleAssetsAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=skye_BirdRockBioSubInc.BRBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â  Â  Total property and equipment, gross $ 1,616,241 $ 138,710 Less: accumulated depreciation (99,629) (95,434) Total property and equipment, net 1,516,612 43,276 Machinery and equipment Â  Â  Property, Plant and Equipment [Line Items] Â  Â  Total property and equipment, gross 1,527,419 78,024 Computer equipment Â  Â  Property, Plant and Equipment [Line Items] Â  Â  Total property and equipment, gross 74,868 46,732 Leasehold improvements Â  Â  Property, Plant and Equipment [Line Items] Â  Â  Total property and equipment, gross $ 13,954 $ 13,954 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â  Â  Â  Â  Depreciation, depletion and amortization $ 47,519 $ 12,788 $ 69,873 $ 38,107 X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Other Assets And Liabilities, Current [Abstract] Â  Â  Clinical expenses $ 64,878 $ 61,352 Prepaid Financial Advisory Service Agreement 284,170 0 Other prepaid expenses 315,556 132,907 Total prepaid expense $ 664,604 $ 194,259 X - DefinitionOther Assets And Liabilities, Current + ReferencesNo definition available. + Details Name: skye_OtherAssetsAndLiabilitiesCurrentAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrepaid Clinical Expenses + ReferencesNo definition available. + Details Name: skye_PrepaidClinicalExpenses Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPrepaid Financial Advisory Service Agreement + ReferencesNo definition available. + Details Name: skye_PrepaidFinancialAdvisoryServiceAgreement Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Other Assets And Liabilities, Current [Abstract] Â  Â  AusIndustry incentive $ 9,033 $ 540,604 Vendor deposits 2,216,427 403,439 Other tax receivables 3,678 158,242 Other current assets 421,671 17,644 Other current assets $ 2,650,809 $ 1,119,929 X - DefinitionOther Assets And Liabilities, Current + ReferencesNo definition available. + Details Name: skye_OtherAssetsAndLiabilitiesCurrentAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTax Rebate, Current + ReferencesNo definition available. + Details Name: skye_TaxRebateCurrent Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_IncomeTaxesReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -

URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsMiscellaneousCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Other Assets And Liabilities, Current [Abstract] Â Â  Research and development costs $ 1,220,041 $ 467,784 Legal fees 370,359 258,213 EHT Acquisition related liabilities 0 180,897 Professional and consulting fees 410,512 69,468 Other accrued liabilities 64,746 22,190 Total other current liabilities $ 2,065,658 $ 998,552 X - DefinitionAccrued Research And Development Costs, Current + ReferencesNo definition available. + Details Name: skye_AccruedResearchAndDevelopmentCostsCurrent Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLegal Professional Fee Accrual + ReferencesNo definition available. + Details Name: skye_LegalProfessionalFeeAccrual Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionOther Assets And Liabilities, Current + ReferencesNo definition available. + Details Name: skye_OtherAssetsAndLiabilitiesCurrentAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionObligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10 + Details Name: us-gaap_OtherSundryLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants - Schedule of Warrants Vested and Outstanding (Details) 9 Months Ended Sep. 30, 2024 $ / shares shares Class of Warrant or Right [Line Items] Â  Number of Warrants Vested and Outstanding (in shares) 11,950,106 2015 Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 1,250 Weighted Average Remaining Contractual Term (Years) 6 months 21 days Number of Warrants Vested and Outstanding (in shares) 400 2016 Common Stock Warrants to Service Providers Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 287.50 Weighted Average Remaining Contractual Term (Years) 2 years 29 days Number of Warrants Vested and Outstanding (in shares) 160 2019 Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 87.50 Weighted Average Remaining Contractual Term (Years) 1 month 20 days Number of Warrants Vested and Outstanding (in shares) 32,000 2020 Common Stock Warrants to Placement Agent Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 20.00 Weighted Average Remaining Contractual Term (Years) 9 months 29 days Number of Warrants Vested and Outstanding (in shares) 32,668 2021 Inducement Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 37.50 Weighted Average Remaining Contractual Term (Years) 1 year 9 months 21 days Number of Warrants Vested and Outstanding (in shares) 84,667 2021 Inducement Warrants to Placement Agent Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 47.00 Weighted Average Remaining Contractual Term (Years) 1 year 9 months 21 days Number of Warrants Vested and Outstanding (in shares) 5,927 2021 Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 22.50 Weighted Average Remaining Contractual Term (Years) 1 year 11 months 26 days Number of Warrants Vested and Outstanding (in shares) 311,113 2021 Common Stock Warrants to Placement Agent Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 27.50 Weighted Average Remaining Contractual Term (Years) 1 year 11 months 26 days Number of Warrants Vested and Outstanding (in shares) 21,778 November 2019 EHT Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 72.25 Weighted Average Remaining Contractual Term (Years) 1 month 28 days Number of Warrants Vested and Outstanding (in shares) 34,213 December 2019 EHT Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 37.25 Weighted Average Remaining Contractual Term (Years) 2 months 26 days Number of Warrants Vested and Outstanding (in shares) 3,783 February 2020 EHT Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 37.25 Weighted Average Remaining Contractual Term (Years) 4 months 6 days Number of Warrants Vested and Outstanding (in shares) 80,694 August 2023 Convertible Note Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 5.16 Weighted Average Remaining Contractual Term (Years) 8 years 10 months 17 days Number of Warrants Vested and Outstanding (in shares) 340,000 August 2023 PIPE Financing Common Stock Warrants Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 5.16 Weighted Average Remaining Contractual Term (Years) 8 years 10 months 17 days Number of Warrants Vested and Outstanding (in shares) 2,325,537 January 2024 Pre-Funded Warrants Common Stock Â  Class of Warrant or Right [Line Items] Â  Exercise price (in dollars per share) | $ / shares $ 0.001 Number of Warrants Vested and Outstanding (in shares) 8,677,166 X - DefinitionClass Of Warrant Or Right, Term Of Warrant + ReferencesNo definition available. + Details Name: skye_ClassOfWarrantOrRightTermOfWarrant Namespace Prefix: skye_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Right, Warrants Vested And Outstanding + ReferencesNo definition available. + Details Name: skye_ClassOfWarrantOrRightWarrantsVestedAndOutstanding Namespace Prefix: skye_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandFifteenCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandNineteenCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyOneInducementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyOneInducementWarrantsToPlacementAgentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyOneCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_November2019EHTCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_December2019EHTCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_February2020EHTCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_August2023ConvertibleNoteCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_August2023PIPEFinancingCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_March2024PIPEFinancingCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Warrants - Narrative (Details) - January 2024 PIPE Financing - USD ($) 1 Months Ended Aug. 15, 2023 Jan. 31, 2024 Jan. 29, 2024 Class of Warrant or Right [Line Items] Â  Â  Â  Exercise price (in dollars per share) Â  Â  $ 2.31 Proceeds from issuance or sale of equity $ 46,167,258 $ 22,991,015 Â  January 2024 PIPE Financing Pre-Funded Warrants Â  Â  Â  Class of Warrant or Right [Line Items] Â  Â  Â  Exercise price (in dollars per share) Â  $ 0.001 $ 0.001 X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=skye_January2024PIPEFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_January2024PIPEFinancingPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Convertible Debt (Details) - Convertible Debt Dec. 31, 2023 USD ($) Total principal value of convertible note - related party, net of discount Â  Debt Instrument [Line Items] Â  Total principal value of convertible note - related party, net of discount $ 5,000,000 Total principal value of convertible multi-draw credit agreement - related party Â  Debt Instrument [Line Items] Â  Unamortized debt discount (610,749) Unamortized debt issuance costs (17,253) Carrying value of total convertible debt - related party $ 4,371,998 X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards

Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=skye_Convertible10NoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=skye_MultiDrawCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Narrative (Details) - Total principal value of convertible note - related party, net of discount - USD ($) Sep. 30, 2024 Aug. 08, 2024 Aug. 15, 2023 Debt Instrument [Line Items] Â Â Â Debt, face amount Â $ 5,000,000 $ 5,000,000 Total number of warrants issued (in shares) Â Â 340,000 Interest rate (as a percent) Â Â 10.00% Debt instrument, interest rate, effective percentage 31.39% Â Â Convertible Debt Â Â Â Debt Instrument [Line Items] Â Â Â Conversion price (in dollars per share) Â Â $ 5.16 X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=skye_Convertible10NoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Schedule of Interest Expense (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt Disclosure [Abstract] Â Â Â Â Related party interest expense â€“ stated rate $ 53,425 $ 60,274 $ 302,741 $ 76,227 Insurance premium loan payable â€“ stated rate 0 2,162 0 5,764 Legal judgment interest (income) expense (384,897) (23,320) (234,751) 158,851 Bond premium 59,929 59,930 59,929 59,930 Premium on irrevocable letter of credit 69,297 69,861 69,297 69,861 Other interest expense 0 0 0 3,102 Non-cash interest expense: Â Â Â Â Amortization of debt discount 108,417 99,587 582,550 99,587 Amortization of transaction costs 3,063 2,813 16,456 2,813 Interest expense $ (90,766) $ 271,307 $ 796,222 $ 476,135 X - DefinitionBond Premium + ReferencesNo definition available. + Details Name: skye_BondPremium Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInsurance Premium Expense + ReferencesNo definition available. + Details Name: skye_InsurancePremiumExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionInterest Expense, Related Party, Stated Rate + ReferencesNo definition available. + Details Name: skye_InterestExpenseRelatedPartyStatedRate Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLegal Fees, Interest Expense + ReferencesNo definition available. + Details Name: skye_LegalFeesInterestExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: skye_NonCashInterestExpenseAbstract Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPremium on Irrevocable Letter of Credit + ReferencesNo definition available. + Details Name: skye_PremiumOnIrrevocableLetterOfCredit Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestExpenseOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity and Capitalization (Details) - USD ($) 1 Months Ended Aug. 08, 2024 Mar. 11, 2024 Jan. 29, 2024 Aug. 15, 2023 Jan. 31, 2024 Aug. 09, 2024 Total principal value of convertible note - related party, net of discount Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Total number of warrants issued (in shares) Â Â Â 340,000 Â Â Total principal value of convertible note - related party, net of discount | Convertible Debt Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Stock issued during period, shares, conversion of units (in shares) 968,973 Â Â Â Â Â Conversion price (in dollars per share) Â Â Â $ 5.16 Â Â January 2024 PIPE Financing Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Number of shares issued in transaction (in shares) Â Â 11,713,664 Â Â Â Exercise price (in dollars per share) Â Â $ 2.31 Â Â Â Common stock issuance costs Â Â Â $ 3,823,752 Â Â Proceeds from issuance or sale of equity Â Â Â $ 46,167,258 $ 22,991,015 Â March 2024 PIPE Financing Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Number of shares issued in transaction (in shares) Â 4,000,000 Â Â Â Â Exercise price (in dollars per share) Â $ 10.00 Â Â Â Â Common stock issuance costs Â $ 2,610,695 Â Â Â Â Proceeds from issuance or sale of equity Â 37,389,305 Â Â Â Â Net proceeds from transaction Â $ 40,000,000 Â Â Â Â January 2024 PIPE Financing Pre-Funded Warrants Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Payments for Repurchase of Warrants Â Â $ 49,991,010 Â Â Â January 2024 PIPE Financing Pre-Funded Warrants | January 2024 PIPE Financing Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Class of warrant or right, outstanding (in shares) Â Â 9,978,739 Â Â Â Exercise price (in dollars per share) Â Â $ 0.001 Â $ 0.001 Â Sale of stock (in dollars per share) Â Â $ 2.30 Â Â Â Class of warrant or right, average share price, threshold trading days Â Â 5 days Â Â Â Prefunded Warrants Â Â Â Â Â Â Equity [Line Items] Â Â Â Â Â Â Class of warrant or right, outstanding (in shares) Â Â Â Â Â 1,301,573 Fair value of warrants Â Â Â Â Â Â $ 10,424,294 Total number of warrants issued (in shares) Â Â Â Â Â 1,301,410 X - DefinitionClass Of Warrant Or Right, Average Share Price, Threshold Trading Days + ReferencesNo definition available. + Details Name: skye_ClassOfWarrantOrRightAverageSharePriceThresholdTradingDays Namespace Prefix: skye_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: skye_EquityLineItems Namespace Prefix: skye_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=skye_Convertible10NoteMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=skye_January2024PIPEFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=skye_March2024PIPEFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_January2024PIPEFinancingPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=skye_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Narrative (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) shares Sep. 30, 2024 USD ($) market_based_condition $ / shares shares Jul. 02, 2024 shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Common stock issued for services (in shares) 5,000 Â Â Amount of unrecognized compensation cost | $ $ 11,758,346 $ 11,758,346 Â Recognized weighted average period (in years) Â 2 years 7 months 9 days Â Employee benefits and share-based compensation | $ $ 274,019 $ 274,019 Â Share-Based Payment Arrangement, Option Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Weighted-average fair value of stock options granted (in dollars per share) | $ / shares Â $ 8.82 Â Restricted Stock Units Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Number of market based conditions met | market_based_condition Â 3 Â 2014 Amended and Restated Plan Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Number of authorized shares reserved for future grants (in shares) 2,464,345 2,464,345 Â Common stock, capital shares reserved for future issuance 27,578 27,578 Â 2024 Inducement Equity Incentive Plan Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares) 246,500 246,500 600,000 X - DefinitionNumber Of Market Based Conditions Met + ReferencesNo definition available. + Details Name: skye_NumberOfMarketBasedConditionsMet Namespace Prefix: skye_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for employee benefit and equity-based compensation. + ReferencesNo definition available. +

Details Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=skye_A2014AmendedAndRestatedPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=skye_A2024InducementEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2014 Amended and Restated Plan - Share-Based Payment Arrangement, Option - USD ($) 3 Months Ended 9 Months Ended Mar. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Number of Shares Â Â Â  Balance at the beginning (in shares) 498,298 498,298 Â  Granted (in shares) Â  1,259,600 Â  Cancelled (in shares) Â  (10,048) Â  Forfeited (in shares) Â  (108,496) Â  Balance at the ending (in shares) Â  1,639,354 Â  Exercisable (in shares) Â  519,839 Â  Weighted Average Exercise Price Â Â Â  Balance at the beginning (in dollars per share) $ 8.96 $ 8.96 Â  Granted (in dollars per share) Â  11.35 Â  Cancelled (in dollars per share) Â  126.76 Â  Forfeited (in dollars per share) Â  9.22 Â  Balance at the ending (in dollars per share) Â  10.05 Â  Exercisable (in dollars per share) Â  $ 11.36 Â  Weighted Average Remaining Contractual Term (Years) Â Â Â  Weighted Average Remaining Contractual Term (Years) 7 years 2 months 26 days 8 years 3 months 29 days Â  Weighted Average Remaining Contractual Term, Exercisable Â  5 years 9 months 3 days Â  Aggregate Intrinsic Value Â  $ 158,794 $ 20,441 Aggregate Intrinsic Value, Exercisable Â  $ 71,783 Â  X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-

types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=skye_A2014AmendedAndRestatedPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) 9 Months Ended Sep. 30, 2024 Minimum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Risk-free interest rate 3.69% Maximum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Risk-free interest rate 4.48% Share-Based Payment Arrangement, Option Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Dividend yield 0.00% Share-Based Payment Arrangement, Option | Minimum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Expected term (years) 5 years 3 months 7 days Share-Based Payment Arrangement, Option | Minimum | Measured At Grant Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Volatility factor 81.73% Share-Based Payment Arrangement, Option | Maximum Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Expected term (years) 6 years 29 days Share-Based Payment Arrangement, Option | Maximum | Measured At Grant Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Volatility factor 99.96% Restricted Stock Units | Measured At Grant Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Dividend yield 0.00% Volatility factor 93.71% Risk-free interest rate 4.16% Restricted Stock Units | Measured At Modification Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Dividend yield 0.00% Volatility factor 94.30% Risk-free interest rate 3.76% Expected term (years) 2 years 1 month 9 days Restricted Stock Units | Minimum | Measured At Grant Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Expected term (years) 1 year 3 months 7 days Restricted Stock Units | Maximum | Measured At Grant Date Â  Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â  Expected term (years) 2 years 5 months 23 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: skye_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAxis=skye_MeasuredAtGrantDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: skye_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAxis=skye_MeasuredAtModificationDateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Restricted Stock Activity (Details) - Restricted Stock Units 9 Months Ended Sep. 30, 2024 $ / shares shares Number of Shares Â  Unvested, beginning balance (in shares) | shares 847,777 Granted (in shares) | shares 290,000 Unvested, ending balance (in shares) | shares 1,137,777 Weighted Average Grant Date Fair Value Â  Unvested, beginning balance (in dollars per share) | $ / shares $ 3.66 Granted (in dollars per share) | $ / shares 13.87 Unvested, ending balance (in dollars per share) | $ / shares $ 6.26 X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type:

xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense $ 1,921,617 $ 160,207 $ 6,228,270 $ 394,657 Research and development Â Â Â Â Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense 360,845 33,724 1,056,564 90,725 General and administrative Â Â Â Â Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Â Â Â Â Stock-based compensation expense $ 1,560,772 $ 126,483 $ 5,171,706 $ 303,932 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share, Basic: Â Â Â Â Net loss $ (3,898,297) $ (24,945,834) $ (16,820,644) $ (33,224,854) Weighted average common shares outstanding â€“ basic (in shares) 38,819,387 7,880,546 35,317,352 5,207,411 Basic (in dollars per share) $ (0.10) $ (3.17) $ (0.48) $ (6.38) Earnings Per Share, Diluted [Abstract] Â Â Â Â Net loss $ (3,898,297) $ (24,945,834) $ (16,820,644) $ (33,224,854) Weighted average common shares outstanding â€“ diluted (in shares) 38,819,387 7,880,546 35,317,352 5,207,411 Diluted (in dollars per share) $ (0.10) $ (3.17) $ (0.48) $ (6.38) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or

earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Loss Per Share of Common Stock - Anti-dilutive Securities (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock options Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive excluded from the calculation of diluted loss per common share (in shares) 1,639,354 442,803 1,639,354 442,803 Warrants Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive excluded from the calculation of diluted loss per common share (in shares) 3,272,940 3,280,940 3,272,940 3,280,940 Unvested restricted stock units Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive excluded from the calculation of diluted loss per common share (in shares) 513,446 843,110 513,446 843,110 Convertible Debt Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive excluded from the calculation of diluted loss per common share (in shares) 0 980,673 0 980,673 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Contingencies - Narrative (Details) - USD ($) 3 Months Ended 9 Months Ended Aug. 02, 2023 Jan. 18, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Aug. 17, 2023 Loss Contingencies [Line Items] Â Â Â Â Â Â Legal judgment interest (income) expense Â Â $ (384,897) $ (23,320) $ (234,751) $ 158,851 Â Coverage received to cover legal expenses Â Â $ 5,000,000 Â $ 5,000,000 Â Â Wendy Cunning Vs Skye Bioscience, Inc Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Total compensatory damages $ 1,200,008 Â Â Â Â Â Â Loss contingency, appeal bond Â Â Â Â Â Â $ 9,080,202 Wendy Cunning Vs Skye Bioscience, Inc | Economic Damages Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Total compensatory damages Â $ 512,500 Â Â Â Â Â Â Wendy Cunning Vs Skye Bioscience, Inc | Non-Economic Damages Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Total compensatory damages Â 840,960 Â Â Â Â Â Â Wendy Cunning Vs Skye Bioscience, Inc | Punitive Damages Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Total compensatory damages Â $ 3,500,000 Â Â Â Â Â Â Loss contingency accrual, period increase (decrease) $ 151,842 Â Â Â Â Â Â Â X - DefinitionLegal Fees, Interest Expense + ReferencesNo definition available. + Details Name: skye_LegalFeesInterestExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLoss Contingency, Appeal Bond + ReferencesNo definition available. + Details Name: skye_LossContingencyAppealBond Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLoss Contingency, Net Cash Received To Cover Legal Expenses + ReferencesNo definition available. + Details Name: skye_LossContingencyNetCashReceivedToCoverLegalExpenses Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of damages awarded to the plaintiff in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesAwardedValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_LitigationCaseAxis=skye_WendyCunningVsSkyeBioscienceIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=skye_EconomicDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=skye_NonEconomicDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=skye_PunitiveDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) 1 Months Ended Oct. 22, 2024 shares Sep. 25, 2024 USD ($) ftÂ² Nov. 07, 2024 shares Subsequent Event [Line Items] Â Â Â Operating lease, area of leased space | ftÂ² Â 2,077 Â Lessee, operating lease, term (in years) Â 3 years 2 months Â Operating leases, monthly rental expense | $ Â $ 9,000 Â Lessee, operating lease, annual rent increase, percent Â 3.00% Â Subsequent Event | 2014 Amended and Restated Plan Â Â Â Subsequent Event [Line Items] Â Â Â Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares) 1,535,655 Â Â Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares) 4,000,000 Â Â Granted (in shares) Â Â 1,456,400 X - DefinitionLessee, Operating Lease, Annual Rent Increase, Percent + ReferencesNo definition available. + Details Name: skye_LesseeOperatingLeaseAnnualRentIncreasePercent Namespace Prefix: skye_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease, Area of Leased Space + ReferencesNo definition available. + Details Name: skye_OperatingLeaseAreaOfLeasedSpace Namespace Prefix: skye_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: duration X - DefinitionOperating Leases, Monthly Rental Expense + ReferencesNo definition available. + Details Name: skye_OperatingLeasesMonthlyRentalExpense Namespace Prefix: skye_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=skye_A2014AmendedAndRestatedPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

<6534&K]./BH664B#0L%G!O8V[MFP<,]HY&7-<4K H]+AY1RH7IW2:\A8O6 MF>. V;Z5=US6E'%G"PR/)V\9-WL-^REQNV^NE?%=PTYG9T?43'C%1G%& K/T MNMX<+:^6F]&C8@NV4SV^WLG^PLU\F9%83$#JG'Z %YY:;PZO3[2<%_NK3U)K MF12',\%#HF!\HM^B' P-02P,$% @ 1(%G68CTZNB)!@ MQQL !@ !X;"]W;W)KU#="E'39@UQ7+=O=9391&F&-YLM)N]^N/LI,XL60WM^N^M%9,4@\I MB@\EGS\J_:U<'F'0CU66EQ>#I3'%F]&HG"W%BI>GJA YO%DHO>(&AOI^5!9: M\'FEM,I&%.-HM. (R'XS/J]]NJ?AK;C^~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

M8W:CBJ:3Z]&I-Q6'6SI /OYYDDK:79C*5Q',1Q M>DQZGU?37D$2!]-IAHUDTU: C^75IV\'E$V3,!E3/"6 Z9ED43&8C=M&L<9(0+D6,VH!Q8BFA[8;[E8R)
M<19F&=*.?!T\5K*X65RQ:SQC*J=3\9R*)$B3<3!.I^Q7KG8NC+! X=UU0]/C M ?1$%=62+PA8"260:Q9,IM,@GDS8-^VX['O-R\XHIGXVCH(XFK"+ S(!XU+^ MI[/]\M#3_#%?-5+>[QI$^+Q+-XKE6JGN&K(5KO3:G^*>!O0-^N"=1CU+NCB] M#1XS8@);)K3M;I_%_\/9FUOH\CUYZSOS7F#)-]1(&>QZ%;;,W'?ZDS87V'"9 M+3$*@6^-6QHPG3"GBA)5!05U68Q04Z.[Q-
2WYT8Y(7O%!0T9"T3+96VTM6A, MYP %MDZC*^JSWJ*(]TD2S&9Q@(VT5;D+U6X<^'!Q=S!F/K,&H"\C MH?!FT+2#RR,+S91V.#3 =8/&5V4W93B3@B^%%.Z>:8.,1FPXW3@/1YM,"ERZ
M(VYZ[\3+V^-@_7&@B)-UVQ8IRANJK$*TLQ,G(8.?#1'()0Y5/_I!*V07>:[] M6)7WP=$([(#M".NTD5W:Y*@%TXA[9 KW.?'#+%.+I! 4+14\F#47Q3M,<U"SR.?
NB*]VF6N+3ZQ:FRI6XD5?;N"E$)NTDO)6<5Y8H)#I+.+P97WNEU:.@M MP5^,+M76&HPE,R%^FI6&<7N] MEGYG;4=;9D31&U'^9+DN+@;3 >1T3II2/XKEG[2S)S+R,E$J^Q^6+:V?#"!K
ME!95QXP(*L;;7_+2^6&+8>J^P>!W#+[%W2JR*&^))I?G4BQ!&FJ49A;65,N- MX!@W07G2$K\RY-.7MW2FSR<:)9G]).NXKELN_PVN%+X(K@L%GWA.\UW^"2+H M8?AK&-?
^48%/M!Y#X#K@NWYX1%[0FQ58><$1L^"6J:P4J]$4_KZ:*2TQ!?XY M9&PK*SPLRY3%J:I)1B\&F/>*RF$SZFP$XRG48DS7Z M>T'A1E0UX:L/[Z:^EYPIR
1_IE*S64DQ8Y$(#Q136H&8@T:&N2BQ.AE?G,*5 M/;RE&:UF5$+@V9@$\%UH4D(M&<]8C:MG4C;4D&X+YT)3^(C%6A)-UY[(@?+/$W M#E?- DL3O*AUCF.=V'D=*-=4(C7C6@
!1;/&;*UO",]AB2@)&E@W,BNPH0!9 M2$JQT:'-1L[@J>/XNN;XV7$\K#FNUAR#$?8+7<"7N]M[!SY_OH&AB;KOGID3 MN_3.1H[195RFT2&P+9A6[" V_D1]^,UP(>:338#6\+=]6$M1(8^0J]:J%O:^ MXQ"; 4]Z@U%^;W,0=N(+@OG;YE%589O&CI?] K'Q\;1+P,-*X(YQ3 4.,JH; M/M'N-!R-NTK8(R\((N(F-A@C%"\QL$:[Y[Z'&O.=<-
Y4%K>EA#E[Z8UO!U'' MQ"-\L[;'?N*;=+ M;T9*F_T611^HMR4:5S"U8P15.+5LCEJ.OJ!09!I/G30)MB*SE2I_J-TX&:SF M5*-E4!"H-7,C)JK>@),B !V9/"59 1DK*.,@?3^&^S7'IRXLP_LN3H?&
M_*OP'AGSWZTEV[X MB%W'3T)^:Q>ADT3>" ?\Ù)E& M'EP+#/D:5Y0ZJ9 .:'VPQN[N'C@:#RZ2DSR*SZ$NJ4;^M")RE3$.<.GZ:F)]I M[.WMVHH\[%FT;_\W<#$7SQ]1YH\9/7W6,W6[AN5,G]!)
(4R>:)A!-?2>*W/7V M5;?!$"G2/JC:RU?@N#'FAS/U O!B)XSB;G,"PQ0O<'$\PJ6/EZO 34RX4Q-O MWURY,/)>$,&A2_1DZT534;FP[S93E0BY?=STI_W3*I]$6W(VW?E%R(7#*=( M2>?(ZHZ3:
"R?:NU&RUJ^SZ:"8VO+;LL\'E+I2' [W.!9=EMC(+^P7SY/U!+ M P04 " !$@6=9F(")294$ 6# &0 'AL+W=OCS=2'6O,"V\^;=XMU'PJ:U-P@0L% MNBY+II[.L9";F1=ZVQ=?
^#HW]D5_/JW8&N_0 %8M%*WZ.Y2,ER@TEP(M>47AZGMCSS8'?.6[TWC/82]92WMO%33;S DL("TR-16#'\8 76!06B&A\:S&] MG4MKN/^\1;]N8=]ED5CA2R^\LSD,V_L088K5A?
FB]Q\QC:>@<5+9:&;_[!Q M9Y/ @[361I:M,3$HN7"?[+'-PY[!N,L@:@VBAK=SU+"\9(;-ITIN0-G3A&8? MFE ;:R+'A2W*G5&TR\G.S.^,.3.]S662H]#NX^E9S\P1,9'#!*FY8P?]B-GO3 MOB%GUJ2?
ML#G#CCJ )[ K10FUW E,LQ>VO>)Y(YIM&5Z'AT%O,.J!W'@0Q1$ MR1&\>!=YW.#%'7AMK'^<+;51)(X_#\7H()+#$+9A3G7%4IQYU!$:U0-Z\[=O MPF'PZ0C!9$) & MU[HF%HRNA36Y6S.#
(%<0AOXHC/WA, &=,RJI?9G*LB1$;;/6)&<CB3T9C?Q1/ M@*K^<55;@<.&*44D-+RW?KP%[5R[G:_MCO?!,JRV8=:573YC=3AT<$>23K!T M-[\,9>>D4CQM(CM)R-,D](,P@!
[\2IC'ZKAAVIE2B@R<1+TXA K5CIFEVJ3" M;@7-UO0<8I$@/H6LE*C(R17&EB;%D)^I*ME$P1,^V*,O3#XW#*J M65=7N^'$PZ-FF6+WL MMJNMWNTE7-
/YG5A",@G]P2@^>%^UE>/BGWK I8%9V1A%TN$I/+"B=A6@*!/R M%4T2V.!S<[K^9Y RG1>HM;T3.-W9) 4:FRQHZW>7#7L+-WR3<%\T;6K?Z1?R MZ=%
[4JUJ1D0Z=8E+8^, ]J7-W1+RT8*6R=$ M=U47A3W0O.V.X?8.^EF2..]&'WJ'AH#^WJQ6HEHW$ZF-JA;&C6V[M[NA M]\S->L_'W<1,:EQ3':# %9D&O=' ^6F4+&ULO5EI<]LV&OXKIVAU:%BGJRN$9.TFO MF3:9N&D_[.P'B(0DU"2A * 4]=?O\P(D10#O^;P7^&JK])U9 M"6'9ESPKS.O>RMKUB\M+DZQ$SDU?K46!-
PNE79JT%3]VF/+N,!H/Q M9O5&DS68@/FIDRS[G>W8A,;5_WPE[]X*-9+ M<2OLI_4'C;O+ADHJ)U[SI\<1/3>K?@=RFVIG7-2).Y4G=T\U/Z
MNC<@@40F$DL4./YMQ!N1940(8GRN:/8:EK2Q?5U3_][I#EWFW(@W*OM#IG;U MNC?ML50L>)G9CVK[HZCT&1&]1&7&_65;OS8>]EA2&JOR:C,DR&7A_,OE1U:
M&Z:#$QNB:D/DY/:,G)1ON>57K[3:,DVK08TNG*IN-X23!3GEUFJ\E=AGKVZM M2NXN;J!7RMZH'+XVG,SUZM*'.JVY3"I*-YY2=(+2C/VB"KLR[%V1BK2[_Q2) M-
:)%M6@WT8,$;\6ZSX:#@$6#*'Z WK!1=>CH#4_16W$M*E4_\!V09=FUUKQ8 M"G?][^NYL1HP^<\QY3WM^#AM"IT79LT3\;]'V#!";T3OZMMOPO'@Y0.2QXWD M\4/4O\I)?
X\2,%^P]?HE5F=\[X>JW5!OQ:K[_J9AJ%DY?&D63O\T+.2W/ MO4_L?RX+P8@K,!"U>7>H.BK7<"* QWB1LH_"6&YQ$R6!HL'+
MTX1HFUL4OCQGVY5,5DA)ZPP>;XEP@IO$SQI&C[2P.Z<8P&U%3I:-9DZ[84<[ ML%ZI+!5P[VZ4E<62K=46>ZIG2+(0KTC1<+7TO*,&>?( V_P5*UMI5)C.:>G
M0_ZOJL]"9M4CQO1>>>HV>MC9RN8B@=&96"R$R\4,N/L5HC@SC+T50-^IO+=/ MG0'P-XC'<3",1\Q0*!L&4PC&2[M26OX%+JA1CJTTIN3P 2LAC7Z:5B>YMNVX
MXBF+)L%H,JU%X!LN,S[/A&.^*&T)D99(*O8KF!,C@"8M$Y^)WGTNI=T=B<:? MRVP',[0DJ_!2^9>>W-[M\%@JDT@! @&1>2J+,R+0:RVCI[WS/OL-SP\>LRT%
M4<48$%?:J:LJ[9U]+N8NT_MA+3TKA!;:+!"*1,Y.M,[009$3*DX8^5OZI M0+-E>R^#%3IOO)0(#!$I();85>N(E*& 'L,*91DJQ$;JTKC5HNBL XAR MC\!*S,=3K?2W3A!
GWR1J**HVAXG=Z+RG,#@;(7MGAW=>;/N\6U85;Y2-AX, M@L%@4"/]A-F(--CXM$,QT 3?NM1TY;Q96^]T,>SS*\.0N!FGAZSL)HW)^,&7KGA9#6OYD&\6Q\SF;]*.J*<5\]L!@/9\%P
M1-S#07\P@CS#(=V,IL%D%K-W7X1.I"&7'R4P"F?!=#BC'9!QS$8DSC,V"8/) M=,B^(U_SQDJRL=*&K$2^)T? ^S7P>:[* F5\OJOJ/SW\7"I2#0BY$Q38$K@_
M$2@^0BA[B+1*U<)K(+H;JPI>01(IYHAN'BC**ZFYP]+1UD;&8+D,$U0'PAR MALQ L\O $&QJXG7=6!;8>R";X3&X.:#["(E,RZXU)4%0;HK6QW\::DINIZ*
M\\")_&S:GT;,"]!ETK+UOTR'I>=8M0D(0)F[$%2^KCAYL;]*$::6Z09-W=W% M;8+^B[*>HW1!=J$%N4I%Q@K\?;+@2'NYUQ2127JUQR%DP[XU,H2+;29&E#'@>
M/&>_JPS==T:Y9,$IM[-IV)\,G[,+-ILA^)ZSC]+<72RT< "%&L8R37(/^^,9 M+8O[\?0Y(F&-;$^@0H%C9SO!M3D'WJ,)EHS[@ZG+/U"!UOB,]ZF@EA0MQ?=B MKDM*<%4?>I!H:Z?
I/0%OXM(1..M]O/T$9%".=SWN%Y&4KI_(><&KP97$I*^]!-BZD! M^!/&J$L^3U92;+P*9\9M=I6FBA'_ M$A9X1-[S;H4M317[A X\YCI3[%;F9>9Y>H!!>$$ )U<[K HMJ21392;F:]PK
M7UFZP5#5V98AW2*L=^W76H5;+6Z6F.JIG27+5_1GSR6'* MCW6AWH'W(.[RLQ>89C"M0*6-N,J?^_ 6>?MO7S3LT9)) 2CR/@K;E;>!S*0L@ MU'>^KK#EL.#
<-8$0?"YS.ZZ>-1OBD,ZOKK?P4_C23"93-#KHDT8-SU[-//S7#CL M3R68=>ICT\:NX.O;_$ZJZPG/SH8 M/CN#IDLAC:>0-
25!A[MQ='^H21*:6L)J%0+GMD1_W#Y"JCBB$>!4W3=D:W>V MY_L$#"K8>!_IPI^AR.8,!7NH03EYR/JN"NUVY#;!7_6N349L[:M3PKY)I8-J MPLE%YLPK,
ND^XRA23*#H>LPLF&/IV23?' 4A39Z#,5 _#&;# MR-&<11AS0PJS$.NC@0NX((HP@D\&Q'X{^/1A+W].P&UD-I0X2/[/-*E=MJ* MNN>735]QT$V0]5S@ 'CU$4H'Z-?IG]CF/?
=19,Z9"%G?YOSBJ<#\]3G^XI MEJ$\TN$<5,-WAP8ID!%T*QUZU.[GM$PZ1/Q/G8:;[2T]162_""^6.]V5UF4 ML1?4&,JB+LMZDO<1#P4."\3(';)QHEYF]G_9(]G@V?1)
X&XC^:%5"CP228>G8+@Z\%5$WY^]D*AET1*GPS"!*?Q108@X&TV#83RN;'F< M.%5O3]=U87/1UM3E4MZ<=;#ZK*-.I OT ^.0N=[@V!>^R]8GV5Q@5*0/SU2> MP,]_G6V>-
M^VK_TGW?UR_V'\%TR:$KC(Q )>!_WJ(;K!/Q P M!@D !X;"]W;W)K&ULI5;?;]LX#/Y7!&\8 M5VB-?R9QNB1 VW6X VY%L=RN#X=[4&PF$2I+GB0WW7]_E)2XR=KFX>XE(67R
M(S^2,CW=*OU@-@"6/#5"FEFTL;:]B&-3;:!A9J!:D/ADI73#+*IZ'9M6 ZN] M4R/B+$E&<<.XC.93?W:GYU/56<$EW&EBNJ9A^N<5"+6=16FT/_C&UQOK#N+Y
MM&5K6(#]WMYIU.(>I>8-2,.5)!I6L^@RO;@JG+TW^(O#UAS(Q#%9*O7@E-_K M692XA$! 91T"P[]'N 8A'!"F\6.'&?4AG>.AO$?_XKDCER4S<*W$/:_M9A:5 M$:EAQ3IAOZGM;
[#C,W1XE1+&_Y)ML,TQ8M49JYJ=,^H-E^&?/>WJ<.!0)F\X M9#N'S.<= ODL/S/+YE.MMD0[:T1S@J?JO3$Y+EU3%E;C4XY^=OZ',H;<@2:+ M#=- U(I4)(E67$"+^\)YQXO?
P/OAFG)Y?J0]-^72V,USL<_K_$- M<,7K<.[.7)B653"+\%(8T(\0S^\2T?)IQ)/%GVRQ2GT_]"=DWBO9WLZ"/ES M V2E!-Y>+!NQ;"G $&?(\%)62E9<<.9O&'I:-)9=
YI9I=%,UGA%I,+!#0>= M@9IPZ>TJ]JI.]*YXMW@5/+CH+-I)?"<)EUR+R1F?7*6:MK/>QUQ@:AK@:.#( M+3(^/G%SXW[R ^G*Q[JY6QS%0_V"^&I\O-
US.".W^RS>DX\Y+2@D1YQAFM,">UT6.4W3Y(5^?31V;FJT^.D*@Y<;)]-R M-V8U+"WY*[,TNP3F6#DT3A_H;_VQHL/=A/>J;7?P :Q<;#"FNI/^R5_&7;;
MLWGX0OC*I)IC%06LT#49C(<1T6'K!L6JUF^ZI;*X-[VXP0\5T,X GZ^4LGO% M!>@_?>;_ E!+ P04 " !$@6=9P%-85\F 1S3=U='O#]N^(^FE>_]%NS)S-H?_'"3GP_&;!"5I )K
MD/BWI&LJ2U8$,WZV.@>;(UFP_[O3_B'Z#E]FTM.U+?_4>5B<#TX&(J="-F7X M8E?_HM:?8]:G;.GC7[%*>X^G Z$:'VS5"L."2IOT7JZU./0$3L9"*$Q;@6FT
M.QT4K7PO@[PXZZFSRJ\I7HH#L>9F(ZG M1_H.]SX=QCU'3[I7U7I@"P*7DB3BRU_Q7OM56E]XTC\]W+F@T.2_.\Q%-(A M1X\?PH7SSM=2T?D
E>')+6EP\>J7R>OQZ3,N'&U<.'I.^\LA^AOBXI]DR,E2 M_*&#GLM4&( %0-1-P/L/SE8BH.Q$L/%_)K0184'"1*V$" &%S7X M+&X U+4T:V3G6LQ(2%%+%]:LI]P^S&*W$WDZ$MM#
()>BHTJI*S_L6Z>D86UT M5S,3+"GN@ZQK:JYG5M]:-FL\7>^9]@0Z>G(+LDE$Q$<5*MGZQ6L+>E.E#2' M;.VL(LJ!$PQ!-N2Z*+3"7M:/F.9:A:&X-*
(QA5Q:)VDWTD_B23K\5U8PR\%$LO;G^L25QIZY$81B'0 M-T8-Q==>)+7O1U$^P I<%198YJZ B!(0M6N"CR5VXGTF9&6Q+04\+!C>3*P< MUHJF%(
!C":3"TMMRQ1QV+U::!]*FJ%E01' 'AD3B'OCG416)6^EF$O'^]=-= M26MQR?@5H(WQ-(LYXBC(4B>52>H:SS#5:'@B5T+.T;-\V,I=1VP$3(:_BES MCM@X^&A62LO()&$A<9I2C4-
J)!1Z6O[A.T0]:=#9F'U$WKBH%]LZG+ O_8P; M& U1#2M^'M MD&L^..0US&Y<$/MLVF![<7# GB3?<"03QV8#P.X!&J4Y8Z?CT\Z:/^3*-SK$ MUBWT:SH>H$(M(D0WFY6#1!";]
M;B&JU 8A(!.,K%WT=LCW9.-E4 M-T9'KFJE(Q"7S1S=74P[&!B_G8BXAL/5DD(-:D30BP)9DTZ-H0';( #(_X+( M;R&S)23V)MDT6G0R%%=(H5:O9DK).WJ\KX*\4:T*.9\
[E#V(&M!HYJY-2B0Z M4)O^ MI?XZ#C279R-$T:F4*V=@L(!JO*VF7GZV40.LN(GRC,P MF9L\8Y@^J6!G>)ZF3#W*>II;)>@3OF%B 3/FI'0@/;%BDKL!&)3,XXL,GB!8,_!D
8L@27TCO<;V#B- M-J8!$*.*Z20FX]S:'$&/$X*)OS#S(3T[!M\/.!L*24F%!L; %04J;7V_&"& MFI4\#:8 .-+5+(Z@?>"ZC,=]#&,BW;.&AOXL2-6V:F1EMZ4U?;?"6*AB(M'(
MP\KH8OW@(/[O*:#_)O)P+Y9MJKR>5^T++K^O6\&-HU,[[$FG?9PRV=9[8>S" MS;?QX)YG\=AQ?;;M2(=$WDTE.S8_.FT\FO.8W88O9][.!++*8OECQ?WRW)&8
MOW:Z[!%_SY9TGNPZ)O!"HZ[ 5SLU%6\#W"O3D-(8@JY^(U'1J);H)+=FQJH_ MH6QQ.M]1R'!);,7M)3/*#ON;SJM[RMV$=MNEHI]^FUF!9+S+1$71F]1ZCOK.
MS!&U]XV$A@LW0OT,3(H3MO'I+*!%,:-Q*F0;;@55(;F=%'!O:C.UE5FU+ MK=89#0[.=Q.^##%S+20JC<>+#8L2O[DQ=^/=")9 +V.O,MJ"$/A@XM7C9IN M>$=3LU-[QSQ-=A-
E)X41K,VAG$>VH-O^EKI;FL_2S9EZ3!"G1,.S3.#*QAY, MQ[WW1+R*"7\UA\!I5*.JV%W#-0M]78AZ0QX[%/(J/?E"A>F>?P^Q^6(,2I] MQ-JL;CX!7J8O7_?;T_=#C%CH9*@A*B
Z'KXY'@B7OLFEAV#K^!UL9C%]5O'G M OE&CC?@?6&!1_O !VP^C%[\'U!+ P04 " !$@6=9SVO^ =D$ #D"@ M&0 'AL+W=OW\B^GJI!,5
M7[/[O;LR6$U'E%*VK*$4B@QO3I.SV9OSA3\?#OPA>6L?/).W9*WUC5]*$^3 MS!/BA@OG$03C^;OF"F\8#@<;G 3,957K!A\][]/?!=MBR%I8O=/.G+%U]FKQ. MJ.2-
Z!OW26]_YL&>I<#,!BT4L5_<3?XX8' Z^P) M@7P0R /OJ"BP_%$XL3HQ>DO&GP::?PBF!FF0D\H'Y=H9[$K(N=5UO[;\N6?E MZ-TM?NW)U '6;TZ+ >
(\0N1/0!S31ZU<;>F=*KD\E)^"SL@IWW,ZSY\%O.9N M0O,LI3S+%_@S4<;YP%O_J4VTE]G:^L,,N+OQ\R-:(O'T7R5O+&=*/@T01E8 M-K>B(;VA,U04PD1"E?2)K1,.
MB\M6R75OZ8,J(( RH:M&*+K$IW!ZS8;R/(8C)5BV$VKWG24D:'%3ZZ9D M8^E6>S"G202%',Y:+C1T":^W]:2\9A,UAS5('6(^2C'/9HNG>$*C5 5ZDHTJ M5=]ZS@"VM8"J_ZLH=-
NB)P3V)*WMQ;H)LH9[Z$:E[VB6+N?+]&BY? 9?CD0B ME.Y\K[$X)1S*=@<+4MV>V[N-UL,B'=5NSQCG0T^[H3:\'V3]F)54*)1;QG+]@51R#X=B*
M::UR09]K#HM$NF6^^X,@0H!FCRC_SC.N-I2.N!E'%8?%/@OXN$SZ4A28,-)! M62G-EE--%%(Y<2=U$R,^ICB7RNY43%?12()8\)Z/!VJ+YR'&8BEWB?BG4# MI]
[W1ZYBD"6_2#B%\Y1+#\S,0J?_20DT?:1)G/5-XNS1ZG[CK$%H9&U*7'.1 MX4NNKN#C%B'\1:<_%O@[3/L7 G:56R()#[67)P.X-DCF+68?3IYY+*CBW6I]
M)93W#=97ZX]Q93)_/D:R;8*8D]8"T#?'3G?E=?W,>;>U\DKWZ^;3;"URL3I MB_ED.7\6][SMPR*%ST^4;]GF"2N+33YFT()@(AR*POL='J%B(X0..I<E\NSB:G M4)OJH\%4BL
QN70Y8B1OLE1TA&EB@4 H#7I997/2OJWZ;$10&[24DCKKFB>GI-(-.QVUT, *S_4G22&U M:LIB2NFVKXIMH])\X*BR[*X.['T:([""^0K$P%^6<"W1V")&")+.::+ZHA8<.\+2Q
L0XTG$] MAT':>G;LJ/^N95Q_>A)3^_Y*!3J9S'\8<^ERB,6D"SZ^-IC92'R0G\7;(8[H M59;L8V:+@89=!KARBYMMGQ5'0^(&+]-H(2Y.'XP_9?-WP[ (."T&.CJ1!35H
M;TD8KL8K+_\.=>)/)9@0!!+NU0.$LJXUEP-8PY-K/(_O?;/Y1)S']E@\1IB/ M018G(*R7I&L\0(X&&Z,TL*4-EEV,AP>J$GIOY(K%:\QG6(6'4R^/A>Q3XY3' M!,LF8(5MUHA^KP_3-
\5W@_0'9D=:X*,I/G#S, Y1;CK:INL58!Z6&[;@29' M'?*IW?<RS MHP"JGVU8?8@#W"%5'WIM$0]._+/!5XR*W#9^JV%MR-KT0:-_VG\.6J6O((?M MZ5O2S]*!?(_H*' ZG[[
+.+2]YET@V8=OXEL; BVBI&PO=V]R:W-H M965T[]&_..VD9<,T7LOR3YZ98N:-/A#%&;) M&;SX(#]V>/$O\):-IA6MX5I8X#>S#FZ#X+BC?)!<&?J(PC4)HD)\)FUE^+
MC3:*\NOO4Q%J"22G"=B:F^B:I3CSJ*@TJD?TYA_>]8?AIS/RDH.\Y!SZ_(YJ M.&M*!+F%-:8R%_P?S. V(PU\RVGHI.I6JZ*YU?D;9QM>DG#4=K^I7E]=*^S\ MT:[>@5,Z[0O>DC
%@I&&E9!29O$,51=RUO)@QSRL<7G$A;5<@ OK+;JZWG%3 M.-/E>GE\9Q-8-#D5$/3'+EUB6#4J+:B"7YYMK[ZB#Y5:>@_O(>K[P_#*'XR' M<,$NX<=;MB^-%B>8GV
]@=O5^@.KZD\WK=@6)>H/Z)? -=.%8,^-R:^ G\="/ M1V/0!:,TMFOI<5@Y!0$'SRIJEKPN;>9MGAT.1;]FXOFCAK2DCB/RSJ-6/'78 M[^/>U9C(V?
&K&^V=*I'@]!E6J'+7\@G=QJCMBX?5PZNR:)OI?^;MD_2=J9Q3 M RQQ2ZYA;S3P0+5MOIT86;O6NI&&&K4;%O0RHK(&M+^5TNPG]H##6SO_%U!+ M P04 " !$@6=9\FA0"I$$
#0"P &0 'AL+W=O4K%R@:(-%7B22XIRYG)G1S ]2_=0[S@VZJ\I:+[R=,5<-V_(;;OYJKA3L9@-*(2I>:R%KI/AF MX:V"T[/$WG<7?@A^T _6R'JREO*GW7PM%IYO#>(ESXU%8/#:\W-
>EA8(S/C5 M8WJ#2BOX<'U$_^Q\!U_63/-S6?XM"K-;>*F'"KYA;6FNY>$+[_V)+%XN2^V> MZ-#?]3V4M]K(JA<&"RI1=V]VU\?A)0*D%R#.[DZ1L_(3,VPY5_* E+T-:';Å
M7'728)RH+2DW1L%7 7)F>:6 7V5^(U87Z.)7*QJ(N,'H2O&&"3BZ _HUUQA] M-SNNT'FK%%Q *ZVYT4\JFV!K40HCN$;O;]FZY/K#?&; .*MBEO>&G'6&D&<,
MR="EK,U.HXNZX,5C^1DX-7A&CIZ=D4G &]ZNPW'N+RSVJMC8)<^W,G80;-_91-O'[;*JAN^02*EE#[.0&02C11I;0 M$42]/86@VD,@S/!J#4$^LM9_^,3S_CQPYR&Z9/D.
[%%/%*&W*, 123 -,E@G M*;8@Y]D}6@/B]_<2BM,X133&24C0-PYEO9-E@435*+GGHY&08BSB!Y?M]*P M$C7/.+A54H,$CH,8$QJ 4(J3P =HK4^A]>1MU9;,\
(Z!H0K%\SUI/=9AF.2 M?8!%A&E(/_R'&AM'YR.HB0,":QIBDL1H(C^B(3^BR?RX@7Y?M"6W$6_ZZN=] M]8^EQR3:<^GQ&/:8$Z^1$N=@@<6A=@/X6QO#S4EJ%P$.
(X(^BYK5$/L2L6(O MM(3\L9:)G".V5=SQCDA*<9#XZ-V;E 3D8]_WGD8$%$& E?C$KTEF2]YV&N4XTQLPDXC@SWT>@7Y.=5:N_U@7\SB#D MHLY!"?R+
(5(9]L,0WA'U7>Q^\+]0RA:)U ),(A JE.2(.J'4"%93X=A=S 2 MY%SLW?\&A3@&HH,HA>HC:-0;2] \$RC-!,?4LD1P'/DX]3-74D&0X8Q,X# _FNQ=@S:F\IUK1P7?PRC7]=%(CWUH M?
-"1X@0G*876MX5"VW#+3N)# _66(6'Z"$%U\N46K'-H:<-P-=UUO?&C^L?R" M%#C*$AA(Y ::*5RWY0MV6/]@] */.B4T*$O$A1GF$)O[P(#G5>U3Y"A3!,:
M(T)PD/DN# _PX@ERPC2++4JAJ,IH%LP=35L75ULV2-LYM;;J!:S@=QM55-Z7= M7^]FW4NFMJ+6J.0;$/5/$FBFJIL?NXV1C9O9UM+ !.B6.QBYN;(7X/M&2G/< M6 7#$+_\ U!+

P04 " !$@6=9"@8/79@# "U" &0 'AL+W=O:+/@3\=;OL8%ZC^V85T; M(I+QSX'3&5P:X.GXR/YH8Z=8EESAG:A?JE)O)D[N0(DKWM7ZJ]A_PD,\B>$K M1*WL$_:];9PY4'1*B^8 )@5-U?9O_G;(PPD@#RX V ' K.[>D55YSS6?CJ78 M@S36Q&8&-E2+)G%5:S9EH25]K0BGIR]<2MYJ!3_\V6-ZI>QKXG6?/2+ \5M
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
]DVRGVBQM8UI*32U.3O"MN8P,0Z&/Y7I_U!+ P04 M" !$@6=9L0]NF/@# !,"0 &0 'AL+W=OHJK6O.P6\M5K,9&^:6L"U(KIO6ZX>+Z"1 MV[D7>D\;-_5Z8^R&OYAU?
VW8+YVUPHU?XQ2U2T(74M!%*SFWGEX>I%8>V?P M9PU;_4(FMI*EE-^L\JF:>X$%! V4QD;@>N-S#)32-#80PON]B>F-*Z_A2?HK^
MJZL=:UER#9>R^:NNS&;NY1ZI8,7[QMS([6^PJ\..3!#QS8SH$YW$,BA_**&[Z8*;DEREIC-"NX4ITW@JN% M)>76*'Q:HY]97,'2D,D=7S:@IS/?
8$C[P"]W[A>#._N!>T$^2V$VFOPB*JA> M^_L(9<3#GO!--87N7C1L?JN:ETV4O<*R-_G2VT4 MGH5_#A4[Q(H/Q[+]<:H[7L+/[S+69B=:5)*<0_*U$BZ2V4W=*V-MKD-
M.JQD@]U:B_4I.7_5U!"NP1%HM!1$Y$[:7A#.E6+LNY0NN=-[[" #"ZD ?(1 MF[?A!BK2<64>*1%XU]@6DM189"T/>DX0&06!_Y*O@K43O_]#<01NM)FD8T"PN MIF]M:JU[+DK
W+:(29A1ED13L0JGL$9A_I-_7L0$5%,HRRD19&3(]0F M([7)3U-;"P-(CB'P@!>KAD,T'XWV\S3OISI&\]U& ;QJ9O(%\[I>L3TYL/\L MW;QZ<6]2.C#A&=`&62G\MWQ'-&8)"FE 61:C$
4,R0U1RE+*6$8^">Q71RH6 MV=9]2QK)!:9YM'?5P;ANCYT11L.4C5I"LS0FO\,:B?^WKJ8X47]G" M= 0\B?*8YD4V)1,6T8@%3HAIEH13$B8YS9.07$A1C;B2@A:L<$L4[&G7.QN<
M/[52<']+A[X!@_E=MRBH:D/2@K(BLTN>AGO:'TB5^L&;Q?KVUXB& 2-?I/A8 M:XO<@0\C#LQMWQ4^%\F)#/YL-WQF>NUK70R,$*78.3#+M-#;-[4(SL MW+Q<2H/3UXD;_-
P!90WP^4KBK;93;(+Q VKQ/U!+ P04 " !$@6=9YPXQ MUA,' !['$@ &0 'AL+W=OT:V>WMHD[&3]*%'S'B 2DC F"14 K:B_OKL 1\T9N+B?A M9#=Q)Y8K0Q/3JXLU6,)
[;CZLWRE\FHXHM6AYIX7L0/'%Y606OKG.:;U=\%'P MC3X8 VDRE_*!'GZN+R<'UV,35X#"V>5@/DM8., M7H LX1?9F96&[[N:UT_W3U&\4<9H)^-U=!+PGJ]]B
,/HB!*3N#%H\ZQQ8M? MPELQQ0>=W[$MAIB!F5*L6W([_GTVUT9AO/S_F/(..SF.31QZH]>LXI<3)(GF MZI%/KK[Y*LR"[TY(GHR2)Z?0K^Z1DW7?<) +T.0YD.M]<
NS/2;P:"A;6;;_YJHC"_#N-O@D3F*']T.? NAKN MN#;,D(D;UMD9VO9S5_>5,S/->WBVP^M0+FA=X#@0=+0A]K4BG-SL:=7)_B M+4AW-8,82Y0+":/K!Q3)D8|
$*NE)5Y)ZH!C4N4>T^+U5*01M5I#*83DP| M'9X(!M2M#4IS0&DN%*TNFDJ>#?_46V[GXN%@L^C1R/_.U4*I%\;E.: TEPH M6ETIYE$I9JM2/D?J93AXT6N,5Q5-+)A'LVG$YT% A-
3K4CZE-,\HK6XN%DI. MFU:$,NKA\:E(('W:H#0'E.9"T>HB.69)<6M6;;&ISB-^*K1:E!P8][O%*M.M MSBVR6US5^1A!B51"\FE^=/W#I0DTPUK0JDL3'HV'>':V-(&F3T%I#BC-A:+5
MM71,H>+V'.KRRQU:I2S06;K&\0=-FH+2+%":#4IS0&DN%*TNDF-:%X^ WZ(Q M9$9R#4JS0&DV*,T!I;E0M+ILCKE^K6JGX$^OWP$4B%),EW/_UE:(L>7]!&"03JC;Y8 M'QM5
IK0!:59H#0;E.: TEPH6EU*Q[0NAL[K8M#$+BC- J79H#0'E.9"T>JR M.:9W\0_RN[H=N24!2GPMOK5Z'LS;I1,+.&[,AP8DQ/DB/K=I\7:P$TC0M*
ME>\BI&H@2"ES9"IE3C4.Y=NX'F1FU-6.,G4SBUE M,A65YJR I22JRG,JG^? Q7'F^,[+Q(KM]MI,N,FTI#M8@_Y2+B6.W#9*QG(H M%!,%D;"=.7?
^[=P/C(=\2^#HSJSB4EE(\2C&3QD,\|DJE0!?>'2V69WL^.".#G!7U/WU]"G'F,'S-(6@<;"'<&LBR7%!-DZD4 M1R+-
;HQF#)NJ]49RK#*GLM825QGZZ>1.*3SZN_1'Q10S=5*$%AE9,%6*EXD/ M9(W-D%4OD:YV ^*;TC@!2'YLEZ0JW?7 MY!UQB=I3B1SJOY\#NUB9MCQ!6Y[ (H5O+0_Y]@FWD <-
N?K>Q;R.-^R.9^[8 MK2II"C,'+Y$">0 G>?^''WD?>]B&+=NP+WIR+_(<*6+3I(]=W&KOR']:ZWI( M D2>C,;1U#UTX Y;W&$O[C]"4TY2[!66@:2F3EWP=9#1F^%'+?RH%_YAN7I/
M_+C@E!S7%W0HP[HP!\%_K ;.FJAH_Z*4[6W-R U!F";'''B'0JLN$M$%"=^+ MHWCH=7.(6PYQ+X>EA)*RC, 32K7ZM>UKZ/@"">CCV7L$=M[CC7MR[-!45IDI*
M^DPW'+IPQQ>X'^)P&(?=R),6>=*+_%GO0:(Z2HFE)OPD/ET4)I<4(C^,)J-N M#KYW4D[O#5U?H#[06A)(XF=@N;]YMWSSO3<[S\]U'TI%$WMA'U,V&%!E09 M31AJ,DJRD-
8RAW5#BBK?8!51T1O1O&)%8UZ3_SHEM$G%OZCH:!A&83Q^)9.3 MV/]ZMB5B:5!2LE2L 0SP3F5V'-(W:X9KB?E[^1;@X[/^(:#R:]DW;,WU'R/
M_$WECN'CQV&+;MX@QGQE_<37 RU*^ZQNA,9'VII[_"P":3;@^E8(_3(P+W7[ MH97\#U!+ P04 " !$@6=9R$_JRV )@]Y5JBY ML]6ZO'%=E6PA9^I:E%#@D[60.=,XE!M7E1)86B?
EF>M[7N3FC!=./%OGEC*> MB4IGO("E)*K*NY\Y;>+&AH$NJ(/SGLU,91!!!H@T$P\L.%!E M!@EY?&E G?8_3>+1_2/ZK[5X%'//%"Q$]A=/]7;N3!R2PII5F?XH]K]!(VAD M\!*1J?
J7[)M8SR%)I;3(FV1DD//B<&4/C1$G"2C4GN W"?[_30B:A* 6>F!6 MR[IEFL4S*?9$FFA$,S>U-W4VJN&%>8TK+?$IQSP=+R56A-1?"2M2\LN7BI?X MCO0564HH&
<>I!RP8!>J*_*ZW(,FBDA(#R%NE0*LZZXZS>YYQS4&1UV2%A996 M&1"Q)G9P|O(6-..9>H7AGU:WY.7/KV:N1C&&DILTQ-|=B/O_07P%Y34)O"OB
M>WYH25_TI]"#NFT3@^ZZ2Y:V/KHMS[Z-5[P#1_1N8RAQJ[BO^\PG+S7D*M_ M;%(/V*$=VZSD&U6R!.8.+E4%<@=._.(G&GEO;,(' NO8$+0V!'WH\1]"LXR4
MI^|=CD6UD4(IF_X#:%2#FHUG%].(1GY(9^[N5)HE+IB,J=>&=4B'+>FPE_0= M*'6#&TI2Y57&-*2X#Z W"6=FI['Q/>"-3GB\GDXC?WI&UQ8V"H/03G?4TAW] M@,
<%:!OCT1,J=$2CB/IGE)_&A8$_CNR,HY9QU,OX TNV."7/R-IX](=R4, M!-;1/&XUCR^X(8R'M&$@L(X-D]:&R24VA(FE7/UQ2,]7V-.X|:3^'MC*==IR MGO9R7HB\K#1^['HKM1?
CN:]H(+".7.H=>P#O@K7:@ _DQ%!H72M.VB%ZB7IM M4#N%&$ZBR5FY6L+":!SX]GJEQ^:#]G[4\0N&G>Q69"GA.7+?@:%K)SIHJS$4 M6E?VL=F@P27KMK>5>;85
Z%UK3BV,+2_A_G>N@TM'17V*.=U^ZVP VOWY!QB M#H$?F-SP0!$,UICG78^Q< &:ULK55=;]HP%/TK5C9-G<2:3Q+H(!*%3:NT::BHW<.T!Y-\4 G+8"Z(+-*4BI=; M2/AN;-C&Z|
]6V^4'C#*44[7L #UD,!%]LR&)68I9)+QC A8C8V)?3,-='P9 M\,A@)P_:1#M9PPW,8%-%ITF MBT]YY[AJXS6!B?'.>DU"?@[64HEL'#_=1FN5O"Z5]"'^4;F-(*Q@:=5@MB"
M$7[Z8/O6UR[[[T1VE RW289[B3V<%/(NB[%TQ0MA683.\:!V.:YH_))&WS;; M<&BYN!W;0R?MH+YG^9;7A!UI]!J-WD6-CY#%7.!YS[ED2G:IJPCZ!PL[CNU[ M3G BL!WG6:
[G#KL%]AN!_8L"JXI2=(]7901L2Y<)=,KLMY9W_6!PHK$=9/<' MCN=T:_0;C?X,-$9U==.R^KLD^NT,828#^T1D.\P.?._,1@>-QN!=- :M,G/\ MOC6PAB&PO=V]R:W-H965T MS9S,
(25LZ)[K>W&\@RZ>V/@K!%?VEQP[6|\AQ5YI475B)*A8W?[3ARX/)P(_ M>D80=(+@OPK"3A#:0%LR&]8MU32?2G$DTEBC-S.PN;%JC(;5YBVNM,2G#'4Z
M7THL"*E_$EJ7Y/V//6OP%>DKLI304(9++#U@O"M05^:QW(,EB+R4:D+E2H)55 M?61TS3C3#!1Y0U989^6> Q&;,\FIW:M;T)1Q]1H57U>WY-6+UU-78SR&RBTZ M]G_
,^PJ:.Q)Z5R3P@FA$OK&DK1,ZR=T70MAF$?%(NQA>KB4732 /OQHR[146>) M/91$GCYDZE.^D5*CSTC=;;%]-IOMK(),A/LJU, MS3]WF4H";7;5>IIOE0S^LE
23XGGB6D21.ED<5H>6ZK%:;;3<93*I4+Y+DD" MJ7@AX^SA;((G3P?>1>N-+@Y,%Z?;B"UOI/Y]NU1F;]I8":-$IGF4I4C)N[/) M.7YQX=.B0'G&AT@^Y*UM5%3E-
LL^%3O7X=G$*R*2L5SIPD1@?N[EI8SCPI*) MX^_:Z*3Q611L;S]9ORHK;RIS&^3R,HL_1J'>G$UF$Q3*NV 7ZW?9PVM95X@7 M]E99G)??Z*$Z5_ )6NURG25U81-!$J75;_ "Y;HA6
4IZ"I"Z "GCKAR54;X, M=+ X5=D#4L79QEJQ45:U+&V"BJ*B5VZT,O)&IIQ>? R4"E*=H^?HQO1XN(LE MRNY0<_B#S+4,49"&Z+>=SK79B-
(U>O92ZB"*\Q]/I]I$4=B:KFJ/%Y5'TN-Q MCMYDJ=[DZ%4:RO#+\E,3?5,%\E2%"V(U>".W)XAZ/R'B$8:^1U.4;P(E_K' MXH$VC41+#
[3'PV41,@MP9(/,S1998D1ITW.EM]:@+MBL)JZ\BF%$VD8J0$ M$"-$[3=1^];V?259JE642[15T4J6O1QF<1RH'&U-8I0]_B/ZIR69KAI4/D2[ M]PGWNGM^UD0VLT;VL;Q8FDP\OY?
*7/S1.UD0I,C%2W-Q4.9:O0MB]%ZJ!#W[ M0YJ(.Q/3[D2I+K0$(S"X-%V(9@W<<_=2&J^)RGF];0IJN!2[@WI273K">D, MW9CL*M)@X];+[*6)2JL[/M'H[,5J%R"$1Y)9]7A;QPX@<")
ZG53F:MM" S_X3W M) ;@"ULY\ZWD-N"%H,>B*"+S(;EA0!AVQ##C 3'1IS@ &!XDV/QP@MF-'9NC MP# |%L3P&!3#@#'L@F.UD[:X+-H"DF$G*!OP@BN6F2'NH+: 9=@1S/ ^S:BY
M*^Q1%P&>D2&>F>KV\FP9FXPS]X<:G:_-=U=@=OM'YBT!FI&Q:$;&H!D!FA$7 M-*N=M$>.I"\G &7$",@RPBPC#AB&=EG&25"S'K:%FA&AFAF1LK7
M:;BK=65CF=W4L1D*+"-CL8R,P3("+",N6$;V649[64: 9<0)RP:|X'*F M+N".C84[-@;N&."N< =V\>=3TY(G^B =|P)[P:|-$\E9X-: |PQ1YAC'9AC MI(JR"'C'[91[*5?':LUN^
M&_!"#@<;![!QI1V#C'8\D_5F?UEH31.QH1U2^"O@ZK8W!-0Y,>324 ,67?3"N": ML'/M?+?>Y;I0&BW:TK2OCFYCB=YF6AXN.[N38Z=1 >+$6(@38R!. .*$"(2) M?<3Q$]PS34|
X803P@UXF=7S1[#W)#_L#^E/ .J$(J2)#M0QK_=UMP##3OL MV@)<7BJ?H:LH#=)5U< *] M 2]'R0_P)QSA3^SCCU#".>UY3> # 'T[ '()TJ>Q)D-+)9]?[8H9ZA!P6X6=
M,V7'8)\/[//'8I_!OM\8)_O@GVU$[^5&-Z)Y^&>M #X^78L?;/,K?U\,7 3 MOH_%?R\0T]9RCD2J=;EH)4>K;)?J:F5'<[19&'->+0>!TZM5-6\"M8[2',7R
MSA3U3GSC754+5:H=G6W+Q2&WF=994FYN9!!*59Q@_K_+S/"OWBD<-,N%%O\" M4$L#!\0 ( $2!9UD"9:2;(0, )H+ 9 >&PO=V]R:W-H965T
G7(&_R.53BWAJ.3H@2"&2F@&KWPI.(4TUD0KCH>*T:I<:MN#W>L)^;W%4N=UC*4MO22R3J36V4 P+7*3RBJV_0)7/0/~%+!7FBJ:E[4AY MC
HA65:!U3PCM/SCQTJ'+8#K[P%X%2JUVB<#*XQ9QC*@4Z1-_U4)\".@A!8I** MCVKU*Z:%N@_(41-\)YM^?2Q]P]??PW>:8B$06Z#J?!#CR#Q))/.;,D47$C+QJR'. M6.<.G<]-
FG5)%G9$MJ.G7^OIM[$'9X_ M(R( Y9Q$ZH(3BF*6I[@+E(.J@@GFT'2+9Z4TKY6S2[*P)!L;,EW<5X'7Z[L3 M>]4@TZ"6:= JTYRS"" 6:,%9AH@0A7KIH"^?
P"GH^P@/!9%/34J5S,.M>/RA M.QQY@W$=4ZG"WX:>=W3D.NY@US!LC?4_+|RP5F+8JD1;V9MS.#PO=-W:/$_1
M)$BK@]=>G2]PH|(=H0=U<*.WJBRC;K4LTNRL".R'3W'M9[CMZELK;2OE;,D M&VVJ::?G..ZS!_TOJU( >ZN;R8 O35=8#F1+#>]T1V3JM,RPT0US\"U@=I?, "8W$^V@;L>#
MWU!+ P04 " !$@6=9$ 3], <<" !\" &0 'AL+W=O8R<+9>N*N$STH;'C<_G]X./ C9V:|R(,+XV,8,V MI7/<'M]%?^.UD8YJSM#5\|/(<34)A@'+8<$KB9=Z|Q8:/3T7+]/2^G^V:6RC
M@&6515TTSD10"%5?^4WS'+84&11:%>2'Z1G,D1VQ&14[KR0PO6!3K=9@4,QIZI0+6;LO:_8]5J'/W?6[NWEFGO[]/71!^UP*%ID?^C1YF M[KCW]4,=JK?
5#T?]3C3HCG;WP[!E&/X>@["VXBH#:@B+=A?)\"%)9Q#WDMT@ MHQ9DM!=DRHVY%6KYHR/1M^IV7^;U&_R7#3AZL'>ZR: S&@WO(89;AXD[E]]S
MLQ3*,@D+|HR.!R32U&==/4%= ^O-EKI%.*S]!( MOP-02P,$% @ 1(%G676KE1]2 P &ULK9?1;M,P%(9?Q0H(#:DT2=-V[6@K02/$)$ 38W"!N'#3
MDJ;"L8/MM./M.7:R*$59MDKI16LG_G_[?,TY=A9'J7[K/8 AJQD7>NGMC)BH'LH*N%NW:C5@M9&,X$ MW"BBBRRCZN][X/*X]+0<+0V7MML;>|%?+7*Z@ULP=_F-PIY?
NVQ9!D(S*8B" M=.F]"Z_BN1WO!GQG<-2--K&1;*3\;3O7VZ47V 4!A|18!XH_!U@#Y}8(E_&G M\O3J*:VPV7YP_^!BQU@V5,-:|A]L:_9+;^:1+:2TX.:K/'Z$*IZ)]4LDU^Z;
M'*NQ@4>20AN956)<0<9$^4OO*PX-03A^1#"]!*/G"J)*$#U7,*X$8T>F#,5Q MB*FAJX621Z+L:'2S#0?3J3%\)NS??FL4WF6H,ZL8-H:\(5^H4M3^ ^0B!D,9
MUZ_QZC=I*">Y8B)A.;8.E!= 9$H2*0Z@#-MP(${:P+$*.#6P)3E5YN^ "'QB M<>"GZ406PDYQ

*MR063L_@/U4C77+::JWRU3?B6Q##3Y+N+ WL!;?[Q@^D:GU0V7Y(LO"19="&R MSH##8[8##88^SS9\B(@ 1M"1-O*#U,26BFY,R#((VXTZAW/4-:/GQ!"!312WC#A)$PT1CN?::@O< MU@)WU(*?8$TR].E*5**NO]"RN MZ!171Z;?RO1'93XUA2XW4REC\$+CJMOS$'+@RV4Z9I"D0N6 /^B/*SO='VP5 MRG=[8QB>Q16=XNHX$+0.!*,_"(V4FG_U: <2')RZQC$LNO1=E"R_*%EV*K3LL1]MB<[3X[G+*1/HW MJ4XS"?UA^(JA.H>_T]?>% MSX2MTX++U6HE4QFWGAP?5A_9ZQM!M]69=$F%/.%6EQL@"; 2() ^O*!6'FS)! M^^%D_@]02P,$% @ 1(%G63QU[;(;" SDX !D !X;"]W;W)K&ULQ9=;^,V&H7_"N$NME,@C?7ASVD28,:2V%ET%L%D MN[TH>L%8M"V,/CPDG4P6_? &E9,42'9FQNJ>=BXELZWU>RCIX21Y3O'HLQ&>Y MX5R1KUF:R^O!1JGMV^%0+C<|8_*RV/)9 M##.6Y(.;J^]]6W%S5>Q4FN3\5A"YRS(FGM[SM'B|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|Y^M_5|*&M"F1."H(9JI@< M5#'YFSHE\CM9M&("?M_93UF;TU='2%BA(5(6(2$41#,4-OTH+8IHI^:(C6" MA 5(6(B$14@8!<$,C*+NG^ZJ(M3-=G7 M%6B7)[H;>Z7_FKTH(//);#[US<*^L+:MKUJ0L! )BY P"H(9:ID?U#*WJF71 M*$%W8DM>R2 NTI0)6$>-FL)?WSI3H[&,\B,% 0S M]. ZC5WC6!6A9_T]IZJ63NY_7 ;DBC)F1[>Y.LN%=AI?64 I0506@BE15 : M1=%,S;0L/AY+>4D+2@IK6'BNRY[M3U)X].1V6V$T+P1E$91-%,FC=GK MVMW>\"L7RT3RWL,2.[>W,J!6;DUK#R:\2|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|Z-0)U/Z&T $H+H;0(2J,HFJFCQB7U1HBYK@=U12&T $H+H;0(2J,H MFJF5QD+U7K%0V5/&RV6L*STJ^<2W.['<,%F-3:QU!NJ>0FF!U^%WSBL7\ZAG M"Z%Y(RB-HFBF+AJ'U;,[K#W[(O([Z;EPQ)ZM_MX*@KBR4%D)I$91&431398TK MZT% <60_JRD)I 9060FD1E$91-%,KC2OKV5W917*3*VKF] MA0%=T%K3IBUA)>.<[QP!)HT.B\I124UGPEM'%??[KC>U4;:WG(]_W;;L7UO M-Y06U+2C94)'-QN:,H+2* (IF:J*Q77V[[6KI*=@#%VS-]|+8UX@+HC:Z%>4C MZJ4#5W4B,7OJG/;8$_=6#70%ZRM?ROC418709D10&D713"4U'JUO]VCU3&?U MNNEFA_16!70Q*I060FD1E$91-%,JK=T)?,14QL=N-(#=:0"[U0!VKP'L9@-_ MA4'K-P:M;S7U0%,9>Y+>4H+ZMU!:"*5%4!JM:<9J?*]QQZU'(TV5--:L;[=F M(Y:(YH'R1UL'!'5CH;0 2@NAM A*H_Y+W]EU1M[(FX].2*%Q8_USMAGXTVM/ MV.F]]0'U6J&T$$J+H#1:TXXKQ:CUL\1>'L/6;EL9%^MJ(S5)JFTB]AMO'=X] M;-;VKMJB;-BI<3G5VL=!\;?]"%=MJ[Z[[0JDBJPXW MG,5&ULQ5G;;N,V$/T5P@V*!$BB MB^5;:AMPHBR:HKL-8J3[4!0+6J)M(9*H)2E[7?3C2U*T+H[,7, B+XDD<|X, M#X>'"*\Q>2)KA%BX$<2IW3263.675D6#=8H@? 029RCEORPQ22#CKV1ET8P@ M&$JC)+9\SN"7^S2I0P2E!*(YP"@I:3SLRY\EU;&,@6?T9H2VO/0'1E M@?&3>+D+)QU;1(1B%# ! ?F_#;I!<2R0>!S?%6BG]"D,Z\][]$^R\[PS"TC1 M#8Z_1B%:3SK##@C1$N8Q>|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{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|%'C9@-UY#V1CAL=K(F+PYV\:$GQ1-)5_U5D7MF!=I[*N MXW3Z(Y.O5S-!*6 ZP32^ H(H6J=F 00#@Y07HK=1A$RI\HD2NA!<;J.&]! MNX9JZ%^107 ;$KH3=2V=8&Z0++>N")^V-GGFB#4J8VH"9;B:XJ-6Q5|=)?=C# M#57(TB)T\^(1R=-|;'&O<:H++;'"Z-(YT@8#(\O R$F AU>A/3C=L@JA:%_U M098\D9L\CTZ@HZJ/>_%3'6\Y&J$+9Q9J@\"1)7#D;D$/JCXEQG?5)XJB;GWU M099>D9L6'_4Y7#"3VD7W_S5C2AZ7(6TTD\B2+^I<.D/:(&!D"1BYN]7]A^,2 MX(##,;*LB,[ BJB6%2/<@PW+6U9$9^L644.[")LVAZ4UY&X8#]H<|SQF,S8M M= >*3&^WR,ABG;_ M&E39^2'332-'[!=<2R8! [C7L%VS)!) ^I5]N#@\I3$BQZ-;#WL(0M6^ ]/SXV M;ND3.C/W6JG&U]ZFP3"N'&C/)W[O!2*N;FIE*" M*5]EJKC.JT:KV]!Q<0=HIQ=7J?=$S%DF04)G6C2X[NGR(XK;R>)%\:6Y$7SA M2O'4/"XHB:G()-C09YRK[4N^0'5'//H74$L#!!0 ( $2!9UFU!"HJ0( M + ( 9 >&PO=V]R:W-H965T2!YPXB0;mN>)&I*FK[VB0'L>K8F6V@E?;A=W9"RM: *J;Q@MB)[^YW M?Y]S&6VD>M(9@"'/.1=Z[&7&%!> ^KY,,/'+W;E4\DBO#F8!;1?0JSEZF0*7F[$7>ML;=VR9&7O#CT<% M7<(,S'UQJW#FUUY2EH/03 JB8#'V)N'%-RL@5OQP&"C=\;$IC*7\LE.OJ=C M+[!$P"$QU@7%RQHN@7/K"3E^5DZ].J8UW!UOO5^[Y#&9.=5P*?DC2TTV[@8> M26%!5]SC-SMPJ3IKA&/"[LK,*'S*T,[$,R.3I_,IYI62 M2YGC9FOJY#HG,ZR =,6!R 6Y VT42PRN^07 ;SD\JJ&D)%>V!&I(;*4RFR1>10QSA@|UEE&VRRGT4&',RA:I!V< MD2B(.N0C\8G.J )?0Y$:-BNX;BF@8 MX*^9HE=3]-ZI#XCT&'%Z;[#"L+U?G7[-U3]85X_NM8+R3-:@\#5)G%P$SSJ0 M:\H4>:!\!4U _?]0;8.:>O!/U99*SJG2I, CXR2UVKX>RZ9TRH"#'7W;K5ZO M6=QAC3E|=^D=@50Z#\/=/6^W!GMV/ Q>7\G!\;5X!&<&;E>[7BOZ6SM_IXGD MH):N56J2R)4P93^I[];M>%(VH=?E92^_H0IW71,,"S0-6GT\%JILC^7$R,*U MI+DTV.#<,,-/"E!V 3Y?2&FV$QN@_DB?-02P,$% @ 1(%G6< X2XJE M P VA !D !X;"JW;W)K&ULQ5G;;N,V$/T50@6*+;*)?1%*^*+4-V,ENNT*#!@DV?2CZP%BT340279*.*?GG:TZ'5^2DA5+48QT)="7 MF*+..9?W0U>ZF1PH>^!; ($>B[SD4VLK1'5MVWRUA8+P*UI!*>^L*2N(D)=L M8_.* 4DUJ'J>58QXV[ M;+,5:L.>32JR@26(+]4MDU=VJY)F!90\HR5BL)Y:-\YUXF!%T(B_,CCPDS52 MKMQ3^J N/J93"ZL300XKH22(_-G# O)<* W!>ZT%OR'XK[40- 3MNEW[K@,7$T%F$T8/ MB"FT5%,+'7W-EO'*2E4H2\'DW4SRQ&PIZ.KA(F6LBC3 M70Z(KM&+L.11K0&]BT&0+.?O)?'+,D;OWKZ?V$(>4)FQ5|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| 4$L#!!0 ( $2!9UE>V)URN , M ,H. 9 >&PO=V]R:W-H965T+,B-$= <#.G:9'7%*%&D M/#,=RPK,'*6%$4[4W#T-)V3+L[3 ]Q2P;9XC^FN&,[*?&K9QF/B4KC=<3ICA MI$1KO,3\X3LB7>C')F/H+]C76,D\99SD-5FL($^+ZA?]K O1 M(@@=/<&I"4Z7X)TAN#7!O32*5Q.\2R/X-4&E;E:YJ\)%B*-P0LD>4(D6:O)! M55^Q1;W20AZ4):?B;2IX/'Q/& /WF(+E!E$,R K,29Z+'5QR$C^"5V ICF:R MS=0KC&B1%FL&2D%@DG K=RF- 2H2D*39EN,$W$28HS1C+P7[\S("-\]?3DPN MUBHCFG&]KEFU+N?,NESP@11\P|"B2'"BX4?]_%$/WQ0U:@KE' HUZ!8[E>)KUS"^GN[IT_B_ZXI^C'Q7#;4Z-J_3<,WJ+PT%H3LXMF,F#,-;M M=*7EZ;6D$XY9B6(\-835,4QWV A?/+,#Z[6NS-<4BZXIMKB2V-&&>,V&>'WJ MX4=QI63B7UE7_HH9**:|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|YFU%:*XM6T> M;R'#_(86D,LW:|HR+.0CV]B\8( 3[92EMN -+$-^!R:?[(:2D QR3FB.&*QG MUIU[&[F!MY_I?^C%R\6L,(<%3;^31&QUMA"":QQF8JO=/\1Z@4-%"^F*=> M:%_;.A:*2RYH5CO+&60DK_[Q4QV((P?)Z7;P:@?OU"%XQ<&O'?Q+1PAJA^#2 M$0:U@UZZ7:U=!R[$ L^GC.X14]:2IAHZ^M1;QHOD:J,L!9-OB?03\|^4<_0 M#"VWF &B:[2@628SN!0T?D0?I%TNR(>$I*5***%I"7#(B"'#T+@2!2CWU>C>*Z/[Z O-Q9:C*$\@Z? /^_TG/?ZVC$03#N\Y'/=> M+W )Q0WRG=^0YWA!QWP6EO[7X^DM0 MUHCN3 MV^NN).Z6%SB&F24UC /;@37_]1=WZ/S>%5F3L- D+#($:^4@:'0:+K_2D4_M\>LZ? =%3G)9RSZ,UHYDZLT4IL)9>>80CS'*2;XX/]H_/$HP^"VDD(K@6(+*,9I7*9-$K6E?)|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`_/)TVB5OC>2H<>ZHY(U>X7V0>4[:JOWK@^Y# MWBN>YGJW/.!U!1QW XLL<9EO6,BO!CH-Y&Q!X(/%;[_0B?%[EU&0, <)YL)=\J@N1,*>"34I8L>AY6+P=V6-[-IT/'_8-UM'/'(U,HJW-Z^PVGEJT MW<_[$KQ MSKL&O!=]ZH C88YU\,M;1OGW8L"10;TC@_K(H $(UC+/I#'/I-<|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|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|?_A/S M/9X)Z"H!@F=-LD$=]:_PW1_@^T[^.8??FL[%\#M2]VWGN!{K?!_U6A>,#-; M52Y=.SI56Q1JM7^-'PS\RH,S<.S*N3,%L4[@KO\9&P_ M#3@/?7G*M3 M0SLHWYQ,_P%02P,$% @ 1(%G6? 1N+4N P[A( T !X;"]S='EL M97,N>&ULW5A=:JLP%/TK1EU'"Z-.XL6-UR2P!0J#;13:A[T5)983@2QYLM(E M^_73E1SGH[JEZ\.6SB&U=(_.N4?2=2TRK,U:L-L%8R9:E4+6([(PIOH0Q_5L MP4I:7ZB*28L42I?4V*Z>QW6E&M'IX,( 8N+I\|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

(T)(3!0QL2F6RDH8N^S*|!*ZELVZJ>Y:U+|%,L$TD1!K E5N M;QF88)I(B#6!2K>/B68GQ/9 I=O'Q,22$(OE*%WV E+B2MB7(1BFDH18)9U] MGX3"_)$0^^,YOSV AIB80!)B@>":Z^7OF%(28J7@(SE,Z1),, FQ8'#,,*E+ M,,4DQ(K!)YPPFBEFF73(9*07S12S3$IL&1PS3))3S#+IH):9A)CH+ABQ97#, MTQ 33Z1F*:8A5)B"P68J^ZTV]!F+^;" <5GU7)EB M$D])>0%W@\D)#;[;@%6L#>L.AZW_[*3;LMNV574.99?J0O/R^&7^^%|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| !D;V-0&UL4$L! A0#% @ 1(%G6<6?2FOC!0 KA| !@ ("! M#@@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M1(%G65&Q&:G#!@ =Q\ !@ ("!*Q@ 'AL+W=O&PO=V]R M:W-H965T&UL4$L! A0#% @ 1(%G6:B4UCPN# UV$ M !@ ("!M"P 'AL+W=O0( %$% 8 " @1@Y !X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 1(%G69="YL(:" =A0 !D ("! M=T8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 1(%G6=9K+F1Z!@ / \ !D ("!1UD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 1(%G62>;K!/Q M P !@D !D ("!/7 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 1(%G662)[W[R @ 90L !D M ("!2X( 'AL+W=O&PO=V]R M:W-H965T,Y6BJP< # 3 M 9 " @>Z' !X;"]W;W)K&UL M4$L! A0#% @ 1(%G6=J7E--R P =P< !D ("!T(\ M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M1(%G6;$/;ICX P 3 D !D ("!$)P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 1(%G66=*V74!!@ ME2P !D ("!X*L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 1(%G6=|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end XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 175 274 1 false 52 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://skyebioscience.com/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITEDParentheticals CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals) Statements 6 false false R7.htm 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED) Statements 7 false false R8.htm 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED) (Parenthetical) Sheet http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITEDParenthetical CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? (DEFICIT) EQUITY (UNAUDITED) (Parenthetical) Statements 8 false false R9.htm 9952158 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies Sheet http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPolicies Organization, Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 9952159 - Disclosure - Asset Acquisitions and Dispositions Sheet http://skyebioscience.com/role/AssetAcquisitionsandDispositions Asset Acquisitions and Dispositions Notes 10 false false R11.htm 9952160 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilities Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Notes 11 false false R12.htm 9952161 - Disclosure - Warrants Sheet http://skyebioscience.com/role/Warrants Warrants Notes 12 false false R13.htm 9952162 - Disclosure - Debt Sheet http://skyebioscience.com/role/Debt Debt Notes 13 false false R14.htm 9952163 - Disclosure - Stockholders' Equity and Capitalization Sheet http://skyebioscience.com/role/StockholdersEquityandCapitalization Stockholders' Equity and Capitalization Notes 14 false false R15.htm 9952164 - Disclosure - Stock-Based Compensation Sheet http://skyebioscience.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 9952165 - Disclosure - Loss Per Share of Common Stock Sheet http://skyebioscience.com/role/LossPerShareofCommonStock Loss Per Share of Common Stock Notes 16 false false R17.htm 9952166 - Disclosure - Contingencies Sheet http://skyebioscience.com/role/Contingencies Contingencies Notes 17 false false R18.htm 9952167 - Disclosure - Subsequent Events Sheet http://skyebioscience.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 9954471 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPoliciesPolicies Organization, Basis of Presentation and Significant Accounting Policies (Policies) Policies http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPolicies 21 false false R22.htm 9954472 - Disclosure - Asset Acquisitions and Dispositions (Tables) Sheet http://skyebioscience.com/role/AssetAcquisitionsandDispositionsTables Asset Acquisitions and Dispositions (Tables) Tables http://skyebioscience.com/role/AssetAcquisitionsandDispositions 22 false false R23.htm 9954473 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables) Tables http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilities 23 false false R24.htm 9954474 - Disclosure - Warrants (Tables) Sheet http://skyebioscience.com/role/WarrantsTables Warrants (Tables) Tables http://skyebioscience.com/role/Warrants 24 false false R25.htm 9954475 - Disclosure - Debt (Tables) Sheet http://skyebioscience.com/role/DebtTables Debt (Tables) Tables http://skyebioscience.com/role/Debt 25 false false R26.htm 9954476 - Disclosure - Stock-Based Compensation (Tables) Sheet http://skyebioscience.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://skyebioscience.com/role/StockBasedCompensation 26 false false R27.htm 9954477 - Disclosure - Loss Per Share of Common Stock (Tables) Sheet http://skyebioscience.com/role/LossPerShareofCommonStockTables Loss Per Share of Common Stock (Tables) Tables http://skyebioscience.com/role/LossPerShareofCommonStock 27 false false R28.htm 9954478 - Disclosure - Asset Acquisitions and Dispositions - Narrative (Details) Sheet http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails Asset Acquisitions and Dispositions - Narrative (Details) Details 28 false false R29.htm 9954479 - Disclosure - Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details) Details 29 false false R30.htm 9954480 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details) Details 30 false false R31.htm 9954481 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesNarrativeDetails Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details) Details http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables 31 false false R32.htm 9954482 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details) Details 32 false false R33.htm 9954483 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details) Details 33 false false R34.htm 9954484 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details) Sheet http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details) Details 34 false false R35.htm 9954485 - Disclosure - Warrants - Schedule of Warrants Vested and Outstanding (Details) Sheet http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails Warrants - Schedule of Warrants Vested and Outstanding (Details) Details 35 false false R36.htm 9954486 - Disclosure - Warrants - Narrative (Details) Sheet http://skyebioscience.com/role/WarrantsNarrativeDetails Warrants - Narrative (Details) Details 36 false false R37.htm 9954487 - Disclosure - Debt - Schedule of Convertible Debt (Details) Sheet http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails Debt - Schedule of Convertible Debt (Details) Details 37 false false R38.htm 9954488 - Disclosure - Debt - Narrative (Details) Sheet http://skyebioscience.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 38 false false R39.htm

*9954489 - Disclosure - Debt - Schedule of Interest Expense (Details) Sheet http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails Debt - Schedule of Interest Expense (Details) Details 39 false false R40.htm 9954490 - Disclosure - Stockholders' Equity and Capitalization (Details) Sheet http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails Stockholders' Equity and Capitalization (Details) Details http://skyebioscience.com/role/StockholdersEquityandCapitalization 40 false false R41.htm 9954491 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 41 false false R42.htm 9954492 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 42 false false R43.htm 9954493 - Disclosure - Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) Sheet http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details) Details 43 false false R44.htm 9954494 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Activity (Details) Sheet http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails Stock-Based Compensation - Schedule of Restricted Stock Activity (Details) Details 44 false false R45.htm 9954495 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) Sheet http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) Details 45 false false R46.htm 9954496 - Disclosure - Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details) Sheet http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details) Details 46 false false R47.htm 9954497 - Disclosure - Loss Per Share of Common Stock - Anti-dilutive Securities (Details) Sheet http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails Loss Per Share of Common Stock - Anti-dilutive Securities (Details) Details 47 false false R48.htm 9954498 - Disclosure - Contingencies - Narrative (Details) Sheet http://skyebioscience.com/role/ContingenciesNarrativeDetails Contingencies - Narrative (Details) Details 48 false false R49.htm 9954499 - Disclosure - Subsequent Events (Details) Sheet http://skyebioscience.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://skyebioscience.com/role/SubsequentEvents 49 false false All Reports Book All Reports skye-20240930.htm skye-20240930.xsd skye-20240930_cal.xml skye-20240930_def.xml skye-20240930_lab.xml skye-20240930_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skye-20240930.htm": { "nsprefix": "skye", "nsuri": "http://skyebioscience.com/20240930", "dts": { "inline": { "local": [ "skye-20240930.htm" ] }, "schema": { "local": [ "skye-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "skye-20240930_cal.xml" ] }, "definitionLink": { "local": [ "skye-20240930_def.xml" ] }, "labelLink": { "local": [ "skye-20240930_lab.xml" ] }, "presentationLink": { "local": [ "skye-20240930_pre.xml" ] } }, "keyStandard": 226, "keyCustom": 48, "axisStandard": 18, "axisCustom": 1, "memberStandard": 19, "memberCustom": 31, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 175, "entityCount": 1, "segmentCount": 52, "elementCount": 527, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 551, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://skyebioscience.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R3": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R6": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITEDParentheticals", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsOfDebtIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 (DEFICIT) EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 (DEFICIT) EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-39", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R8": { "role": "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITEDParenthetical", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 (DEFICIT) EQUITY (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 (DEFICIT) EQUITY (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-19", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPolicies", "longName": "9952158 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies", "shortName": "Organization, Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://skyebioscience.com/role/AssetAcquisitionsandDispositions", "longName": "9952159 - Disclosure - Asset Acquisitions and Dispositions", "shortName": "Asset Acquisitions and Dispositions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilities", "longName": "9952160 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://skyebioscience.com/role/Warrants", "longName": "9952161 - Disclosure - Warrants", "shortName": "Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "skye:WarrantsAndDerivativeLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "skye:WarrantsAndDerivativeLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://skyebioscience.com/role/Debt", "longName": "9952162 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": {*

"contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://skyebioscience.com/role/StockholdersEquityandCapitalization", "longName": "9952163 - Disclosure - Stockholders' Equity and Capitalization", "shortName": "Stockholders' Equity and Capitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://skyebioscience.com/role/StockBasedCompensation", "longName": "9952164 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://skyebioscience.com/role/LossPerShareofCommonStock", "longName": "9952165 - Disclosure - Loss Per Share of Common Stock", "shortName": "Loss Per Share of Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://skyebioscience.com/role/Contingencies", "longName": "9952166 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://skyebioscience.com/role/SubsequentEvents", "longName": "9952167 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Organization, Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Organization, Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsTables", "longName": "9954472 - Disclosure - Asset Acquisitions and Dispositions (Tables)", "shortName": "Asset Acquisitions and Dispositions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables", "longName": "9954473 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://skyebioscience.com/role/WarrantsTables", "longName": "9954474 - Disclosure - Warrants (Tables)", "shortName": "Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://skyebioscience.com/role/DebtTables", "longName": "9954475 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://skyebioscience.com/role/StockBasedCompensationTables", "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://skyebioscience.com/role/LossPerShareofCommonStockTables", "longName": "9954477 - Disclosure - Loss Per Share of Common Stock (Tables)", "shortName": "Loss Per Share of Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "longName": "9954478 - Disclosure - Asset Acquisitions and Dispositions - Narrative (Details)", "shortName": "Asset Acquisitions and Dispositions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:GainLossOnDispositionOfAssets1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-65", "name": "skye:DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R29": { "role": "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954479 - Disclosure - Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details)", "shortName": "Asset Acquisitions and Dispositions - Schedule of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-68", "name": "skye:PaymentsForAssetAcquisitions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "skye:PaymentsForAssetAcquisitions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails", "longName": "9954480 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesNarrativeDetails", "longName": "9954481 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails", "longName": "9954482 -

*Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "skye:PrepaidClinicalExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "skye:PrepaidClinicalExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails", "longName": "9954483 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "skye:TaxRebateCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "skye:TaxRebateCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails", "longName": "9954484 - Disclosure - Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details)", "shortName": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities - Schedule of Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "skye:AccruedResearchAndDevelopmentCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "skye:AccruedResearchAndDevelopmentCostsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails", "longName": "9954485 - Disclosure - Warrants - Schedule of Warrants Vested and Outstanding (Details)", "shortName": "Warrants - Schedule of Warrants Vested and Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "skye:ClassOfWarrantOrRightWarrantsVestedAndOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "skye:ClassOfWarrantOrRightWarrantsVestedAndOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://skyebioscience.com/role/WarrantsNarrativeDetails", "longName": "9954486 - Disclosure - Warrants - Narrative (Details)", "shortName": "Warrants - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-114", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails", "longName": "9954487 - Disclosure - Debt - Schedule of Convertible Debt (Details)", "shortName": "Debt - Schedule of Convertible Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-104", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ConvertibleDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ConvertibleDebtTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://skyebioscience.com/role/DebtNarrativeDetails", "longName": "9954488 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-108", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails", "longName": "9954489 - Disclosure - Debt - Schedule of Interest Expense (Details)", "shortName": "Debt - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "skye:InterestExpenseRelatedPartyStatedRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "skye:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "skye:InterestExpenseRelatedPartyStatedRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "skye:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "longName": "9954490 - Disclosure - Stockholders' Equity and Capitalization (Details)", "shortName": "Stockholders' Equity and Capitalization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-106", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R41": { "role": "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "longName": "9954491 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "longName": "9954492 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-123", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R43": { "role": "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "longName": "9954493 - Disclosure - Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details)", "shortName": "Stock-Based Compensation - Fair Value Assumptions of Stock Option Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-130", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails", "longName": "9954494 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-138", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-138", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails", "longName": "9954495 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails", "longName": "9954496 - Disclosure - Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details)", "shortName": "Loss Per Share of Common Stock - Schedule of earnings per share, basic and diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails", "longName": "9954497 - Disclosure - Loss Per Share of Common Stock - Anti-dilutive Securities (Details)", "shortName": "Loss Per Share of Common Stock - Anti-dilutive Securities (Details)", "isDefault": "false",*

```
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-149", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-149", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://skyebioscience.com/role/ContingenciesNarrativeDetails", "longName": "9954498 - Disclosure - Contingencies - Narrative (Details)", "shortName": "Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-5", "name": "skye:LegalFeesInterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "skye:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "us-gaap:LossContingencyDamagesAwardedValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "unique": true } }, "R49": { "role": "http://skyebioscience.com/role/SubsequentEventsDetails", "longName": "9954499 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-174", "name": "skye:OperatingLeaseAreaOfLeasedSpace", "unitRef": "sqft", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-174", "name": "skye:OperatingLeaseAreaOfLeasedSpace", "unitRef": "sqft", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "skye-20240930.htm", "first": true, "unique": true } } }, "tag": { "skye_A2014AmendedAndRestatedPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "A2014AmendedAndRestatedPlanMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2014 Amended and Restated Plan", "label": "2014 Amended and Restated Plan [Member]", "documentation": "2014 Amended and Restated Plan" } } }, "auth_ref": [] }, "skye_A2024InducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "A2024InducementEquityIncentivePlanMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Inducement Equity Incentive Plan", "label": "2024 Inducement Equity Incentive Plan [Member]", "documentation": "2024 Inducement Equity Incentive Plan" } } }, "auth_ref": [] }, "skye_AVIBuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AVIBuildingMember", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AVI Building", "label": "AVI Building [Member]", "documentation": "AVI Building" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r477" ] }, "skye_AccruedInterestConversionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AccruedInterestConversionExpense", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued interest conversion expense", "label": "Accrued Interest Conversion Expense", "documentation": "Accrued Interest Conversion Expense" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "skye_AccruedResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AccruedResearchAndDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development costs", "label": "Accrued Research And Development Costs, Current", "documentation": "Accrued Research And Development Costs, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r17", "r97", "r361" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r526" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r381", "r588", "r589", "r590", "r591", "r649", "r671" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r539" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r539" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r539" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r539" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r27", "r28", "r252" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued with convertible note", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r6", "r20", "r71" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r572" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r498", "r508", "r518", "r550" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r501", "r511", "r521", "r553" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r573" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r539" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r546" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r502", "r512", "r522", "r546", "r554", "r558", "r566" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r564" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r281", "r286" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r4", "r50", "r221", "r656" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of transaction costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r50", "r221", "r583", "r656" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of debt discount", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r221", "r461", "r462", "r583", "r656" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive excluded from the calculation of diluted loss per common share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r146" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r15" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r15" ] }, "skye_AssetAcquisitionAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionAccountsPayable", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Asset Acquisition, Accounts Payable", "documentation": "Asset Acquisition, Accounts Payable" } } }, "auth_ref": [] }, "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total net assets acquired", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r645" ] }, "skye_AssetAcquisitionCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Asset Acquisition, Cash And Cash Equivalents", "documentation": "Asset Acquisition, Cash And Cash Equivalents" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r470", "r646", "r647", "r648" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r645" ] }, "skye_AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionEquityInterestIssuedOrIssuableNumberOfShares", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, equity interest issued or issuable, number of shares (in shares)", "label": "Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Line Items]", "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r645" ] }, "skye_AssetAcquisitionOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Asset Acquisition, Other Current Liabilities", "documentation": "Asset Acquisition, Other Current Liabilities" } } }, "auth_ref": [] }, "skye_AssetAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, percentage of voting interests acquired", "label": "Asset Acquisition, Percentage of Voting Interests Acquired", "documentation": "Asset Acquisition, Percentage of Voting Interests Acquired" } } }, "auth_ref": [] }, "skye_AssetAcquisitionPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionPrepaidExpenses", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Asset Acquisition, Prepaid Expenses", "documentation": "Asset Acquisition, Prepaid Expenses" } } }, "auth_ref": [] }, "skye_AssetAcquisitionSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "AssetAcquisitionSharePrice", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset acquisition, share price (in dollars per share)", "label": "Asset Acquisition, Share Price", "documentation": "Asset Acquisition, Share Price" } } },
```

```
"auth_ref": [] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTable", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition [Table]", "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r645" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r80", "r87", "r99", "r114", "r150", "r152", "r157", "r158", "r160", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r301", "r303", "r319", "r353", "r405", "r454", "r455", "r477", "r489", "r613", "r614", "r660" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r93", "r102", "r114", "r160", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r301", "r303", "r319", "r477", "r613", "r614", "r660" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "skye_August2023ConvertibleNoteCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "August2023ConvertibleNoteCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "August 2023 Convertible Note Common Stock Warrants", "label": "August 2023 Convertible Note Common Stock Warrants [Member]", "documentation": "August 2023 Convertible Note Common Stock Warrants" } } }, "auth_ref": [] }, "skye_August2023PIPEFinancingCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "August2023PIPEFinancingCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "August 2023 PIPE Financing Common Stock Warrants", "label": "August 2023 PIPE Financing Common Stock Warrants [Member]", "documentation": "August 2023 PIPE Financing Common Stock Warrants" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r561" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r562" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r557" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r557" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r557" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r557" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r557" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r557" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails", "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r560" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r559" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r558" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r558" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "skye_BirdRockBioSubInc.BRBMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "BirdRockBioSubInc.BRBMember", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bird Rock Bio Sub, Inc. (BRB)", "label": "Bird Rock Bio Sub, Inc. (BRB) [Member]", "documentation": "Bird Rock Bio Sub, Inc. (BRB)" } } }, "auth_ref": [] }, "skye_BondPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "BondPremium", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bond premium", "label": "Bond Premium", "documentation": "Bond Premium" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositions" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisitions and Dispositions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r76", "r298" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "netLabel": "Cash, and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r14", "r95", "r449" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r14", "r56", "r111" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Reconciliation of cash, cash equivalents and restricted cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial
```

*institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r56" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental disclosures of non-cash financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r537" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r534" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r532" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "skye_ClassOfWarrantOrRightAverageSharePriceThresholdTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ClassOfWarrantOrRightAverageSharePriceThresholdTradingDays", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, average share price, threshold trading days", "label": "Class Of Warrant Or Right, Average Share Price, Threshold Trading Days", "documentation": "Class Of Warrant Or Right, Average Share Price, Threshold Trading Days" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails", "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails", "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails", "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r242" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://skyebioscience.com/role/WarrantsNarrativeDetails", "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total number of warrants issued (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r242" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Class of warrant or right, outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://skyebioscience.com/role/WarrantsNarrativeDetails", "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r24" ] }, "skye_ClassOfWarrantOrRightTermOfWarrant": { "xbrltype": "durationItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ClassOfWarrantOrRightTermOfWarrant", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Term (Years)", "label": "Class Of Warrant Or Right, Term Of Warrant", "documentation": "Class Of Warrant Or Right, Term Of Warrant" } } }, "auth_ref": [] }, "skye_ClassOfWarrantOrRightWarrantsVestedAndOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ClassOfWarrantOrRightWarrantsVestedAndOutstanding", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants Vested and Outstanding (in shares)", "label": "Class Of Warrant Or Right, Warrants Vested And Outstanding", "documentation": "Class Of Warrant Or Right, Warrants Vested And Outstanding" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r538" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r538" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r37", "r82", "r355", "r392" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://skyebioscience.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r64", "r180", "r181", "r445", "r602", "r607" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r479", "r480", "r481", "r483", "r484", "r485", "r486", "r588", "r589", "r591", "r649", "r670", "r671" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r40", "r393" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r40", "r393", "r411", "r671", "r672" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.001 par value; 100,000,000 shares authorized at September\u00a030, 2024 and December\u00a031, 2023; 30,338,290 and 12,349,243 shares issued and outstanding at September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r40", "r357", "r477" ] }, "skye_CommonStockWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "CommonStockWarrantExercises", "crdr": "credit", "presentation": [*

```
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock warrant exercises", "label": "Common Stock Warrant Exercises", "documentation": "Common Stock Warrant Exercises" } } }, "auth_ref": [] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r543" ]
}, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r542" ] },
"ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation
Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r544" ] },
"ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r541" ] },
"us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember",
"presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used
in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": "us-
gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "EHT Acquisition related liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service
to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r244", "r245", "r246" ] },
"skye_ConversionOfAccruedInterestDueToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname":
"ConversionOfAccruedInterestDueToRelatedParty", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of
accrued interest due to related party", "label": "Conversion of Accrued Interest Due to Related Party", "documentation": "Conversion of Accrued Interest Due to Related
Party" } } }, "auth_ref": [] }, "skye_ConversionOfMultiDrawCreditAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930",
"localname": "ConversionOfMultiDrawCreditAgreement", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of multi-
draw credit agreement", "label": "Conversion of Multi-Draw Credit Agreement", "documentation": "Conversion of Multi-Draw Credit Agreement" } } }, "auth_ref": [] },
"skye_Convertible10NoteMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "Convertible10NoteMember",
"presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails",
"http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total principal value of convertible note - related
party, net of discount", "label": "Convertible 10% Note [Member]", "documentation": "Convertible 10% Note" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note - related
party, net of discount", "label": "Convertible Debt, Current", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date
that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified
amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ConvertibleDebtMember":
{ "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": [
"http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails",
"http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified
number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r66", "r200", "r201",
"r211", "r212", "r213", "r217", "r218", "r219", "r220", "r221", "r458", "r459", "r460", "r461", "r462" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [
"http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants", "label": "Convertible
Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } },
"auth_ref": [ "r617" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConvertibleDebtTableTextBlock", "presentation": [ "http://skyebioscience.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of debt", "label":
"Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized
premium or discount." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract",
"lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails",
"http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to
borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r189", "r611" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails",
"http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers
without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r189", "r611", "r612" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang":
{ "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --
MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [
"http://skyebioscience.com/role/Debt" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire
disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial
paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying
arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether
or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt
covenants." } } }, "auth_ref": [ "r65", "r112", "r173", "r174", "r175", "r176", "r177", "r188", "r189", "r199", "r205", "r206", "r207", "r208", "r209", "r210", "r215", "r222",
"r223", "r225", "r331" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails": { "parentTag": "us-
gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Total principal value of convertible note - related party, net of discount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized
(discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible
debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r9", "r81", "r226" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [
"http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion
feature embedded in the debt instrument." } } }, "auth_ref": [ "r67", "r202" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Debt, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time
of issuance." } } }, "auth_ref": [ "r200", "r331", "r332", "r459", "r460", "r476" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://skyebioscience.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate, effective percentage", "label": "Debt
Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest
compounding and original issue discount or premium." } } }, "auth_ref": [ "r34", "r228", "r331", "r332", "r476" ] }, "us-
gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt
agreement." } } }, "auth_ref": [ "r34", "r201" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentLineItems", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails",
"http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt
Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r117", "r200", "r201", "r202", "r203", "r204", "r206", "r211", "r212", "r213",
"r214", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r458", "r459", "r460", "r461", "r462", "r476", "r584", "r655", "r657" ] }, "us-gaap_DebtInstrumentTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-
term debt instrument or arrangement." } } }, "auth_ref": [ "r9", "r22", "r23", "r29", "r69", "r70", "r117", "r200", "r201", "r202", "r203", "r204", "r206", "r211", "r212",
"r213", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r224", "r458", "r459", "r460", "r461", "r462", "r476", "r584", "r655", "r657" ] }, "us-
gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails": { "parentTag": "us-
gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role":
{ "negatedTerseLabel": "Unamortized debt discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of
debt discount." } } }, "auth_ref": [ "r616", "r654", "r655", "r657" ] }, "skye_December2019EHTCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri":
"http://skyebioscience.com/20240930", "localname": "December2019EHTCommonStockWarrantsMember", "presentation": [
```

```
"http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2019 EHT Common Stock Warrants", "label": "December 2019 EHT Common Stock Warrants [Member]", "documentation": "December 2019 EHT Common Stock Warrants" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of prepaid expenses", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs, gross", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r655", "r657" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r616", "r654", "r655", "r657" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vendor deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r579" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r16" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation, depletion and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r150", "r155", "r158", "r454", "r455" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://skyebioscience.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r250", "r254", "r282", "r283", "r285", "r467" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": [ "r2" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r91" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate purchase price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "skye_DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableInterestRate", "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, including discontinued operation, consideration receivable, interest rate", "label": "Disposal Group, Including Discontinued Operation, Consideration Receivable, Interest Rate", "documentation": "Disposal Group, Including Discontinued Operation, Consideration Receivable, Interest Rate" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from disposal of assets", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r171", "r583", "r601" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r464", "r465" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r493" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r525" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r536" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED",
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r123", "r124", "r125", "r126", "r127", "r128", "r133", "r136", "r143", "r144", "r145", "r149", "r296", "r300", "r313", "r314", "r350", "r366", "r451" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED",
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or
```

common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r123", "r124", "r125", "r126", "r127", "r128", "r136", "r143", "r144", "r145", "r149", "r296", "r300", "r313", "r314", "r350", "r366", "r451" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Diluted [Abstract]", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStock" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share of Common Stock", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r132", "r146", "r147", "r148" ] }, "skye_EconomicDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "EconomicDamagesMember", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Economic Damages", "label": "Economic Damages [Member]", "documentation": "Economic Damages" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits and share-based compensation", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll liabilities", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r284" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized weighted average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r284" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails", "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Option", "verboseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r490" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r490" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r490" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r575" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r490" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r490" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r490" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r490" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r530" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r571" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r571" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported

*in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r571" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r90", "r105", "r106", "r107", "r118", "r119", "r120", "r122", "r127", "r129", "r131", "r151", "r161", "r162", "r170", "r243", "r290", "r291", "r293", "r294", "r295", "r297", "r299", "r300", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r324", "r325", "r326", "r327", "r328", "r329", "r333", "r334", "r338", "r365", "r372", "r373", "r374", "r381", "r432" ] }, "skye_EquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "EquityLineItems", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity [Line Items]", "label": "Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "skye_EquityTable": { "xbrltype": "stringItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "EquityTable", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity [Table]", "label": "Equity [Table]", "documentation": "Represents tabular disclosure of Equity." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r540" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r498", "r508", "r518", "r550" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r495", "r505", "r515", "r547" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r546" ] }, "skye_February2020EHTCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "February2020EHTCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "February 2020 EHT Common Stock Warrants", "label": "February 2020 EHT Common Stock Warrants [Member]", "documentation": "February 2020 EHT Common Stock Warrants" } } }, "auth_ref": [] }, "skye_FinancingOfInsurancePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "FinancingOfInsurancePremium", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Financing of insurance premium", "label": "Financing Of Insurance Premium", "documentation": "Financing Of Insurance Premium" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency remeasurement gain", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r429" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r502", "r512", "r522", "r554" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r502", "r512", "r522", "r554" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r502", "r512", "r522", "r554" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r502", "r512", "r522", "r554" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r502", "r512", "r522", "r554" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r535" ] }, "skye_GainLossFromEstimatedLegalContingency": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "GainLossFromEstimatedLegalContingency", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in estimate for legal contingencies", "label": "Gain (Loss) from Estimated Legal Contingency", "documentation": "Gain (Loss) from Estimated Legal Contingency" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 }, "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails", "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gain) loss from asset sales", "terseLabel": "(Gain) loss from asset sales", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r583" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r48", "r415" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r48" ] }, "skye_InProcessResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "InProcessResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 }, "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cost to acquire IPR&D asset", "label": "In Process Research and Development Expense", "documentation": "In Process Research and Development Expense" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r46", "r84", "r86", "r351", "r363", "r453", "r454", "r593", "r594", "r595", "r596", "r597" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r172", "r178", "r179", "r316", "r317", "r318", "r369", "r371", "r416", "r448", "r471", "r669" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r178", "r179", "r316", "r317", "r318", "r369", "r371", "r416", "r448", "r471", "r669" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss",*

"weight": -1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r88", "r89", "r130", "r131", "r150", "r156", "r158", "r288", "r289", "r292", "r367", "r469" ] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other tax receivables", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r79", "r577" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable - related parties", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDerivativeLiabilities", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of derivative liabilities", "label": "Increase (Decrease) in Derivative Liabilities", "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [ "r582" ] }, "us-gaap_IncreaseDecreaseInDueToOtherRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDueToOtherRelatedPartiesCurrent", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities - related parties", "label": "Increase (Decrease) in Due to Other Related Parties, Current", "documentation": "Amount of increase (decrease) in related party payables classified as other, due within one year or operating cycle, if longer." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll liabilities", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r576", "r582" ] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest - related party", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r582" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r582" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r582" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "skye_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPR&D asset", "label": "Indefinite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [ "r168", "r600" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r502", "r512", "r522", "r546", "r554", "r558", "r566" ] }, "us-gaap_InducedConversionOfConvertibleDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InducedConversionOfConvertibleDebtExpense", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Debt conversion inducement expense", "label": "Induced Conversion of Convertible Debt Expense", "documentation": "Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms." } } }, "auth_ref": [ "r21" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r564" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri":

```
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r494", "r570" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r494", "r570" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r494", "r570" ] }, "skye_InsurancePremiumExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "InsurancePremiumExpense", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance premium loan payable \u2013 stated rate", "label": "Insurance Premium Expense", "documentation": "Insurance Premium Expense" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 }, "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED", "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest (income) expense", "totalLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r154", "r581" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "skye_InterestExpenseRelatedPartyStatedRate": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "InterestExpenseRelatedPartyStatedRate", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party interest expense \u2013 stated rate", "label": "Interest Expense, Related Party, Stated Rate", "documentation": "Interest Expense, Related Party, Stated Rate" } } }, "auth_ref": [] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest - legal contingency", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r32" ] }, "skye_InterestPayableRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "InterestPayableRelatedPartiesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued interest - related party", "label": "Interest Payable, Related Parties, Current", "documentation": "Interest Payable, Related Parties, Current" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r150", "r153", "r158", "r454", "r580" ] }, "skye_January2024PIPEFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "January2024PIPEFinancingMember", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 PIPE Financing", "label": "January 2024 PIPE Financing [Member]", "documentation": "January 2024 PIPE Financing" } } }, "auth_ref": [] }, "skye_January2024PIPEFinancingPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "January2024PIPEFinancingPreFundedWarrantsMember", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 PIPE Financing Pre-Funded Warrants", "label": "January 2024 PIPE Financing Pre-Funded Warrants [Member]", "documentation": "January 2024 PIPE Financing Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r63", "r337" ] }, "skye_LegalFeesInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "LegalFeesInterestExpense", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal judgment interest (income) expense", "label": "Legal Fees, Interest Expense", "documentation": "Legal Fees, Interest Expense" } } }, "auth_ref": [] }, "skye_LegalProfessionalFeeAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "LegalProfessionalFeeAccrual", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Legal Professional Fee Accrual", "documentation": "Legal Professional Fee Accrual" } } }, "auth_ref": [] }, "skye_LesseeOperatingLeaseAnnualRentIncreasePercent": { "xbrltype": "percentItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "LesseeOperatingLeaseAnnualRentIncreasePercent", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, annual rent increase, percent", "label": "Lessee, Operating Lease, Annual Rent Increase, Percent", "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percent" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r658" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r31", "r32", "r33", "r35", "r36", "r37", "r38", "r114", "r160", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r302", "r303", "r304", "r319", "r391", "r452", "r489", "r613", "r660", "r661" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r45", "r83", "r359", "r477", "r585", "r598", "r653" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r33", "r94", "r114", "r160", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r302", "r303", "r304", "r319", "r477", "r613", "r660", "r661" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Carrying value of total convertible debt - related party", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r9", "r81", "r212", "r227", "r459", "r460", "r476", "r668" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r9", "r603", "r604", "r605" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://skyebioscience.com/role/DebtNarrativeDetails", "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails", "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes,
```

*line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r9", "r19", "r603", "r604", "r605" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r182", "r183", "r184", "r187", "r287", "r377", "r457", "r609", "r610" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r182", "r183", "r184", "r187", "r287", "r457", "r609", "r610" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r182", "r183", "r184", "r187", "r287", "r457", "r609", "r610" ] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate for accrued legal contingencies and related expenses", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r182" ] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual, period increase (decrease)", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Change in estimate for legal contingencies", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r608" ] }, "skye_LossContingencyAppealBond": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "LossContingencyAppealBond", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, appeal bond", "label": "Loss Contingency, Appeal Bond", "documentation": "Loss Contingency, Appeal Bond" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total compensatory damages", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": [ "r608", "r609", "r610" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r182", "r183", "r184", "r187", "r287", "r377", "r457", "r609", "r610" ] }, "skye_LossContingencyNetCashReceivedToCoverLegalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "LossContingencyNetCashReceivedToCoverLegalExpenses", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Coverage received to cover legal expenses", "label": "Loss Contingency, Net Cash Received To Cover Legal Expenses", "documentation": "Loss Contingency, Net Cash Received To Cover Legal Expenses" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "skye_March2024PIPEFinancingCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "March2024PIPEFinancingCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "January 2024 Pre-Funded Warrants Common Stock", "label": "March 2024 PIPE Financing Common Stock Warrants [Member]", "documentation": "March 2024 PIPE Financing Common Stock Warrants" } } }, "auth_ref": [] }, "skye_March2024PIPEFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "March2024PIPEFinancingMember", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 PIPE Financing", "label": "March 2024 PIPE Financing [Member]", "documentation": "March 2024 PIPE Financing" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r249", "r287", "r315", "r348", "r368", "r370", "r377", "r383", "r384", "r438", "r439", "r440", "r441", "r442", "r446", "r447", "r456", "r463", "r466", "r472", "r473", "r474", "r475", "r478", "r615", "r662", "r663", "r664", "r665", "r666", "r667" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r538" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r538" ] }, "skye_MeasuredAtGrantDateMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "MeasuredAtGrantDateMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measured At Grant Date", "label": "Measured At Grant Date [Member]", "documentation": "Measured At Grant Date" } } }, "auth_ref": [] }, "skye_MeasuredAtModificationDateMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "MeasuredAtModificationDateMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measured At Modification Date", "label": "Measured At Modification Date [Member]", "documentation": "Measured At Modification Date" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r249", "r287", "r315", "r348", "r368", "r370", "r377", "r383", "r384", "r438", "r439", "r440", "r441", "r442", "r446", "r447", "r456", "r463", "r466", "r472", "r473", "r474", "r478", "r615", "r662", "r663", "r664", "r665", "r666", "r667" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r557" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r565" ] }, "skye_MultiDrawCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "MultiDrawCreditAgreementMember", "presentation": [ "http://skyebioscience.com/role/DebtScheduleofConvertibleDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total principal value of convertible multi-draw credit agreement - related party", "label": "Multi Draw Credit Agreement [Member]", "documentation": "Represents the information about Multi-Draw Credit Agreement (the \"Credit Agreement\")." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r539" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": {*

"totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r56", "r57", "r58" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 },
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "terseLabel": "Net loss for three months ended", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r47", "r58", "r85", "r92", "r103", "r104", "r107", "r114", "r121", "r123", "r124", "r125", "r126", "r127", "r130", "r131", "r141", "r160", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r296", "r300", "r314", "r319", "r364", "r413", "r430", "r431", "r487", "r613" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r109", "r123", "r124", "r125", "r126", "r133", "r134", "r142", "r145", "r300" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r109", "r135", "r137", "r138", "r139", "r140", "r142", "r145" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pronouncements Implemented and Recent Accounting Pronouncements Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "skye_NonCashInterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "NonCashInterestExpenseAbstract", "presentation": [
"http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense:", "label": "Non Cash Interest Expense [Abstract]" } } }, "auth_ref": [] }, "skye_NonEconomicDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "NonEconomicDamagesMember", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Economic Damages", "label": "Non-Economic Damages [Member]", "documentation": "Non-Economic Damages" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r538" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r502", "r512", "r522", "r546", "r554" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r529" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r528" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r546" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r565" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r565" ] }, "skye_NoncashConversionOfConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "NoncashConversionOfConvertibleNote", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of convertible note - related party to common stock", "label": "Noncash Conversion of Convertible Note", "documentation": "Noncash Conversion of Convertible Note" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other (income) expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Other (income) expense", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonrelatedPartyMember", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r586", "r587" ] }, "skye_November2019EHTCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "November2019EHTCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2019 EHT Common Stock Warrants", "label": "November 2019 EHT Common Stock Warrants [Member]", "documentation": "November 2019 EHT Common Stock Warrants" } } }, "auth_ref": [] }, "skye_NumberOfMarketBasedConditionsMet": { "xbrltype": "integerItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "NumberOfMarketBasedConditionsMet", "presentation": [
"http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of market based conditions met", "label": "Number Of Market Based Conditions Met", "documentation": "Number Of Market Based Conditions Met" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r86", "r453", "r593", "r594", "r595", "r596", "r597" ] }, "skye_OperatingLeaseAreaOfLeasedSpace": { "xbrltype": "areaItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "OperatingLeaseAreaOfLeasedSpace", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, area of leased space", "label": "Operating Lease, Area of Leased Space", "documentation": "Operating Lease, Area of Leased Space" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r336" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r336" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r335" ] }, "skye_OperatingLeasesMonthlyRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "OperatingLeasesMonthlyRentalExpense", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases, monthly rental expense", "label": "Operating Leases, Monthly Rental Expense", "documentation": "Operating Leases, Monthly Rental Expense" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://skyebioscience.com/role/OrganizationBasisofPresentationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Organization, Basis of Presentation and Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r59", "r60", "r61", "r78" ] }, "skye_OtherAssetsAndLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "OtherAssetsAndLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Assets And Liabilities, Current [Abstract]", "documentation": "Other Assets And Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "totalLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r101", "r477" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Miscellaneous, Current", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r98" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other current liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32", "r477" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense (income)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r51" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r538" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other prepaid expenses", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r578", "r599" ] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r18", "r32" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r500", "r510", "r520", "r552" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r503", "r513", "r523", "r555" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r503", "r513", "r523", "r555" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r527" ] }, "skye_PaymentsForAssetAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PaymentsForAssetAcquisitions", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Payments for Asset Acquisitions", "documentation": "Payments for Asset Acquisitions" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromPreviousAcquisition", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash from asset acquisition, net of transaction costs", "label": "Payments for (Proceeds from) Previous Acquisition", "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for Repurchase of Warrants", "label": "Payments for Repurchase of Warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r54" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITEDParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r13" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r12" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r53" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r537" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r537" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r529" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r546" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
```

```
"PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r539" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r528" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails",
"http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails",
"http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r530" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r574" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r529" ] }, "skye_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prefunded Warrants", "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r39", "r230" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r39", "r393" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r39", "r230" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r39", "r393", "r411", "r671", "r672" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 200,000 shares authorized at September\u00a030, 2024 and December\u00a031, 2023; no shares issued and outstanding at September\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r39", "r356", "r477" ] }, "skye_PremiumOnIrrevocableLetterOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PremiumOnIrrevocableLetterOfCredit", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpenseNonoperating", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://skyebioscience.com/role/DebtScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Premium on irrevocable letter of credit", "label": "Premium on Irrevocable Letter of Credit", "documentation": "Premium on Irrevocable Letter of Credit" } } }, "auth_ref": [] }, "skye_PrepaidClinicalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PrepaidClinicalExpenses", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical expenses", "label": "Prepaid Clinical Expenses", "documentation": "Prepaid Clinical Expenses" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses", "totalLabel": "Total prepaid expense", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r100", "r163", "r164", "r450" ] }, "skye_PrepaidFinancialAdvisoryServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PrepaidFinancialAdvisoryServiceAgreement", "crdr": "debit", "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Financial Advisory Service Agreement", "label": "Prepaid Financial Advisory Service Agreement", "documentation": "Prepaid Financial Advisory Service Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible note - related party", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount paid", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock and warrants, net of equity issuance costs of $6,434,447 and $265,053, respectively", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "skye_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Financing costs allocated to warrants issued with convertible debt", "label": "Proceeds From Issuance Of Common Stock And Warrants", "documentation": "Proceeds From Issuance Of Common Stock And Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [
"http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance or sale of equity", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r379" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of assets, net of sales costs", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r52" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r337" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings,
```

machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r63", "r96", "r362" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r337" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r337", "r352", "r362", "r477" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r63", "r337" ] }, "skye_PunitiveDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "PunitiveDamagesMember", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Punitive Damages", "label": "Punitive Damages [Member]", "documentation": "Punitive Damages" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r527" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r527" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r247", "r249", "r277", "r278", "r279", "r287", "r315", "r346", "r347", "r348", "r368", "r370", "r377", "r383", "r384", "r438", "r439", "r440", "r441", "r442", "r446", "r447", "r456", "r463", "r466", "r472", "r473", "r474", "r475", "r478", "r481", "r606", "r615", "r651", "r663", "r664", "r665", "r666", "r667" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r247", "r249", "r277", "r278", "r279", "r287", "r315", "r346", "r347", "r348", "r368", "r370", "r377", "r383", "r384", "r438", "r439", "r440", "r441", "r442", "r446", "r447", "r456", "r463", "r466", "r472", "r473", "r474", "r475", "r478", "r481", "r606", "r615", "r651", "r663", "r664", "r665", "r666", "r667" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r495", "r505", "r515", "r547" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r159", "r248", "r339", "r340", "r354", "r360", "r386", "r387", "r388", "r389", "r390", "r410", "r412", "r437" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r115", "r116", "r339", "r340", "r341", "r342", "r354", "r360", "r386", "r387", "r388", "r389", "r390", "r410", "r412", "r437" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r159", "r248", "r339", "r340", "r354", "r360", "r386", "r387", "r388", "r389", "r390", "r410", "r412", "r437", "r659" ] }, "skye_ReleaseOfShareLiabilityToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ReleaseOfShareLiabilityToAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset obtained in exchange for operating lease liabilities", "label": "Release Of Share Liability To Additional Paid-In-Capital", "documentation": "Release Of Share Liability To Additional Paid-In-Capital" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of insurance premium loan payable", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r644" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r496", "r506", "r516", "r548" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r497", "r507", "r517", "r549" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r504", "r514", "r524", "r556" ] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r14", "r95", "r111" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r42", "r71", "r358", "r375", "r376", "r380", "r394", "r477" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": {

```
"verboseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r90", "r118", "r119", "r120", "r122", "r127", "r129", "r131", "r161", "r162", "r170", "r290", "r291", "r293", "r294", "r295", "r297", "r299", "r300", "r305", "r307", "r308", "r310", "r312", "r333", "r334", "r372", "r374", "r381", "r671" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r565" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r565" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of anti-dilutive securities", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of earnings per share, basic and diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r592" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r26" ] }, "skye_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": [ "http://skyebioscience.com/role/DebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of interest expense", "label": "Schedule Of Interest Expense [Table Text Block]", "documentation": "Tabular disclosure of interest expense." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Nonvested Share Activity", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of other current assets", "label": "Schedule of Other Current Assets [Table Text Block]", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5", "r337" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails", "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r251", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of stock option activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r7", "r8", "r72" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value assumptions of stock option granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r75" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://skyebioscience.com/role/WarrantsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of warrants vested and outstanding", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r24" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(g) Security", "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r492" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r491" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-
```

```
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r269" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning balance (in shares)", "periodEndLabel": "Unvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r266", "r267" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning balance (in dollars per share)", "periodEndLabel": "Unvested, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r266", "r267" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "skye_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAxis", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Axis]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Axis]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions" } } }, "auth_ref": [] }, "skye_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDomain": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDomain", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain]", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions [Domain]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r278" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility factor", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r277" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r279" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails",
"http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails",
"http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails",
"http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r251", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of authorized shares reserved for future grants (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r260" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r260" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r264" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r262" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair value of stock options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r272" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning (in shares)", "periodEndLabel": "Balance at the ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r258", "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning (in dollars per share)", "periodEndLabel": "Balance at the ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r258", "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails", "http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails", "http://skyebioscience.com/role/StockBasedCompensationScheduleofRestrictedStockActivityDetails", "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r264" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r262" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationFairValueAssumptionsofStockOptionGrantedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r276" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r25" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r25" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://skyebioscience.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Contractual Term (Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r74" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r6" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying common stock price (in dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r40", "r43", "r44", "r90", "r105", "r106", "r107", "r118", "r119", "r120", "r122", "r127", "r129", "r131", "r151", "r161", "r162", "r170", "r243", "r290", "r291", "r293", "r294", "r295", "r297", "r299", "r300", "r305", "r306", "r307", "r308", "r309", "r310", "r312", "r324", "r325", "r326", "r327", "r328", "r329", "r333", "r334", "r338", "r365", "r372",

```
"r373", "r374", "r381", "r432" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementLineItems", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r118", "r119", "r120", "r151", "r334",
"r349", "r378", "r382", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r407", "r408",
"r409", "r410", "r412", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r432", "r482" ] }, "us-
gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-
us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract",
"lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders'
Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable",
"presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive
income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r118", "r119", "r120", "r151", "r159", "r334", "r349", "r378", "r382", "r385", "r386",
"r387", "r388", "r389", "r390", "r393", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r406", "r407", "r408", "r409", "r410", "r412", "r414", "r415",
"r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r432", "r482" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR
Estimation Method [Text Block]" } } }, "auth_ref": [ "r499", "r509", "r519", "r551" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive
cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Common stock issued in acquisition of IPR&D asset (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock
issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r39", "r40", "r71" ] }, "skye_StockIssuedDuringPeriodSharesAcquisitionsPeriodIncreaseDecrease": {
"xbrltype": "sharesItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "StockIssuedDuringPeriodSharesAcquisitionsPeriodIncreaseDecrease",
"presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued during
period, shares, acquisitions, period increase (decrease) (in shares)", "label": "Stock Issued During Period, Shares, Acquisitions, Period Increase (Decrease)",
"documentation": "Stock Issued During Period, Shares, Acquisitions, Period Increase (Decrease)" } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Conversion of multi-draw credit agreement - related party and accrued interest (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible
Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r6", "r22", "r40",
"r43", "r71", "r216" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Stock issued during period, shares, conversion of units (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Units",
"documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate
investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r6", "r22", "r39", "r40", "r71" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [
"http://skyebioscience.com/role/StockBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued for services (in shares)",
"label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number
of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": {
"verboseLabel": "Issuance of common stock and warrants, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation":
"Number of new stock issued during the period." } } }, "auth_ref": [ "r6", "r39", "r40", "r71", "r379", "r432", "r443" ] }, "us-
gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Common stock issued for fractional share adjustment in reverse stock split (in shares)", "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
"documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r6" ] }, "us-
gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Stock-based compensation expense (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after
forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } },
"auth_ref": [ "r6", "r39", "r40", "r71" ] }, "skye_StockIssuedDuringPeriodSharesWarrantExercises": { "xbrltype": "sharesItemType", "nsuri":
"http://skyebioscience.com/20240930", "localname": "StockIssuedDuringPeriodSharesWarrantExercises", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Exercise of pre-funded warrants (in shares)", "label": "Stock Issued During Period, Shares, Warrant Exercises", "documentation": "Stock Issued During Period, Shares,
Warrant Exercises" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Common stock issued in acquisition of IPR&D asset", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to
acquisitions during the period." } } }, "auth_ref": [ "r6", "r40", "r43", "r44", "r71" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit",
"presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role":
{ "terseLabel": "Conversion of multi-draw credit agreement - related party and accrued interest", "label": "Stock Issued During Period, Value, Conversion of Convertible
Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r6", "r40", "r43", "r44",
"r71" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Issuance of common stock and warrants, net of issuance costs of $6,434,447", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact
of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r6", "r39", "r40",
"r71", "r381", "r432", "r443", "r488" ] }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockIssuedDuringPeriodValueStockDividend", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Exercise of pre-funded warrants", "label": "Stock Issued During Period, Value, Stock Dividend", "documentation": "Value of stock issued to shareholders as a dividend
during the period." } } }, "auth_ref": [ "r6", "r40", "r43", "r44", "r71" ] }, "skye_StockIssuedDuringPeriodValueWarrantExercises": { "xbrltype": "monetaryItemType",
"nsuri": "http://skyebioscience.com/20240930", "localname": "StockIssuedDuringPeriodValueWarrantExercises", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel":
"Exercise of common stock warrants", "label": "Stock Issued During Period, Value, Warrant Exercises", "documentation": "Stock Issued During Period, Value, Warrant
Exercises" } } }, "auth_ref": [] }, "skye_StockIssuedForAssetsNetOfEquityIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930",
"localname": "StockIssuedForAssetsNetOfEquityIssuanceCosts", "crdr": "credit", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for
assets", "label": "Stock Issued For Assets, Net Of Equity Issuance Costs", "documentation": "Stock Issued For Assets, Net Of Equity Issuance Costs" } } }, "auth_ref": [] },
"us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation":
{ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 }
}, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel":
"Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent",
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r40",
"r43", "r44", "r62", "r395", "r411", "r433", "r434", "r477", "r489", "r585", "r598", "r653", "r671" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders\u2019 equity (deficit)",
"label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://skyebioscience.com/role/StockholdersEquityandCapitalization" ], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' Equity and Capitalization", "label":
"Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r68", "r113", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r237",
"r238", "r239", "r240", "r241", "r243", "r311", "r435", "r436", "r444" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is
expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member
```

*elements pertaining to a subsequent event." } } }, "auth_ref": [ "r330", "r344" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r330", "r344" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r330", "r344" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r330", "r344" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://skyebioscience.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r330", "r344" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://skyebioscience.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "verboseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r343", "r345" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails", "http://skyebioscience.com/role/WarrantsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental disclosures of cash-flow information:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r545" ] }, "skye_TaxRebateCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TaxRebateCurrent", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://skyebioscience.com/role/PropertyandEquipmentPrepaidExpensesOtherCurrentAssetsandLiabilitiesScheduleofOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AusIndustry incentive", "label": "Tax Rebate, Current", "documentation": "Tax Rebate, Current" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r537" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r544" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r564" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r566" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://skyebioscience.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r567" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r568" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r568" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r566" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r566" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r569" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r567" ] }, "skye_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2020 Common Stock Warrants to Placement Agent", "label": "Two Thousand And Twenty Common Stock Warrants To Placement Agent [Member]", "documentation": "Two Thousand And Twenty Common Stock Warrants To Placement Agent" } } }, "auth_ref": [] }, "skye_TwoThousandAndTwentyOneCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandAndTwentyOneCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Common Stock Warrants", "label": "Two Thousand And Twenty One Common Stock Warrants [Member]", "documentation": "Two Thousand And Twenty One Common Stock Warrants" } } }, "auth_ref": [] }, "skye_TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Common Stock Warrants to Placement Agent", "label": "Two Thousand And Twenty One Common Stock Warrants To Placement Agent [Member]", "documentation": "Two Thousand And Twenty One Common Stock Warrants To Placement Agent" } } }, "auth_ref": [] }, "skye_TwoThousandAndTwentyOneInducementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandAndTwentyOneInducementWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Inducement Warrants", "label": "Two Thousand And Twenty One Inducement Warrants [Member]", "documentation": "Two Thousand And Twenty One Inducement Warrants" } } }, "auth_ref": [] }, "skye_TwoThousandAndTwentyOneInducementWarrantsToPlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandAndTwentyOneInducementWarrantsToPlacementAgentMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Inducement Warrants to Placement Agent", "label": "Two Thousand And Twenty One Inducement Warrants To Placement Agent [Member]", "documentation": "Two Thousand And Twenty One Inducement Warrants To Placement Agent" } } }, "auth_ref": [] }, "skye_TwoThousandFifteenCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandFifteenCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Common Stock Warrants", "label": "Two Thousand Fifteen Common Stock Warrants [Member]", "documentation": "Represents 2015 Common Stock Warrants." } } }, "auth_ref": [] }, "skye_TwoThousandNineteenCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandNineteenCommonStockWarrantsMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 Common Stock Warrants", "label": "Two Thousand Nineteen Common Stock Warrants [Member]", "documentation": "Information about 2019 common stock warrants." } } }, "auth_ref": [] }, "skye_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember", "presentation": [ "http://skyebioscience.com/role/WarrantsScheduleofWarrantsVestedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Common Stock Warrants to Service Providers", "label": "Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]", "documentation": "Represents two thousand sixteen Common Stock Warrants to Service Providers." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r563" ] }, "skye_VDLMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "VDLMember", "presentation": [ "http://skyebioscience.com/role/AssetAcquisitionsandDispositionsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VDL", "label": "VDL [Member]", "documentation": "VDL" } } }, "auth_ref": [] }, "skye_VendorDepositWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "VendorDepositWriteDown", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Write-down of vendor deposits", "label": "Vendor Deposit Write-Down", "documentation": "Vendor Deposit Write-Down" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r533" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://skyebioscience.com/role/LossPerShareofCommonStockAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unvested restricted stock units", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r479", "r480", "r483", "r484", "r485", "r486" ] }, "skye_WarrantsAndDerivativeLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "WarrantsAndDerivativeLiabilitiesTextBlock", "presentation": [ "http://skyebioscience.com/role/Warrants" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants",*

```
"label": "Warrants And Derivative Liabilities [Text Block]", "documentation": "The entire disclosure for Warrants and Derivative Liabilities." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsNoteDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Warrants and Rights Note Disclosure [Abstract]", "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://skyebioscience.com/role/StockholdersEquityandCapitalizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r650", "r651", "r652" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED",
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted average common shares outstanding \u2013 diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r135", "r145" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED",
"http://skyebioscience.com/role/LossPerShareofCommonStockScheduleofearningspersharebasicanddilutedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Weighted average common shares outstanding \u2013 basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r133", "r145" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares of common stock outstanding used to compute earnings per share:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "skye_WendyCunningVsSkyeBioscienceIncMember": { "xbrltype": "domainItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "WendyCunningVsSkyeBioscienceIncMember", "presentation": [ "http://skyebioscience.com/role/ContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wendy Cunning Vs Skye Bioscience, Inc", "label": "Wendy Cunning Vs Skye Bioscience, Inc [Member]", "documentation": "Wendy Cunning Vs Skye Bioscience, Inc" } } }, "auth_ref": [] }, "skye_WindDownCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://skyebioscience.com/20240930", "localname": "WindDownCosts", "crdr": "debit", "calculation": { "http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 5.0 } }, "presentation": [
"http://skyebioscience.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Wind-down costs", "label": "Wind-Down Costs", "documentation": "Wind-Down Costs" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r531" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "40", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481194/470-20-40-16" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-

30-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",

"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r227": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r228": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r229": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-
10-50-13" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r233": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r234": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r235": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r236": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r237": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r238": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r239": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r240": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r241": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r242": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r245": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-
20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r250": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/718/tableOfContent" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r252": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",

```
"Subparagraph": "i" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r613": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r671": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 69 0001516551-24-000110-xbrl.zip
IDEA: XBRL DOCUMENT begin 644 0001516551-24-000110-xbrl.zip M4$L#!!0 ( $2!9UES3A5<)@(! "X\#@ 1 MWXLJQ[_?
S5^B2G&1F+>'1^^'9X2[&9G8XF;$=XTG.OE^R!&IL983$ MEL1XR%]_JUH2;S " 2WHLTYF&]"CN^I7U575U56_-^? U_X0:+8"X._%F^ MDOXLD* 7NE[P_)<_-SLW[?:?
_V_COW[Y/ 7Z_WYZ_ "+WG83#L>1]_R2"(JD:/EE^:_1M6,3 MR['D?IWHDEG7B-NM=[NF4B==33?DGM(GW:[X?&WIIF&;FE3O]BVEKDF&5;=E
M6ZZ;DJT3U399Z4M<0W>L^L5W%< SBV#U-UKM=2[U\2F#/, M.XBO2<_]2^TE28;7'S[\[$;^54QZ5\_ACP_PPP<<<"V[$']TO?EKP^@9KI&, M#^F/^:7Q]S&97(@?NEX8]SP@*
[G]A0/Z6,E6I?QZEWBKQP_S(\AGE[X^OIZ M]:KF0Y __.7+YW>"QDX=2^($P?>E=_E_4SJ\,2Y._,W>('O!00Y^R&)G"|& MQCD)0 $>*NMUR:JK\O0Y=>'9:JZ_>-
"=%JDM*75;RAXR2:.TK[0_P:W;A*K++MFU_^(E8FL6(MVG" M"YSYN33EN4?CKY.!QO5GQQE.+NX[<9=>FOTPAY,X2I8OA"^G%UW[#LAWC03U M;YU:XY<7XKB-
7P8D<02|K4Y^'WD__E*['"8,$+9+W^-![''F'OII[_4$O(S^4#G M_:'Q7__U7[\D7N*3#}@*]GD/[EP_IE[]\2!_=#=UQXQ?^R'$R=@'Z7"]>.@[ MX^L@# @,P/MYC1>2*/W3G6 9> ,\$G$
MNVX%\+KQ#8PN\L^XZXSH))D,Q:XU; MTA/4/8;1!/7KH@K^[#O/DP=;M4;?\6.R^W-SS3Z=WV?X)IZ\P:XUD+MEO> ! M+@_=N5> 1FS\75UZP8=Y1$2D3R+4I?$*(*/(7,=4#\
(0!"I"UPG ]R^UV!L, M?10]^MU+A".A1X"1UU_.+ C[7\^P%Q MXE%$&NFG],=?/LS_EG_&9RP];P1C6'Q8IB>OOW5NBSX+J-S!04R>"2+HN63V M4DIG)PFC'5^[=#]^>4N"<.
%]QZ[+6GF'0%A?O2;9AV,!ET2K>'(S/XL1,.! M$WTGR;]PX7'_!>]V/5Q)EIZ.0+!>2%VAU\6_]Y.EA\,R=(T_;/.D3/[HPU#* M\N\)U9#Y)R B?.Y[)!*HL)"5QL%-^V_SFG/QYLD(Y[\^I**=?
X(E+TI03U+U M49=D^/_|ONEODV&Z,Y?:=5Q)YG_)/^\I6@T2*X'OQ*(R&US*^Z?B0^ MQCD>@ KC)W0GG1ZNZO&G\>POS9\>&(&K[DF?_,N'E2^LN#*)SER_YX(;
[^7+L1#+&F(^AE&>ORHPY&6IY3H9\<"]C5SGK M)(!$O*?U^PA#F^%@& ;P,9X7+?A^$ :=).Q]+U^L#N/^R ?W?PY,\Z;;!G8< M_\'QW'9PXPRJQ/$K0_^#.UX'IO\C21PO(&
[+B0(O>(XK0_B#NWKG OP]+#!U MAEE[K><'=T@K0H>#NWJ%(XQJ2?*H,.L6L;#X,X ]A5DOB)F5B@4N'=SSJ;(8 M'4AU'=PE.Q=3XD#TK[K?
>%0;NDS"5]UY/.J:K6V_&AAE;;57W;L\F9-S"F8Q MM=EX(CHPN_O(C#IG>QUUNCI"Y6G4?^42&9FGTYR[PB0C/\'Y>
MF5/CSN..B]X)LN34JGN:1W5X3L&@JGNDQ[<=3\&EJKNE1[0=RTJN4/E^YVGI MS[W:$Q&>.ZI'3U+3N*-Z6OIS1_5$A*_Z]NMIO+EB6<)E[95K+*32LD '[M4R
MSB#NU5:!2]RKW3:+M[0,!(U[M:>E/_=J3T1XQC*!2YR:SIW''1>];=, U/+2 M '3FBIJX8^PI0%>
]/V@A%Q[X=8MQB+5Z4V!EU@8E7GQX_'=H^LNJR58J^8S:F<7J*+_K*LS1_PU>> MO70O@6 VHO$0A3"19/P >@XU'+H/0ZKYQMA79UX5?W5Z+^ ]1./9"ZN2]VXR M&Z]@G
M>CA$35DP%FXQ<,T[],_#,;QBA$_R_$BR0Z(?7 M(Z ,L9M>5!UA8M8%KPQC6! O9CWU ER\ P>QXDN3Q:RWSBH?&! >BUGWO@#3
MP/! ^>H6GCU]36;CY7R.^WF/7[*\,8%L2+V>C!+ER\#T@[<$!2YQM^3%U@/JC+JQYWKP3CPG>]^G#-]B0(?&@EQ2+KDL,1N18(?T> ^A/
MN:1RX++$;M0B(JZ7?'9ZG@_#FF'0C,$H2V@REB647|+@.2'1X)9TDU7GFR:O MQ0N1GWBWD?.:7M%\C@C9XD39I3.:W5A*6:*|+['Q[+A> M#K'9C8-
PXSLE>:VR\R&4%AVU11[:U=M>NE^0L'#*]4#SF)X98J%_626V?#*L;!0 M52%F-MYR_C+#;B"$ZT^F99;9P JC?%IPP]^NYZ>7PR=F8S)O\6GU7N#AI4D% MHFTI3;.7[LV@AR_[
M08Y!=[,N*>70G=G@!)-T+P_OS 8"FJJ.Y"['KUN#H1^.":&+Z_T0JT^7Y;4P MI-+*W-=5F T97!Z+]TC947@XU"K/;&2C-!97 M5?B8BV90T'=>G(A||W/:0V<|O>3!&>-7E)6?'2_ZA^./
M2#..1X/A8G.SQE$4?)]2,2(IL8?/SJ!=Y@-#A3 MC#(7^.$8W06CSL_SQ:C*7*#LTK2$RESD[.)D@-D8&E^;#\|9S'K^[/#EG+J!W M9O88^OB1UP,OGZ+T6^
E\6/GVYFBB;EP($<37^E6X)2Y,"7'*5^=5^"4N5CK MD7#Z-72|O-LWLW"M*JB8"Q.SPIT#;9JKS,4\62$X'^<9,1?M8X4[!]I U)@+ M[N64;0>]<$ ZN">+=WX)TP5HB?P$DV^;
#KR@_@A[<#:^HGKX $.6BZ*B'D* M$6$V&,@\Q]3M.::6R3%F0WG,<^Q4RQ!S@;C*<$S=GF.ERAASP:Y"'/N5!"1R M?
&!8TQUX@0=&A8,IQ^>]DC$7^*D0STZUEC$7!*D0STZUFC$;8Z@ STZUGK$; MIH GN)X_0A9T2&\4>8E'XM;/GC]RB?LY"@<8AQPEE)/W_983!5[P'#^0* U#
MCE<_@(§TT5.L@3[[ 8_SY/.)UDV=V3C+F?+Y1&NMSFQTYDSY7*+U66=]:K-+/QH+/F]G6:F9C26?-[5.MV,Q&H3V%.NM<=EQKZ,7Y3_%NFM< M=LSKN#P^T?
IK\'C74>7X).LPCW(=58Y/LAXS%]O"()DPOW8]'S(76_*\ MU(K4G,QQG]-[)K/1M5+KK6[]5FS407X?P5!;/^"?Y>..:"Q<6(_\'#>#O$, ^VZ MLE7;KX5+]R/$P6-
=145_;F[;BOX'[^=U1.)P%/5(G'Y\(8Y+W^]Z/QJ_P#]T MREZ?V*YB. 9Q()XFZ]VNI=N6IBN*YJBN8VK_0G-A>D^F[Q.7>.@$C5^ZT0=X0/IW^ISEISG1,SPP"8?7
M\"2X/7&Z/LE_[881#+S>"WW?&<;D.O_CH^O%O]\9 U%+R!U>M/'[P=$,$G" M 3[N(PW0]AR_[OC>6KN*P$Z\/XN8OSF9T!3/ZL/R];5W9 MTNJ?I"N9?O^\/B_*?\P(IJ93=
68")+E+S6UMC#7;/3R,!'BT/=](J>4?AX[K@G%Z+0GPV^3]'RA=-E-=5H!.E# IC;!Y#8EJ*0OSZV&X872= MOZP/4*OWG8'GCZ___ 1Z-1;NR*OP& Z>3,C)Z5T79:-
]|>VT_M5D=HWMT* MK?^]^6OS[M>6<'/_J6N[TVG?WS$_A7\Z\0O@)@D#4;B]NKD2%$G7[+7#/CYN MK*VF\?G^\:OP"VBZ( SN1@-X2$_(%.(CZ5/M7A, "!S6W2[SKV[ W&F0K?
HWJ MPCYOSRF_#8>KA_?!*^W=VV'@707$^G@G19%>X?!5E_Y[X7[C\+ M3W]M"3-*;::+0FC=/^+-LJ]K6JF$-'%-E\>]1##;1N'1ML1VC/H>1D+P0X?<<
M:T)J2PG4V=A!CSS0VUNI\3D/61> ^J0_@$2]X6]UUQO4Q<:(Z"7((@U/6(<.$ M.A$I8%1)%-#^>U,7G4XM;X> ^,"H5+154:$\1O,[#H.)ZC=9W,'BBTK1,I6D7
MK])6C^GIL7G7:5/UE>FTAV^/G6_-NR?AZ?XDFNW$:BR9("S78_TH' C_FOZ? MD(2S'QG6(ZMG>A,.!EZ,P1OALP?>(0@$*,MKX70K:TH:E_3"B&X87&-;X0BO M*J(C6C00@%-
*9Y2K )T&$NJZ+JL&PXO =K9Y47(\DF=:LR-(,"*8D\2 5?+[ MF C3C1=1: >]JZW)PPJ6_[7/_S$_NW>MGTXOH3P5PKX037@I.+$0#TD/(V&N MX 6"E\1"
[X4:8.MJFDI&AS3MRE3,C=&A;1)E7BF:7LJ3Z*"L/4)6Z^)3>8A) M&?[$(-.R?EFB9S@\OMTI[:)RL*Y0-,Q4.2TO=!..@B0:WX3NO#T/(^I=TYV(
M813^P.=,#7FSUK@C/QS76:N3$O:71*O6T/2Z M9-B*92D;"?P&C&?"J-*5OC:0NC6%4X5Q?'5+B?R.@E4 0S $2S 2_CV*O-CU M>D@_>''>S-@IM>&CT[@?=@|+|*VKQZO.E="5J
DHL20S'W8QNR3=>-2!QG__D"SY!S\;5K#5E6=$EH^<(-S"((A4?B^.*B)!<( MOJQ[IS*)Z$I@,XX\D _@Z>*+Q%W?= -_WD=/X>M$[\LRO ?X=NN1Y["T]U#)
MOH\)8)D!"9Z&J15PAYIED>TAA+7,_W_>,%WHLE>HM8:MR.H2S=BW/K-IH>DY MC(!LWM#Q!?*3].A)#O@:A)?$[X5W,&4!Y[R5Z5D1<7VW/0@0Q,V(.'-LUVH- M2[<6F?Z^
+:P(*/_\!(&"_ZL# ZMALD-BK&]/\L,J*8.Z9_^8"FR^3$6$N*3 M(+B MZ#GVE*<'XS(_GT0PD>$HBD?H|">A %=02TE6WG7?HU+&<&6SEUPS[/#KAES4 MX5?
@+GMS.LC6C[JR#*V<)S$[*.6H48B3NA%/7N+30!AQ>BJ"#\|0[/F$PX+2D MB!RZ/';&@V[HOXM+]#RK18B[+#9*(4%^I@M ZJP'PNN+!]J.U>DI(QO'B!VM
M)M'V%F>V!HUEY9G*VL3B--)=(R IK2T]"D,G$GY@^SKAC]*5A&FVAPK272(? M,NE.A7O"!!.,A+_]UF*1U+AYNYK0;%E:.\I#*],KZ1;:8@ ;M&+]B[79)=
,^)0TQOSN;P7J0>RCLEG6,7< &_=_\-,\#KZ:5P M$XXB>PXFML1T$'20Z+78DN ZX_AJIP21DK)S)JF I\M.*1R)NQE%$5 S30Y"
M%9HXR2B>R*5=:_Q&XD6A7)>74S0CHDRZ:Z>E^UVX2RBO2CH(91/$3HU)^$=P@N\Z.B*E?9!L7KE2N0.1=@0?YD($I]
<#_1+A@4LJUI5AEY.8I*A7FK'ZEJ*/DNTKU2@G\0I&94CE/ I'96YU M6/!P8; \@9Z9R,*7U4)<(#*PJT]?O8,'THHE<,;_KCX8FAP&^\/@\G3(+GGV
MT0V@[#F,QBN"8O0BBK]>=M$T/J;(M<;=*DMGC]CFEM ]ZG\@=L=S)@JGL\[T M.S/N%9402I=/HQ@>%,=O'KU]^^SM 113N9=M#:J:3\K&UVOLX(%]KOU(6Q7Y.
MXU\IB6]2"K]Y6%-1WSRM>09;)?T-[CJFOJV,,GC]50%,&K:$Q3,(:=1Q%*>N M/DPU/7R]XC!C&-%W^6-|^:L'KX;7"@',+405_L.+Z6(<.$'/.ZZ]"3UG?-^I=?.1KRK0D@I'G"*7XCOYV
2W@%$:-@G/22V M.:CR_O2;32<.2OX&SSK-[ N;%LCFK;6J5E99#QX#;M+8Z5WX8Z; A)'6EQ!1 MHB(BO.(_&4,_T[T"4(I8AI:R,\:6"& -SK-8J8&<]CPP&:,._U-IWGU=L;-+T
M&YI]0[LJQ>CA"ID -\| H+1H.Z&-*T='PC&"U@D|"QI@@>J)UE E454M4;$G MQQ+RH6:[%>DX&TX'N57,5C8K MG"\$?)\BUOU;LK MG7$(J-
3=>XFFEOPSJ7._^J,8Z3:P8KSL7)RX*GYZ4L+ZW3< MW-\]M>Z>UI>&.WW^^ Z":5X95CGYU99\I:KE)'WCH(SBNQ9VF:YG ?SU^X?! MG_3&$4F'F;$(+Q$NS7_8HJRG5&L\-!^?
A+90%SZW[YIW-^WF%P%6\?O'K\TG M6K?06>N_+BT/LKYA?3AP>.>ME&BG]QW<52!2/>-/KT<(\*=<<+YIX96$B%61 MCE.AL^!8"J!3!3\R(0-!OEH#0\
[K<^+UYTGDAAYIJFEURQR_K0IX*O8>\ W M+K$7'*ZBG%4V+R/;I[-/_V_97=CQ?JX(V%,$]+P.[A=@,!?^HHXBW6;JY/@. MGHWMO!"2Q%A'"EQ\1-
:ZJIE5G;_P[EO@C%P/)OV>QB)N22_M7:#*=&KJGEKQ M(&+ M>*IM.+"(E=8*W+SB'6M@%OL:[3BU%9"=7@_).EK)H=R*,BJ.F>JWI_@ M%D+UX!T\0?
B:'B9HT5W"B>H7'=+^MCS[OWD\/>EF6I(16ZJG9$618::W%3C6G1+N&"9 M[S"!,24A58 352"L4:ZK-CAX)*_J6@-@8!_(JN)2SYS46TJV*:WP3>E+X/57
M)W"">J:J>I)#>>G%OE#8A0@.V&3C^./:HP3S5\+@$I*<7\)I'$H_\Q0@MB_CA MJK\@/A3Y0!8CUP?,Z0-9,C+EK^ZK_#FS*\'LO^,),2^A^>%4D<,7?OX9UP$_
MC$=X,#IAJ,D*XTH/'KQ=Q;QP95[4?YCZPMNV5*^P-N9=M>X:7\1S 8;/8F MGU2S/T1AC[BHS%ED/E?=19G[ENIF_>P"/SJ3@?,SV(0K/4"#)VCNG_[:>N2G
M9_@*Q\0*A[VV^/&9"V+V%_+L^*D=0RLOZ,&$@|%M,N_)E=C0WHBNOWA$ W(@^0\'6=MN-YSQEFZ>W MI._0;*EO0^P[10(OC&:4-#>KJZ)W-6Y67Y;PFGP#_:*8_14/>76B8;
MBD7F<]5=E+G<9#X_H56E3$/KW&0^)Y[>TZKZ[2 MI@V/XD9R130MJECP>;.!-LU < JW4SV&5E= MH_^M@N([$D%]@PBK^X^=A :;]%B6D;>F%L
B;8KR^HT6&/PY_#DE/<=@]>T* M0RL;58%*&;U?L!(P$\U?-]#GI,U;@.G_[K25\:M]W;MJMNYN6",O,S970O+L5 M.M\ ^==JW[>9CN[6^0PPKT[BYO[MMW75:MQ]C4IG/_I7W;?
((/GYI?8/5L"9V_ MMEH;^MRLFL716]V8DEFXU8UT9=GE]+J1E2M=W=RA9OOO=54M;U!F\;8YIZTI
ME4+H1"UO5QW3J37FRL91=45KN[_=\9;3C])OMG9\3CZU2%]F3D=*QU6U4D\( MOF,?W3I&C_;5A&]V.K,+X XQDYG6@Z#@YYH/EE;F=-?["XWM #5EUG0Y/QV[ M;T91!-
(O.'%,9EQB%D2-55&EG[,>Z_8*D^T(O%P=X:-%]C&GMH=_D-]'W@_ 'M!\5E%_E:A 224#3X>8JY_W&O*T/+.7=@4=Q M_=EQAM>(D&;@XG]:4W@TDQLGBK#-
^S^P1V_!)L%8Q]4P14U61$/6UC0)WH<[ MV+^V$)?*65:XC)RKC&C'EQ&EUI!%13=$35<9$9%#53TL#8P+
MY%I;1RE&@Y6R7VT!V;R(3.EX$%%1:PU;E"Q)!,JY7U%9#=F#K2;;6+(<79O5 M[X'1I;&'KHOS4QXB,G3 ZR8_AUBV?;W7N4E6MK7"JBTKFS5Q1LA62L?,E2\J
M$3J8[X8F&M(9V>X<05MJVU(09(!Q:VM@WMJ,(.CB3-LT(;FW72R/6R";M2HE M9I/2<$>!,&L-131T2;2DO46"F[ , FBS4MT?0!:&"V39%FV%%0 ==>-K,>,B MT[FR-
4F#.C8ZGL+$|==IV-7IQ5O8'MML1YVI"&W6P7M)CUUKF#;H7DM4]A>? M@IRJ@,%[P:#;K+?W 9TF@TC0K:F*JVRHBEN=K5\&MXY/N/._ M+@H3#F$L8(ICC)O%0\R*%X6
)#P@LW- )]7I@^|$23-P6SE9[TAAA2*C#:C+ MAFC(>T62&02B]%9DI#TI*K:&IHF(:C.#H2,VZ3AB/2;O.!<^"3YR8")0> MJ;!?'\$'ZCSPZ,RNT9FUM^UL>[+L#*VCG7?A4%O-
]=7!^P;HBI+C)@7 MW$P]2:Q[=P 9M88EJOLOPE4T3UD-=6|*<;]%B+TBC!5.FRTZ_?-1$MM$\XMJ M!1.T@BSJJBX:QMY+2T'6G,AVYX+%!:OXCD51P;+H5H6M2:
(FRQ40K%*V*LH_ M0 CO%JQPA(?_63O;^.;03FKBG+AD$)7!+^WFI_:7]E.IU4EK6#S=W_SMK_=? M;EN/G3_]Y5D)Z/0^ONW]M-OPKO;UN?V3?OI_1OL[ 7RCZ)0;79N/N/]>T_7\
MK*C][L>;3RWF1Y-E9K,=F[T>3"<)A:$SQC(J^X36SM12.E-KZ TW(\/%0PJ+ M'1,Y,'O(DD1)T1F)Y![!K^ 2P=+<2O0/RI (7:+9J+HNFA8K,G%Q9Z: D]&( MN(*'E7I(G
AU@9;T@Z^&3I2, ^0Y(P44C_CXFU^\,FIE\/*84?0""@I&X4EKZ MWD_BUO]#HG"%H,BU!O4=E(^,1++Y3LCA=>V.0'I;[6+- ,4 0\1D!$V7Z&A0
MI0M^:A3Z_E8>}_^ZV&RDMP9#/QR37$2^3$FZHYA@O0 )LJO**F4R8*]S-&UI MX):.)JW6L"Q+5"U6T,0MW;K@=D\<2 6WPHQ(T./6[J[:=|%.*6[BZMS$/6?T M;-
:VVZ#G;15K8*JD)IHZ*_EB%V?7SI<+X%9M27F4^UL?M'" 9.BBH5N,V!_< MFCUR,N7^*++ ([(M4==YA:L30:(5)|";A"#C!"M6& P/7N9QW%Y.:P] ME?"7,
(YOIDX"=20,.B&DKHJJR$HSC=N_Q]/+!@&5(M88A2KHJ M:L;>"SZWAG$H+07MM;HD7@A[ NN%]/M5&XE[UI^?$KI6])- M"D!9>5$U9!!.9$1!=G'F|>#P^CT" JLV#
M$L,P2ANK"#I#@7HC3+%O@_,0:PU=-!1-5)2RRDTP?C"2 Z^,,,;> MP,-*WZIH2Q)8SV65S+F4DX/,W7\)[0WOPJ!>9)^3G^&KMON81>JX%WE0+W+G
M2B^&"0N(9(F2P3W)C[N/YX"XK=W'@H@S\02I)DJF4D9'A@>S&PNUK&=Y;!=?<^8F' R| M9$ [LM,V[7.I8_N,/? +KW*3-$UYV2L70>>#W2+L+WFAXL[L9 K8FG-V A-A MEU-
FG]]S+JKY]IZW,IDW2^J#N?LO7@UTDK#W_27T07/&>:DI[+^1C(5W+NE[ M/2_AI::V#U.MX_O)>MOV"3BS:+| FT7ACYO4T .).BJ.1#::_NV[SRO:=J9O MH5AZ<*+[J)-@QAK-
19P^=KQ77CT0XU'JW6D*XD:?FPY=(7F(LG_,#' M?1363B'&U\3[49,.-6Z.DI

OY(D$<1@"Z*G M Q:&N2]*@2(I&;9I;TIO]2:8_J859M@M)VG$\6B3' MIFQ"TRS,J5V0=#]*X@1( SJLP-BLHXRM,,GLHX!{)Y)9X&0&X=N8WA[U'J4.
MA74X'=%N$K!_K\@SCS\V>E\!B5T52F #%Z7YZRA|V:+|SV@H[ &G6.[3ZCT%04-5NM !O1N@V'">IX9^IZFJ56^Z5SBX##W*;6;&;>=*S-L ME17X-CW*MYZ7!K;6#GQ[=& _
VU5U1(5>QMF408<&GR[$;I\[FM$0MNXM:.( MJF:+RHJ^QT>QK44!GC@D\((?Q!_OO^:\YN;26V?
T)MA882N]C0C:#FY2JLY(3U'!P3ZVMB':IL%0,AP/\Q[OGJ.SA8ESP:G)FRWJV92J%B5[4:DR:PU3%RU0UJJY=U)\0795 MP+@^,^0=0M/OCT$+J[_*JBQ:\G+T;'N]?
@3TL6"'GUSGSYQSHL'IW=> +8\Z MI/1?:N[*FT*701RV%=9!SHTU W=_I64?KDO[GBQEM-&,,/P M#M<:_@323,V4#PGVJLB7W!EC8N!$SUY WXQ'+X\%#H^1!"L&9X M.
(!W8WUA6I0V%)O2%K(@,49N1Z& $H+A8,IW1]M'(8-\+G^G4:<4QJ!G MEJ[F[8[5IV+F)MWXI1LA!=?HO3A;&/DO6WL,*7Q1S>F7]QM"A"7I_8KF(X!G'LGB;KW:ZEVY:F
M*XKFJ*YC:O]2E%I^T\OD@-C0>2;U;D2<[W6G#Q.\=OQ79QPCA&?Q"F!=H/LB MR=;SCD'T+YV.2M'_M]]:PJ?V?>>FW;J[:8E"^^[F2FC>W0J=;Y\Z[=MV\['= MZFR/Y[DR-
AG=3C2UF_N[V]9=IW4KP%^=^R_MV^83?.@\P7^^MNZ>.L+J9^'^ MH?78?&K#!9651G3W4&72)@"KXSC,EU_L='
MUXN'OC.^]@(Z$'K3Q^SIF:+15Q0NPO>E/T\%Z$I*A2AS:K,W9S]?P4|?EK_7 M["M9TE?^)%W)*[J?]RA9NK)4K="CUG^O:E99@[+-HB^_W$&]B805GD6.8+"R
MR&FN>B.4LS%P:"]=ML(IR534:0SPU2=P/X<1M:6>7B*PM;["]2^QT +UZ=*5 MMUGAWC#.%DS"
MW:9NXG9SOC#*J875R,60AH/JD*"JC(%1A6JRT\*C;_9J*QN[Y4+\8E_&O#B< M>4[Y(XF)$_5>Z(:I2WX0/QQBA++@ONBV*;\5WA!9-<7SV=;0-VYKY"AI!N[M M%".M5.>V?
O;\$=*DV?M]Y$7$;021%NR1)V91EA<=+CHK!4= MDQG1T=!<4Q13M VVS;4*>IIG=5@.T84Y,TX*.Z']\/@G9S#|>"LX<4PN|^#< M_AY:_'U,KB<2O%'PMR^R)4LZ[^M\SEA:
[;/LC*4ME@DL<@K.B:S#_S2.J3/$ MU&IK_D#ZR>3ZZ9RQM-J\:1^LBJCGRIHQU:JO^&O)""1X],]$L<=>($7)Q%- MJ^:-#'?<4M?>)$!4)U9#9$U'JU MO.!+&,>?HW#0R@CM?
D$B3UL-%C[,+:OHI.BZ*FK&/O5D>,B*00-@0TAJ!S!M MC'[*&H]^5@U*A133AE#Z8123SA73^:)I0S#],&C"@IBZ+%K:"'^[2:J(IZ:)IHBZ8HB&7%;@E>/O?/"W
M>1=@;_PI$NWE96B6:,N5UG_,&.#YSSG+TT)=^WB@@&O9WGAP>B='EM_/ROW, M8+=,YY'AT@Y^&*\OZ\!+Y1?R!]>4RI\0NQWTP@'!D%#AM4G>Y!HR52R?'9/H M[/&WZ!
>$'_*1M^0_ R ;CH$1X0@.I&YY #\#(!N.@2'A" VD;OL ( 9,:R M+M\K%>=X?=S=W"/O<0Y]_%4OF+R0B+AG4=5Y_M\,_&-O<1]USU^/ROW5U " MSRHGM8VU6$F<%)5
GINS;7PFIW"V<7 7!I/4B<)6HEYKV-*>/C)/|&)P\VGS MYGN9$,)B#J8LJM+>>Z <2 P":?,N>IE PB:_MB$JRG*F( =2]8&T>3N\3"!9 MM89F&J*L[MTJFN>=GE?
MAHEQFMJF%U:PH83S4%-Q_0%DQ!HK:8@R)VQA6;71 M #5%PRXA2%ZQ0/BY(^@M$[0 MFK7/>2>.(18Q]);561*&%# Y;=$PENO#, *@"AJ;6X9%F34VW^&!NOE\!)!T@]ZMD
M1!F8!F:DK7W"2$>"SVO6.@MZ28(41A0C-B%,8YZ!'VAI1W[RPB/EAD=15*Z M-Q/BWO?3OQ.OZQ,D?/$]YVIY55Y3UGS HP,]K -.-DTL+K)94 MX12)>
LTQ+9L<0&%K\D|^E4UR)1Y9/KFG'&SH3CI?DH&^]+JNJA+O)L7PZ<'3WYV*3TZF$4_)P>8]B]#>N9B MNVU=&:3N;&)WFG,S<0J7Q5:O-2Q)9MKCXZ&$0X0[WX+*]A:#P2-
2YPRC;2NZ M%,#3%N:$23-&)8E#JB*0*C%EM/@J9M4:*D\+9>VT?'9_'2]FH/C]RJ(5HA"0 M9/]S\^=7AK?$?-+R5@6L!RU*IB1J*]J$%@YF,5()NJ3 Q?E!\ "%#TN#HHX=
M:S5)E%8T\-DMWL'1R#8:2TQI+0^%]&"5*1NBI"W'W;A"/#,('B 7MCPH8CU8 M43<5454KK1*9L=?SGW%)4#JM#*,)4M@^>\3@>> 9!&06_J0+ $2#V.JHJ+( MHJ(SJR$K:*.?
51)2&HUXB,(?'CV"7*1B;L^*%@9KJ+:*//@9J8$LCC3)Q*0 MOI<42#C12S^FR5N_G /NWCK>N3?N2C_,R7%W#KA[ZQ#H%KC;PK#![K6])E,RR MV\=%RT%>P:V01:-
TI+Q>*.KZ@^Q?P:(VKVGI2&7L^-5 M#2.3"QD7LAWS2/<2,J6D;3PN95S*6)GW(78Z]Y,R-=V;5+!%,Y&ZX\-E1^;&B_V($")';#4=>/$N(6]+7X_L6E[%^4[*-
E<%NEJ.R]O32^*O+TK6CT[I!NI2]W=93 M2A)!)TBG^6?] -Q!0>&Y#R3-*$E%L+^),,E"7O? MA7"4Q(D3X*2$40S7)R%>, 1E+9!,A].\&)X0^-E>N.2R^=%!@NJC*IJCJ"@?8
M>0)L#_ ^E_%Z.[%Q*F:H2C>6, M-4L:H; R,,LTE\ME=W4*K'%@EV:DEP9LJT0SG>-Z*9Y\03VD2G012D.W7::3 M< BFBHL(UQ1CR=#XG3]4ENZ<_X(P,G>O8"2A19F<=X
MCV!'@N/#64$X=P@1G![NBCG!&#?*@C"!IR>AD+P0 +K@UWTO<(*>Y_@P;OAB %.)K^;=G1V(T/BE&R%%VPSFFT W\C\,P]A#0
MUQ'QG<3[03Z^>F[RDLOKS(TY:*>W.%V8"|C:VEM8X9.VX$/._(NC18'W^L1V M%<,QB&/W-%GO=BW=MC1=431'=1U3^Y>BU_*;7B8Y%4-0//5N1)SO=:%OO[6$3^W[SDV[=7?
```

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{(BE[G#RH\1!{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|+-+#*V72KSH(VJ MY]&CL=?3&J+PMC;P=CRZ 9I<6(\568MM02XLQ#,T-[QI> 85!]U-!ZKVJ@I MOJF7U1.Y>]35=SITV%.U7IY'G6A|>F^'|>G'F]$"I/F MRZ;@'AD;:?;O5=EL7U4Q;#LSY_K?XPG7-/IW$=KV1DP.?F:RHB<6380NWEJW MROQA' ??Y+'63UJ^RHEX&:VNTN#PHX.X=,DW#@HJAW$A]F@%2|+N-)S37OXW MH%V190-PGS';?7RK)BE"L7P_9'SX>M$)Y6]7WGQC(H(_>DMSX@MO7!H/.-9=M8<)L5M9H-R,]_F4WDUT_CLD^W6:RX[QZA=0%E8:-/S)@(&)W- '<6]V8M4?)M@:6$:]@7@I:FVX=.I^CB.ZG?,P MOQC.CW! I1#-0S*EW?2RD+P3"_D,Z[@12[CUOADX6IZ/DZ^ISPQ[6-ZI]].I MIO:T?$(>QR&)CR8+F+XQ%5H3E^($78K\ G]]INHKC!LJ* M,?X48=\C?"BAF);QLRR83^*Z\&/GO5@!-8#VX[2^$H+OOJ!:W.35/1O_V>B M:^/W/H";7'D^N?(02_#M/I=$<+V'9V'2&G#2O*

*W Y-3@'\2/@3#'DJ M,\.WYK0!TJ)#7#HS/!SS[,?DURV3&L(B?SX6_/_)EY.FE%&T8!&VL?;9._G' M>]/RU[:Q>6 M! H&PQ+.6; U^Y0>^-/7('#=1Y0E5:RZ(9=)1Y7@6@_MBEY=&3X9=(=C M_6@RO.0=F>^'_2Q!9,"^$=9#+OT4T=XY&!S,:TI M(.$ZC(KQ^QHY#?LIS_9K& 7.PW)K#RPS:PU_/1AV2!Z'),=UT-ESH7C,-M D M6QM> ':IP\B*!+0C,[*M.YD>/S4/7M%NQJ7NIX M,,WQI+=GF0=|MK0:17KFKE^I!.?T!L'+S&4\,,4NF.[1=6GTZ' MG4MMK.K#?+^8ZF3:)BI63A63NEYL"@5D(^5<4!F#Z.1D6R)H*R9H"7=6-E7H M7*VCXO.M;AT=%CA-X7PU$R1W8'R_NLX]%J2ARE*;VXTZEP.U/];4Z33?#?IL M4Q_W1)Z=>?53P:&2##^Q^8'>':-_>^WZE"SPCIB>]QD%MM?&/;N8>O#W TYQ03O640$U'Z9KM G.A?!52]"XE14NB M-TV)5M&&;AV%U]AS_J -N2,YG61'.$U1+X&K&(K/YB%^)+|JY9+Q5!EE'7KS MI>'#E_<>X[-/WN!S.M_$'5_D'2*Y1KF3=US).SIO>6+@;Y_WJC*K[]*>K\!P MC*;WWN,W]*?V_JV*[T*K(!4I.D>E-5\6I@6Z]!Q8<\TM;&M99ZU",Y)U6WMN2O8G.MM./@Y?+-H"4"D+*KH9 0T>'4KG@J!T9AZB)PY!GS M;A=T\.!%F7]MV#8S/VRR68RU83;9WH>#)UCYW/^?R&1S,T@^X4B^!7AQ]FDGMF2TZ>"MSR#*7+PT3,T4M(A(_4#Q@![B$K7!V"#A/P#G76"&-=#?B;5_A9=|" M9$!WS$/A \P]@AKPV0AL.)@D#[&?*"_-<&!)A#&T%V5A_8C0SL>ERRWMF/M:MWK$IXZN.P7L=+8 R8 OR78?:MBY-W4KITE,!?L0]V/F;B)@-C-LF:1;DT5.CL(B-:V416[?.Q*KY:>0F/FA M'<39F\D$Y=H\<5JZ>ZJ\OR$9]!'XGW,/M&&Y)I&"Z/U[>)W>$]M%,,W0!^C0= M3=3I..]32;# =.%)+K47?UX;FY7,IW/O9#+>,|&(+)W67Y(FX+'91E2;^*#+ M^0OR,*1?0$X%=P:$9/ $82%\SY2K[*PP"QU@!4EW/P9@J+'/ %ZBD I7Y/ M,4%_EB '<1C@%_B9&:"7X/$YIN').T7>?"K,X4?.&)9+>M|>+)^@9M5Y1G\ ML2O6?1"4@#G)\?EG.$+HRY,#\PX+,1Y81G*M6+!TS:YRQ9\H?<#B 1+Q!GXB>R'VOF^/@*Y982R-| XW%7[&WTBP"B6"P9D 0'$FH\ M'1Y>?@MBBJ,5TC58JO=-[*"5++YK^R!V8H>)6 9EB=<9DL+MW@6ZTD99N29#%HF\%X Z/H'"W@EB$C2GP-RSO$/\%:YA63NJK.P/<>R"$ M$ #:?!4@W*9-].EV=(*I_%AH(EZ. ^$]PY< Y!S@J4/A@-FR^=+H)52#'2=XC-$M*JRK5(&"D@^I*U2>YN'*]2L,A)%JWGP]"_53M-)M>!"=AHGP2!/OFAE/P M#BFC5'_\;YD9HCE./+1XLE;,D>U02YSM-ETL34+-,<5]\L"S>PW\CP=-R]T M.N["$=5-"QWVNL &#I.V>L.I_4>M?WI_G3:O$4-!RJ]4>-]\F=+ [W3W&6- M3_#DB8TD3W_C8O03BE%RLZ9$:860W8N$S1?4,&J 9A_|*6Q&D UV%,0[&@["MJOUIJNWYE4&NOR_AO5S0M$AU&*1Z69DJ01'KGTD[QR3&$]AY615>A97C MQCU-3_[8-S5^!P@T)<-C_^SXXOP.LCXS-J? 08K=\C *VOZU';+#SN6PKPX. M-JZI'G,[13/KEO1:TBLBO>)8\3.2WJAS.>JI^OA0SH*HT_5#^VL6_F.<6DF?WA:V')/J1J]+_/1M9;YO&3D M*=4##\|-|=$R('8_V]GL)5_AN8]IA\6/Y_=BY2]$%P_LR8GS&8:A,(9N1-!NIDFK>-CMX8HNTR%8UP;&5_H(Z'>2]IBT>-PZ,#*7L'PYY1YU(; M3M1) ?:\Z)&GI]/W/KB.*9UXK8]N%Q\=0E 8.;7Q'2NBI^I4S]=3M.;Q^2-- MB6]N'Z29<*3I'ZH[98LT34*:$H?396_'C.M8/O8^=9,*='4!'1OG9L8MK\2:&|7UP38 MVA2B=2Y'4U4O<+Z=QEYI3=XC*7#/@$LZX=)DU!3;M\6E(^EUSX!+_98OO6!< M*E'WG@&7!@WC2R_>)|=[QV1+Q%KO?$V=3W8]R3BE";HUDECZPS:)Y24C3WF_ MQWV19]0BSTM&GF*M[E#(,VZ1YR4C3[$:5QV*NANV#Y6U7I-R=U]#87^7[:UM!7RW58/;UR)[IS_^_0>R0HB$QDVV1K*=,:L-+&NY>[E1DH3][4(.NT:0[AJL MH9;7$W6@[>WS:96%!J)3N9ER<'0:]#J7TZDZG+38]!*QJ=QN.3PV85_SB:X. MATT));?H=#Q+YO#HI#>,.1W(KCD_93#PX&$"0Z/\P(0V^G?^>%1'$]P3C[ H2)UH+1Z]1#RJHP/NB4D#H;YR44M M(IT_(M71_O9$I%&S&-*^3L!*S;;$/>W8W^<'3E-HLA@JARQ"WQ)E^N(Z+A|^ MY-S7)LXQ6&4]=3S*<_G:L\]/-XFW%4J<;=.$C8R384?>'(4 M0W\TP&X4W2)4R!K5&4%2G)8@Z%@0VT#OC=M_*:=QZ.F8;C>]HF<%2M)K@D;A0I&+WX%F/FNW88;+\EP=KGQ#E/Q-FU009 B7\O/;F:-5B'%S./&7]< M& M8[#O#?D2S|^>T] +1E8%A=OM\DY?_,?-^OBQZ\?:L@^WY!8V2E%L,AZUDMM\5L."C7.:CJCB.XU)'64T?3?!+53EJRL89//^!] ;,W!]YX?76$9@N8[4_ MF:K]7AX E?368R-LW109CRW2+BW)HINXN:?TUK^&@%21PEI;YYD>.=0U&@-/M!M32U.$X7X=8&&@4ZIWE/.6BX.S(0-TV\$" M>;*@V&'NZ@YTU*RD6+|RC&Y M$-|'(.4]>H 3D^?YF/_RB.+6D[(VHHV"#/9KZ/OEC+5Q4XV=#&A%$)I(@K M[:(&[X02D4HKL)[6((R*;'AZB)KKYQ0(WV F1\!+9U[T.PM MU^1V6PS4V\7O\)[:F#G&+E^CB3HMXF1;;#8P;'_[_/%&"=?4\R4Z5B#<16C; MU!6&P.)0=C)&&3!Y5E&4-SX3?P_?5M+ZJR4CHZ.J65ZH4DH8UTU&CM..;Q>( M; S,3VZ2@M'#3%(2"1\^8%Q+J1+Y%.5Q05KP>%N*|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|6>@6/+Q-X<]P@Z6%CKRV6IMNQN&B.MSUUOT?+CR MGZYP2DNQM<0,&\5J4/9!6&.G1_.4!T*+,.&%_D6G(/A2?TD=7>AVKR5,.)X M!?LQ!Z9K418C9O'QO:V,#:@\R\,H9@[J-AJ_$G#ZQ1U!O7>#*#ON*XZ.%G#Y8; M^G0U&NN#(DEOFT66#QC[00$'UX%MDX"_H1$!D(5G [?QU^XF"-)86/ M'D'BEO7UF2>JH ZDST@F!]S\%\2TVDPJX:+CX)D,CG%JYMNX\4 M[0"< F&Q6F% "(C0Y2S=$#M/8%5-.2'-W@PRJI%QXL#*%& CP1+=%_B0+0S@ M744-!>!)_2;BE MJ;P%PM8VUS[|)/]Z;EK^VCI6G=X6!8 MZU';OQ_JHW91E;[O3^K=4;JH:>FCGFCP6G&J5,GX,IY:U*C&0%RN C>B'" N M72N,+GN1L/@[?6 F@4(4^M#?,N%"H:2X%CP9\'QE*\-R,}$:#W@U"5"@V; M/G\' TAY\[_\/Q<9]C7 KJK**/U)LKU^!OF>OS?%$1>UL3$8E DV?@2*GKBZ+C8J&UUC;$:,FS_N($SY15E!0)IAI$O%C\[JQ(ZT)6P>:/]W*DE:6%":?'T_IC&PG,IWJ*I^3'D9I MU<&@6@.'5RU4A"&:J<33AMSQ>\!IJNW]YW?_R_)2%%/E+SR0V@XX+?MMYA&>&AZ6V[' _6]:OA8TUM[=D)MV_.I3N7)OD \XU!Y3V8!!3R|< 1LIJPNP ML*[PQ_XX^J@[WGLB=@,Q\1SO?PT6[&?76S#K]=FP31-BXAQ"[+RVJQ ;HA"; MJ(.">%AU'*=9 R^%E8FCI5@!&M:58]/.Y;1;..RSM6 ;;,&>F2%6(5K[F&=MLIA>WF/XY,EB$VJ]>I/U?ZPVI'IAH;LZF-5.ST!E M9ZR,'!0V9\IYJ3FCS)MA/39MW*E+*7E"-U%ERG3KW'VJ?9T%G1[.3M]/0-CM9M>]I.GO9!K"=2-DY<5]4*K59H'<:V/@RAI6UKK;;2/.A?+#M/VB(FIA16=3!C_?OQ#ZNS!1-<_.SU^F=O(|^ M9[@X^G%+IS[1V_UL[?@]^5+Q":ZED.+|:.^HYG5O.G@02[9Q0I.?B,?WBD: MY9)4CIJ!#$_V9'P4:N*%P?5$WM;SPD1<6!B6%P_B2L-6]EW0=QLLJH^?U2@N+;6B'S_"27V&@Q*>_;Q^,<0HUZ3:-/-CP3K;'+:= M?IJ=?CH\A^FG-,^H:,I1_RG3MTI_W"0Y)/OC{J$.0)+/'OMO3*G8[RRYN. M\K.?SH5;ISER0KK^NY_BSYP]BQ$=#%:]HA:Y+N_I;HHYVZ*#LR\9^ <;>/ %M'(5K8Q=N>M(%"D&|8.6:S$XTYHV;^1KQ,;RTIKD3O=L?E[=*K=QU==@=Z.4- M7%]EUU54&G[C2L,G5!IX]]7RF.++BK$6&^ ?K0?+!#5*V5C,WEZZLE^CJC*(MG!19:M83.")>6:]<%7>QVD4YB_2MA 3Z]&/-YL!DY;E]!28;J6,H)J5(&G577O=LLY6\W-)|<'\WCL]N* MZ-BX4.L6C%C]2;G8/DUCVQZGC=SCM',YG19U9_PIHT:_%K'UU?+_N%AXC#Q) MH'WZ@>(!\ X1*WJ%E-WO'0_K\>0^P|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}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||TJM2VZUGW4QK[O3)Y-91AVQNUXKR/=.0Z7:!-A@;C(EU>97>5;.%_*!U.QD("9Y6"UFV<]8-0-K( Y M+Z9SP|"'&_.E1XP8&S;9@LN@ @_NH%)(3\K7K!WX^WT@O MR.G1M>)|HQPLS:=AR4=+Y691.69<&L&^3ST\0G&#&"+/>VH[O5WQPB!J M]P^3X0*ZR71XL+2;XI>TBWK18UZY;E. ^R0H3<|T*>?[$DLYRIJ:TU8.E?8 M5*A,K9.M5'7>]7D66!:#L&+A;L4]OS+(;<__:I&J1:J#(-7+"OULJ5AD/C,|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|@ M_'H;02G?ES@!V,53>F=L21+I8I]0WF4+=@-T8)=ENLOFHED]7H%/!L>|?X! MGUU/?(7759@LU*?)XZ/<9"&%QD%MGX=Q"OPJX:' +;OY5>8'*\LEO\H!1./M M XAPN0A-:\&FICXR1LR8S@?:<#:;#*>3P5#7!T;?-,:#?XQP$-#)IA85"]VC MJ\VPI[=RJ=L_Y)/A@5IR[\N.8G^'VBM9OM_]*?Y_Z^_NKZOP&,4>ZRS&13 MIIVZ;-LK:C*Y1$.4S-: U5EST!P_6D@RYI;Q2M@!+;VQ<[#R$4#X@Z. MP2 IY\PMV^*@%8:&@] T M?S1=FGXY+U@E_0]'F+CTP'%6 N\[#K3.$(;^# M0U%Q6*#8>/0@*GE#)=+2PH";A_D)ZG5 >18]5/]3;F]2KWVUB8SK5/2)4>*LJ;]}E3E3F@+Q).%?JI; 53VUNE;8-Q?KU5MS@\N>V+4 =#I_&#V[\U5&I M\7Z554=E2Q-J!:N#5)\,FTCH6SRGPUJ>TZ8Z3MK[6\?34YY3/J5/>?,Q3O3: MS7O:5/?W:[_ V.[_*&'VV")<#HB-8)C5*KE+I2UQRX6(57F/!HXU#;(U/#M,@']}361JS X-%>]DAGH M*\M;.4.ZC4^KCKHQ/(C&4E_4 ^!S&4><(N,8] MB6$ HF&HJK6QVA_FVZ"VU/ R]&\ ^1>|>N^*]7K>NG2K8ER^8ROM1?8@:'3%)98#92#[LLQ2RUSO2M MONMLI6?D3Y>,Y F7^7._?G+4UPLY(%]>9A,_]\M'8.KVNEI1K\;:7]2.#1R( MKAH:/VQY:LM3=^*IHX,0]A,)A = ^>9:CCC CL%O8G[[E&BW7:+G&P;F&=B#" M?2(A|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|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`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|A<67(,"^Y7- M&9R^^=V]1OC]B@ZD3Q0BQ:3QFBJTCO-]>R6^0GE&BLT$Q9KHV.*U;QBV(0N! M>[&86$4L,&89SYT@! (4D0C"? B0*/:@$8M^A?)#@;)$(T&X)4+_9Y:('>6="%,%[(5' M5QRGC(1(+NYZ%IP%O#AEKQLFGH2P_3.TL MRJ,)!P"?&P$7\1H.[=H77'6QY M'@GF6FQ"2. J7.?>Q:-)Y&>(; (QFTEXIIOT6!WY#Y#\X9|I:6'.THY*&A0E' M:+MKTEZ"V&&< LZV,Z##$AX1BW%9#[*7'RWEME/VR"R."S'"%/1AV&(79R5&# MH7:PU=0\:G.,6P#O]:5*A7?PMP?&'XCBQ' =WS)%;HUO)#OT MR()W7.4^-$BI9-S"+_+<^>%\#N_"= ^+N[PDWTRX\S"M400V<R8_D3I,OE"FFD_GV8Y[><+:1(N;OZH M;24TI2$'_N2"]Y6G=3;C;&JF@%ZMUYX+3) [B"BM&/GDDVZ] "40'MRO'FH4^ M^E60 L!HN[-A1V?'0V^WA3AB78V:M2U=V\2,S@=7B%.#(,1=:SYF6B!O $ E M8AD$JF3<-7YF(4SUGC;8!EC4;D08FS.6D*8^P8/CF7\Y[T<\I(^<'#S\@8R7 M)[+--DK=6MUQ>:|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|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|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|-3.5-)_O+58@U_;9E8#]CPXD_.^34AO<%] &(7%R> M N8 ;_JTPOEWIO)?S !FBE0+JA +@>:NDEJ;<(X=QXD:J M'Z2(OHXO\FG$U)L/V)O27\(O=@B"V8 %?D"?E2,180M8%OVZ%T? OGZ@'2@? M0>5X1%:V6HC+KBD4@PX-T(SI6"O$MG,>#Q1Z; MR#6>4L6I\C%2+B]X7'JFN>NE 6)S3NA(/GK9UAD(EN?[A@YV24*N3+*G'>)'7QT' W--<2&Z1NB"40UOZ? E:NB>X& MIOQR01$] "FH46N;(L@HE5!O?=/YY>[ZJX]],>@/&=+&C#4^,G"]!":#>9=1 M)AHN./J"]L;YE&L;IR;9&Z&&B?XL(ER>V)R[8BY #]A7-T7*0E\!#&"!$$ZX MKHN$_A_!" [5&D&@|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|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nI!^]9"02 _ZW:%T,)1]@#R_(>^$_Z_75L)D M ZO5=/EL H_*.Q*=QWFGHJ@H7E62R6RJ*,28R07$^-E5E/,SX%&M"N]#/T@/ M@[]V'0I084(4=7-_DYY[3M\-);1 H^=9A,@C?Y==C:GK-&^&?)WH.KP51$V M"1E-<=_LN+\JZ DB?0&HVL%R#9M:8Q "_"4:%4Z3E.<<>%(5FXXFZG3<+U%> MSM#Q<^, ($XJC39_XA+%>@\4DV%MROG!!M6$A1DUWPBBE\,"4F".D1FS#K:%' MZ'Y%RY76;.HB3#+=.MHQ_3@2ZGR"=32P6XPYYO @CO%@S"/&GQJ!C3-U27>( MG/HXSE"@2OO<[EH*IW@6;DH'+O*AUS:@IK.>V_7(=YTA4\DZD0|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|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|:EF@^]DQM",<0.CAH@2L/<]NP5G*41 H%: N)1W'[478N%0WY MJ(+"5%:P$LZXT8^77T7Q2Y-=G;8\CO@1;[D GSSL2P5&/]9+!32Z*F'9H3N/ M_T!MJRSG_!#L1FPXQAN$:..+T-XKD$>+|-]1V<1X7G?!NE]@5D4^>I^./%06Z M-VI>&&F<5!N9>:Y/I8K6O^@YTAL>GX5<*V#Q\-]7";Q7+ I+))/R4;$*+[ MN$.5F,H<[3I3BOTB]@4DDH-4!@Y&JA59>O])>,J9B!)@R.KXUOF\M4TT+I%R M6Y.PQ4N%+WO+CAV4V&#D-<_QBXV,$,2"4UQ,OF.*".0(I3?K4A3FSKY5WE[TO+9@EGJG2"57\&N;7$@%%T646F&3HIQ'QV M.!{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Ü^SR+DTSDH>!WWU^_5RXJD/9U?2L,2O'9 M7^N*IE%&=?\FXEXQ[R;B7C'NUA68R M6B/C7C+N==2XUZ^/WX%E[$LZ, ]+9&MUS($Z-&0IGI0.*1TK%R?$,&UU,.Q6 M=8F4#BD=AY$.2S-5S1B\0.F0\:JUU(7.:13M MJA;B;=42ZK%2/(2AKU;9C6#0B8"&?ZVK |-1#6V@C&,8-L2)/];&JFQ^XGI3 MG]VQ'&4]!_&%91&,<.@Q4^);QO%+GQF+K<^3'STB@N@.XO>?&3Z Z4LZ/HC=53/C0.W2ST7*/^9$M\ MUBU5'QHY[8NN;$4[&% @\V,VM L/NCN_\A/JH8F],7&9U\Y1=T[ YW23O;5;^ M>;GQ&B>?Z+L&K\66G,2QQ=:4=<6> C3:Q:CFA!#E<5]54 M=N7R?.J:WQ%+LC!$DGJR[Y,YPQ%A&H81;EF'.^1D)@4/LN8ALZ&#R(M&6 M[0ZTPFY[5)M[^G!#?ZPVW/E$>_DRJB#];QGF6T6D8<#DN5,TNU;5.U MG$%72BQD+$Y*AJQAEK(A94.>&C)&W9(- ?_ME**4,>I]^O8;=46DYN)%ZV>W M24B@#E1RN$]$21X&CD(QJ42AB%1=O$&\%$%;1=C3C[ULEJ083EZ(+6*QWIIF M[>R'G_FV47$V TH'IU,&0-1@#&V+|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|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

*_PHE4T&E 5DG1\.@BB^T16&,ML"YEM(,,M9+:%S+:0 M\6Z9,;%OFADRVV*?E&QCMD5A,1S:RWJ]Y]5UYR0*2^1M+DCG(J9DO5EAT)&\]D&+(&>8}!,.TW=)!%.#;$ M54S-*

*;%FP1T;%##A856[WS3.B?;1W",EPFPV4R7";#9>VDF0R7G7)Q\M`"95?( M'K#H5N[$1XV.O7!O9M?]E?VAHQJ&\20/55M]DG('OX0=;/4=53=MN8/E#N[H M#C8-*

*3=4&3RMB;^L.WB$N=")J1GR=V%3_AR,X3'$.MQQ$;NG\DKX39M VSK!- M\E1#LX[(S)FA&G CM08-$JJ=\BS*,L7S!QKJ#K.4"F?9P!L;$<=:!+YK2/ M.99M.&W-L0_>=/*T[QIJX-FOKA^^48(H$?W>.5X\EO;O'2ZPR56Z@V)RACCY M>?T#;YKW3$!IX/,,4^F*@0@=)]AQ =FS#5C6G>8\;R9P#7)0[AV5+)X_^ MKAGZ'}@HQ6Q*F!#"_X]/\X\CLNT'}>3MO_S-*

*7F49LRAD -5UDCGX49=;)X[Z]QGU]}1%'=*ZO0^],+T"MY:G@ M:TKH#@:6LD*?MHA@/6'.#+6O.ZIF-3?[]D:B=A=#2!%YX2)BJ';?4$USD!/H M.*[-@T(^21&5(MHA$3VS56,P4,W!*

*?$C6R(B33R?)PJ4M^YFHW4&,_%(: @~ M,/).")QNZHZ5D*7"%N.F&/6X*F[#!3Y+)?XC&]}2WMI2V[K++ R1-I_<^R3SEWNMC7E//MZ4Z)ZZ.&9Q3 "$*

*M$>*6;1B6:X[=OO5WD,Y7+4,3 MW-B$X),/Q!KG+?8NW3FB#BK7+(&=A%"+W<)'?&R-G8-$_ /UW5U%H*(YPR:_ M(&Q89R)Z"(;LEK=%]=QDJDRP%Q@7"?*

*%M5&*)C\B7}!_PASF76VH:2J)4*%MN MK*QHW/LH_HYO]<0.0>GK6ZH^L%1-UJ@]- M_D;JG3J- CB/$TK[Z/^D,&!1^L"'M=4!?-WLVSWE#_[V+$0M%?L>=CDV+))!V-*

*M/^"#=Z"7PS3)^V6Z_^KV2@_6DKF'ICI3.Q*V: MLB*>;1+!!W#&SA+JU;<,K^OL$5X76X{JU,??H@0P*XO6A./Z(W(2??V-D9- MP7*L7,Y5.&YMVJ,V8Y*\X6'L132K7-B+X_7Q1<-*

*Z)G U)T7S=8HW%$/Q@-QX M,U9 @G$TV*#1B"4H[^D4;O*W0*)HKB!3BF=@H2XN"-4)LL N6L#.(^PHBP/! M3('CHH\NOG#&X H,5/)P@;>Q.^LIG=R)O{D/Y,8C)#;;,W5-*

*;Y4ZQ|;.-.A MUL#!)?/-6%4_ =!51(6!$HVYUI6@[LN_I?2_AB;9$>S&74:QC;,Q2Z!H6ZP MG!+63PU_OU7&AMVCA1'9=7"HP1_$8'PNJX0K8:%1]?0P)AC\CKO,YP-%(}@-*

*MX@ZLB@,GQ ]$6VAZB9N(-KP"=+JZVGL_R#&VJ:\P=NK]SA^CHM#|_9LG*GOO M+O;>'2R2HY6[=]NF4/X[*W*- O:5IJMVWX1MS,Y15Z-MY<;87SY1>7=P,C:! M68-R}12X7&7"-*

*--4"X8PAJ288CPJ6.SY M3=I?M8@%VV1V{B)W0EX-VJ\XL9 MMC4G `8^"4O7*A*/"GQ!ZL\2QO9_3&Z%^-XV_EUDMS %P4$D!+\}YPIDQ>(O M&0,?^W"5{([HZB]\/28N-*

*#,@=^>/=NZ0(F'WEN%^J9SI^A W=.V#OKV=:Q M(U-$M(G;RDCLDWY^2@4A3Y8#//17@2Q:3'?)! M8\&5$+_TBG]+N<2>}G[ZZ@TY4[YX.33B+"W9S+\I0DCB@Q>!%/LT*

*'MS/MZY MGIMS\;6C:KQ+63EG[D@!*HW%ESR\8^$E(9_WTHQSE/Q+>#J%\#).[!(;! MYZ'OTM?0?W7/+W8]Y3WW,#&_TTJ-QAQHXS@IRADU.R>VC%$:'X*+!^=./M>*

*M#U5MH(':"BYS4?;EONVR.3+!JR<-F#)QVZ2/XBP$/2\&=8,@\O*7H.83UJ.8 M/(?T3'XSG?MSAONB@Y9+Y0XDC.ED-]7(/0TCQD(\&K@E+'REI-!+,<.O-^)F M0QY3[-EP&Y&#(*

*+6Q&'9FP'HI.B&L$1AC^1-0' ;DYF)IGIN[,*$8K3H8SZE M1;-T!"QB=_E-J_H\\9ZN6R.X3F43=#[@WW-K!++\M[9_,'(@5$QKVL)@XS(W MJ_/<$+-*

*<(*22<%29."I#WEK]$}^EM5VF[P-N;AF\2(H@$%M_H8>TOR:R^_-]$ Q9EQXY()ENF,@%.WN")8\GT>H:K!7KDZ;J4!+X7C?7P> M1!%Y<(K9"3*&=U&*

*1(W]Y#MW)V7(P=0%W>.S1#B)O#3CLX 3'3TE68!Z)\8K M/5RO8(9H]>?>*M[H)9W"^XNN,ZBK@("S.9\;O1O, ;I,TQI@2?=Q%-[R%Y*] MC2_)$B;$F]NB)2&2")4)CA266J:G7 BO-*

*$Y))%2<;6+1L)W[\X'R "_&F<>;AQ MPC'QCYQ'BX8JT0!]S3A.;GW":O!Y&(I,3!P6/Q(>[-P%!7,NARC(V;VKQQ?< M@UF:Q:Q"_U(|^5X14/RJ$OA@I">DJ?+N263BW0K!*

*MS=59>;>'|\GG9Q?>XD@I3QDNJN)H1MO!OR-%_$UH\&AX768+7F(0Q,LO6<&<T,HCGR$,UKM.>! ?JDDFW/S384/F00O"## MRPS/;2@/1[AK!\?0%N-#,W/;)&57YECAPI?*

*0=B8U5Z7&Y[ZNXQ"C^1.'7H=P0 MC==H2PK?<77+>!M!=.%7+KFP7>+O#(T+57CW<7N,R7,RRNB]I-4EXY^;\84M M%C(VYM%\-TU1_0J_$+\[?*

*0?,!7/$6)Q$8<@"R9A#2&2"7H (I#&EE*YT"G8_M>9"4>38*Z"9+SA|)C>?F1IDE@QF!88,*#..?#V@U>LPG/8=^L.]IEHQH^R MW-:D?\9LPL(B19:%<*

*QZY$V+DH2"3W,W)7=LX/JS]@<([-$48^G%*5A8.8+6 MV#OFN%!=\Xf[^\DFT9[Y$Y@+0OF)2WI?_OB(&$213 1"ED6]&N9I>*-S{W(6- M>VKL\R@4 >-;R"\2T%WV-!PNXQ:8.*

*{7&&Z_Y.Y M,5A8P8-RS;@W/,1DN)FB:^?_L]X'N=+<^>#=G(?#GNWH39LY.R#7YF O[0"- MGMZPL?#:=L!FK\]V[21]D$EM[C!]@"ZZ0]F)^,DT7-/7U'BTNJOEO4UWZ4:*

*M8=$OC79'[ ][C'KBSTQ$O+..$7^+*HH#2M7$D4{JM-E7;*G:?HP7A8R1H2WGA M.M"Z/G804,U^<[CZANJEQ;7L,D%H?5F3BM MWN3\YV.L2/7#.Y&2\\2CZ^6BCIV9IJ-*

*JAD1Z;Q]K'-713-7J'PFQ[^73Q!=T9([B47C&7R9TA@Q+%B.UE. ^Y/&&34X.Q0V2 M"&8V"7AFOS?%%$?*PL:1++($6]!PW9@*O1>[PT )..XS"IDY!B}>.:A@#U>AK/*

*]JC8@4J#XE"A.FX6 R%$771.E9 M;OX!\.JO?D`<6+8=<;XHU/Z1L4(GO2@]10" *38#X,)>$9>8 )6# *$0A?FT/*

*MAXA.@EPJF+T"J422*4NLJR760UEBW8QB"JH>;"RU@@_&@<<=6<,1<*E*D%+0 M1Z0Z\"G#5$V++|+!V'C("@\6P54?7RL'O8S]EYZ#P\ UWH$%!1F$Q)7#A(&Y[$YH:3N(H.M,-*

*);*#CQ%%U4ULYBDU[H/9-Y]D.XJ[9+%>%$[7+ M-LN'IG? :FWP/ /3A&X#>(6S$97,5.BB !<(,#AX37B$E<&,,,/FE=+X F.P MHK'QSL#2$BEI17G7PD;R)+L<.I(G5V+*

*(RJ/-4"2),HM.9V+*S[Z ?GUA6(U]@0'6.1UTN02@6.=+KA@TXNS;H"7P4,)LVKB\@<01K*NX M:G30NF^L]++RT5<,$-3+]O"240MQ0QK!F@RM9]B+8"IVN<_54 Z4C-Q!ZfRQ*

*MLFS* @MA?E1G8#7BP H043W!>>G<:[CN]TUX$;=UMGX)+FB)LVL8NPBT##=* M!U:D5Z_YH4!$%2!N:++#,_&S&973]I7];+&"S4UC 7R:3|_<"6^=FRH!N%Y6: M\<[)R#?*

*#L>D\3#"C7">XP8EM+:%>GB"(R'L$jR9CM$4=),H!/8_@/GPG7$( M,] M-%8+7 YZ9DQ7%!tC%2^%P[TD!6(+KHBG7T1QW2FT[29W.K3)^3S&<./GM'Q'*

*MH(OHX5<_7X'25,P>UA&$<-<3(0E05/"'(/_]@V$1+E*5XTJ K\MI/ MOG?O* W?3=J]8\(X%C& MH8K]2_A=Q1+GJTL\QGY$'"M 8^W?=\=*7FVDLI$4)3"N*!J":!5[1*

*M6$!,B??SVX7P^45Q?@++<(R)*0(= DHUF?EH!9;TI,_$??PBOTP7'Q-.')D<0 M=V=T U-1S:),(:9?!/X4_L@+JLC7P U(?+FHA!43(BBPO*P*,;7]B5].]^;C M98'R%F=YF3DN-\GA0V*

*=%+ZL4@&KN2KP[!P.:#,;+0E&T!<0A &4W=/F16"W> MHZ824Y]-8.%4& AZ\ N9U!S<@GJ6NB'$9YPB6-)}!A.\[1:5*,*POHS7"D9JC M&"*Q;MUXS-%-!+_ *G9H00")G=E%*':UN*

*0_OJW5RN)*ET^^F02<'3RW\AA< M'H"(<&0J4YCY/2/$*[*OR*=$YS(RUW,1IS!X* ""BTL$*W&*R>]/0:UB{C!: M3,$S/H%H] \.1"XXZN,F)E_&+8\8Y&,&&(@786(^^,(BX>*

*(,NXK;JK0?2I% ME?] ]'@($LER9,LEHN(=^GS$0C;Q13\0Y-74GQ/&5%[S^9@:ZM!5,6 MB+,%,-?!V5JI)`-*

*^WY7@FX590BYN!%#-5>W.8B.=GC0K"Y"4(.SIC-.>RC'U=HP#LW9+0W<[<8XAD2ZJ-PQC5?++]2(V8DMSM1 M&M4*-+>*

*$JVDI!!2*#=AJ>J3JU!U2RT@<(MSRB+VHULOIB1<'3SN+TL[@T+= M(3@:FM MSSMH8(OHQJO692NT2T=\O;C^1EQ=*>?*EV]__7BM7'W^YHJY1-<20-N^C&\F:YW@+7F!O,+*

*7+#%<&+_7E:^,RC/?/AT#"^]*M($_U4(H?@4?[!3^:@RY)CGF2OJA>G+3WN MG2Z4U9GT>R/M17/04?DM<&]Nt7^D>EC>)A929G*B56*2 M;SM$ZLYAEA>1/C64_8L89^2CO6Z(&&*

*'/)3W@[IYL<2NLC[WQOD4 M_ITG[8OCI]U^Q{4)Q$]P*!O6*3'?[(&D35P*Y?R.UO4-"WT0H9+I+X_|_5-B M,.BYWS .?^-.&*

*AS)4K42<;N)RAD=]D5[J,LMGO*%THOOBK]ZNUD[O8W;>1^ M=)T%#$[UD7W.BUZP\]/ZMV^Q2Y[YCOT/_\>[, H_ M9S-XK4=>&F#/-9O S,_M5TKHSF*

*1S!N.0SH@&7I8_4X@O'\OQP3N[2N%;P$0 M@Q-INXG_@XUA@4'"7I%L3,[fOZJ:/TWODC%%U4@1Q2K/3R[_%S!= M=]MU&S;N- M9N^&3;#SZ\V:UYM/>GTSTELU[!?*

*P_2'S28*KF:,E;KY/>1;DEL;,Q86Y_MS\ M]XWVZ63R;%Q29$A P1I1%QP7.[,NOUJ;'C&J'W&V/B,6?N,N?$9J_89"Y_! M%KN\[28#R\1/B@:[HM?]S<=+M(NX-G/<<_UL\J82RZG&*

*<=\0!ZL3^'G7OQS% M,T'Z< -_-W-R,||V3 MB\)'OYA;G]54_.46:-6>A/MB[1.,6;,V%1#X[)V#N"(X^3L!MOI35R](3@\$ M:NJ/_"USFNWC0*WVM7Y3J-5AS]$VXX=N.])@T.-'_:=*

*D>X"V[C9+<&M\7L MZ?M 9&D*O+;IGOI<)[*V67+^PZW5!8P+TD]'GZ"UVJXGDW=3Z\>_OV OZ^.M!/LW49W;R]B;X9+F_9^-.WV+!K>ZK3NVK;^%^8H?#0LG;PW>)M\?*

*V+D; M4Y9$P)((#FIXWQQ>V9NFP)T+GCM%)L@U+XD=*V!T*^CFK_*'\A#&]?D3L/. MQA8FFE:ADX2;Y+(_YW],(T- M$O[^(7#ODQVEV<@3%]<+,$G="R;Z-*

*@L;DT0B!5[J;"*+_D;9E\Y^'K!>RS(-`M./P8W%,_K88P+..:5/B;Q H%@OW0-7WD1^[_G1.E(PG2-(1R"$EJ>D!Y?_X MKW'D_>]%WK)8&;'T'E-J M))U*.I')*PE2$J0T-*

*BBM,.XI7[.0USS#I&HM$$F^"OEB)LE1DJ-JF4JZE'0! M*QU-A=+I)HE3$J?B@+P4D *E T,2JB04.7,D04J"#- Q7>MS+K%?K#V[G;L8 M9M*K7@KIG^BP5541*

*E/[P7Z8NOXC(60@+A&7R(D)5K.+V-#7&&YP_MP-5@M2 M582+0YP@*F3ER0:F>ZY;=!74[3'^*-(*JGZ^]DQ';UG["9N$RMA6N*

*MFO+UU@E7%T\N0YY"KHF(NFXL$2_R/7+4D_6PO+R0(N6UPU>4 M60M'3LI"#NST/DM\@AZZ+I!6/L$5+7/AEG;F_]_[ZT]OWL$/;];5NR] B2;*

*M65$@_T:%Q}8_5ZF.!X'X4L!>KHRP[1 5J.JE(>ZV'.$&L\BG40#J)1$9YEC0 MZ7M^NC@DWG'/8-0N9SN#6+?62X(&^HEQ=(?R. MR[&I/KBI"UL")/$,)7<\7L0)% *+G?Q3^M*

*MP$*JK\=#]UW^J\=#/BK"]-YZ?!NE(5#W[ MMS='IMG"JIH%4CD]TT(Z_$*^?40(08'JHFV*8^EZ.,F M# .:>9%X4S8F3',2%B6:^>GR99I7&VGZF?OFS'XC4HYBBL1 M?DP-*

*$9TLX]'"VT"2S>Q_&'E$Y$?$P? M#*K49TV.6[X%U2.")J%\!0-Z&;I-"+( M[-96E<+.[FE\=S;P[V,9 U[_?[@*16J&[NQ.RM?V]Y"M.U:##]16!)\[6)L"KI,)*

*<>,>=.\;K05&>N&J(I?'28:6+K=J8?>NGRH>1 M'P3UTG,821%G!9XD6@\$5'"OG))3!?.D/A29NR!=5VGR1/':N?KX>?V}3C\ M*E[J8L;F+?(^",*6XV-YT:S/-*

*L2]WZQW@-L_LH7J<VXX\5T_7/V;ZZ?!0ZA< MQ D+$%4GJW/1>Y#DKH+4O;T_6XAN"FTW4E/80LP;.Z_!$\:R\\++|"BJ&O M'&GK0W6M64M,C R-# Y,S N>'-D[5U;*

*<^(X%G[O7^%EJW9[ MJHI$R#W;Z2W"93JJ)+"!3L\^30E,@*J-Q4@V"?OK5Y)M\%VR@8XS9!YZ M:Y M?D?2T9$1/O_S96YJ2T@HPM9-I7Y4JVC0TK&!K.E-Y=NH6[VL_//+AP^?*

*_U*M M_G;[V-/:6'?FT+.*U%H' AH;VC.R99L^@]AV3'V@)M(S)[ DF\VKUBR!KX<6* MH.G,UAJUQJG?S'I*KL$5O 27]4D5GM4NJJ?0&%?'XXM&%8Y/S\[K>F,"Q^~/*

*MT^O+LXOSJXO36G4\N6Q43VOGE]6K^E6}>E&[.H,G5^=Z;7PNF+[0:ZK/X!QH MS#2+7K_0F\K,MA?7Q\?/S\]'SR='F$R/&[5:_?BW^]Y0-*UX,4UD_0BU?AD3*

*MTV]_HQ43MFHUDZ]-6@DH:J)@MJ>';L M/]OHX0!#@>&CLV[#*DVW`"}.1.-8/#?H'C#'1+X4^&+#A9$)>:"$&@0>VX!,H?T YI N M@*[FQB\?-(WCB^8+3&S-BA%/*

*!T+92FQ!5E%C%VI4CM6E.K0Z!6"12W*0QI7N?9-'@ZQ02E(CD81_JOIT5?Y5M=Y@ M@5%8ATUWR:>#3[>E#HF](PT4&:7X3+=58]W592{GK*F+A$W 0SO(( MI%*

*_FN+EL0&12D>(-N=_Y G]$!.H&WED^LWY'PDR@65A6]#S;[SO%@MD3;#[ M!?N^Q^JU'[''/<.(/HK&9Q)MWZE=75\?B*1MO!3$@.L$FS&Y]O"!X 8F-( W.*

*M0H+!C,#)386/FU5_1/QJ0> 1T\1O$A,0[G7\,9, *1NOA;Y[C4$^^QYX3 K* MP82NB\ILOP$G>>UG),A"2PKK33#.:STC@>;;-UP'9E[#&8GNF$6BGI./V',-*

*M&3>5%F9)=$7CWWU[O,O*9H14M[G/S^>X"<$O-?%?7:MN,NZ}}[@^'T?;1K@X M%!HJZXOX.]J[V<0209AQ"W*=.%>E$CF?>F[+\N1_8=VYV'8:;,_AOW>7;LY MZK1OF[WF0ZLS_-*

*KIC(8Y/"[GE0''U=59HW[&X1@R9T(?#Y^G%F2]>5PUE^T[ M7@$?#P!AYLV@C9C"NP0OS%B*9*,(DMK'D)1?#AW9X8C]>]]Y& W[W?Z@\|@<*

*MW;&GWQZ:W]HW[/&6\,JX2S$^4<-X(T?K=[6-).WC6M8[T@$L6LWAUVZO_WTO M0"$26-@;/=Q4!DE*?O01% :CC1M_[] MM=]K=QZ'[4[WKL5<1]HO=Z/_[F,P4!*

*F#8SS(H$1%/RWOUXVZA?_T#YZ&ORB MN3J\#QM%O=ME#KB-9&GL7/R,V#G@1+)/IL!"_Q-:W ***)X, @8!RQBBJ84F MS"^6W=1U[%@VLJ8#;"(6'#DFH&T%22/EDJ_3$=5-*

*3!T"V8>@Q$^:D*GAB1:4 MJC&Q6D"NMA&L^9(/*!B:E$+F^S|<1 5+RMS#7+K WD=UM*61>$4++4@ M3X%>D.L!035PBW(KYH(.\\B"#X\LLA<*

*&9V7!;0HI'TVGI&60_C()IS'0>@A M,$8FLG/UW5T(DP%^7HL"[DL5,*_E?M(\R9HO^I,FA&N>=#=0W. (*'! L?$= M$,(&LQP KRFD*-6C*/FD!^3?-*

*AS;ZKX5K:5^;43]RLD.R*=#&^L_9M@T(*&\ MKXO!{@46R -F-X>KNUR%F121DR@B0:Y_UUR^810))T%0%)RW(ZH"PZ&%*!Y_9VPE@R?,"7-L",>HPY'.0HK(6101SDM€*

*MS#3!C>?=+C\7J@/"I87%^B,*?S#809TEC!7 M#A2CE#K]C8,K5EH+IH\#Y$2],@EO3OM@AQB 'C%PCR MHAZADT(76Q3X# {1Z;QZD-?A*

*1JILV/Y/B<^1$4X>."ETWZ^L322D^E@PRI':P.-K@G,YY3S42IC3>#?639DYMA>OK!E-TKA)D4J5EI-Z$8^*

*M,S^U.4CP%$Y$X8P!T9D>Q0J7B8>O#!3.V6UQ\E%3D)P4Q5@),W8<^]+$T MV>-#9SX'9(4GXG%_P-JKZLQ)+/9W!*J*"""G.L<);!LZ>0#X0N[O:KDS-%_H. M_]I;78#(S*

*=*;SA)MH"*A?>3Y?8-MS-^*D89'\PDQR6'#AFI"N!<3'HL13 MX3U(-AUXG3,]LIR&()VY1[3<]4"A*D<:%LHOZT3RMHU<+R;>AXP,E)*2%\W. M=R)-&AFQ4I-*

*B9*0V.^0,/_5XV@8U"(B%K"E=L)R:-QL#RE]., QD.D7FE=V) ME(9*K+HE.3L7#AA?"XVIH0D}/FE"$[&B\'1YCYH@A$W+1L(Q+!+$4?0MTAQ39#*

*M"O*7QD/>LY15C0NL^A*UC\;=SZ&[R/E-Y-{O*PBX. J_^7& 5CQP]N.T.0_ MT#$ XOID;V.TH%$Q2VC!;M]4)L#DMRGS*]5O*FK%%C)_ OBF8A.'W\3,?]#B*

*MFLUL"!LC<56R^_L!MO]H##$S^:P(W%9U_';YQF:-K(==Y&'G<5-Q6V);#BO M:.Y]R^XW; 1E.)/5'7O"F6\N9D\P?4"P#BEEB3N;[E9*

*MAO%JY'+S#8=X]Q!$[#=8+|F,^;\"9/%)}$OPO,/XSSEV/3@%YF946Z5:KTB] MA?'I!?\[8FCA9ZN%*7_G.L7*2*NR0OD$+0.3-A2GL;^S- %RI5.M2FM>5O.: MNL[T,?*

*S1QMUFI)OU6ZJALIT72'1$8;KEF32E'9,V\=F?W#NFC=H$/+>$R.:40-$ZPV05XC=A>Z3; MMATXPH'<(GU2RL>DM+[H(HN)87-H?W^)GL828RQP0.$?./-7T3)JR=FV&!P24*

*MC4EB#>P?OUN-<-,?1 X,S %#$-O#S75^OR,2@N^&+3X- V-+B,N^K<8'-/KK,:|-%,LG@E:BNI9\!X4^&+?FN)6N+0UFC]'GX1/.W-:L?*

*MHQ+J7JF_'SU')EZ@EYNL3%\6@Y_;O7LX'_;?NTH.V$"#_>E\> Y0);*BO/I M[M9!)C\7GJUW0L,RZ'^+B/'(=SP1'CKC.TL_NGV\S;8DDZ0,-KEOFP-3\&3Z MF8YX30!1712[RR/(*-*

*QV+68/;J.,=&9 MBU3B.7*/P,"E!%,VA#QA7J[SE5Y?(9!>5"G"*T<-><&].R,R'@I<;N-\S[ E? M5+2A^_]B>98*W]?.O 9@Q,^@_E(AJ'-Z<2F3J+295537%ELD-/DI8#KC:Z,E*

*M,&%624V5O*PK[ECG#,_GH[[HW1OQ6#O6DOJ,5DI&QRC>S,1GO)&IK+EJ?1O MQ@AWA:2?7C/,#TRF1=F^2EW@U(6_2=B>R)A%&U(EX]<7@*2%76U*,F']/7*

*MG@&CV@N]!@3IZ@-$D&2OV8X0I+2%)(,HEHDL_AM1TB$^M7WQ_?L];Y$)?;W"_M-S*;QA)13%9#2)8,!?F.B3J#DGI@!%X>X9BM,F3G-.(-2V1MVF3?*)"5*ME MIN;@4-9S*>*

*(4Q8#@":14,%UT(11F96R-9-*4U=#1,Q[-L,/ODNBBB0VA%=^W MI=E5BUPL]ED-4RYC!#0>HI<4C4?8&X08I$M>8E!W0Q&F97/_V(QM&4X*/ H MF]ELL!H]LX>K1/-&)M*

*%;7/*_E'V0Q&FI75,WX)WEN&X*N<.'34V;\OX[>,B M%]LR\>;T4*1SQLS?R^?!=;&C0>\%.HT:O6KSM=1JJA0IR^%N6VH;V6N.V3'.4MJR:I1:J2*F*M.7PISF]*

*[4H393]B1>B6WX44XE#C5 M:4H7,[5,E@4FEWJ-3R_9)J4V+\7XDW:.7C+62JA*85KDX%CP9/S0YG]F']1 MI"[K#ECTA+S\5;^4]F4U4)2#NY"-PV&@LNO'B01E-?*

*$66X,LI8A0Ff(:XBG8 MM^X(@4NL"82;[*#S3*]USJ.[&Y[CZ)'-M2X(FA)KL0% #OIZM^"DX9RRVA0MJGC/M>H7T*L_$G;C<*)}$*E-NY49.#UD"*

*M9YH=8(%FK]TI$M0'M+U;QBSWQ4,V+J;/WW+"/<4J8O/G%!*50]..\,\4N3FOR;C<536]7 MFR;>F>$+F,R!&TFV-S1>4.FKM0=!N)E<#,5'4Z]@%1\"=&M<6 7^YC-*

*&UQR68;R&H+&03ELN<>&VB"=/<'ZAQFI=&5P;KO;(Y:(M1R+7V/W M+1Y2+W4&X%%-=:1+<6GB.]#>8L]Y!DS2F-2V$(6UKELB6]?2G, M&3C\&JTE5+(EI7$I#.&W+*

*7N5&HN%A"8O+*17LQ)IRCK4<"(R@_0YLM\]YTZ M:(QP"[/<7A2H.>8B[ JZ7%8[fU#:JKC+XHU"03]B?C3&"Y QMET*=T>9PB6 M6H#H!3""$*6Y0"3&^"_':Bj5)E1K\W%*

*MY>>^A"KN'J3Z#,[!EP__!U!+ P04 `"!$@6=9-3G584,< #2# $ %0 M `-K>64M,C R-# Y,S!?8V%L+GAM;.5=67;,1Y)^]Z_@:E\WK;H/Q]@3M$1Y M%*&1%)(\GC=$'5D2PB"@*

*4!9W%_6(#-[CR^SJNRlO[V M]\^L[U/N%Q-%`..?"; $?V;,]G*=%GL[?__SH\O*W?Z^R__/"W_P+X]ZJO M7R8YP?:2C0YRO}XXL:.PQ[_TU77=[G&4F3$*

*MQIEBK!1DWO+6JR'M'5]}XQ;S[KXG=1(,-J$PE&+H[$EC-D+@18$0$:WU'$MN MG=UMTC F%[BCWK<9N#N+NV&-R_N96VKRD"W$760[?#7EB'*=&,$I2CH!,C*-0<*

*M@F"FOEG9,;2_-*\(W$C4F.*A5HAHJXD-@/SM\::D7M#OC;=UOGU"7_J'\/+= MVU?/7KT^>+/_[CG]]?>7^[_?4Y_ODS:#AL],WK.@%L_\5BH|V@+W']?$YD M86VMG\A83.#1 ??*

*=LJC*X&R*QS7)GZ4(\==EPB8/<-7?5.{\+GTQ:I7W0-.M8?YZ@EF:+(DER9VF5Z>V2!7M@% >I# Y&>L,|W4%*;=T-S"H=;F[\K_>SK6[ MX!MNZSOCZ1FQ?*

*%+O/"+;=VH$%_/5KU@62SPG&E<'G]?+0.*?SL/R^#D)K6L6 MH/AD>=)CVL U$D\RSSPYKJ N!!)#64$DP8 SRGDK=+(Q#X*D0=@9DZMK#<9O MK__V<=0% 26O36$A@/0U&JA-*

*5U&S (EI:4HN% ^TS@:VD-&,LU.[07QQ[VM7 M&5BL[8F,0A"?*-"QZO?%WO]+UF+R5QMKA,RZD!F23#*"?JE<2,*:(9*Z3;..+)]=-'/ND+Q-F4LEP6AA0'FIP4>*!4M( MECFM.,?6*

*SANB `Z<]5M/?PM3.=G>C]8K:>`W?P;?%\KRN>[UR<2'>-UR5[+ MXDB'44"TK`!/+%IC1-%N{}2Y8I=GK\>-,ZBYD\XO;?-L+ ^N6NUZ0;E/W43S% M3SA;=*"W'IRP??$ZSHSK*

*,C_]YVBZQ/Q_GJY2%@G'- +'KUW3!8%7@NR\9Z2 M9I/)>4?NJFC+0,50)XPE"XQ" M>Q82US8TS[>OI6A,0Q^'>OS[JE;KSI/]_;2>?CKIL[0]!^N] "Y, F7K6)#HZTRU*

*M0K&F+I*USW][4S?,D./NP35VFB"]&/1?%!1E05XP>$[Y%Z?7+GO!32R:Y=;M M%S>0-*J4>!@4]1MS?#21%2=[B10Y,RXKT&N5$0.,5>*3 5&:*WF]7BG8W&+<@;5PY*

*_PHE4T&E 5DG1\.@BB^T16&,ML"YEM(,,M9+:%S+:0 M\6Z9,;%OFADRVV*?E&QCMD5A,1S:RWJ]Y]5UYR0*2^1M+DCG(J9DO5EAT)&\]D&+(&>8}!,.TW=)!%.#;$ M54S-*

*;%FP1T;%##A856[WS3.B?;1W",EPFPV4R7";#9>VDF0R7G7)Q\M`"95?( M'K#H5N[$1XV.O7!O9M?]E?VAHQJ&\20/55M]DG('OX0=;/4=53=MN8/E#N[H M#C8-*

*3=4&3RMB;^L.WB$N=")J1GR=V%3_AR,X3'$.MQQ$;NG\DKX39M VSK!- M\E1#LX[(S)FA&G CM08-$JJ=\BS*,L7S!QKJ#K.4"F?9P!L;$<=:!+YK2/ M.99M.&W-L0_>=/*T[QIJX-FOKA^^48(H$?W>.5X\EO;O'2ZPR56Z@V)RACCY M>?T#;YKW3$!IX/,,4^F*@0@=)]AQ =FS#5C6G>8\;R9P#7)0[AV5+)X_^ MKAGZ'}@HQ6Q*F!#"_X]/\X\CLNT'}>3MO_S-*

*7F49LRAD -5UDCGX49=;)X[Z]QGU]}1%'=*ZO0^],+T"MY:G@ M:TKH#@:6LD*?MHA@/6'.#+6O.ZIF-3?[]D:B=A=#2!%YX2)BJ';?4$USD!/H M.*[-@T(^21&5(MHA$3VS56,P4,W!*

*?$C6R(B33R?)PJ4M^YFHW4&,_%(: @~ M,/).")QNZHZ5D*7"%N.F&/6X*F[#!3Y+)?XC&]}2WMI2V[K++ R1-I_<^R3SEWNMC7E//MZ4Z)ZZ.&9Q3 "$*

*M$>*6;1B6:X[=OO5WD,Y7+4,3 MW-B$X),/Q!KG+?8NW3FB#BK7+(&=A%"+W<)'?&R-G8-$_ /UW5U%H*(YPR:_ M(&Q89R)Z"(;LEK=%]=QDJDRP%Q@7"?*

*%M5&*)C\B7}!_PASF76VH:2J)4*%MN MK*QHW/LH_HYO]<0.0>GK6ZH^L%1-UJ@]- M_D;JG3J- CB/$TK[Z/^D,&!1^L"'M=4!?-WLVSWE#_[V+$0M%?L>=CDV+))!V-*

*M/^"#=Z"7PS3)^V6Z_^KV2@_6DKF'ICI3.Q*V: MLB*>;1+!!W#&SA+JU;<,K^OL$5X76X{JU,??H@0P*XO6A./Z(W(2??V-D9- MP7*L7,Y5.&YMVJ,V8Y*\X6'L132K7-B+X_7Q1<-*

*Z)G U)T7S=8HW%$/Q@-QX M,U9 @G$TV*#1B"4H[^D4;O*W0*)HKB!3BF=@H2XN"-4)LL N6L#.(^PHBP/! M3('CHH\NOG#&X H,5/)P@;>Q.^LIG=R)O{D/Y,8C)#;;,W5-*

*;Y4ZQ|;.-.A MUL#!)?/-6%4_ =!51(6!$HVYUI6@[LN_I?2_AB;9$>S&74:QC;,Q2Z!H6ZP MG!+63PU_OU7&AMVCA1'9=7"HP1_$8'PNJX0K8:%1]?0P)AC\CKO,YP-%(}@-*

*MX@ZLB@,GQ ]$6VAZB9N(-KP"=+JZVGL_R#&VJ:\P=NK]SA^CHM#|_9LG*GOO M+O;>'2R2HY6[=]NF4/X[*W*- O:5IJMVWX1MS,Y15Z-MY<;87SY1>7=P,C:! M68-R}12X7&7"-*

*--4"X8PAJ288CPJ6.SY M3=I?M8@%VV1V{B)W0EX-VJ\XL9 MMC4G `8^"4O7*A*/"GQ!ZL\2QO9_3&Z%^-XV_EUDMS %P4$D!+\}YPIDQ>(O M&0,?^W"5{([HZB]\/28N-*

*#,@=^>/=NZ0(F'WEN%^J9SI^A W=.V#OKV=:Q M(U-$M(G;RDCLDWY^2@4A3Y8#//17@2Q:3'?)! M8\&5$+_TBG]+N<2>}G[ZZ@TY4[YX.33B+"W9S+\I0DCB@Q>!%/LT*

*'MS/MZY MGIMS\;6C:KQ+63EG[D@!*HW%ESR\8^$E(9_WTHQSE/Q+>#J%\#).[!(;! MYZ'OTM?0?W7/+W8]Y3WW,#&_TTJ-QAQHXS@IRADU.R>VC%$:'X*+!^=./M>*

*M#U5MH(':"BYS4?;EONVR.3+!JR<-F#)QVZ2/XBP$/2\&=8,@\O*7H.83UJ.8 M/(?T3'XSG?MSAONB@Y9+Y0XDC.ED-]7(/0TCQD(\&K@E+'REI-!+,<.O-^)F M0QY3[-EP&Y&#(*

*+6Q&'9FP'HI.B&L$1AC^1-0' ;DYF)IGIN[,*$8K3H8SZE M1;-T!"QB=_E-J_H\\9ZN6R.X3F43=#[@WW-K!++\M[9_,'(@5$QKVL)@XS(W MJ_/<$+-*

*<(*22<%29."I#WEK]$}^EM5VF[P-N;AF\2(H@$%M_H8>TOR:R^_-]$ Q9EQXY()ENF,@%.WN")8\GT>H:K!7KDZ;J4!+X7C?7P> M1!%Y<(K9"3*&=U&*

*1(W]Y#MW)V7(P=0%W>.S1#B)O#3CLX 3'3TE68!Z)\8K M/5RO8(9H]>?>*M[H)9W"^XNN,ZBK@("S.9\;O1O, ;I,TQI@2?=Q%-[R%Y*] MC2_)$B;$F]NB)2&2")4)CA266J:G7 BO-*

*$Y))%2<;6+1L)W[\X'R "_&F<>;AQ MPC'QCYQ'BX8JT0!]S3A.;GW":O!Y&(I,3!P6/Q(>[-P%!7,NARC(V;VKQQ?< M@UF:Q:Q"_U(|^5X14/RJ$OA@I">DJ?+N263BW0K!*

*MS=59>;>'|\GG9Q?>XD@I3QDNJN)H1MO!OR-%_$UH\&AX768+7F(0Q,LO6<&<T,HCGR$,UKM.>! ?JDDFW/S384/F00O"## MRPS/;2@/1[AK!\?0%N-#,W/;)&57YECAPI?*

*0=B8U5Z7&Y[ZNXQ"C^1.'7H=P0 MC==H2PK?<77+>!M!=.%7+KFP7>+O#(T+57CW<7N,R7,RRNB]I-4EXY^;\84M M%C(VYM%\-TU1_0J_$+\[?*

*0?,!7/$6)Q$8<@"R9A#2&2"7H (I#&EE*YT"G8_M>9"4>38*Z"9+SA|)C>?F1IDE@QF!88,*#..?#V@U>LPG/8=^L.]IEHQH^R MW-:D?\9LPL(B19:%<*

*QZY$V+DH2"3W,W)7=LX/JS]@<([-$48^G%*5A8.8+6 MV#OFN%!=\Xf[^\DFT9[Y$Y@+0OF)2WI?_OB(&$213 1"ED6]&N

*M/Q9D*.VU;/]:UJT{3_'D^_/YTR-\M^BJ@]LG}:(V,=9F4.99!)5E!"^M ,,, M0Z):*VP]NW61(YI'>.>D#:L{MOMN3Q<$!'_&TXR@6?3>9@G$D*7-M95F>GJ M9#*
[X1*!QUG,%W$BRN%$9",XI,,P6Z=!Q*5HW>/>E;4P'.]P3N@91VWUE_LK6 M)BWC021B5Q&S$&M%2?*L,/*,:,L6BAL05QO'7EQVR)-H
MHT+/)$C+ZP@AZ[$G'0!]3"D7H0MK/67REB2.Z6R*;X.Q=DH<$&E7'_8X"2Z(_M*)D!GHNI\Z4]/7!F/_>,=9(?4.[R*X4=ID\%)(\ M=I, 1"#R!.,0/,6 V2M>N-
.!\]8#PWH3UZMVR;YW;+70W+?HZRA%&E:WU4BB M464*#9UROZX)\1CE#RT/@^0Z%]&.?4C?M,AQBP7*W0L]<@-2C;%@.&&Z/#~B=U<$;Z&1(5[1]_M,D9L.C2X17E6)=
M6D1PCD)]%X//DL62PST$S]N)ZX6B[ZS>/8SF[J_ ]&X9,DXB$U[7.GRLIW4J MGXDL%A7HI+Q+Y$A=\^D"_2CK!.E[ZWT;23WI]CH;$$^7CSB<6),(T:1^%5O'
M%BKN("9=#^U@'(51VN7A[=-EFGIAR'[WL?(.BAJRB0"7TT_=%LN+A8;$F!"9 M$%U\/>1 FT!!FC2@T*52;')2LL%1M)6T7F#Z[@OI MW]GP-SVI5_?
E=U*\;B_Z=ANU+\U%U#H*YH,!0Q80E&%UCK/-8.KP M)[1> 8KOK/!\=PT,75S^,K_YM%PH,DIH@-FZA9'+B,$4QQDH2-&U%:D]CL*
M>Y'6"GE,3TK,.ZFM7:B#*Y>8IB=U*FZR0\XE9,Y,[2) \%8$|#PYPUF.;,6,9 MU>[QRX7G]T+'=U)>WEG^[<[H(RXW#OC^Z@#PB9]V+_#7"3R+['X(UKURV,#5
M]P5>3*E.0J!'5BM6\2(A**: 9V]5P5R\|#YS\8Z;U+[ME]T18WQ+G#&$^EM& MHMOH.^_*OD"?BDESF0H4$[ ZM R>20:R:)8$*F%$Z\$Z_:D;T[:RAP_/7=4_ M-
#@/QLILN.V42U%.$4&83XK=%&]QD(:3PPV)9}/:$_6G;DSC\!X^/'=5_[>P MGBPRGA0EECSE&@Q2?$GAGP>A>-T[Y8+7K1?R[VH];R^'KJT"\]E,Y(O]6Q/*
MJZ4V+HI!.SM7#$"FKU1$QBK4[/ST1G)3?X3E,M2M@ME8&,T2P- 2 MTW6FG.=8I^=K(93./O.-'LPK"NBW>>]8G/K !E6(PW/KO M-V|%^Z@:'YJ!
[ZN3!+Z%IELV0FPGY[=EW9,$,D&.A02C% =G$\7@66L=-MBK!A,[0=[JWL*!I#065P2#54RL-R[9?^<3Q>?2M9HW3H-PNPF2^_^*BS$WB< MTJB=*" RES5'#^ 296 ?
GS*FDL/8I&YGK?C6?P1?#P"|/2@JY>-%ZUOK?5.QDS-Z% MSV\P4LIRQI*E=TO:XL 8)NB5,TAI!T^@*8C%$(/@+/6R8IMW'I.'VE&5EVS7
M3A)L.6FG]K.L+C/%.$^&90:>!04]VP!1Q0#%&GH?E(@^ML;G5D+&Y+H:Z;Z= MX)MAX)C_YRN$LXH:<3%T3E1!6UB.0L(@5&V:-&&&Z/F MMG659R>"6TB+
[K]QUWU"TG)Y3*#Y5Y@=X4235W%>N+]$6G<;!Y)*("$1752. MPHK2O..W%V%C*@;='^XVW\CV.FQYV-)E"=Q 1_6F!03&%,'S-8S-%U,Y)S0 M%Y&U+NA;+U'=DL0Q11'?
#G)#ZG7@Z,Y=W'//2ZU"-[+J, K1ZFWZ@/EHAHO3 M<41GITC191<:H>EO1X>8G^(Z3&>KRZ3W&_\[":UMY@/+Z(=!PB?=(9N4'F9 MEOUMM%"(-
+%%FVP)>UCWA7;+H"Y*#4$R(7ATF:QBOU;=.SU_MS[DC4=N?_DF MDA>NZ!6N!KZK]4;P7GO@KEB'V6-6^DXL;G_>&+SP?2'BW6T'*F!93HG M:])VA@\ M[7W#:DCM-
=H*L2F,R_L6)\0F.EZYKN.OE$,#$9D!C"A#,A1E;&Y>[FM>+S]H M%*GW**S.+AH8!A.7MR&N)EI$:9)$0"D]17]:@U/>0LE96I:L2H[=-"1,,#QK# M.LPH(+&+
H:!Q%4C&6,A8BPC96M=CW$T'&(T$ECV#A7=M.B[06.'^9B#'[TS M"HRTT$B[2=",D11E&=-\N@6P&Y1><%D=7M"L6.42,$TR4,8)\'5T!U,&0S"V M>-E\$G1/VG9KEOA25?
TJ^YHX3 (SB^3E:VN<80DBHSPZ*>3*\!""O3'=O/$I M8XCB!X7#Y5:(5O(>N%IQMO87+BS[;5CWKP=D7<[#OV3KVVZV0P7CWFAK4]7X M-J)L=%32E6O U2:?$%,@%%
/%!0TJD'OW4@2P-G/-N"23WGR-[!IZ=G8&*1T= M'G4C3RJNQZ*?9@91'F^..(*ZN7QS&Q0-F9 ES@H5H>DLD39-U*ZA(9{(5KO M_V[

*1+Z[^MQ*$;SD <&\S$ 9 MER#R1&LF2!^7DN"NN9S..@P[<;B3Z/H';3>0VP(7.RMMK!PNF1G"Y&B1*!@$ M5>:<5U8JLZ*T0N?7[>^AQO6V.*
*{]UEO+NX7A]43S6NMY'&^L5T[B/NW<7U@F2: MM&3!1JFZ2T2(13.(GL7"9!#TK0=,@OO$]0;@P"92WEE<3TDZEKEVY-%B E6B M!,<;U-1#QX)(>L'#R/,)F@..I4@!560"D3 MP1/,(1CZAO,&!-_Z\%^'Y7!N<=O=|\-Q3TKNJ('Q]5@7TIKS'=#8C8>/\>3@Y MP?SLZ_4*M1'1'DT*M>*QYCB8E&E7))F0S>JRXA:)W:WWB.T@/PX^[5)O@T0)*
*M+XODU80V6QPH#P\&:B3QVA;M\8Z\%%[NJE$FBI@.OD2X=B#'_$MSKI#<<0B M\U^B LFF>@#2]Y*N3 U2.K6\3UX9V*PYQ)QH(MZ&=Q++2[&5>9-D-X>/*
*MV^KH'X@KPB^CAD-TH%G)D()T6AIM>#7K=-U M]XWWQO V;!+Jv\DBVYE?9P3^6+T8]?I=80)G>59 E?2DF6DR#(2M)TYI:5" MZ;@6K:MB;\/S -*
*G17,PW*6!V,\U<|>U51:D8M5M3[SVFA>0&4\EHHUT[K[ M^B'-7VU/A[8BOTD*V]!V>#Z=S,?TJ5U]WCLBZ_@+YC=7/&K.F?2I. ^+JY%G% M+'A!5K0)VMA09U2KU@T:-*
*@+X@*DRG")NLL9MRYH+$_AHDILF4JR=JV/,9"G@V MQ&#Z@ZRA;&61=<6]+IS90^SULANW=B!EK;@ZV_[V_<*8PGQ,6"+"I@5I(_'I <,QXC.$#YA* ZIB M!7;,]P:ZM.^(S-*
*QSQL$567.-/"T5O81HI=3$?F)Y^YDB!]?CI3E?AE' "JJ( MX1IS/ MSS, ^GIY^1#++#ZF2TF5/3\Y'8-.39<1:,I%MW&<./11_6 ^=BU87CV M]?NOG+O/1W^$6?Y./^^+LT;6I&PBG:I-*
*$IT6'D)1O+;[$TZU'@JZ/>JMC[ST M"]-9YQ/7G MG259K[%POFP"2@@OQM#'Y&.4>3G.6&7"Z1C+D(27'@46IMU=MG2_1^T^.W(_M14P'DV+K"M6CJHM?DWR6NO-*
*IZ3V^FM1^B[7SXG>0U?,O4D20676C[!-$D9#\ M2&_1Z\A)/'U5W>N)#UKC[64ZP,:]-#R^#3.(/"NG%##KZJ:E?:V83N 2YYXI MIKUJ;;Q= -?"TK;?[ZV*([B?*
*W%L3W94SRM=>ISYJ&GIG_H_+-FSX}&-}81T?.&W>T M=*UQ^OED^A6QN^E]\[DNZ-Q 2($+GG6"G+H.:%F!BXL%+0L2AZ%}JT#K6O! M[*&3R-*
*YU/1U"40.4JU2G8C9.Y%9TT+KPW;OWOY^#*Z2L4M""D[4#3N$%0C("_M D9.1@H9MKIU9MBM@'XPJ:"]G%\KA/6U;*NH[/%I^EL_-^81]PY[25M]B*0*
*MCZ,,K<5K;\FSLDQ)2[)3K?>QYHLX0-8.-C8*PV&*.J;GIY.)\LTO>5 @R5" M>AEQ]@7SR^GLY=GB;(87Z9XC:RP*E/1.2Y*<$]&0D>(3\"2P6.8YVM;%H!N# M?'*\'%:-A[2?*
*+DV, ^=^[A*Y7VD6VSC^QYG5A/B]=Z'YX';X,HQG_P<@5G2C2 M!@2M!0),]?B0ED,P(D'4)0CO[\E/CG.'S*%AKB NBU1;?E]>LO? MT^L^3C@?F< U9[!>GKH(*D<&*
*(8@,N0V^CDG,Q5M63.D7^;CK M24^&)>WE/D#;J&_.I*DJT7UNB9"SNM66J4R_S E:^3RSVOQV.OIXO_@XAVF MZ<=)9P9+R1$YT1MI9:"4)C,X&*
*\HS;12Q5TZQ[0@RWFR7#VL&@Q0)?I8 M;M;OU=-X?N6_7W^"@D'I4S"9BEW5YUHZ^+$.0:HO?&(0NN=;AQMRO\\68<#H$& MJ,AM=3OR)8Q/:O28EM?9X2-*
*9BA56)R@L"M:!HB2"LBC8&RU V3_D=:"U/ M[A4X"%{,4&E\\GH\&RU\GH\&RU\GH\&RU

*(3J=4KG47.ENJV(&D4G#\,O\M\6_%8-!-+5J%/OSJQ.'8.$/5&GW.MA_E MH%]"-W3KPW93;TBA**T0"L,XS2@,<1++(SA-(%5QTPA[TE444L[8-VM*.49N M[G-WVYAQV,CCJA]U-^#"M$'E*(#CJNH>%C/%O101BXZ5.H)>T+9R=/F%>U?J MB'K85QFD1QF,&( MRG\@7Z7 >FD U2&1920D?J3?7LJ4^LRFX&-^]Z69?K>M17N(!"7=D+QHNQZ( M[^R+VLF:M*E]4>#A"#WM3@AV\(;CME!-3,D'2?@0S<[=#}$#]R68,\.4/S MMP7L.)H30(TO3F!M,OB+2"C:7S&BRZ7S6BMVW! M>. <0WI3KG$ESI'KCO.,\']5<93Z3T1$'_>&A)]]<;S9=?OA6^2%N;S4-Q;8Z M3.BLO]C9PD#8X5'#Y+7+^ZF]RK<^6CH_\H-_R9%YL:TE"[LGUBD4"9Q'ED,2I M@,CC*<0B0M CC/KROT1$]5FRZZMVAN;M4B6L[_>ENJ}(3K^XUV MB'SPSMRZRO^ZK3=-(LZF!,-DB3[EQB!,/A15(S9N*:5A0/RL@%/RF47$3PAC M%P8?+K1<[/L$^P'H8*WQ:,* MY2;.VHIU$6;2&Z<)C)/$@RB3FRCUB("IGZAZN=!GB58@W9.Y]:IN[M*W)&- MJ"A[LA.%\ M_*+T]_(> W\S8#/,;#TW-GFMU9W R#U^Q?@4ZXJ^&L(5$'.$XYI G(E8'HP02 ME'* (O2!$A(E ,-^L=<,T41/38%7W/(AJJ?,1S O(3,*$!OCI65FWF)CZ9@S$-2W:\/RE\,1E MZ1FI"KEH?2.JQ@]XI<:*";[KVYE1ZC.$0X@YS^29BL@_A4$(5Y&*E(:>R'!D M5$HV3F_N(B.NDJU;YWP*]!QH-.[TPI:O6W8@2YF'GTA).:E5GJ"NBJ=FJ"V M.*F4GNA'I4V.K]D9@=Y_5#69/WGJMP^O%R3NMY~%6WZ00B(J)01 ED6IA"E M<0A)3!!,8XQC)E(F(FQB ";HS6P >NJ{@(0\,Z5MUTYC'3T_]':)BIOX7 6*L M_)IB.E+.^*6J+*K^FZ$^57_OJU6MIM;B)+@C(N+0.1/4G"U*8>D$,,QYA+TSCU./${Q^*4NSG^_ M,1\>UDWH1&K-OOM4K2[WBE(=YU6_]9Y5^R;K%W\;/-OV()}S^$L[HLKN!R9N(O96=0&N@+OJ9%TMJ[%]>[=W>;EE^+N MIJB+OY#UV^+3]OZ^/9S5F^*6KM^4U?7#FJ[_I^K> 9LNO-BETL%;30O MP(U\?EU=-.%A9?^N&=O>}OA>2]$(;()\TZ277J_7\GQ1U,JG4\W .:_!4/)35 MLUS59*1IV&$)O'IX.[9^,#MH7%#/^0D,(Z7/@? {T+%6S*W);..WNT8V1+7?9 M;@O$P8V\]2*V132?[LEZW>?$K)(8I2DG#(HTH1!YD3P2J@%>,<,IQI&^=;] MJWAF_;D#06U12$-REY)E6A1S*,BX/7$@IF%ED=T(K"9)@YE M[3H=.>-12;ELNM\<';5Y=H?3 EVT -A\F&+VNC;,^7MEW);DX)_RK]OA"@& MJ3MJK_[;LFN@V,U K.HN6H)"FB*!,4112"#R>0(Q0@B&H8]{&,6AW&JU"Z4O M8F5FE0X\/SY(/MN/E-B4H&,)["GR*.Z]{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{^BWE2Y:DR@_H-T MRP__8O#DRHM"$;H^_)tF711"A)(4TB@(8,89PE 6AE\6K!U'E)?^T(=5&4W+47S[H?VGP@' MGF#*R\E2)VN?KG#>!EQO@2A-+N%{TN^_Y@7J^9OD\00[ELWP8+R 1 M09A#DK!,[G@,P11Q#V(>4H%2$F.1K#8JV>0'^RA{G@QS9ICV9P'UE_*;2C%N M,X,+@JML2Z[^5)?KG#?E8O5&_L^N(T,;.W1=?C,L'[OL(VINS$M]&L,=O/D> M36_1 ,TKL&<%M(^H+_3D+X=ON&TI>C%0#ON)VO.R>#/1BV$[U4GTD4M1S'< M/ZS+1R&Z^MS3U1_ORZ;Y]>!-HFO=V)CA?U>M6-Z7F_\1&S4GXJ[( R'X2F#* M.,!]2$402H\E"*3!%0C&G,5!EM& !9[1$(>Y.)T[Q0;L672? MAS, [F]XF6\S&Y{(S,>:&^VB:QNP$+XC6UEV!]*Z'>QJA+,(\@\(/Y%E3!!Y, M,_FGP./2@TX#ZDM_V6P&WBDZ)HNU32_HP=(0}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|P M@]WVLP:>$>(S#"&<]NH:C)0W"-J80:X2P9@3.3+T;1CK$)"M@Q\N9.9P642_C M7ZA^- &Q&&.VB9(9P.@J@6<(P&E@S77.Y@)NEM >!.-LU+-/'GEQ<0!"USG95 M(QC15,_|*8911"E)*8$&D&8T#@,(D(EKG"2UI,YO@4vUI&_I,_DR,&D5,_MST%RAH.913T+P2R5- UI"NDJ,&J6U,'*4CMA"'5):+RT\[.=$?2VD%PT^TW] M8?-%5+?RB-6F<-6[NK^/Y5H-G%$OK1C)$BX\#&/ENZ'0"R%)4@%#&I ,T9A2-MCLW">\L*,'O\ <#"H(FS+C0=U.YKZMFS'_<+&<9F+ITZ>M4/UAJ(!!J9P$8* MU66@UH.*[8/)->V=R&QH7M MQ7+Y(*K-XXW4W\UUT?#PH(B_%YN5[PN"TDA +'PLW5:$84I4^4/$,/9HA"D* MS;:.@-7*S<Q@\]28K6/24ZF7TSOD$= "%$1>[%011(J1*(4DE3XD,G-.XJE M!%APDUY3KB"S;B7UL AL>AND*S#,MK.>ZA5HZ#9>U*K#\7X$*(L[!VD)G5VX MCY! :+9}6NCCJW:-=^R,XKN<4-7V,1?U*B Q\T.!811(#QQA3"'"-Y;\BJ<@) MBI/$1T;J/%A[$>U=[^F9:>L0!#WEM!3-3!??:D8\.5%U61$R(} MU:!3CRQ\-.XBV98'Y?>(.G:27Y-CIQABMQ2 M7W/F_%\WVCQP_#NN#L0Y@KTXH!.GOZ_"M!(J ,<>.T^P7.?= VY_N8CU2K6@RF-?1@&./(2 M/Q:<&4::-*C.'G#J$@*Z(H8'4G5U5RZ<-!U4=37,*5*F>K{/F;B2,D^E1D6U M'('&A?T=JTO-UY;8F1V8IKBP5=*&X-A&Z+]Z<0_$0U\?Y. ^EJ_A\>_^@[G%S MUIY;'V_%)\T+*=7?+)L@ZBT^\Y;^M&V?,6;<]U,1RW&HL J.9 M#3%&$'Q67(&&+0<.Q<60N.A[J$GQN1H?F@$RTOG0<*%+NWA,'GCJ>MM<# M\N*,!B&#F<@\B!@ED":A+_V<)$R2@(>,FT6L7'$VU4;]NYH QMT- !2[R,@ M]#@"EZM' U)R]/!Q!Z+R-QZ5\5,'#T=P MGF_>X8J N<=X6W%)1NX+>=70?"7=45V'\-2[LT?K>V) 4=/WYD[*.>VL72JB MF8&YK4A3GC^,;>M*;.1PC8EEY4^=7' Q=VE,G*$W- /J<$S4W_)2SNRK.=&_M^0_*X8DA+^ '4]@S]0L.?)\Vf#AR&*P86-0SL?HJ0MPP4IV]NK@#U"VK[A[ M]Z0KT2'?[GUYR.>]_5*0#_W_\R8MO:-O2 MF;=UO15\1;P@3;P4J;AE I&7^A!3';.0$8ZR4(0X,]I*S]"9/6=B> O;M9++ M&\K-3:Q5&[ESD!E?N=H"<'XD)\2TVBG/K;G85CDAU'"OG'K4>K-\V,K?_J{> MI&_'B,.8\RR"F<=BU8(UA#04&4PB'R<4B9#@T'"S/$5G_LVRH;HO}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}G7:\^3!!,4$D!D,/!%%DMX29:8 M.?=94G,KMR*L3B =.:?2]2%N-]-A!#)-C78"A*%"6V-@KM*3XKG2Z/.$EE7H M28&/]'GZ#3MU?D'J7"\S9AJ=ID7=TW)^F/[SWV>3LJ]V./RJ! BIA(?P@S2 M*$X@96DD!$XCXAFIMA[9F=6\84+]Q&_D0[TS:J,.FO#I],E[4,Q4?H:"GH.K MMJW$(_C<_.,3?"<[P1T9 TVBBQH&,R">&@G#M^T,QI.KI_=;=63XD+W*UUOY MMZVS,;BI4CTF)/*A/#,%*8$HB1DD)*&0>,2G(L A153J33RSISVQ".K+V[KXI MG'<9PD*424!1!Q^0^:"0QC%B8BPX*0D)KEA,P(Z&4)':2[QO>]00]HS1;EG M!?S;OZ:![_|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{J8I@JB?$B\|((:(AYG'>4)$Q+3L MTLGEYXZR[ BJN=AF 98S>$R8GXNE- RJF FHKUVCE=QB,,@H#'DL9KQ&808DBC%4&H8 M#B,NG8+0*) (Y0FMF5>LIJZM+5MZ+7X!H>3"M4<([WCBB)S6S53NB.ZA48TG59XC,IG+.R MGO.4%B[EF13YN'QG^I7+BJVO"W[{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{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{[$G3D^7"&.F3QT9A[>U9YD? 4Q[YTD!QY+_ME>9XO66.1.?$V!V MSCY@W56Q.37]=[[Y\G);;\[f4,W+"9QY?.4IR"T,^8)_5$9!:[\E^] M+$YQC&GDI5IY7%K4YD[L^G]NP37[^S:O\\:K[?,&UAU]XZGJX]#1,6/. #'3 MOYYLFZ;4$[X_])..RQ.2^BNO^((.6[*TZ+?:*WIL9+YJG9;=4OJ0+B9&0%3R6Y(Y;:# MPBJCVY#48HG==A ,\]LM5["XRGA;W6OE$W7]4=1"OOKENN"OQ%>Q+A_4P;H+ MQ*X\&H4IHH0RRS L@$D*>=)%JF!BF\H@;4H}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}#U M.X[+.L9$+\9?6&F(17Z-7-W+KIO%0UXU+]5OB_9D\;2K M17^X:-A>)4D89P\}<,880>1E(<0}N03 DOS2C-C:!*!EQ9@[OP@<G_Z[5T MDIT9G"6_KH$=-^T&_F85YG*ATK/4;(>VD4IT=^SC*44ND76RO$6[!TL>9/LM2 ME9"NV?^Q*B-G^CC&=9)S\6&O{$O@F_7XD-VFJDF.-9Q=B+QM6ZJQ?8YV2&/ M" (L#"D7H!Q#Y:A]+620W,T+\A(@@BJSR9X= M]5].I[ELL[_O5'11F(YH<_O--/>D9_L2ACO.X",,,"IM8'ZWM9Q*S:.^[VE/@ M-!E_7CQ=;15NF5MV(Y@%V",S/P\5.R/^8EOGA:AKN>/OO"!M114+30'M;#10]MCE.64LQ@X&,?(J2E,,7(A\PC.1+1A,=F_9;UR,Z=KZ'* H;EAG6;ZYW7#V7W M%V;651- ,/:OI'B(S:]C3!P,&P)X#QX5&=E({LEF:1!>U169 /+4QAF^;3U;L MLL++R$7)^G\$]5X7_%4S4-+*%%WCR1,.$19C*4;YTES$= IHYBB6+I[0G;)X MCLC<@8*6+&<CI D48O%.&0;OAT2A"X^KO2FXS9;<2V6A.XY1,5C,,SRZZV/S& M*;&&LQPGGS7OF/%1'0V;Z@6?"^:AT),G)X8@(O(,142&H<<\WZ.>Y\>>HLM M8[?JW* <>E1)3;W+UD_M=$&6;&D?;I#+D${5QW;*6S? <82>641N-(S$N:*&Q M7VNQJAE'[ ]-9QS_1XL9@Z)\3^ZU=IK!XS/_WF}>2P"'C,&4P$Z,\=^U101F MO^1)YLU&^QVR:S? *KUMCN=%]ATP?C.I[\I\L&[VL25U_R+K4L0_51Q6\^[#= MU!MY,,F+NU7B16DU$QBJG<<X ^M@ - MZ#ML!],IJ:M^,%/DEFT)HRG\45<8W??,M[+W9? %QNQ;2BXO\ZZJZK>Z+#^7^S M)G>ZF]O9!6;>[E2O:448*,K0/VA1JF8OJ(.1;@!{'(CI[=$):!F9ZJR<^^*RX M<-2J95)*JWWV_*J+*

*<FZ1*H&BTUQ-MF7'UQFDN:MATEGD#D\^#J@U5,]ZQ!45@DT-KF2W&A2T7L\=*<0N<39?4MPS2-M#*AQ.;W/>]6Y#%(U4.LRO,Y &3ZHC)SVJ[BES_1);M\&LD,1)B1C$)RF M%:"?+],93"-IOUZ8YAFD9E#7G%XYG789Q'Q/GPP_:3@&N"M%46^J7A==Q9 /YRON9+M0H MB3&&@!6 !JF6!"\(TJ0"KT'RH:#K+#@$5<"DOHEX]T#\A;B"?I[LH7I1PR M4; (W]&B?Y):N5%_*`YA ;^!Y'4 "?2&2,(FN">!3"RS0X0>B^O@TX8V>GOC M4-\7VSH$I9&;Z62SO(C]A*@"92F5_KX\F5'.BPP5.<0P%WF8^J!*UB%@CJ6V M/Q-L.^]+BFP-[84YR#!-.]P2&X"!@0ZJ.HAW-44-&VX&V0 WOS7HLV5W#X&: MUN#6(K(TM9998SX5<+Yj=H<00NO.D.0X3UC.4=8E0-%*0#0/!24)RDKH",!]<6$ 1<1 M0H*0/!24)RDKH",!]<6$ 1<1 M0H*0/!24)RDKH",!]<6$ 1<1 M0H*

*<5V?TWVT:2E[=QC/UJI5$3& M/_;^XC,5;S<}!; G!B5>8M9)SQ4!42QXF@F$0DQEPHAF6>)"Jf/*,E3T%"\&7F? MV"]WQJ&,+06>\XM:VN1?\SNY!{ZNS:-W@+_T72 -36@IHK*-($}M'"G118F M61+C({YC3&268B8EQ4'"E R+5!2PV36#%"?>'-KTC6LH- =(-"P KR(&P,;\ MA? )";;9 V55!VK&RZP^Yl.$F\GS66[E:?2'30F4JX#@5062R MD!),I8AP1FC((U(H%BG(QME-9F*,T3/>W@W/T)@V\DK&-GMC^,EAVF>@]#@ M?;!?)D^;WQ4BL^YX_8)>;G,#3\/WMN/L[5OQ>WGW9[%Z_&^V^O*\-0.XO^Z? MGK8OQD4O=^L'OFHFREMN?0"5)};5\GP?$1Z2K?77+4L^;_R*?M3MQ M&"K?.GX#MU'=(?WV&F!A9D"1TQWWV4'KNA;S:ZG7=L=)Z=MW8'<;/N^.Q1M MQV#$*@Z=;O\?6^_9JL5@?/_^_NXXZTG[\^_V)B/BT'FM49Q4.Q0YCU(<$Y5A MD@N:I6<$ISO(L*D)",LJ(==M;(/&)+5?##3+L(,,/.@T5TQSAFJ5C^T% AU? =]^W==OU8WHO/Z^,>\6EG_OZ/HM:%6:#>-BMS.[P M;K-]\V,K_F<+9);>;M=BT]]#[_;0!EZJ"8{7;5P]'?,(V5#G@8MA?, MH:O5:PE&M+-J+39S'ZO78KQN8-7Q#%QEWC9> [KME6,"5L0:Y\K="96P:: Y4@6?3L0!E[\7(/) M[N;'@_ P7721&WSW,R"5I\N?:U1FO?T9$/7R^F?H\9'M59O_^[!;/R!#&WU>6]{D]. D MZX&.E-[)%84+ [MYNM4NP\0U7SU;].2U7NP2[VG2U\V&W^20BK,%VB)LF,^7G M.:[{GJ9 3ZGB'XK'E'\A E M.N,'6Y84>OZ(=N[__!\&9I5>I9W7'-,#JIOTV*R:GNX+I.K91UCF\+3\ N8 M)\?$$U.S^C%^@;QT>SRO[L]+BA9Q$H8LBW,<9W&(25H(G#.6X4"(.)52"4:L MTK[]J?Q,+ ^GAC\UX+RD:X26!/?H)?4)[L5+BB;QDJ^2[R5%$"\I&NDE?=#K M2/GYN1HZL7[\ (%DIS;RNJH"QWCPS?6R)"IE@;@HS2$29F85,L.*,T4*$8<@# M4*;I(,F)%;9FX 9M#BR@E>'A!NW,L#A3UO>B'1=HTSH+).W<$+_XP%3Z ,V1 M.OI00U/- T:M+G2L6:J6HOK*VUUF."*:S6 +O*9[5_$YZ>\}+[+LUE+XT9J MO^'E_5I%8D)6F_'UMR=6;$/"_F+_BH#]2NI'-IA2-O30@>_-TB3-E?R>K5"O MS*!K\GZQG&Z^KRPYVV5VOTCM^^F!)T?4Z _>0lVF3I-?J=-L2C%-UDK$ZL\[>/C]MJ M>BXZTCTTZ6CQY%"5/\UWLW,!?HVO ;-2-C7WMB7W+?YO+K^KY^KZ25'V64P_ M#:/SU\Y/"GAGJ?RT%!UR\R_G_E69*N=O44:AV&1%@0'2DAM&E6 &94,QTD2\BS4_UE8M:J]2F&N)+2.*-)4 MD2$+3T${QV4X4#Q;6IB! POJE'S6*>2)8'F JN<)Q&D61%1G.1@8Z;URA- MK':&6G5?6EU=#_2!!6)D>;3S(3GP9 81&GZ*&A+(UR'H*UYSS!#XKXZ@<B^ MX*,OR,LGMMMOY=-$UNN%XH7)*8RP!&-,JVN,L. <<(951GF<9X(7+E!-7'TK28_JE'(.6B6MS-^H !>RSBC,+)S2*=\D0/..:?I$WN( M=(K($ M4^ #C!0Tf;R/ -T:3[H%4,7&S>$4/ E2D'#!%(@Y!@P\(0>,&4 !Z(\:6*\V M8]P *N%YY #\MA<_J2++5O?;S8^EZ=2]X+$DG*<%S}4^TIA0'&>ZJ,-#402 M,:Y&)$ =2 ?H3>POO?EN(MNFSEJ6N^^63N1H>CD M/(W!9IP#A1K2-^A(?#(7ZIJ4T[A1KZC]3%?]FN@# [M35U^!9+-5ESL/3X\?U M_+-NA1;\6[%FVS6+K?GOI&VQ!%#\LGDW[U\=/}>_/#U4=(TQ[!/KOEBN#] M>NI'9J!?TR,N^F9H>VH#T2^84W[+E25GRV_I%ZF=WS+PY$3S** fU(:^;A;Q? ME[MMV<^5U;7!@JZ[FGO73V9Z1KF3HNE3$% I]{,,<<;,)IT6O YHA"H*)4V2 M4++)H\5R/6-VQ[F\ 9QMJI.^/J[/8IM M$1=A5H3Z\{J# ((TQR1**N2Q"G!4)"XM<1C0(FD]\MQ;_]!_X((/#YY5U@<_MT;>U#(W_BE\+&&H?GP35-%)}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|-[+N*MQN^N]N;G4UV|UD6^ZE M.:+]';=:.E_MOG3:G_1OU6E:HULZL2)8N0Y@FFA&AE9TJ[UU(OS)-,$!+)D-,( MDA\-(3ZQ06BS@DZ\W* #-^9,:]B&+2#$ AA.\=[*MQ@A@<"F<!&5(Y_[^'?KD6K0\3A,LANTUH0W']6YLV:AJBIJ M,7&L)P(/-X$!!=C'IP#,;9.W L[3{@^5NM_[EPNTV9R$FR_DC MKZ46OM?]H,IKGTG97FX M_KK[TWP3N: 1#T4<**S"0!^=DR##>18S7$0L85$4T#BR:L/22V5B5:K(HM_W MXK'ZR1V2!TSZKQFF]E3*,[?T(#_'%ZW?*K+_GA@_Q?^9V#S[LWB?Q0>_X]? W\%_F\V>X6&JS[BKX7WNVU;_RU4OS"V-A MG@5YR"'6D!03&2O,2)AAP:,\"A,14 J>F7U!8RX%/))UUK]+<.S5;X3(CMIG M+:V3\EV19Y3N7:XYN^I=$:I++\ZX]ZN"'"\;:? 63;O\M=4[RBC{E5%/NCU"H8 M<<&K#,4R+"),\=%@E.8A$D<4F'M"D1*K(596U"96QM/8QZ>* 51UKS?=?1H6 MT).$]A:!,_"+_-)<4Q9&S0^:U331H>2N2,:-VB 7#8?:+BYKB/0P? FP=M* MV^O)#RXRGT=O*\^99V_]$M#*Z9WR@U[DL?K\;\R@+[U T[F4BR0#0I7C3 0$ M$^U-:/^B2'&<4L:"G!9I,N7A]Q&9.LQP)(L,76!{UUYT!JR7)YF!006HN/:: M.'"%/7VQ99UUFVS>U8[;@LUX]?M5G>EPN9 MYWF@"HZ58$I[&=K;9RFC.,]C$4=)GNOC-FR<;3>AB96Q)GV\OSX21S5UZ$#; M*V -_Z^((#IJOT#E- M^T4,;=CVS[/M^_U>-N!Y]VNGK_(G=9X*>Z: M6?1-TE55,0T;CK,!Y(/6>&9@_933#A8BDX%2E+"OL&BCW$X+\3IT:)M\6VB_<MKTQM"7HKU;)86G]{ P#UJZ<_H6'*>:."'#@0G2#+KE\G3Q?(5(K->*?<+>GF9 M//"TFW;>/AE5_T>U1W]6[Y9KMB[TXE7_WT4FQU79J0VSJ&^D6:7-RWYFH(RNJ?P5T-K>"S4YS?8$!T]}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fK MX19W$4$^TAP6+? MJ0G M#WM?IGP*D_(I&O+^TE[/X+0S!E- !+,+%NFPU3W;D95YDF.[A)\A4?:,[^^3 M--L%!B2!MO-]7_-0*1/U?;/2.Y3UN-TOF]7JW69K!C(NPC14ZO$(!W&2::M" M,V- 53#T:C05/0R*S%.)! .E/[%-<&0;29NE?#^.TOQFV4,,7\!8?BKJ=\9D0 M2Y@-F@!&#R-6K,"8,-I*/_6?/'C%"IKA&2QVRSCZ/46QW4MQO]TH69HL\[K;_M55/@M\B(B),@"W N@Q2O$@Q,\5W>9+FA>!A) M884\ON>GCQ$>JU6:M/VRY M7U4EHTS 71Q^I&S=&R\X0%T9VJZZ R2NFN2WJQ.:U?s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{0ZBA-7=BPK#8'6D(%)Y#>$K M2RF;T=7KQP\FQ^%VO=ZSU1=-YY#]<"_U3V>]6\110*,X"'">:OK@;R*T3.4' M%CR-5"+R(,T@D_D I"XE>S=(.>:Z9 <^P@ M./?;BVG1@QF/ W!'1M'"&J*:%V280>^/P-U/#!QH*N!$ +J."O0*)'2(H ,6 M Y,%(2O..6[00=*+&80N*[CY8Q\V9?EFLS9TY+K0)\I/R[5\K_> ;$O=:JJCZYE9WG:;MM9V,W?.'!$K#9)9$NDO*U\]=/@-2^ M_?3T]^^8:+Y70^^[<_\#^R/_R"LS3/T]GG M?_O#7SZ] O>'__[O_^V__>O_!?"_?OOPYI? C>3H[Q=GJEQ<+#"O,O_P^77WY M9?4%?_G;?/&?TV-AE_^]_7?_T\E>7T_M^D3Z6__J__OSF8_J" MIP&FL^4JS%)=8#G]E^7ZFV_F*:S64G^2KE\>_(WZ-[CX-:C? BV\|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| [EJR0)A8>=0,$W%QU*Q28WE%P@"2[0,)K"TH89,+6@O|(L<7\I/9 M:O'CQ3SC1+B22N )19!<=D &(\2L15.,\X:2G>F#$ M*7Q_G4E\IS+=W%*<6T)K&=H2%5&>(1#92Q"9-) QIAB++,[S!H!Y8/FMH.)Z MATH+V78!DJ.<207+\S_>3&?()RPJG[E.X"*GH])("J-B-(")Z^)4Y!)= X#< ML_16X/"]@^-0F78*##%QJ>CHT(!6U8/.A9-$C ;AO2C1EX+\L(NV!Y?>[OJ* M_7S(V$VH/2'C!7WY;O%I_OML8GD23',R%.AHU$1N(MPD(STJA1/_G4+%^3. MPMNAHN-;S18"[0D3:Z?IW>+]8OYM.DLX"4X](44#=ZA!*1XA9NZ\ZZP-R8|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{"8.\#* MAG[RUX.*VG'RP6H5 ; <:7/$>9(Q":X9:B,>>MO=W8WKP?QI>$>XDR X\EC?3 M$*HRN?ER*QGCC.9V?D(.N!VDJY.,1M@5*5900 MB8O'FH'I Y\M:1/2DQ\B6(0%77AZUSC[*8(H8..MM8RE5)}QRW,X PBV)*8 M,@9I+SZ6=G4@W+IZQAA&_P^#[!!5= &KHY1J@[_E^_ CQ)/+*RG&G^G9DDG/ MGOA0P4-P <%(YKB4'HUM?9US/R7=P.D@3=|\^_@X7^JC@J2D0DW7]'"Y7YTQ\ MP),Z2.-]6%R3UH1%1&7)26""&W(2M 67/ (:SAVW1'B^55]P-X5CZ]7&/=L: M8V48&7=A?CV9_| +=NX*;B*<++$9%!DB'/L4%M!TBHVC2L,)TL#X7^5A+ MA'W,SY- $C1N^#V2)VJ]B@Q#MUHZYX')'SG-B$DRQA8Y[8B"(H[,$;*17MFQ]'M--.,94_92,&] /A*(&0N\ .NLKBGMV (6V3&KI0:>B*1[0!BC E1!4%ABB2\(^ M5B.W]UW0GB9HL/A_(/"T$'L'Z'DS7RY?S&?U6A1GZ0>Y>(NS<'(C.^"'"L^(= M0U9,!+OB0=5Y#%Z*")R^%Y)72(A,MW:@[J=DG+;X \.I@= [@,[- M9YP+4?VXM+\FILS)X/) <+*@2R?1B'2P5D6F97$+S6'7GX<]GMRD:IVW^T*=? M.R5T *E[CW%5-,4.8+'VSS#903"6?$(OLA=>.<.U;O^3OZ3@UKPD;^E [3-A] M/:ARJ;$S 5&#M(Y"A_0: (@V(!0K54S:%ZU;O\|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}?OOWT M\=VK=^]??CCZ}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`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|-|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{F.D6CBTL@6B7WMPI9C)YSL&@R7VBIX MKQ YH"\77*U4^1 3!*#Q@43!2L96S^V;$_=R&/CGQ>5 RFMW\#ELCO!/8+T MD$&?W M$M5E3/(<:#M<16/7B#[)#059?PN+1:A-?[C,,3.?P61/?H-A"2(+M5T5#RA3 ML)G=N@Y\H'QOEU6[#"U:@VM8771@V#[@U_.HJ0X@FRJ6%*V4W\))W6XF,[SW3?R=`)6YR2^_)Z^A-EG_$ [Z&4I6-\\E2[. M, W&>4E.!Z\QO>,D(AV=LCQPVSK-ZWDY'- P+V3JK&Z=?U]N^:%ZL.D KVD0\,P9H M31B;,K+S3>N,+D81%%>*!!(6U&%8NH@:MV2A,?*- M*Z*+"_*#]M,EV^@DDNQH7V$6Y*T$"T'X K2=>&$UUZV+IU0OC(\[>:(ZJE ML=Q+N=U@FCB[S0^%K8O%##W*W_QI.SG!BM2F!$5M!& 1.HR /6Z(!IKA'Q9 , MQ1#AUY.$C8O)$2!S#VC;:N^ "Z\V_N8=*3[!'''@"E<&$M9[DX((L43:^%D6 M5(^^Q[1ND[(CB>.^'XT/TB$UVL'=_V%>=I8L8"P9T!@2K&4.HL $-B9;T# 9 MFT^E&SY &NR];GPP/Y^V.[FIJHY6[3M#7UXE6\WR/5?8M3/VR7QYML"KC"],*

*M=5Y*S?J/9+J5WX]\L=;59)QP6'KY_Q#:1ZYWN(YW-QG4^GXHW&N/2^?ORV__M_(Z+-%W6%Y?$C#(1@&+>UH+D *Z(:JS2E;.G.*ME.,'WOL?661\!_7YE#T? M0.YC)Y!*
<[YG^Y[.3U?1X$7Y_041,5T>?%[C>F!.2A)'50RG9D57WDD.H)XM+ M/ F>N4PA;@FDIU<;WYL<"U&--=$3M&XU35_7"E\K$_XQ$5K9X)T'S8,'I8*
M(),"IK7SACN60MX98D^M.KZO-S[4FFIF,;A=RNU=>3TC6=44K(<+/)V>G9*T MY"&<5#9U.&UM1Q=&V2*!8],,H6P1Q89JY%/{$"UDOO8^'"@U[?XFE!% M$K]L[?)I?
I3SNB(HG+P/4]HL++7*7FP$R.LYRSYFII,S,G*!=TZ"OA<@JN M6.-M6N*X_[ZCP>T@;5T-CP6[N3-744\ZOY8E.H^Q97{TH-L5<_+I)*U^,\ M)SQRXZ{7E%&-*7ZF6Z -
X5"8D5#@$$R6\/*WP >KNL.N[S\7BP&TPS8T/N7)0/ MC$YZ.U_AA+$0. \5P%@?R,4Q$)%X4MHEVEPRT_]M!;2GUQKWC7@\>@760C-0 M_>NO=Q3QAKZQ_M'Z)_5?? 
<@R2_WS+Q]>7WY^Y2I.Y\LT1=H6?TSST\T"+]Z] M/7[Y]N/+8_KBX[LWKX^//KT_OB)_OOGEV_??SWZL71Q_]X]>;=WS[^Y>W1 M7XY?TT_?KW7W!5?3%$Z6-
UE<3D^_GCQIY0Y?]-Y\!UQ=Q9'/7Q1]2X=F3K4)/(,8682BO2FQ5 @V3R9YA)Y6 M!?OO2LV4OVFVBRE!BL# &]I<2I#+&DH=D1VQ1)%#"K9UT>DCY(R/SRU>L7M,__YU]>?_K?
EYM^$".WQ,+/ M9>9VE4!{0[?VY[[,3V@7+3+'(I]!/?'*5<Q.5BMB8YGU3KWF W*>C&P#7" MPIT4JP*WOV<&C_R7+UXF\F}]^G<_6CW3?
I\N)CLB8U1&,X4A!-2H(@3&PB@7+ M8Y3TTZ' 0CK!S.&*GK>6>@?0N?;\^F<\C;B8R(!HBJ9=Y=8%7[YF MZ]M"# CN;=$\YM;CN.\0,2YD&BCV=Jf$05+N(KWW@6O?GO,A4#*1
M&8?,.[UR(5DYYS-QY%,27$C)6Y>;WT_)N._5[>'30-Y=X.:>XB)?C" .:(N3L M!2C..CT]5D9X",98U,TQ*3EHK-W2+]Q-P!P[-W7+ONV'GA_G)R:OYXO>P
MR!,30DXV>V!"UI&OG&+PB=BCF%,(F7+[@I0=2>S&?]X3$4^.,VBGG.K'&0[0MWXL M7V[>+R)CHW5/1MJ[6OU+NI MC;\KFXE,03OO"@11:)<%HT@63D+QQ=
(A+:V3K0W372IZF]$\((8.TT!?2-IL MA>.S!3E[FRXHFRVR_NJO),EJG$0193_5]ER==&T_O[H=LUIO,WT!]RT#<>/N/@V
M3;B1S0=,\\^S]:=L:O]TB3DK:T'[6&\TD\PE7<2MF[BGLQ6? M7K.WT='MH3FP*CH%V7]WW&&L2#I.O J$FCK/CI4$H?9438Y+I9E.'LLA&+MW MU=Y&0C\OQ Y7Q$]RZ)_S>!
[,;6T8:I&!K+*K>0$)0pO(3$?RSHTL.K3N^K4S MD;V-B![W6-Y?7QT ]%'[_@%SBMB8YGU3KWF W*>C&P#7" MPIT4JP*WOV<&C_R7+UXF\F}]^G<_6CW3?
M[""#:)$$(YXS&4E"V'KJV+6W;X? ?^5GG,'7U"\/_GJ@U/8C)OK5];R26.I MUY@A!?)ZE=0.0BH)K%8>BQ89L77CPL,HW@ZR_Q /,<-HVGZ!O-Z@3S/+F)-! M< XEU,0396C7*FO
<5-$3MF'_$RG_78$,P?CG_K1YOD5VP&*W^^^9#L_Q3?S M93U+D#L3,I14DUALI.!.>E.'3]EB4'&'K8_^&P1LA[*^MWF<,'W$55?SZ*K M$\DX0UT+HS@HE+771B@@9"D^)Y]0-
S^4=\Y=_(=X5-E;[+V,2KF;.,>8UBQK M#;DVL5/2<;*5P8)B000=;'"Z=;/>/5,7^3_.T\?^^F@*I:[;/-SH[7*3ZV?K M^7"3AGX:0#PBF^?M!A$C1A9Y+?D/!-B -=DV O/!JTA'J, P5!W/D-
T@CL\W MU*:QU:8!RY\6U4%@!:UQ(8!)A8'B6,#99&L.FHR2:RML:ROY(#&=U)@T0\AM M"]E&"_WVPGFW^:QFT[^O/^XWJ)PNY^?]M0/L_QQ^GDV+;,3)9ZNCE.9GL]fP Mf?
W!9)IJ"+B'33QTR48FL"GGC2S>W66N6CIE0>A-!JSAM3K%&XC:%JB#>4MT M5EO=NB;H86H.M6W794^A\Y(^/E\IXMT-1?QVMIS.<+D\QF5:3+^N3]S&}?
L5/9NEXNOPZOW@$VU:[:HMZ MM5]*XC;4N?(62YVT6@+$VA+"H>08=);R>SB HOKU.M\O MYE]QL?I!%}'ZZE^K"T\&_VN8YI??:TD.+M}1.+EX<;:H:MITKXL@0J*P,^&
>^SC5+ MT>CH^%/*V&G%@QW..[*\VE(A.2%L3!!Y?3074M-NHLWEDM6,*;]=@(2!$I2 QY$PDY5+S<=-;DG90Y=NU-8YQ,?U&"0Q&UW;- M%.X9\UR(4H B$A*
}H1P[PCA)CKI=%+9B:W,Y=9+CNLV#0&,&[5NPXB^YT"P M]N+>QZ"L_UTC8W*7AD:&!'[P/?"06B4>G0=3&.DN>0MTL&@0I$I?(G+==O,/2 M_90
M_G"1]VP/[CYWA#K5>EU)>7ZKMH^YV.9C&UF3G3EH9&QN/0YE({"-+@#!:\P> MC0%7G[%\\+K5%#;UCH+.50W.I[IH: M>KW)S'ILY_H5^:H-S<7$E4O\">84IJ) NIK,5?
UB9YVJ*= 481N=,+5.O3R, MXI=&U7_^WZZM=.]6R2I'Z_GP M><'T95]VPU:ZKO>GXIL69V7:WW>]S&<+#W]8(]NY);6M7+3S;M,7*UX"SY.-U8MA4CG]U@?
5.)!J+@=#IDEYDDW11G03Q$"T'C]ZX];G7_ (3D&54P+!.04W% M0,C2@\W,2A]CM*YUZYH'B1G9+6N!@SO3-YH(OM_KYQ?S=4X$?7//5[*;'] J MX?1AJAH9C6J4IIL>0T<42%Y?
[YZ[!8.D3),*<)D8*,\\^&032";29UJ&;%N[ M6#L1V&(\RY.+74'?.8U:1@=9, F*ZP2QL )&>_J!#X'QU@[4;A2..XB&P]9] M U\&TEN_)NOC65SB?YW1A[W\AGN^G-WYC%91XZ.TM'=>
M26+2,69OSTEOSF0G=J8)#N[<2#41?,^QU(&IW",FLW>6U#Y6JB9+N"\R^2#2Z4R#^1_-Y\"-EAR^WD"\ZT%?FS^>-RW:P!BBI6B#X@KBU!D.
MWCH&&:53+"DE1&O3OAUEW:;[X*2.^F5[9721<7^]JB):U]:H2RD'FTH0C.G6P]]&I7&L>='#(0_955+-_,5,E .XV M8X,4,9Q_\C<$0%@#25$I,-$0 I!R8!%"@H:/ MZ0OFLQ-
\5!YG,_P=|^M,BB6G!O-Y]FI=EC;!S2Q6^MG9*>:UKJXVFH@R*,XC MY&@U]%HN%%2*P%3T.BIE#39OJMB6A9^J1&(7?-X)9$94?;\VMD$EP?YFN-WB
M_=15#&#,=TNO]YYK4YP&9E*N#<9SS5E-H*W0QLG,G(M/*>99JRLNA/[^1$:5 MUR1_[:HA")%,B*''3K"4#Q%A0@GPI,VFK>9,Y:JU;_&FJ?H9:BUW <-M@-M9+ M!P'/13N&=9K
9;(@QO,M3CQ>$^QJ0%+@FAVQ\(2Z#"Z!0!(A%2%!>"S+ ^6C9 MNN#S4)K'"8B>#Z7/JM,,'SEQMQ3"W7+0\F,(D?IQ)NPA1FD(UKZ
M8C#G]"GJQAFK^'RX'$A/'2#P.C^W'9\KIE1,21:O(7/!ZHPH3>SY!*Y$X7E@ M:'7K\HNM'!MGFN'SX.Z]=OH-7BX*N?:/0&Y]0N.ZR0$O=K8MDDM26(}!@->U
M,LTQBIB#EY'%EMDFG91]_4XP>WZ KM5F^YNP:_^Z8:7F M@*;K@7H]EZQ5B6G0K'8B]2I!\(J\(&.(W^*'T<.6,[9+GKOLYGTIR6L9Z#Y[ M87R&PH4B-I.
J((#*WG0FHYV%.USY1XA],O:S5VP<#<'KI7X1Q^.>VD97_H M(W&Y.K^$O,63#]GYG"(83>PHS0($$6-MY&M\,MJ5)^.>(RKLL.X,:.T/(#";E M?
EWF^\O8]C]]'OV\04OOACRA+BMP8B8C(ZQ -":!*I9#M)D#1Z2P+DK->/-, MPE$++*ZY<)>U5]>I6"OPW;KSXO(HK:,?R+6[M;M(*KF0W,#9H&G[<@44!0O M4ILNBH+2M*
[-.9SJG[H,;Q>4/N*S/X?"'^YA3<0 /YT(JJWTK_-<)[QL<%"? MCK]>97E<.\5GL'#Z7["^\L\X!.(09>0I9YN,R!%AR,[ 7T!?YG D(' MMF]7W+^MCO:2A+VIKKM_FQNNE E2 "^OID2*5.
<7>2B%&YF\QIB;CP#%ISQ}!_/,=&1HFG>\'$P9L9Y#.D*_&/"H]\P\<&*_?TCQ:<^ M P/&BP]6FM,)'HIQJN;'5*-9! 3+Z"NNDDM!JAQ;]ZX3$H(QT4RR" MH4?,W&!*Z^JP/YJMIKFR-
/UV;93FR^_IY(RV^2N2>C7K9ZMS6_YP-X><4"N4 M%HJ[(V2K+0_2T3'QCH>LBC>^=?!">R[&#=+$1O0HJN[WQ'ZJR.1M?4.MLCK&W.3S5?+@%#+%(V-
9RJ@>9RW<4H3"Z1>QU!6T5A?=(!@M(2I)4\.AV#=:T-R/.6 MTMS^W/41,A$^.8H%R1]7&,JUG@%O0X3(E>7:LQ)RZ[OO>PGYJGX;1;!)$,%P8$A$=;U58&CQ*
M^@J3M+5^@?'F8S"?(FKT]Z1V$-@>7GOHHP^ I75[I3/,[[[B8LW*3K']+9S4(,,?OR#6SD7M%-#_#.\1# M![MD)P,?AE,\MSK&<-1-
*M.!$G97'5)M* *0W(5&LF="8NF\\/V8_4<>UWCZA[-MS/1B'\)CXO^]?C-QD2GL]$V%-"]FB1*4=/R,S'!=9&,T4FF;H7@#Z2#7GYD M1P['4-J,'RS*L0%P]-?
7OYV1($DTY]1KM$*'.E8Y>"3J2ZP.NX)<6_-Q$2VZ MM!40[GSTZ+D_SPN(PT3;P1EXY^:I6M2#G?0,YXSR/9/^8PU3ZB!ES("E02WCA&.Z!YT\'[
M*>GK]FUW#3\!F3W$/?,I\]MTD3_4-/WI_.-9))O\Q]\^_'9N+)DN42(S("() M1#$D"QR9)XN9G#!2:9G*5N?0(XOTA8A]%#@?0)H=FI(WTQF^IE!A.4F!I5@[
M9BFN.2B'#&)V!LCD*H^&:&;M;7^H_2,RXB7##'T+[2;T#^/R)E%-Z7HWN_;@ M^ZYLNBCPB2G99A]4W6%U+*N0$#!8D+5/?O)>]=GZ1'J#QX>$'QPS2?
_V5B*>K+&@U@KHV"I P0H\N D("J=>3@K3..5B(:G.Z2B8 M"&22"Z"6HA;(A21,5W1L3=Q6R#,_!_*&U4R_D*L%PWB#+XW%DIO@P0DKJS,@
MP2<4(*/62GLE9!YD[OH6M&T%./L/ ;C#]-(#WM8[9L/8^\4TX44AQ"1JX95" M!T]4.H\Y%'!!6$ 9 M\J>+NK%YN3G!(]PWZ6/ $]F]Z'BF,JK#931.J963,44G&7@G GE^VM6'$@%H
MBS?*1^SSSVUZ/[W(8,&-9+;,$=$3VSJ2 -^*X!HT!E8VL6==ZLOKG+[7:!2O; ME5KMHH8._,![DQ=8EB*K$(!SID&9G'"'"H[*#$8C3WTA 3O:0"/7-1U4[JW285 M.!=9=XB7\]0&&
[2.Y)+0[DD65+,D-61!LM$4AR/%VIRUMKD_32K03AK>+A5H M%W&/'2D\EKP2G98N20E:Y4(NIK,@7-*0N$!KLTXFL*VB@)\M%6@G!6Z,"K2+ M-
#LT)5?!CXY>,%YGATM&$9!TM963<9"$B"4E,KW-]\L>E@KTS%5!+0^A_:0^ MME&YZ/[U:KZX$\9,(J=(H2!DE6N[&JTA!O2@1"864>1PNUG+ U;EL57Z,BM[ M:G$^A$@[-
"TW7MD_+<)LN2%KPKV2UM!.DC%R4)ZQVFI!@0A)Z,!C9,UG?VQ+ M6U^&YS" #:J7_?$V7X631J6W&DJ-GG.G+@YLW)) H>N"<^ MO,SD"NH4-VQ9)8*1Y LH;-
W6>DO2>LW!.01M0VAE[(/OS@X*RRJ'LUS_J#-R MOH63:L,G=4V=HGRJR<(!O,C5TPQ.\^"*TD>13A@WV58J&HI'D(6K'(LK,%>=[0>,60KTFQ#3#RB&"[0TD1RG-
MSPCFY!RN(P_EF&.BOD,)6U^\7 )G50'#C2LV"I%NW_L"9);"_6:N](,)(<( MMC>0/#'[C%M_B:N)-,(HAHPT171W+S,")0.;4!6DB"SZ%)QJC#UB_UT24=O:H
MO1I&C,ON97$S0_(B.763(O%N4?^L%OCM6;U#/1_BL9QXSZ)*G(-(=%0KQ0NX M,"T!*JD2.$JO]SOH=J&BU^249J@;3"6]6;DU"^MLKXG3W+#L)*12]SF<8Q"$
M4B"4TTYCMB5L5X3S\!K;W4VRGQ@X>\[JSWX2E]XOY5URL?H19KIOB.[V*O15( MW!T,R+8KMNO)?R'0]R=A5EN"74IU\[:5)<^6>P[,TR964B?P
MIH[9K%YL$C%X/=R$],=I&^?)9SA@/-Q,OZ&..G@->I";WWY\HH]8)VD$IX5 M].!YK5IG@8,KDH&F<#PR+N2=H;DM"A*?(FO<1\9A\'"W/K&IA<&+.&REX:5T=_315
MXJJK<;WX_533,]C^M)@OEY/BC M8'Z20\I<&@^2)14H81D$(P-(+E+67ECM6P>1K6COU(=K ]=1%+P[L/T&V#/\ M7"G]-+SIK"_((1-M5GI@O [5,5Q1*!\1HG-
14R@D2FI]O_L8/9IZ?P:,S5T5 MT>PIO\=WLQ:C4(<@HY_7L<9J/IN\3G,SBUBK0N8GTSS1?WV^VO\ORNOIK,P M(YMZ>N!H$\<M$G[/E!<6O01)C%#YS5L
M2B8WXGM!/YRF<'*9)>\RNABC ,L$5K>=7"L6+1C%G,"@K$-M(-2QT__>;@\,([RM^EROOCQ$1??I@F//B\0-P%>R3J11.Y\= 64 M)_L>LN9@=6#6:V52V2X9<-
L5QXF[GQP8716G(W;?6YS":18]%%""B& MUXS*5&7E7+TP4$H8P95J[[=(]3,TXP?3PX&LAPX0=3\3/F!RQ5A0)A 3OC8D M\>3.EL(E"FZU\NU?3_;%4?-RTN?
#T>'2_X> ^D+GR3^_ ^9B]_L.4]>CG;RG' M9W7UN>1,R,+HY V>(F;4X';M)6)214OA]+857<_BZG*WS]@I+#_8K=/:>PGY&5SX0R!TN/0[ M@- U2?UYNDQX5O
17)T=F3WM"AEJ!USHOX F2 M?@=/_A!8M=1(7P"[X "+]/W$AT))"%F#]D=' <%'TQ9*M>\8OW!0/W$,TGHNB##&Z93N3;9?\&<+*173LSW ((+?VYQ^PT6H:?PPGM M]
(++)6DJG+Q"7/,;3B:.HATC$,$H.F)4"1&<8 J,DZA#2%K6>1G M^^^CW!DTKX7;@K[V8S],"^-MT]>7%V7)%(<{B0F0_)BRL,Y M!I2@GR'\/ 1;[;31"[3N82,@QF1@_2,=HBV
M!J(S2!NFCE3P=.S;UJ?A Z2,T^3TF>%TH ;ZO=+X6TV*GZVN1=$7W_DK+E:'K M,7GOSE;+%?TYG7T^X')BOX4.73,TX+)1?<#%NH37#}//7U;+M_,5'D^7Z62^
M/%O@6))=AA2#."+D:"XS%#[+X"PEGQW5#%CZ^%6Y)U1=_$I,+=Q<*>+=8 MK[6IW74V>9>T!QG">D05Y@ -0(E),EE/AM]%$!Z?D MO9RL. ^TX&45F&
(&'($#)&@+7E$FFLPDY)9YTZTJ:XD9%UGM4M+T-B'86?:\8 M.F]=H:SA3KE #*"]P%REUY!G%(VBSU9Y+$USSNX>'R>D01LK?!L8[2']L7/F M/_T^__1E?E;?*%Y-RPIQ]F)^>C]?
K0=:7QCU\!8EPAA1A!.@=:S-9*T'1UL. MC(^!)51:97&46[7KHAUB9Q\MSY]!Y\U!Z>/T^P-\?9J?EP6\7\R_U2%4%YQJ M9,F0L@Y<#[64CVRZT\& 1L=EX4*KD'8%U^YDC-
L@86BX#:R6C@#X=CK#QW<6 M>N)+$V.E5!^"ZWJOXCQP5C0+C1.LPJYX>W+5# VOMD+O*$T4U'SZG03\ MXJZ=\ XDI0!P?U &K/T&4:[?
&X0#CT&!P,3)ZR#/(FY78G80&>-. M"'L:,P.K9?R'Z/MX?3?#U[-\MF'MMK? LC39,)"^3@FUP4),.8(4MF@OB[$Z M@VZ1Q8>=[C8L\&LE>A[M&$W\O; )D(KHK9,
T>DN*E(54>")$@!DT7+E)$[ MNVK{$#+NN+)Q8== -9W"\)%@*/&BDO+GC3-]JG-,> 3,0BF&+KNR?7K6KBN/ M.^+L.8'61O@_#{(>Y$;,:1!E%?1RKZ4?
D)B3:1D'27XT2QCK%16Z,M -,W& 3 MT$9&7@/EC(W$M[7W+Q$M&/DU\04W[+] MS;8KCCSO;! (#2+ML2'T"N/B+"Q^D^K9HTSI@M8Z8T#X3$SQ.F?2:XIIF$6G MZ7^2H:V)
<2JG L%S!3E83A$P*\%MYZ+ONO)VX/JY+O$'E?[8T/IS M+4ZJ>M^2MY(S^"J;W*

*X5"MVBCP:_MPM(F-4UIRBE7< H#)X@+QY#5(:& N8A6$Y)4Z;A@2VG._25YN%;L%+,6?L@X M7MGDK$TL%S5I'Q/B<#20E1@C+QB3B40O1+:PZ/RA'CS@%,JSQ 241$S&8B?*%}B^R[.<<%=1?(@W :9 DZ\C!Y2=) MPAGB.4$5''-G!452Q2BE\R'8TKWG7GK9STFP>HZRGU-DW #.]U>01.,])BHB MEGL&<6X4LHDF).#@4ZM R_C2G3C_D\I^3L))Y[*?4X36 /H*!%*%U%*FW/Z6 M&9X'IRMD,/R!P3)B6AG@;.D(T\]BBQ+FP3/+_1+1OLFJ?-12]>-L,GD[F^=_ M' 5%+(.H:AY+O7S)C=U<$AA0V6"WP$;6CD!!REI_)8OC,?''*,<%P/&RCLCZ MW784+7L"D]SGY MNLXL7'MKYLHG3\C1-_]?Y,+$8<:RQEKD%L@_ B&0%]@,1%^J_M!$*.P\2+\!3>70Q M;-7>/QG$G. ^QM+G'4C{J4JZ0$XKG$5T46\|J/Y87Z.6V< MJH%!U? O8P1[<[++(.WDC[7!QD)/*(DRU%D/:TX&+@4!%20R=/R4RZ?A[07$ZH> M!.-UCN1)<+NM^DN36B>,DC1]"WA%FGF(C (/$SG"$-)P*\9 ZL:M]./ M^63R+M28;/1,5H+=)9BEQUBS(RQZ^-[B$#DL4'&*XHX-CD3+#ED4XQ.;]<] M:TYOGDCCBPGS7\0!'1* EW! "QG\+ HJ762(6F &)Q@CYSE%E&J"A8U.F]9> MV$KZEY?PB-##$<:P MY?W['#$}28^>0$FOM4.<'Q@SJD M8E39UI*M#A)TH;JLC1-4#BJMG!MWG!GN9$7],>9J,_C]]JETQ9I;_DE\S+?H\H"/)=QZ]AQ+7S''@& MD_9K^7U,(B/+/7.$@"U-E4!<: (J,D02!%'LF#HB!E%RSTOF93])M'LLAT9<_M*[JRC%@QGB[&C+@<QGB[&CY<% ENJ9!0,F:09F#-!(^M-0@+8'3'!.FU]PD/JYN7^XE MYN(;0#>$6$%HY*V6NDZ>, (",=@_!&1,0D=HAS3E'N182B\HQYS:1EI;MR M#4?-Q3<6/_NTU ?)I?6?O9}>=+58W-ZL6?&D/>LJ$2"&XKUH3_WPH'UIS^)" M&SUJ,?=!6A\0Y:O{FO% (*PP7NS#8R40P3:7SQ5]*C]HD?=1)2F1-`4HA4 N M-T!/6DLF0TQ!%6^^\K-'[8F8':Y'[2GB;\ :VNH(O "NM2>!(+#+0)/D$@#<.K/N -MP:RV#NRUE!M/!##D M"$66$H$H\R(R1H45SUZ'<>DM D^U?.T"#Q%Q@W@?!^W..ZB\TP31)@50(A2 M"-Q@"UK(.TF8D3[\;!'X3#CIW"+P%*$U@+[+CY^^G-# M##B84C,MD91"(^XXF$ $=!%GG 8J11;%NSL=W%#C<>WG1F$YX=7L0#Y?COTeY M#JZTB56):)U;'H:@UQF'UG*&2-)<,JUTZ/8^ ZL^0AO\[0%I3S[X4CI)S$3 M^W. ^!;AL4.XUW+:&D!STBF!^!(*<=/ 'L])A%4.RG= [9NP"FIBH\0UC;XN[! MNK_:[ J9K^Y,2;PD(G@$V*>(6_C),!80=8$%8;AS<2N:NF>& M2?&MO91^U;V,D/K"?E%0W[@5.&D!1UTAD0,RW"H,=SQ+2-G$E6,!TNWIHL\! MJIK1JQ: -ACF>TB\NI_CS2KY>H-\[5=WBD{0H)3D1%$1<:(>Q_R&%=> M_ML DR*@YT"-H)NWL_\5{0V$?LL^(R: =)O\_"_(W]BJ6/B.'220\&#W+V=\( M!7:/!ZO7!I6<5C1&KT\$U.XO53(6&\95 8DT$"4MD$)$F5*".7"Z-,_1N 1Z MP@>#A,!$>T*=(\}>RUUFD,IP16A-/*(^L^PO&>V[KI(W?W^-.4+]>OQM'.(T M?(1+8!2<8UR$G-BY&GY(W;A2"9B\&H3\2Z90;(;AR2]\1>RPB@M=4@&@;(U@9]P3US11L=B>K\3>^ M"SQ'9\#FI9VDC^/%/]_.8\ZDCH"LY8HA5 DP,55"EIO,$$R0IMHAR1TV+@A& M>#.%*5V)NM#&5PV>HK,AT\H9ZE.#<.A:69>W@:>FI,^-$SB6H)>Q1EI:C3 3 ME&E-55*## ;A)]+;[IQ]JFI#Y)+*U2Y\U)G:2L=Y\HOP8!=?B}>H=+YBX.6 MIO2CNXI:E&24=1J@J 6CB!O"D##BXHB28|)QKQT7!EXOI2:%$"Y#]XI "GB M&(ZRHU&AH)W3'DXC7#\_:U(&J$DY!;/#U:2<(X&#)^GJ>HAX6"5I,A3ZT${ M4HYT,!)4)-744"V]+CWFYT76I)P$@H,U*:=(I $X#9(;'(V+@?V">,(XI99 M9),3*)!DL?'_"I*?V_V\!\}J4DV#U'#4I\BX 9P?3BQWP083+$,DY,>[?!%H MD2SE] <+J$LXQU1X9ME?,MK?_.L6/.YW4SCYMRNIO%]^ MB?//7^QTTT7DC]GT&JP+,3R>KN@4)=PH@R1?916GW/Q8Y\,"WNB<@J'}LUL> M12EL7#,4QF^IXS,\F-II/S@L?S;S$1-<@%)XB)HA+H,<2Y\A8JA$6.$D6<%*J MF9$9IQ)WH4?L&3^_>Q!]PN9QY9;_8\G1@UPE31H#U&8.Z";ZAM0EKG"<,L M8:6=YZZ=U]X3:,O0UC{F7=!;/ -M_AOUY-5)81$8E!7'Y\!=4 )X8Z3@RFA ; M#?SC"U>)[>5>O*1C> [<+GV$2G?F;/4POJ\!N7_0?RSH&)D/2L,MYEFN&A8) M7!&XSY3PPF,=E"\-A%&&8<&%JM>+\28'@^_.AF8]RKY1PH(89AFRS%+$&0G( MX$B1LBY)KA@0WDP-2D&Z7[R+.MS!:?2. G%_W'N[7'V@7&6B$P1V)>;1OO( MD4M@L(4$"% TV>@O1X^?2/R%:O#_J)M@2#S_ - 0V5RCX0E);FUL3QBQY"I+7 M#FEM90K.8-O.D^AS&P*7{)B-@.,_$(J+.O7/GEF^^]}SCOUT$0;+_TW6?M*M,C^=!%WDF@=IJ3 "86X)F*LY0):(10D<\6A88H&43AU0=BBJ0;.'ZBV(TPBLEH2? WJ>/T<^NI^/_@4VMCMUJI^M$$I64T[EPA"J<'[6"0R[F 6!P4T5K MF,.^^,SM(0BY[!ST$[%\/P>]%BP:L/[>3>&^B^!6+E=:\K<-B:NDU<2-HY9S M9+F60 "H,T-X0(+J8(/ 5*32O>D/;*>57/5]8)D-([EV0;A)/97"AZASHP6= M>Z6(W)4GRH0D"6 8NN0X+IT4=G!#=8%83.S=X-1#!@T ZB/(!#;PY6H:7L=O M<3+[FFG:F&9W36<)9F0U%R(:FTD2R(9 #K.1LER_"T^)<7.<,N<1X[)/+28:62! MQ88[f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{")NP#P\D^9?ON]>8)4W%T.4"2>/XJJ_.B(K%,& MK!7CP4BFC(O2&88#DM-*HNSSHW3{(;D1R#1[>A[U=Z5.@ 6E/9+,Y==T19$V MG" 7N,W IY.H.XIR0:0>9]YDFW#=.EXT][-M(C%OC+?ES=VE@"\+I?Y5+-^7(,BN-U M=,L'5MWE?%(7@M&&49ZH.7(ENJ&B ;%54EA-(&N M_[:YFGBYV7[4FHF@%*+1)\0=ET@GPY$R0CJF, <&D=*K"DPW4C?\,BIS^C&X" M)\O OVMS+[*[7,4CD='ZC#MP@N$'S! ALJ'58\|<IP?@& M[*$S[+[2!E-P22'4"\60<'DB9(/4'PS&+2F3T>%HE?H>B_[8_TO;>2VG_I'FP- M,%S^(;BZF=U.ER/#HX+,A"+O M?/^AR\1))XSFD(BX,T*(G*!54)6)HXX99$QPX-@11/O3MK@N5=H?G]['HF[ M\3=>"A8MPC;/<2)<(XN30-0X =Z8(X*5KOO;O9.ZE]QP6-F^R0K(H:)"7LR7 MHJ_@[KU>2>.57:S'V44;='ZL0B+'+KG--HTB!I%$F0Z,$=!MQC8L_PA!\+<'MJ.S^%<(H**2%$2G"(NK$fK_,,3I$FLM/- M>A(X'KY?!R(EY+D7&CV96Q,@8!6,_ANT^O=7M]-LFOVU^ 2_^N7>4'@W]7==_M'QSX_-)$9'(-/J<8[#-'*FRP.V;1=/]<*^CH*]+9H/QMP/7[X8[] MY?L?=KGI#W;WZ^^KP\5]PCR *\U)-*'6P,P'2CFBG)C$2=+4EWX@ZKZ[NC&, M@IJ8,$T![D-57>-2'C0PHO\-L$LXA++5V,P>)2>2:7,#LF5#0,O^$V<DB9(/<V?S&+2F3T>%HE?H>B_[6G6JQU%9_;_QL.KL9^-]? VQE[?/WMA.&IPRCQB2M,\\D+!=6P2,D1BDXM0 MDB"=U-W.Y5L"R!F2FQ5E8VT@_#&;[B9",F,MH1I1BUF^CAURS@P!FAP8B=%Q MOJW ]F!AWQ=:4D*%X%"$F;41\>%V.EZ%PYY2D-N<$5#'1,N N(X.M#.#2U.R MY.$>]62[)},>..Q<@^O.:LF0 M$2H)YPQQN'0=^O[=M(2?80S.?HQO#D+?- \=AU<X^ALU0"FDH8]@C@;W*611 M41(1:8-\XDR84L/6#B^JY:LE?[R/VR^GBN,]N\UY?W\UDY>V?G\>$X)%+)9 M3<#>3?T\VMS\? OV_(Q*"3(HDQ&B./6!)D59<(2*]$8Y9;TCI1Y,>FVW)5AH* MC .)KK8YM4WEUZ_13GZ93<,H8N>X"MGQ%")/Y #]{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|:OP$R.GV?WVUT- M1BUW^HZL7\5A/\T(=N-2L_(<2(R=I* <;E5XC0GLW#>-OXW!K)ZLDS',$M;54 M7:?L,,]GQQA0^RA-)@_[NFL!<]8AVK5@-0GMX?FL&P,;>)99G_^[FIJRCRM/MUZ[K+'9TH"PCCXU+_.;]-3]0- U;*3}>L>+C^/K+$1Z=6=\ 3'(IP'SLES&L=OWG=+Q9L/*N]=W"7:1O!K,\>SO76WRI[>J MG10^KB^U0RQI061O_I[[#W E%#A?#TMU$DX#[]0_$-^"1%8)OZ_M,KZUX_FZ M >79HMFQ9B<9-? ZO9\=E87U|&1___V?RQ647GV97G_PYUU[1Y;N)+JZ#}_= MF-JH5:.#$L:M'B7+Y*&=633!1*R/D:?N3'PD?Y}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{:L]#*D=I?O7\OO5O^=AD;=80%2[UJO7 M=[O3M7> !:T(9V!SY)3OU(OC'1#+>FC>C WRK+ _O)-5A0'[_E^%'$DJ? MT&Z?JU>D>:+,3^9@9=`_8_YF&M[F=A?OTST1O\ZG>>.OOLW#/^;Y+3U,KZ^F MX<_IM\4R% ![X^VIL0[T`'_?_[ C Y_6O5C,(R\.C-WG9ND:O%^{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{JE>'5X@/(S4X[YU0&&Y% (9$?',P4S!&%H5!>_%)+AVM" M+_!]91TBS8B_6E>*I-_].\'NI[L%B'?*^E2!2:$C;DW:$[EU#-6FN> UB%A& M>)<3<*\.D]/^Y;#?X<2%LWSQ0F=YL'>S_$YZG F;0D0T3-"Y46PM?T M8]5^#@Z:3LB!4GF->H>DTUR% AWT%?(IC4[]5FB:S=#-&31Y9BT,+QB5PS\.M*D'DRN"\$X16\XR9W6!U+'9KY'YX/D[-(W(&M$*1&)C?KYR+_F MR;P5T@'#!F&@)BA3*?)2^DY4S[5UM?8CAC661WQ4SF, M0H:OO3A"N&2_^(N8>*1N200[*(9/CB!:D9QD\2D^*M*Q)N*6^2,A/ZB^ M6W8>*\P4(X#M3E^\>18@T3$,W3,V7?YNC? Q>W'WB!WU+M(*I WX#%4.(.< M#K\,KPVEZE36?OZ92ZP$-"KQ'[(@*Q:A*:RTI Z!;,,1*\V"+[*K6Q1#^-0&JB"2-[2%[!BGO M/;8G^X3MX6@3VSL3VP;$=Z?$G9&.JV.F,@*P]-9(XG[I$?PD4PG5TF4MPA#S M2DZ45F%!VF#;L+3>&(R,L^41SC;Y$U/,?>-05;L*<>Y9RZ2I=1D;P()W"@8E MBD:X8PGPX0)503$?(-J"??*(7-8&$N3YE[=58M)*25Z6$".! M#E'L-LGV#8<&N+7T6EH? M)#T=Q6)?/L6.VD.DHR>:Y ALY+I*M1O#<5,&?%9!QQBF7MKU.EI52+]4*<22 MO! @X_3!\6BH?2&TN@/=%P\]M]Y=HB>"?Y]W^V=O)S='I^19NW"Z:SHC-AU M';PK9B/X?85PV9*2^LD2N-@G5]J:7Z!79:E"@'@,]EC8E&-4'FFT#[NY @A MCE3M*17@;Q+H[;JD+R]H/J_!VO `"/_Z_YNZ;ZH1WFJ4?!@L_J"'-M$NG<_8 M59/GEYNK.<@[2MQ1 G+]9O"*Y[!M$=57@C!NA.+1QA8*E!FV]+!DP"<1VVA> M;(*P0VG:B? +!HW;P=8F@P3"Q-TWFV7:]]*EP1YNN]ZB L@=\@M! 9@5$4U\ MIM[ KA,3J#(SJV= 6=3(:?-IP#5$"F6E[0*P=%[82)WR :@1A+*-X.Q.CM@@PF M_J0 &[6F=(*0!-?%4&M9>1BW? UPBPU=:+L;"<,"XT673U\2&8$OJ[G)&F0)5 M1X,L1E0L;JY"'7%STSOIG=!LB./R?M0,W%R5Z?%'B.&2;9:/SWD7_Z>) ^+WFR M[%?]JA-CF9C8'PES9N#X4';H ';>%#=+B^3A"B,L/8Y-#,MOM\2XQ[$*.%KZ M>=2S^Z\.1X@P_OGP"_0224UX/N-Y7S!3[Q2M!FF$PSY}$,$G6Z)U_8\=S&\1 MP#V+T&?C\,Y0D&^Y%U)A4C.M4GM'LBQ^%;HA- DSP]?665))\)+W=^_G? MG+$;S&HL<,7WF&/HCH{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~>GW=$:W1GVEX[G&D M WJ;,6#0OR42Y>XDHJA3FC M6T >1H?':R<]OM*X0$P8=:G2%X)O_?EPGP_4H/3WA&%X5J,Y02$@XF&*:[) M,-9>_%1+APQ1S/!]91VN.R.^M:X4_;3['UJ$/W.0+S2UF<:3 8=<6VRGLBM MXX7;- !?,2+BR<;&7*;@7N_WCY/PPZ7 .QUD^>Z.S/-BZ67XE/BL5#&3@O70S]E+*6V"0S/OT^$ZA,3ADP2*OH?],.Q1U6 T!YM$2 MA8B:CG4V%KZF/XOV4W#0=$(.E- H7]/Y(2$YU&*.#OL+L0J-3QC0:9A6Z.8$F MZRZ%X1FC\O#O@TH0^5S'!+>89=8[!ZECLELJU0=HIHQ1+%5C4Q#F{:5)[2 ._M-;%9A5 @%]:.ZBV(!TP8A_L'0N!*4IHX[5 - SI"=L6@00#^?9GDSZL<@+._4M M'60?#]O?EZL7LZZ)^<^P9DC2@A(K%Q-[G]WDRKX5TP+!!&.@413OE/D"LIH7V8V1!U4KD4>)2>E,:9X7U-,8C MAG6VB/BIG,U X6LO}A N"A! $1/WM#[M#'S<&ASM0,2B?Z3B4WS4I.I-Q"WU M+XCAEN ZP=].G M0+P!CZ'"&>1T^'%X=2A39[+VFS>AE)D"0J49*29A6SOL &ELHCV3{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{J90A%Y_'MD=4GP3"9A43S;6,*14V-## M6 ?!6PC>;$)H@Z5:2>]!X_2P=OPB\3VM*4X0DN"Z&N!^5AU'[XQP)OBKD;*0-!XP;G3=]I38$ M6U)WYQ-*%"@Z&F0QHF)Q]-ML^3QXJ37?[3L3^KV@$V.9F-@?"7-RYW#G;9! YS1H+H3_?LKC+#T,#8Q+)]O MB6W^T9O=?!{$[1(3Q7_'H!_ V1!_P/A%,UAM%K$$;83$A%2+X<$NT[O^]_I7 M!7'+HO3!F+P>:\A7+R+]$YG+O<4]K:O%>503G_TG!]BMTXX8:WQ"/_^?<_(& M,SMK?/$]YEFZIB%.X=2P&[82)

*C6N'$5Z*LTM1T2(!)B;.4[D@F$_*PINC$M>Z30I-C_(F688RJ9_/L#6 MO0#>5Y),.,FY$$H&<)QSEMV7|\^G."!=&UTGI2M !695P2',X'@U2[DS7W0:U*N$S197,=V!SJ_5T MO[_)!H,.H&@*3S$8>C"AX2-<,54NM MEKP>+4W?;6!Q^*VPTZ,6&FE80B.W=;)*2V[R:P-/F3L:..*"7F895"6^J=W$ MAO\D,H:NI"R9"J9*YTI3ID,D0)#2L$G[SY1R4PJRGG#I8'2+IHVMN;)6%;6Y MZ,*>/BD1#,V.:2]N#MO#..X.(I\QGK(M;7=NSN)=+^M9>E>8#/ONW/Z0_-'% M7\YRSSFN6XTVHP8*^{JE(PRR>M#I=UJ=IH@G27D)\)6N}3:'MK,)X:YSUFCT0>U7$_ \$F,>NTC!%'@E.(46 MCN\;X*\%ZC>&VJ,8/>>0_(4A'3X!TAMV_F>Q9? $$QZG{&H"W:NF^OV#LO[R> MQ5'/S:..-:??@3<{&)+QU&50fXPX\$\T$J5/LSO70=2]R\RZZ7D+FV(X}>W?) MW]PH-/_^?JOG[M7^ E!+ P04 " !$@6=9_1.64M,C R-# Y,S!X97@S,C)XU8;6_;-A#^OE]Q<[ V 2Q% MDNWZM0'2M$6# >W:=.B^#;1XBKA(I$I2=KQ?OR,E.6]U%ZQKUV[S!T/VO?#N M>>Z.%!>Y+8NC18Z,'WVW^#X(X*E*ZQ*EA50CL\BA-D*>PSN.Y@*"H-4Z4=5& MB_/<0A(E0WBG{58L49NA2WPJ/.S.&Q^+P[}(HNEXINC!1 VG\51}$//JQXM,B4MK:?)OGELW-QQ9O'2!]P0YW+F4^HUITX5872[W( M?^9.$F2L%,5F]O"M*-`2US#&U4R^;!OF#2!02VR1M&(WY%BHO#\SW34)IC\ M%$)BET*"/T%M M12929H62H#+X20N9BHH5\%Q(1H_T]"HC#=1]J&IM:D916@7Q!'X.S*3$,XP MJ=;Q8!3U=R+PM63,##"N*M'P")GRM= M0AP%KR%3VJ_WOED/4'+"_PR)AG*)^L%>_"B.#Z*^GTI](XR49#&-E"BI],"M"D*$20[/+M.5:6PAA?O-)K-M(.-8& M):L+VX>37&!VM^Z{>F@S[$/:- W%0H7C)$LT'Kl<&+B0:DVAG^.N=G')CN=-.MM\":.FQU[E6,?9(S2FPTF=^[+BO&.>T.08$9!E_R^E./DZ*1:2)9##N: MGY:1*;=_/64=_TRX 5H-([JOA.SH@ RHVAHC)"@(NY-WUMEV_%"#KGPKMU( M(RT:0KY25(7-@#6W1D_X{6T\QV(H" )-T1F-4B^:E&A0KJG<+4H*B(#R)]>V M8S@L-S? VXYRFY!))M=)J)=S.T<[=%A:/WUH0YDO7=BU+Y.2V3E9K*4Q^Y> ^ MVXH&0;10E%D&=47_N#!IX-^+C)%O*YER8JF"; MF9 >1F\T;WTME;6J=.[F*[?[I*QHZ?5,-^+V+#V=AN-Hf({3EL!OEG<+MR?M MT)-T#RV_*QM.PFFT6QR%{4]9W^3VT(?M;!I8/E_E>X\S86FU]..IX-- L#<"_OY__)B=/:>_WKR[P4JW\NR"[F? 3^+CT&^>U[;FG;=*U[;M M6Q=3E3+^=#;36-!J;(5WKJJN9JS?G*,K${!:D,5O;NR9_ )E\#+)$I(((V%%.O7S]W>AB5)N603FETF[5(739146C4ZC=HZ*Q;1KZFNWT>/'LFO7I6K MVRI;7#*71\>'QD^C7LGJ? 72O^OLF:7'JK[O/-W_GO,_Y.#_EF5J:WWWZ39M=1 MEO{G%|FSIX\3/4|.9WJ6/GD\2]6+Q\^.U?'LR>-GSU.=J/]W] 5<"C_G.^KF M-M? _^<4R*QY=;?S^U\^/5\W+FRQMKKX^.CS\RQ?TNV^_F9=% P^KX&+^)]^C M=Z=&?V@>J3Q;%%\G,%I=?<'7FN^3,B^KK{!\I/|[B=\|FJMEEM}^_;?+;*GK MZ(V^B<{+I2K^%/>JJ!_5NLKF_,Z^Y?^^@C'1W_>R(#A/G26:/,"\|G9V\^>74:1V=O7AV$8_?7?U4+F(9V33EDA\QE1GTS>3O MU!')F!?1^>G%Y_7@: MG=`>@O^\^_G\W=N+4WK?D]=OWUV>O7T3O?T^NOS'O_62_VSK)IO?\D=9D<([ M?_WXV:KYPU_[R>!K'QT<'OWURZ-GAR_[_VW>\;\?%\\.B(FR4DU6%E^W,%$5 M_NJ++}^UU:JL}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dE_60R[4/&ZB H5:UJF[./,JS? M77%45F;J0>1M#I37F#=LI2*$Z2/ZK]^^? 3%R^V8F^,USL^TM44*IQ3L6/BFK":@"C*KD K MXYZ1G1+5*YUD\PRV5H9:F87)XRVQ+8_7V);3WCO@4>39-(P*GB[<+^0BH7_4 MW.)N(25C?!XP T&(P9*,OYJKJFP75V#L:? QF65;H5*\'TN+JQ+[U$>'&5$V4 M:P6FI8KFV1R>LM(5ZIYH[^GA7_:C\@9T6'V5K?A&H'"ASJCLX-_XTV4&CN,L MUQ'-I-W-3PZ_.G&V3@JJU'M.'*

*<%-'-EE#J9V[C1%Y6"H=_?7ECI @WSZ"TYEK%Q M@ZP8D*,8R2FT\0#1 MKI,JF[%E+9@NO!3SG%T:RY!;ZK**()W<05;O[8^EOF4 M[OESD8W?!6[53E=PS&#^'$G#7Y#I=T!TXQ>%=CC'KX&KQ*A**0=:Z MH2 Z')WFRMO%^-"D!+TBHH T(L\GZ4A,?]N-OWZO^^GH?D"HFZ V5\G1.'27 MJ%E=YFW3O^2.G#,_]U5E[KQ2"_UH5FGU_I&>P]M^K?(;=5M_\5%Y}($L.67] MOJA_@GW39,#3#98!H!RRVB,[5QN%?^J\U^CSOX2[VXRO!D);-7TE9 B+=24%+Y#A!'# M/<3PZO[>W;IM<'KVV/2"6Q<68:H>;M95&*U$FW3IX0_=XG=5[EN3<[M/47%X MFT_W.HFJ,!#9-C'O ]@AM[SRN-2@)^=M+C@359>%PF@_!R89B.4+K6KT%;(E M)2' #JA;F++KK,;QRKO(RPQ=UQ;J;.[*BE*Q;4U[-8,"M#-8#M@=9P:SE8305QG}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{ZA:. {TMFWP M$10H@^$OL6B00'I<63MJ})G0+D,#]PQW:/F1[_C[YL9[$T3,WA1C^-E8/-FT M;IX__0NY7FY"\'M*3Z#$*KTYJ!FW2#%FFHW:SD9#&PIZ%W$8K>R"6][ZIPIK@U'C$JBI;8D47!LN3P^_M-D,0UZ>38_BH":9LB[_OJ*!1+3$.6JI*BFMR:0A9Y;D=#[ZA^M.R30(M_? <$ M6JUR[=! .'EZL?M1<4.UK77=3Z2,BCCS'.\)&RW.!M_G[G?>B:G[B"DP.!+P M<>U$RE.;F@0:WM/#TB9R18@;+G#TJ,!1G#'6L"_R[+?6* Z>(?+./5#7M@%8 MCC:S3!:+DJ851J?=<8:!FP+$^#E&OULNGL*M<_35BV=TR(3UX@!^,=<416?R M%A17X3[#K#\%Y3GU]]D)-#\C['W!7#:JXOB,N4-E_FFKQ^9M@U"#7"^R.O<@ M%32:&E&$JQ6G26O6;.A::?"K0%ADJ;G=]FSZS:SO}.7_!#=_H+J[]A5LTNA: MY7 D_N/PX/#P")UW5OO;LZLVLS!0EF@R&PKDSZ3G"WG@)C!9@BD89*4#30-/ MNT8 @5? SRXE>1*L0:!Q,FVH-5N6S2WP\WB4^=HF/#=$TFUGU.NJLD^=ASMPR$'BO.LC39T _-_C@9\6WQT;:S%I-Q)DY@:T:#=2]F>('4X1=6+5. .4H MAS9XGW$XU;M:8ED8JJQ7Z\VB;P\[B0JS,6>Y+%MF{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~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

*C6N'$5Z*LTM1T2(!)B;.4[D@F$_*PINC$M>Z30I-C_(F688RJ9_/L#6 MO0#>5Y),.,FY$$H&<)QSEMV7|\^G."!=&UTGI2M !695P2',X'@U2[DS7W0:U*N$S197,=V!SJ_5T MO[_)!H,.H&@*3S$8>C"AX2-<,54NM MEKP>+4W?;6!Q^*VPTZ,6&FE80B.W=;)*2V[R:P-/F3L:..*"7F895"6^J=W$ MAO\D,H:NI"R9"J9*YTI3ID,D0)#2L$G[SY1R4PJRGG#I8'2+IHVMN;)6%;6Y MZ,*>/BD1#,V.:2]N#MO#..X.(I\QGK(M;7=NSN)=+^M9>E>8#/ONW/Z0_-'% M7\YRSSFN6XTVHP8*^{JE(PRR>M#I=UJ=IH@G27D)\)6N}3:'MK,)X:YSUFCT0>U7$_ \$F,>NTC!%'@E.(46 MCN\;X*\%ZC>&VJ,8/>>0_(4A'3X!TAMV_F>Q9? $$QZG{&H"W:NF^OV#LO[R> MQ5'/S:..-:??@3<{&)+QU&50fXPX\$\T$J5/LSO70=2]R\RZZ7D+FV(X}>W?) MW]PH-/_^?JOG[M7^ E!+ P04 " !$@6=9_1.64M,C R-# Y,S!X97@S,C)XU8;6_;-A#^OE]Q<[ V 2Q% MDNWZM0'2M$6# >W:=.B^#;1XBKA(I$I2=KQ?OR,E.6]U%ZQKUV[S!T/VO?#N M>>Z.%!>Y+8NC18Z,'WVW^#X(X*E*ZQ*EA50CL\BA-D*>PSN.Y@*"H-4Z4=5& MB_/<0A(E0WBG{58L49NA2WPJ/.S.&Q^+P[}(HNEXINC!1 VG\51}$//JQXM,B4MK:?)OGELW-QQ9O'2!]P0YW+F4^HUITX5872[W( M?^9.$F2L%,5F]O"M*-`2US#&U4R^;!OF#2!02VR1M&(WY%BHO#\SW34)IC\ M%$)BET*"/T%M M12929H62H#+X20N9BHH5\%Q(1H_T]"HC#=1]J&IM:D916@7Q!'X.S*3$,XP MJ=;Q8!3U=R+PM63,##"N*M'P")GRM= M0AP%KR%3VJ_WOED/4'+"_PR)AG*)^L%>_"B.#Z*^GTI](XR49#&-E"BI],"M"D*$20[/+M.5:6PAA?O-)K-M(.-8& M):L+VX>37&!VM^Z{>F@S[$/:- W%0H7C)$LT'Kl<&+B0:DVAG^.N=G')CN=-.MM\":.FQU[E6,?9(S2FPTF=^[+BO&.>T.08$9!E_R^E./DZ*1:2)9##N: MGY:1*;=_/64=_TRX 5H-([JOA.SH@ RHVAHC)"@(NY-WUMEV_%"#KGPKMU( M(RT:0KY25(7-@#6W1D_X{6T\QV(H" )-T1F-4B^:E&A0KJG<+4H*B(#R)]>V M8S@L-S? VXYRFY!))M=)J)=S.T<[=%A:/WUH0YDO7=BU+Y.2V3E9K*4Q^Y> ^ MVXH&0;10E%D&=47_N#!IX-^+C)%O*YER8JF"; MF9 >1F\T;WTME;6J=.[F*[?[I*QHZ?5,-^+V+#V=AN-Hf({3EL!OEG<+MR?M MT)-T#RV_*QM.PFFT6QR%{4]9W^3VT(?M;!I8/E_E>X\S86FU]..IX-- L#<"_OY__)B=/:>_WKR[P4JW\NR"[F? 3^+CT&^>U[;FG;=*U[;M M6Q=3E3+^=#;36-!J;(5WKJJN9JS?G*,K${!:D,5O;NR9_ )E\#+)$I(((V%%.O7S]W>AB5)N603FETF[5(739146C4ZC=HZ*Q;1KZFNWT>/'LFO7I6K MVRI;7#*71\>'QD^C7LGJ? 72O^OLF:7'JK[O/-W_GO,_Y.#_EF5J:WWWZ39M=1 MEO{G%|FSIX\3/4|.9WJ6/GD\2]6+Q\^.U?'LR>-GSU.=J/]W] 5<"C_G.^KF M-M? _^<4R*QY=:?S^U\^/5\W+FRQMKKX^.CS\RQ?TNV^_F9=% P^KX&+^)]^C M=Z=&?V@>J3Q;%%\G,%I=?<'7FN^3,B^KK{!\I/|[B=\|FJMEEM}^_;?+;*GK MZ(V^B<{+I2K^%/>JJ!_5NLKF_,Z^Y?^^@C'1W_>R(#A/G26:/,"\|G9V\^>74:1V=O7AV$8_?7?U4+F(9V33EDA\QE1GTS>3O MU!')F!?1^>G%Y_7@: MG=`>@O^\^_G\W=N+4WK?D]=OWUV>O7T3O?T^NOS'O_62_VSK)IO?\D=9D<([ M?_WXV:KYPU_[R>!K'QT<'OWURZ-GAR_[_VW>\;\?%\\.B(FR4DU6%E^W,%$5 M_NJ++}^UU:JL}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dE_60R[4/&ZB H5:UJF[./,JS? M77%45F;J0>1M#I37F#=LI2*$Z2/ZK]^^? 3%R^V8F^,USL^TM44*IQ3L6/BFK":@"C*KD K MXYZ1G1+5*YUD\PRV5H9:F87)XRVQ+8_7V);3WCO@4>39-(P*GB[<+^0BH7_4 MW.)N(25C?!XP T&(P9*,OYJKJFP75V#L:? QF65;H5*\'TN+JQ+[U$>'&5$V4 M:P6FI8KFV1R>LM(5ZIYH[^GA7_:C\@9T6'V5K?A&H'"ASJCLX-_XTV4&CN,L MUQ'-I-W-3PZ_.G&V3@JJU'M.'*

<%-'-EE#J9V[C1%Y6"H=_?7ECI @WSZ"TYEK%Q M@ZP8D*,8R2FT\0#1 MKI,JF[%E+9@NO!3SG%T:RY!;ZK**()W<05;O[8^EOF4 M[OESD8W?!6[53E=PS&#^'$G#7Y#I=T!TXQ>%=CC'KX&KQ*A**0=:Z MH2 Z')WFRMO%^-"D!+TBHH T(L\GZ4A,?]N-OWZO^^GH?D"HFZ V5\G1.'27 MJ%E=YFW3O^2.G#,_]U5E[KQ2"_UH5FGU_I&>P]M^K?(;=5M_\5%Y}($L.67] MOJA_@GW39,#3#98!H!RRVB,[5QN%?^J\U^CSOX2[VXRO!D);-7TE9 B+=24%+Y#A!'# M/<3PZO[>W;IM<'KVV/2"6Q<68:H>;M95&*U$FW3IX0_=XG=5[EN3<[M/47%X MFT_W.HFJ,!#9-C'O ]@AM[SRN-2@)^=M+C@359>%PF@_!R89B.4+K6KT%;(E M)2' #JA;F++KK,;QRKO(RPQ=UQ;J;.[*BE*Q;4U[-8,"M#-8#M@=9P:SE8305QG}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{ZA:. {TMFWP M$10H@^$OL6B00'I<63MJ})G0+D,#]PQW:/F1[_C[YL9[$T3,WA1C^-E8/-FT M;IX__0NY7FY"\'M*3Z#$*KTYJ!FW2#%FFHW:SD9#&PIZ%W$8K>R"6][ZIPIK@U'C$JBI;8D47!LN3P^_M-D,0UZ>38_BH":9LB[_OJ*!1+3$.6JI*BFMR:0A9Y;D=#[ZA^M.R30(M_? <$ M6JUR[=! .'EZL?M1<4.UK77=3Z2,BCCS'.\)&RW.!M_G[G?>B:G[B"DP.!+P M<>U$RE.;F@0:WM/#TB9R18@;+G#TJ,!1G#'6L"_R[+?6* Z>(?+./5#7M@%8 MCC:S3!:+DJ851J?=<8:!FP+$^#E&OULNGL*M<_35BV=TR(3UX@!^,=<416?R M%A17X3[#K#\%Y3GU]]D)-#\C['W!7#:JXOB,N4-E_FFKQ^9M@U"#7"^R.O<@ M%32:&E&$JQ6G26O6;.A::?"K0%ADJ;G=]FSZS:SO}.7_!#=_H+J[]A5LTNA: MY7 D_N/PX/#P")UW5OO;LZLVLS!0EF@R&PKDSZ3G"WG@)C!9@BD89*4#30-/ MNT8 @5? SRXE>1*L0:!Q,FVH-5N6S2WP\WB4^=HF/#=$TFUGU.NJLD^=ASMPR$'BO.LC39T _-_C@9\6WQT;:S%I-Q)DY@:T:#=2]F>('4X1=6+5. .4H MAS9XGW$XU;M:8ED8JJQ7Z\VB;P\[B0JS,6>Y+%MF{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~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

2024-09-30 0001516551 skye:TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember 2024-09-30 0001516551 skye:TwoThousandAndTwentyOneCommonStockWarrantsToPlacementAgentMember 2024-01-01 2024-09-30 0001516551 skye:November2019EHTCommonStockWarrantsMember 2024-09-30 0001516551 skye:November2019EHTCommonStockWarrantsMember 2024-01-01 2024-09-30 0001516551 skye:December2019EHTCommonStockWarrantsMember 2024-09-30 0001516551 skye:December2019EHTCommonStockWarrantsMember 2024-01-01 2024-09-30 0001516551 skye:February2020EHTCommonStockWarrantsMember 2024-09-30 0001516551 skye:February2020EHTCommonStockWarrantsMember 2024-01-01 2024-09-30 0001516551 skye:August2023ConvertibleNoteCommonStockWarrantsMember 2024-09-30 0001516551 skye:August2023ConvertibleNoteCommonStockWarrantsMember 2024-01-01 2024-09-30 0001516551 skye:August2023PIPEFinancingCommonStockWarrantsMember 2024-09-30 0001516551 skye:August2023PIPEFinancingCommonStockWarrantsMember 2024-01-01 2024-09-30 0001516551 skye:March2024PIPEFinancingCommonStockWarrantsMember 2024-09-30 0001516551 skye:January2024PIPEFinancingPreFundedWarrantsMember skye:January2024PIPEFinancingMember 2024-01-31 0001516551 skye:January2024PIPEFinancingMember 2024-01-01 2024-01-31 0001516551 skye:Convertible10NoteMember us-gaap:ConvertibleDebtMember 2023-12-31 0001516551 skye:MultiDrawCreditAgreementMember us-gaap:ConvertibleDebtMember 2023-12-31 0001516551 skye:Convertible10NoteMember 2023-08-15 0001516551 skye:Convertible10NoteMember us-gaap:ConvertibleDebtMember 2023-08-15 0001516551 skye:Convertible10NoteMember 2024-08-08 0001516551 skye:Convertible10NoteMember us-gaap:ConvertibleDebtMember 2024-08-08 2024-08-08 0001516551 skye:Convertible10NoteMember 2024-09-30 0001516551 skye:January2024PIPEFinancingMember 2024-01-29 2024-01-29 0001516551 skye:January2024PIPEFinancingPreFundedWarrantsMember skye:January2024PIPEFinancingMember 2024-01-29 0001516551 skye:January2024PIPEFinancingPreFundedWarrantsMember 2024-01-29 2024-01-29 0001516551 skye:January2024PIPEFinancingMember 2024-01-29 0001516551 skye:January2024PIPEFinancingPreFundedWarrantsMember skye:January2024PIPEFinancingMember 2024-01-29 2024-01-29 0001516551 skye:January2024PIPEFinancingMember 2023-08-15 2023-08-15 0001516551 skye:March2024PIPEFinancingMember 2024-03-11 2024-03-11 0001516551 skye:March2024PIPEFinancingMember 2024-03-11 0001516551 skye:PreFundedWarrantsMember 2024-08-09 0001516551 skye:A2014AmendedAndRestatedPlanMember 2024-09-30 0001516551 skye:A2024InducementEquityIncentivePlanMember 2024-07-02 0001516551 skye:A2024InducementEquityIncentivePlanMember 2024-09-30 0001516551 us-gaap:EmployeeStockOptionMember skye:A2014AmendedAndRestatedPlanMember 2023-12-31 0001516551 us-gaap:EmployeeStockOptionMember skye:A2014AmendedAndRestatedPlanMember 2024-01-01 2024-03-31 0001516551 us-gaap:EmployeeStockOptionMember skye:A2014AmendedAndRestatedPlanMember 2024-01-01 2024-09-30 0001516551 us-gaap:EmployeeStockOptionMember skye:A2014AmendedAndRestatedPlanMember 2024-09-30 0001516551 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001516551 srt:MinimumMember us-gaap:EmployeeStockOptionMember skye:MeasuredAtGrantDateMember 2024-01-01 2024-09-30 0001516551 srt:MaximumMember us-gaap:EmployeeStockOptionMember skye:MeasuredAtGrantDateMember 2024-01-01 2024-09-30 0001516551 srt:MinimumMember 2024-01-01 2024-09-30 0001516551 srt:MaximumMember 2024-01-01 2024-09-30 0001516551 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001516551 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001516551 us-gaap:RestrictedStockUnitsRSUMember skye:MeasuredAtGrantDateMember 2024-01-01 2024-09-30 0001516551 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember skye:MeasuredAtGrantDateMember 2024-01-01 2024-09-30 0001516551 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember skye:MeasuredAtGrantDateMember 2024-01-01 2024-09-30 0001516551 us-gaap:RestrictedStockUnitsRSUMember skye:MeasuredAtModificationDateMember 2024-01-01 2024-09-30 0001516551 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001516551 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001516551 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001516551 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001516551 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001516551 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001516551 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001516551 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001516551 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001516551 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001516551 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001516551 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001516551 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0001516551 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001516551 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001516551 us-gaap:ConvertibleDebtSecuritiesMember 2024-07-01 2024-09-30 0001516551 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-09-30 0001516551 us-gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-09-30 0001516551 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0001516551 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001516551 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001516551 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001516551 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001516551 us-gaap:ConvertibleDebtMember 2024-07-01 2024-09-30 0001516551 us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001516551 us-gaap:ConvertibleDebtMember 2024-01-01 2024-09-30 0001516551 us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember skye:EconomicDamagesMember 2023-01-18 2023-01-18 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember skye:NonEconomicDamagesMember 2023-01-18 2023-01-18 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember skye:PunitiveDamagesMember 2023-01-18 2023-01-18 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember 2023-08-02 2023-08-02 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember skye:PunitiveDamagesMember 2023-08-02 2023-08-02 0001516551 skye:WendyCunningVsSkyeBioscienceIncMember 2023-08-17 0001516551 skye:A2014AmendedAndRestatedPlanMember us-gaap:SubsequentEventMember 2024-10-22 2024-10-22 0001516551 skye:A2014AmendedAndRestatedPlanMember us-gaap:SubsequentEventMember 2024-10-22 0001516551 skye:A2014AmendedAndRestatedPlanMember us-gaap:SubsequentEventMember 2024-10-01 2024-11-07 0001516551 2024-09-25 2024-09-25 0001516551 2024-09-25 shares iso4217:USD iso4217:USD shares pure skye:market_based_condition utr:sqft 0001516551 --12-31 false 2024 Q3 10-Q true 2024-09-30 false 000-55136 Skye Bioscience, Inc. NV 45-0692882 11250 El Camino Real, Suite 100 San Diego CA 92130 858 410-0266 Common Stock, par value $0.001 SKYE NASDAQ Yes Yes Non-accelerated Filer true false false 30338290 67412614 1256453 9080202 9080202 664604 194259 2650809 1119929 79808229 11650843 1516612 43276 184509 237983 26310 8309 81535660 11940411 780025 1155785 0 126027 903271 888381 0 234750 2065658 998552 1792337 6053468 0 4371998 82932 72038 5624223 13900999 108062 171230 5732285 14072229 0.001 0.001 200000 200000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 30338290 30338290 12349243 12349243 30338 12349 196976230 102238382 -121203193 -104382549 75803375 -2131818 81535660 11940411 4883337 1254653 10908538 4227967 0 21215214 0 21215214 4638927 2235899 13171547 5357577 4553468 0 4553468 151842 4968796 24705766 19526617 30648916 -4968796 -24705766 -19526617 -30648916 -90766 271307 796222 476135 907697 16562 2296488 49669 72837 0 1217978 -307086 0 0 0 1383285 0 -14677 0 455504 -801 0 -2200 3 1070499 -240068 2716044 -2572338 -3898297 -24945834 -16810573 -33221254 0 0 10071 3600 -3898297 -24945834 -16820644 -33224854 -0.10 -3.17 -0.48 -6.38 -0.10 -3.17 -0.48 -6.38 38819387 7880546 35317352 5207411 38819387 7880546 35317352 5207411 -16820644 -33224854 123347 95880 6228270 394657 0 -3 599006 102400 325610 0 -4553468 7009 1217978 -307086 -10794 0 0 1383285 0 15952 0 21215214 0 45350 470345 -782265 1606490 236779 18000 0 -375760 -112021 0 -113601 -126027 60274 -234750 0 14889 -11904 -52274 -60647 1109443 -570473 0 -95850 -17064377 -10107460 1217978 5532266 1554003 5533 0 -1076740 -336025 6603473 0 4973684 6434447 265053 83556563 11734947 0 -6026 0 236681 83556563 16465924 66156161 12961937 10336655 1249107 76492816 14211044 67412614 5126245 9080202 9084799 76492816 14211044 0 282905 0 1565470 0 31766 0 203884 0 241134 0 20532846 4971004 0 12349243 12349 102238382 -104382549 -2131818 2478179 2478179 6434447 15713664 15714 83540849 83556563 -5019531 -5019531 28062907 28063 188257410 -109402080 78883393 5000 5 1828469 1828474 -7902816 -7902816 28067907 28068 190085879 -117304896 72809051 1921617 1921617 968973 969 4970035 4971004 1301410 1301 -1301 0 -3898297 -3898297 30338290 30338 196976230 -121203193 75803375 3654119 3654 63726057 -66737765 -3008054 131579 131579 66566 66 282839 282905 165517 166 2980355 2980521 -5167520 -5167520 3886202 3886 67120830 -71905285 -4780569 102871 102871 -3111500 -3111500 3886202 3886 67223701 -75016785 -7789198 160207 160207 265053 2989981 2990 11731957 11734947 5436378 5436 21604150 21609586 925550 925550 26349 26 -26 0 -24945834 -24945834 12338910 12338 101645539 -99962619 1695258 Organization, Basis of Presentation and Significant Accounting Policies Nature of Operations Skye Bioscience, Inc. (the “Company” or “Skye”) was incorporated in Nevada on March 16, 2011. The Company is a clinical stage biopharmaceutical company developing next-generation molecules that modulate G protein-coupled receptors to treat obesity and metabolic diseases. As of September 30, 2024, the Company has devoted substantially all its efforts to securing its product pipeline, carrying out its own research and development, preparing for and conducting clinical trials, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so. Basis of Presentation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods. <br/> The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, from which the prior year balance sheet information herein was derived. Certain reclassifications have been made to the amounts in prior periods to conform to the current period’s presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's condensed balance sheet, and condensed statement of cash flows and change in fair value of derivative liability and interest expense on the condensed statement of operations. Such reclassifications did not have a material impact on the Unaudited Condensed Consolidated Financial Statements. During the nine months ended September 30, 2024, there were no changes to the Company's significant accounting policies as described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Pronouncements Implemented In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entity’s own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. This standard was effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted this standard as of January 1, 2024 and the adoption of this standard did not have an impact on the Company’s Unaudited Condensed Consolidated Financial Statements or related disclosures. Recent Accounting Pronouncements Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax

*information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company does not expect the impact of adopting ASU 2023-09 to be material on its consolidated financial statements. In November 2023, the Financial Account Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM"), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. ASU 2023-07 is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the impact of adopting ASU 2023-07 to be material on its consolidated financial statements. Basis of Presentation The accompanying Unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year, or any future periods. <br/> The Unaudited Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the Audited Consolidated Financial Statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, from which the prior year balance sheet information herein was derived. Certain reclassifications have been made to the amounts in prior periods to conform to the current period's presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's condensed balance sheet, and condensed statement of cash flows and change in fair value of derivative liability and interest expense on the condensed statement of operations. Such reclassifications did not have a material impact on the Unaudited Condensed Consolidated Financial Statements. Pronouncements Implemented In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40). The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entity's own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. This standard was effective for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years. The Company adopted this standard as of January 1, 2024 and the adoption of this standard did not have an impact on the Company's Unaudited Condensed Consolidated Financial Statements or related disclosures. Recent Accounting Pronouncements Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity's exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company does not expect the impact of adopting ASU 2023-09 to be material on its consolidated financial statements. Asset Acquisitions and Dispositions Sale of real estate The wind down of Emerald Health Therapeutics, Inc. ("EHT's") operations included the disposition of real estate held by Avalite Sciences, Inc. ("AVI") (the "AVI building"). At the time of the Company's acquisition of EHT on November 10, 2022 (the "EHT Acquisition"), none of the purchase consideration was allocated to the fair value of the AVI building. As a result of the sale of the AVI building, for the nine months ended September 30, 2024, the Company recorded a gain of $1,145,141 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations. Divestiture of VDL, Release and Discharge Agreement On February 9, 2023, the Company sold Verdélite Sciences, Inc. ("VDL"). For the nine months ended September 30, 2023, the Company has recorded a loss on sale of asset of $307,086 in other (income) expense based on the difference between the carrying amount of the assets sold and the net cash proceeds. On July 17, 2024, the Company reached a transaction, release and discharge agreement with the purchaser of VDL. Under the transaction, release and discharge agreement, the purchase price of VDL was adjusted in exchange for a full release of any future claims by VDL against the Company. As part of the agreement, the parties agreed to an installment payment schedule for the remaining aggregate balance of the purchase price of $2,047,080 through December 2027. The remainder of the purchase price receivable bears interest at 8%. Upon signing the transaction, release and discharge agreement, the Company received the first installment payment of $72,837 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Unaudited Condensed Consolidated Statements of Operations. BRB Acquisition On August 18, 2023, the Company acquired 100% of the equity interests in Bird Rock Bio Sub, Inc. ("BRB") pursuant to an Agreement and Plan of Merger and Reorganization, dated August 15, 2023 (the "BRB Acquisition"). The purpose of the acquisition was to acquire BRB's clinical asset, nimacimab, an antibody targeting the CB1 receptor, for development to treat metabolic conditions. Pursuant to the BRB Acquisition, the Company issued 3,872,184 shares of Company common stock to the former preferred stockholders of BRB equal to $20,000,000 in base merger consideration priced at $5.16.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the former preferred stockholders of BRB were entitled to additional merger consideration for each dollar invested in a concurrent private investment in public equity transaction (the "2023 PIPE Financing"). Because the 2023 PIPE Financing and BRB Acquisition occurred contemporaneously and in contemplation of each other, in accounting for the transaction, the Company allocated the shares issued as additional merger consideration between the BRB Acquisition and 2023 PIPE Financing using a residual allocation method, whereby the fair value of the consideration transferred was first allocated to the monetary assets and 2023 PIPE Financing proceeds with the remainder allocated to the in-process research and development (" IPR&D") asset, nimacimab. As a result, 1,564,194 additional shares of common stock were allocated to the BRB Acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 18, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">21,609,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">(a)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total consideration</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,609,586 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-*

size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets acquired and liabilities assumed:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> IPR&D asset </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,215,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,740 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613,695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total net assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,609,586 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> (a) Equal to the aggregate of 5,436,378 shares of common stock issued, multiplied by the Company's closing stock price of $3.98 as of August 18, 2023.</span></div>The cost to acquire the IPR&D asset, nimacimab, was expensed on the date of the BRB Acquisition as it was determined to have no future alternative use. Accordingly, costs associated with the BRB Acquisition to acquire the asset were expensed as incurred. 1145141 -307086 2047080 0.08 72837 1 3872184 20000000 5.16 1564194 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 18, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Purchase consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">21,609,586 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">(a)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total consideration</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,609,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&D asset</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">21,215,214 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,076,740 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Prepaid expenses </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,800 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accounts payable</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(73,473)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other current liabilities </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(613,695)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top">Total net assets acquired</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">21,609,586 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> (a) Equal to the aggregate of 5,436,378 shares of common stock issued, multiplied by the Company's closing stock price of $3.98 as of August 18, 2023. 21609586 21609586 21215214 1076740 4800 -73473 -613695 21609586 5436378 3.98 Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Property and equipment, net consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td

style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Machinery and equipment</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,419 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,024 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,868 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,732 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">  Total property and equipment, gross </td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,616,241 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138,710 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(99,629)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(95,434)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">  Total property and equipment, net</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,516,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">43,276  </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <br/> Depreciation expense for the three and nine months ended September 30, 2024 was $47,519 and $69,873, respectively. Depreciation expense for the three and nine months ended Sepember 30, 2023 was $12,788 and $38,107, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical expenses</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64,878 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,352 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial advisory service agreement</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,907 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">664,604  </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">194,259  </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Other current assets consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td

style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">AusIndustry incentive</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,033 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">540,604 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vendor deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,216,427 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">403,439 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other tax receivables</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,678 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,242 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">421,671 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"> <br/> </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,650,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,119,929 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Other current liabilities consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Research and development costs </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,220,041 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">467,784 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Legal fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370,359 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">258,213 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> EHT Acquisition related liabilities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">180,897 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Professional and consulting fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">410,512 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,468 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,746 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,190 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,065,658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">998,552 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Property and equipment, net consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td

colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Machinery and equipment</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,419 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">78,024 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,868 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,732 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,954 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">  Total property and equipment, gross </td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,616,241 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138,710 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: accumulated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(99,629) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(95,434)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">  Total property and equipment, net</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,516,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">43,276  </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1527419 78024 74868 46732 13954 13954 1616241 138710 99629 95434 1516612 43276 47519 69873 12788 38107 Prepaid expenses consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Clinical expenses </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,878 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">61,352 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Financial advisory service agreement </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284,170 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Other prepaid expenses </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">315,556 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132,907 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">664,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">194,259  </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 64878 61352 284170 0 315556 132907 664604 194259 Other current assets consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">  </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-

align:left;vertical-align:bottom">AusIndustry incentive</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,033 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">540,604 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Vendor deposits</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,216,427 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">403,439 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other tax receivables</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,678 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,242 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">421,671 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"> <br/> </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,650,809</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,119,929 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 9033 540604 2216427 403439 3678 158242 421671 17644 2650809 1119929 Other current liabilities consist of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Research and development costs </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,220,041 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">467,784 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Legal fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">370,359 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">258,213 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> EHT Acquisition related liabilities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">180,897 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Professional and consulting fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">410,512 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,468 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64,746 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22,190 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,065,658</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">998,552 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1220041 467784 370359 258213 0 180897 410512 69468 64746 22190 2065658 998552 Warrants There are significant judgements and estimates inherent in the determination of the fair value of the Company's warrants. These judgements and estimates include assumptions regarding the Company's future operating performance and the determination of the appropriate valuation methods. Warrants Warrants vested and outstanding as of September 30, 2024 are summarized as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-

align:bottom">Source</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Exercise<br/>Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of<br/>Warrants<br/>Outstanding</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top">2015 Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,250.00 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">0.56</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">2016 Common Stock Warrants to Service Providers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">287.50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2.08</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">2019 Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.14</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2020 Common Stock Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.83</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Inducement Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.81</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,667 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Inducement Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.81</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,927 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.99</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311,113 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2021 Common Stock Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.99</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">November 2019 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.16</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,213 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">December 2019 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.24</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,783 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">February 2020 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.35</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,694 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">August 2023 Convertible Note Common Stock Warrants</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.16 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.88</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">340,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">August 2023 PIPE Financing Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.16 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.88</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,325,537 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">January 2024 Pre-Funded Warrants Common Stock </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,677,166 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Total warrants outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,950,106 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt double #000;padding:0 1pt"></td></tr></table> As of September 30, 2024, all of the Company's warrants are fully vested. January 2024 Pre-Funded Warrants  In connection with the January 2024 PIPE Financing (as defined below), the Company issued the Pre-Funded Warrants (as defined below) (See Note 6). The Pre-Funded Warrants have an exercise price of $0.001 per share, and were exercisable immediately upon issuance until exercised in full. The gross proceeds from the issuance of these Pre-Funded Warrants was $22,991,015. The Company determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability or derivative. The Pre-Funded Warrants are indexed to the Company's common stock and meets all other conditions for equity classification. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time issued. The Company also determined that the Pre-Funded Warrants should be included in the determination of basic and diluted earnings per share. </span><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">`</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.584%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants vested and outstanding as of September 30, 2024 are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.137%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Warrants<br/>Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Common Stock Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,250.00 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">0.56</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">400 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">2016 Common Stock Warrants to Service Providers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">287.50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">2.08</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">2019 Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">87.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.14</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,000 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2020 Common Stock Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.83</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32,668 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Inducement Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.81</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-

color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">84,667 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Inducement Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.00 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.81</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,927 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">2021 Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.50 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.99</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">311,113 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2021 Common Stock Warrants to Placement Agent</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27.50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">1.99</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">21,778 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">November 2019 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">72.25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.16</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34,213 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">December 2019 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.24</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,783 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">February 2020 EHT Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37.25 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.35</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">80,694 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">August 2023 Convertible Note Common Stock Warrants</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.16 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.88</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">340,000 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">August 2023 PIPE Financing Common Stock Warrants</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.16 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">8.88</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,325,537 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">January 2024 Pre-Funded Warrants Common Stock </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.001 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">Indefinite</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,677,166 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Total warrants outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,950,106 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt">

style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:justify;vertical-align:top">Unamortized debt discount</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(610,749)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:justify;vertical-align:top">Unamortized debt issuance costs</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17,253)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:justify;vertical-align:top">Carrying value of total convertible debt - related party</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,371,998 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Convertible Note - Related Party On August 15, 2023, the Company entered into a secured note and warrant purchase agreement (the "Secured Note and Warrant Purchase Agreement") with MFDI, LLC (“MFDI”), pursuant to which the Company issued to MFDI a $5,000,000 secured convertible promissory note (the "Convertible Note") and a warrant to purchase 340,000 shares of common stock on August 18, 2023 (the "Convertible Note Financing") (See Note 4). The Convertible Note had an interest rate of 10% per annum and had a fixed conversion rate of $5.16. On August 8, 2024, MFDI exercised the conversion option under the Convertible Note and converted the full principal balance of $5,000,000 under the Convertible Note. This conversion resulted in the issuance of 968,973 shares of the Company's common stock and the payment of accrued interest in cash, thereby fully satisfying the Company's debt obligations to MFDI. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued interest was payable quarterly within 30 days of the last day of each calendar quarter. The debt discounts related to the warrants, and debt issuance costs, were amortized over the term of the Convertible Note using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense in Other (income) expense within the Consolidated Statements of Operations. Through the date of conversion, the Convertible Note is classified as Level 2 of the fair value hierarchy model based on market prices that can be corroborated with observable market data for the Company's common stock. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September 30, 2024, the effective interest rate on the Convertible Note was 31.39%. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense (Income)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest expense consists of the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:50.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party interest expense - stated rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">53,425 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,274 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">302,741 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,227 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Insurance premium loan payable - stated rate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,162 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,764 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Legal judgment interest (income) expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(384,897)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,320)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(234,751)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,851 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Bond premium</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Premium on irrevocable letter of credit </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-

align:bottom">69,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,861 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,861 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,102 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Non-cash interest expense:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Amortization of debt discount</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">582,550 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Amortization of transaction costs</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,063 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,456 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90,766)</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">271,307 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">796,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">476,135 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company's convertible debt consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.572%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">As of December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Total principal value of convertible note - related party, net of discount</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,749)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value of total convertible debt - related party</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,371,998 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5000000 610749 17253 4371998 5000000 340000 0.10 5.16 5000000 968973 0.3139 The Company's interest expense consists of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:50.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td

style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:top">Related party interest expense – stated rate</td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,425 </span></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">60,274 </td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,741 </span></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">76,227 </td><td style="background-color:#ccceff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Insurance premium loan payable – stated rate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,162 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,764 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Legal judgment interest (income) expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(384,897)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(23,320)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(234,751)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">158,851 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Bond premium</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,929 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">59,930 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Premium on irrevocable letter of credit </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,861 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,297 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">69,861 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,102 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Non-cash interest expense:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Amortization of debt discount</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108,417 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">582,550 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">99,587 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Amortization of transaction costs</td><td

colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,063 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16,456 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,813 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90,766)</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">271,307 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">796,222</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">476,135 </td><td style="background-color:#ffffff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 53425 60274 302741 76227 0 2162 0 5764 -384897 -23320 -234751 158851 59929 59930 59929 59930 69297 69861 69297 69861 0 0 0 3102 108417 99587 582550 99587 3063 2813 16456 2813 -90766 271307 796222 476135 Stockholders' Equity and Capitalization PIPE Financings January 2024 PIPE Financing On January 29, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on January 31, 2024, the Company issued an aggregate of 11,713,664 shares of common stock and 9,978,739 pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 9,978,739 shares of common stock (the "January 2024 PIPE Financing") for an aggregate purchase price of $49,991,010. The January 2024 PIPE Financing was priced at $2.31 per common share and $2.30 per Pre-Funded Warrant based on the 5-day average share price preceding January 29, 2024. The Pre-Funded Warrants are exercisable at any time for an exercise price of $0.001. In connection with the January 2024 PIPE Financing, the Company incurred $3,823,752 in direct equity issuance costs for net proceeds of $46,167,258. March 2024 PIPE Financing On March 11, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on March 13, 2024, the Company issued an aggregate of 4,000,000 shares of common stock (the "March 2024 PIPE Financing") for an aggregate purchase price of $40,000,000. The March 2024 PIPE Financing was priced at $10.00 per common share. In connection with the March 2024 PIPE Financing, the Company incurred $2,610,695 in direct equity issuance costs for net proceeds of approximately $37,389,305. Prefunded Warrant Exercise On July 1, 2024, 1,301,573 pre-funded warrants issued in the January 2024 PIPE Financing with an intrinsic value of $10,424,294 were exercised on a cashless basis, resulting in the issuance of 1,301,410 shares of Company's common stock. Conversion of Debt On August 8, 2024, the Company issued 968,973 shares of common stock to MFDI upon conversion in full of the Convertible Note (see Note 5). 11713664 9978739 9978739 49991010 2.31 2.30 P5D 0.001 3823752 46167258 4000000 40000000 10.00 2610695 37389305 1301573 10424294 1301410 968973 Stock-Based Compensation Stock Incentive Plan On October 31, 2014, the Board of Directors of the Company ("Board") approved the Company's 2014 Omnibus Incentive Plan. On June 14, 2022, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (as amended, the "2014 Amended and Restated Plan") which replaced the 2014 Omnibus Incentive Plan in its entirety. On September 29, 2023, the Board and holders of the voting power of the outstanding capital stock of the Company adopted and approved Amendment No. 1 to the 2014 Amended and Restated Plan. Amendment No. 1 to the 2014 Amended and the Restated Plan became effective on November 6, 2023. As of September 30, 2024, 2,464,345 shares were authorized for the issuance under the 2014 Amended and Restated Plan. As of September 30, 2024, the Company had 27,578 shares available for future grant under the 2014 Amended and Restated Plan. 2024 Inducement Equity Incentive Plan On July 2, 2024, the Board adopted the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). The Inducement Plan was adopted in order to grant share-based awards to newly hired employees as an inducement to join the Company. The terms of the Inducement Plan are substantially similar to the terms of the Company's 2014 Amended and Restated Plan with the exception that awards may only be made to an employee who has not previously been an employee or member of the Board of Directors of the Company if the award is in connection with commencement of employment. The Company has reserved 600,000 shares of the Company's common stock for issuance pursuant to awards granted under the Inducement Plan. As of September 30, 2024, the Company had 246,500 shares available for future grant under the Inducement Plan. Stock Options The following is a summary of option activity under the Company's 2014 Amended and Restated Plan and the Inducement Plan, for the nine months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of<br/>Shares</td><td colspan="3" style="padding:0 1pt"></td><td

colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted<br/>Average<br/>Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Intrinsic Value*</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Outstanding, December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">498,298 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.96</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">20,441 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Granted</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,259,600 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.35 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Cancelled</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,048)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126.76 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Forfeited</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(108,496)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.22 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Outstanding, September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639,354 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.05</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">158,794 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Exercisable, September 30, 2024</td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">519,839 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.36</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">71,783 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2024 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). The weighted-average grant-date fair value of stock options granted during the nine months ended September 30, 2024, was $8.82. The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">0.00%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 81.73% - 99.96% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.69% - 4.48% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Expected term (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.27 - 6.08 </td></tr></table> Restricted Stock Units On February 29, 2024, the Company granted restricted stock units ("RSUs") to its executive management team and to certain members of the Board with market-based vesting conditions. The RSUs are eligible to vest subject to the achievement and attainment of certain market capitalization target goals and share price targets (market-based vesting conditions). The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market and performance conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions:  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">0.00%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">93.71%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">4.16%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Derived service periods (years) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.27 - 2.48 </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <br/> On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. <br/> The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions: <br/> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">0.00%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">94.3%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">3.76%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Derived service periods (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2.11</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The following is a summary of RSU activity during the period ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of<br/>Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested, December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">847,777 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,137,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.26 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Common Stock Issued for Services Additionally, during the nine months ended September 30, 2024, the Company issued 5,000 shares of common stock to a service provider as

compensation for services provided. Such shares were issued in a private placement outside of the Company's equity incentive plans. Stock-Based Compensation Expense The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period or derived service period. The Company recognized stock-based compensation expense for the stock options and the RSUs discussed above, in its Unaudited Condensed Consolidated Statements of Operations as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Research and development</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,845 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">33,724 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056,564 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">90,725 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top">General and administrative</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,560,772 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">126,483 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,171,706 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">303,932 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,921,617</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">160,207 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,228,270</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">394,657 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> During the nine months ended September 30, 2024, the first three market-based vesting conditions of the RSUs granted in August and September 2023 were met. Stock Compensation Adjustments Related to Board Member Resignations On July 2, 2024, the Board accepted the resignations of several Board members effective August 1, 2024. Concurrently, the Board approved a modification to the option awards granted such Board members, which modification accelerated the vesting of all unvested options as of the resignation date and extended the post-termination exercise period to December 31, 2025. As a result of the modification, the Company recognized $274,019 in incremental stock compensation expense during the three and nine months ended September 30, 2024. The total amount of unrecognized compensation cost was $11,758,346</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of September 30, 2024. This amount will be recognized over a weighted average period of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.61 years</span>. 2464345 27578 600000 246500 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of option activity under the Company's 2014 Amended and Restated Plan and the Inducement Plan, for the nine months ended September 30, 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">498,298</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid

#000000;padding:2px 0;text-align:right;vertical-align:bottom">8.96 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">7.24</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,441</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding, September 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,354</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.05 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">8.33</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">158,794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable, September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">519,839</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">11.36 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom">5.76</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">71,783 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:2pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company's stock exceeded the exercise price of the stock options at September 30, 2024 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). 498298 8.96 P7Y2M26D 20441 1259600 11.35 10048 126.76 108496 9.22 1639354 10.05 P8Y3M29D 158794 519839 11.36 P5Y9M3D 71783 8.82 The fair value of the Company's stock option grants were estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">0.00%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 81.73% - 99.96% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.69% - 4.48% </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Expected term (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.27 - 6.08 </td></tr></table> The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions:  <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td

colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">0.00%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">93.71%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">4.16%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Derived service periods (years) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.27 - 2.48 </td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <br/> On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. <br/> The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions: <br/> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Dividend yield</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">0.00%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Volatility factor</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">94.3%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Risk-free interest rate</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">3.76%</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top">Derived service periods (years)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">2.11</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.0000 0.8173 0.9996 0.0369 0.0448 P5Y3M7D P6Y29D 0.0000 0.9371 0.0416 P1Y3M7D P2Y5M23D 0.0000 0.943 0.0376 P2Y1M9D The following is a summary of RSU activity during the period ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of<br/>Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Unvested, December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">847,777 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested, September 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,137,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6.26 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 847777 3.66 290000 13.87 1137777 6.26 5000 The Company recognized stock-based compensation expense for the stock options and the RSUs discussed above, in its Unaudited Condensed Consolidated Statements of Operations as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top">Research and development</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">360,845 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,724 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1,056,564 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,725 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560,772 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,483 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171,706 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,932 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,921,617 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">160,207</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,228,270 </td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">394,657</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 360845 33724 1056564 90725 1560772 126483 5171706 303932 1921617 160207 6228270 394657 3 274019 274019 11758346 P2Y7M9D Loss Per Share of Common Stock<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, (Unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic EPS and diluted EPS:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss (Numerator)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(3,898,297)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,945,834)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(16,820,644)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(33,224,854)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares (Denominator)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Weighted average common shares outstanding, including shares issuable upon the exercise of pre-funded warrants </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,819,387 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,880,546 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,317,352 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,207,411 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Per-Share Amount</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.17)</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.48)</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6.38)</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30, (Unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, (Unaudited)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639,354 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">442,803 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639,354 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">442,803 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Warrants</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,272,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,280,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,272,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,280,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested restricted stock units </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common shares underlying convertible debt </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, (Unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, (Unaudited)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic EPS and diluted EPS:</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Loss (Numerator)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,898,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(24,945,834)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,820,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(33,224,854)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares (Denominator)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Weighted average common shares outstanding, including shares issuable upon the exercise of pre-funded warrants </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,819,387 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,880,546 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,317,352 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,207,411 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Per-Share Amount</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(3.17)</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.48)</span></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6.38)</td><td style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -3898297 -3898297 -24945834 -24945834 -16820644 -16820644 -33224854 -33224854 38819387 38819387 7880546 7880546 35317352 35317352 5207411 5207411 -0.10 -0.10 -0.10 -0.10 -3.17 -3.17 -0.48 -0.48 -6.38 -6.38 The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>September 30, (Unaudited)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended<br/>September 30, (Unaudited)</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639,354 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">442,803 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2"

style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639,354 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">442,803 </td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Warrants</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,272,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,280,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,272,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,280,940 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unvested restricted stock units </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">513,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">843,110 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Common shares underlying convertible debt </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">980,673 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 1639354 442803 1639354 442803 3272940 3280940 3272940 3280940 513446 843110 513446 843110 0 980673 0 980673 Contingencies General Litigation and Disputes From time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company's operations or financial position, liquidity or results of operations. Wendy Cunning vs Skye Bioscience, Inc. The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The case, entitled Wendy Cunning vs Skye Bioscience, Inc., was filed in U.S. District Court (the "District Court") for the Central District of California (the “Cunning Lawsuit”). On January 18, 2023, a jury rendered a verdict in favor of Ms. Cunning and awarded her $512,500 in economic damages (e.g., lost earnings, future earnings and interest), $840,960 in non-economic damages (e.g., emotional distress) and $3,500,000 in punitive damages. On August 2, 2023, the District Court ruled on the plaintiff's motion for attorney fees and awarded the plaintiff $1,200,008. Based on this order, the Company reduced the aggregate estimate for the legal contingency by $151,842, the difference between the attorney fees awarded by the District Court and the Company's previous estimate. On August 17, 2023, the Company obtained a stay on enforcement of the judgment in the Cunning Lawsuit by posting an appeal bond in the amount of $9,080,202. In March of 2023, the Company appealed the judgment in the Cunning Lawsuit to the United States Court of Appeals for the Ninth District (the "Ninth Circuit"). Subsequent to quarter end, on October 22, 2024, the Ninth Circuit issued its decision in the Company's favor which vacated the judgment and remanded the case back to the District Court for a new trial. As a result, the Company will be able to recover the $9,080,202 restriction on its cash related to the bond. Skye Bioscience, Inc. vs Partner Re Ireland Insurance In February 2023, the Company brought a suit against the Company's D&O insurance carrier, Partner Re Ireland Insurance DAC ("Partner Re"), bringing claims for (a) breach of contract, (2) tortious breach of the implied covenant of good faith and fair dealing and (3) declaratory relief that Partner Re is obligated to reimburse the Company for the defense fees and costs incurred in defense of the Cunning Lawsuit and must indemnify the Company for any settlement or judgment in the Cunning Lawsuit (the "Partner Re Lawsuit"). The Company's allegations arise out of Partner Re's refusal to reimburse the Company for costs incurred by the Company in defending the Cunning Lawsuit. The case, entitled Skye Bioscience, Inc., v. Partner Re Ireland Insurance DAC, was filed in the United Stated District Court for the Central District of California. On April 17, 2023, Partner Re filed a motion to dismiss the Company's complaint. On June 20, 2023, the court issued a ruling in favor of the Company and denied Partner Re's motion to dismiss the Company's lawsuit. In April 2024, the Company filed a motion for judgment on the pleadings. In June of 2024, the court granted in part and denied in part the Company's motion for judgment on the pleadings. The court granted the Company's motion for judgment on the pleadings with respect to Partner Re's affirmative defense related to whether the Cunning Lawsuit constituted a “Securities Claim” as defined in the Partner Re policy, rejecting what had been Partner Re's primary basis for denying coverage. The Company is pursuing up to $5,000,000 in coverage less the deductible to cover legal expenses incurred and any potential loss incurred from the Cunning Lawsuit. Estimate for accrued legal contingencies and related expenses 512500 840960 3500000 1200008 151842 9080202 9080202 5000000 Subsequent Events Approval of Amended and Restated Omnibus Incentive Plan On October 22, 2024, the Company's stockholders voted to approve the second amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan to increase the number of shares of the Company's common stock issuable thereunder by 1,535,655 to increase the number of incentive stock options that may be granted thereunder to 4,000,000, extend the expiration date of the plan to September 10, 2034, update the name of the plan to the “Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan” and make certain administrative amendments (as so amended and restated, the "Amended and Restated Plan"). Stock Option Grants Subsequent to September 30, 2024, the Company granted an aggregate of 1,456,400 common stock options to members of management, employees and directors under the Amended and Restated Plan. San Francisco Office Lease On September 25, 2024, the Company entered into a new lease agreement for approximately 2,077 square feet of office space located at 632 Commercial Street, 5th Floor, San Francisco, California 94111. The lease has a term of three years and two months, beginning on October 1, 2024, with a monthly rent of $9,000 and annual increases of 3%. This office space will support our continued growth and operational needs as we expand our development activities. No material changes to our financial position are anticipated as a result of this lease. Legal Contingencies See Note 9 for disclosure of the recognized subsequent event related to our estimate for legal contingencies. 1535655 4000000 1456400 2077 P3Y2M 9000 0.03 false false false false

"